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Abstract 
Mitochondrial DNA deletions are a primary cause of inherited and sporadic 
mitochondrial disease, whilst somatic mtDNA deletions contribute to the focal 
respiratory chain deficiency observed in post-mitotic cells associated with ageing and 
neurodegenerative disorders. As mtDNA deletions only cause cellular pathology at high 
levels of heteroplasmy, an mtDNA deletion formed within a cell must accumulate by a 
process known as clonal expansion to levels which result in biochemical dysfunction. 
The mechanism driving clonal expansion remains uncertain; this research aimed to 
investigate clonally expanded mtDNA deletions in sporadic and inherited 
mitochondrial myopathies in order to elucidate this mechanism.  
A number of different approaches were taken to assess the mechanism driving 
accumulation of mtDNA deletions. The effect of the mtDNA deletion size on clonal 
expansion was first investigated by assessing the longitudinal spread of mtDNA 
deletions in single muscle fibres isolated from patients presenting with mtDNA 
maintenance disorders; no relationship was found to exist between mtDNA deletion 
size and the area over which the mutation has accumulated. A longitudinal study was 
carried out using tissue acquired over a 13-year period from a single patient with a 
sporadic mtDNA deletion, to identify whether the mtDNA deletion heteroplasmy level 
continued to increase over time, as would be expected if the mutation displayed a 
selective advantage over wildtype mtDNA – however, both the genetic and 
biochemical defect were found to be stable over time in this patient. A subsequent 
study aimed to identify a correlation between mtDNA deletion size and heteroplasmy 
levels at the whole tissue level in a cohort of patients with sporadic single mtDNA 
deletions, but no evidence was found to suggest that larger mtDNA deletions 
accumulate to higher levels of heteroplasmy. Finally, single cytochrome c oxidase-
deficient muscle fibres were investigated using single-molecule PCR to assess whether 
clonal expansion of multiple mtDNA deletions could be observed in single cells. 
Evidence of multiple clonally expanded mtDNA species was found in approximately 
40% of all examined fibres, with no correlation between mtDNA deletion size and level 
of accumulation. 
Each of these four studies has highlighted accumulation by random genetic drift to be 
the most likely mechanism for clonal expansion of mtDNA deletions in human muscle; 
no evidence has been found to support the presence of a selective advantage for 
mtDNA deletion species over wildtype mtDNA.  
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Chapter 1 
 Introduction 
1.1 Mitochondrial Origins  
Mitochondria are widely believed to be the evolutionary result of an endosymbiosis 
event, the engulfment of a primitive bacteria-like organism by a eukaryotic cell, as 
proposed by Lynn Margulis in 1970 (Margulis, 1970). This key event in early eukaryote 
evolution would have provided a safer and more stable intracellular environment for 
the bacteria-like organism, while the eukaryotic cell would have thrived on a constant 
supply of energy in the form of ATP-production, making this a mutually beneficial 
relationship for both organisms.  
While phylogenetic analyses have pinpointed the time of this endosymbiotic event to 
approximately 1500 million years ago, some of the same studies have created debate 
as to whether the primitive bacteria was engulfed by a nucleated a-mitochondrial cell, 
or a prokaryote which developed a nucleus after the development of this symbiotic 
relationship (Embley and Martin, 2006). Evidence is now possibly weighted more 
strongly for the endosymbiotic event occurring before the development of a nucleus, 
as the existence of true archezoa has been brought into question. The archezoa were 
an amitochondrial eukaryote group believed to have diverged from the eukaryote 
evolutionary tree prior to the symbiosis event, serving as evidence of the evolution of 
a nucleus prior to the symbiosis which led to mitochondria. However, the discovery of 
mitochondrial genes in the nuclear DNA of members of this eukaryote group has 
provided evidence of the ancestral presence of mitochondria in these species (Clark 
and Roger, 1995; Roger, 1999). Subsequently, the presence of hydrogenosomes and 
mitosomes – double-membrane bound organelles evolutionarily derived from 
mitochondria - in these species has provided evidence beyond all doubt that 
mitochondria must have been present in the ancestors of the so-called archezoa 
(Embley and Martin, 2006). In light of the lack of evidence for any eukaryotes which 
may have diverged before the symbiosis that led to the development of mitochondria, 
it now seems more likely that endosymbiosis occurred between a primitive bacteria 
and a prokaryote which later developed a nucleus. 
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While opinions are still divided over the eukaryote or prokaryote cell involved in 
endosymbiosis, the bacterial origins of mitochondria have proved easier to trace. 
Sequencing of the genome of α-proteobacteria Rickettsia prowazekii, an aerobic 
intracellular parasitic bacteria which causes epidemic typhus, revealed a set of genes 
encoding elements of the tricarboxylic acid cycle and respiratory chain complexes 
similar to that found in mitochondria (Andersson et al., 1998). Subsequent 
phylogenetic analysis of the cytochrome b and cytochrome c oxidase I genes from 
Rickettsia prowazekii was then used to confirm that the evolutionary ancestor of the 
mitochondria must have been an α-proteobacteria, specifically from within the 
Rickettsiaceae family (Sicheritz-Ponten et al., 1998).  
Prior to the endosymbiosis event, the free-living α-protobacterial ancestors of 
mitochondria must have contained all of the genetic information required for 
independence. Over time as the symbiosis between host and mitochondria has 
increased much of this genetic material has been lost, leaving only a small vestigial 
genome present in mitochondria. This decrease in genome size will have occurred due 
to multiple pressures, including the mutational degradation of genes made redundant 
by the sharing of the host’s metabolites and the transfer of genes to the host nucleus 
(Kurland and Andersson, 2000). Gene transfer has been possible in instances where 
encoded proteins have a targeting sequence, allowing translation in the cytoplasm 
prior to movement into the mitochondria. This gene transfer is believed to be a 
neutral, multistage process, beginning with the movement of an inactive copy of the 
gene to the nucleus while an active copy is still present and functional in the 
mitochondria. A tagging process can then occur, activating the gene copy now present 
in the nucleus and leaving the mitochondrial gene copy is essentially redundant.  The 
mitochondrial gene can therefore be harmlessly subjected to mutational degradation, 
leaving the mitochondrial gene present only in the nucleus (Berg and Kurland, 2000). 
For each gene lost from the intracellular symbiont by mutation in favour of a nuclear 
copy, reliance on the host cell becomes greater and the bond of symbiosis between 
becomes stronger; this has caused the evolution of mitochondria from intracellular α-
proteobacteria into the organelles we see present in the majority of modern 
eukaryotes. 
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1.2 Mitochondrial Structure 
Mitochondria are typically present throughout the cytoplasm of eukaryotic cells, 
though notable exceptions such as erythrocytes do not contain any mitochondria at all. 
The mitochondrial content of cells - including size, shape and number – all vary 
depending on the energy requirements of each specific cell and tissue type; a highly 
metabolically active cell type would be expected to have a higher level of mitochondria 
to supply its energy demands than would be seen in a less energy-demanding tissue.  
Mitochondria are typically depicted as single oval-shaped organelles, as shown in 
Figure 1.1, though morphology within the tissue can vary from spherical to rod-like 
structures and the mitochondria actually interact dynamically with each other. While 
variable, mitochondrial size is usually within a spectrum of 1 – 4µm in length and 0.3 – 
0.7µm in diameter. 
Early visualisations of mitochondria were obtained through light microscopy, where 
only basic morphology could be investigated; here the smooth outline of the organelle 
was noted, as was the presence of an outer membrane and an inner matrix.  Lamellae 
were also seen protruding from the inner surface of the mitochondrial membrane, 
reaching into the matrix but not reaching the opposite side of the organelle. These 
‘folds’ in the membrane were called ‘cristae mitochondriales’ (Palade, 1952). Further 
work with electron microscopy revealed further details of mitochondrial structure, 
including the outer double plasma membrane consisting of a smooth outer membrane 
(OM) and highly folded inner membrane (IM) (Palade, 1953).  
The outer membrane has the simplest structure of the two mitochondrial membranes, 
forming a smooth structure around the mitochondrial periphery. The shape given to 
the mitochondria by the OM conformation can change depending upon tissue type; 
the OM typically displays a tubular shape when adhered to the cytoskeleton, and 
forms an ellipsoid or sphere in isolated suspension. Though the OM does partly serve 
as a barrier to prevent free movement of molecules between the mitochondrial 
interior and the cytoplasm, ions <10kDa in size are able to freely diffuse across the OM 
through the voltage dependant anion channel (VDAC) known as porin. Proteins, too 
large to be imported into the organelle in this fashion, must pass through the 
translocases of the outer membrane (TOMS) and translocases of the inner membrane 
(TIMS) (Truscott et al., 2003; Ahmed and Fisher, 2009).  
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The inner membrane is responsible for forming a scaffold upon which the respiratory 
chain complexes can be assembled and can operate, as well as providing a permeable 
barrier which the complexes can subsequently use to generate an electrochemical 
gradient (Munn, 1974). The IM can be separated into two distinct regions – the cristae, 
which serve to create a much larger surface area for assembly of the respiratory 
complexes, and the peripheral regions – which are joined by tubular connections 
known as cristae junctions (Perkins et al., 1997). The proportion of each of these two 
areas can change, resulting in greater amounts of cristae or larger smooth peripheral 
regions, as a result of fission and fusion of the inner membrane (Mannella et al., 2001). 
It has been suggested that this varied morphology displayed by the IM could be part of 
a functional regulatory system (Mannella, 2006), as some mitochondrial functions can 
be affected by changes to the IM topology (Mannella et al., 1997; Mannella et al., 
2001).  
 
 
Figure 1.1 – Mitochondrial structure 
An electron microscopy image of a single mitochondria aligned to a classical 3D representation of 
mitochondrial structure. Taken from http://academic.brooklyn.cuny.edu/biology/bio4fv/page/mito.htm 
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1.3 Mitochondrial Functions 
1.3.1 Iron-sulphur cluster formation 
Fe-S clusters are formed by the interaction of iron cations (Fe2+/3+) and sulphide (S2+) 
anions, most commonly in a rhombic (2Fe-2S) or cubane (4Fe-4S) formation. These 
inorganic compounds are able to act as protein cofactors, participating in electron 
transfer, catalysis and regulatory processes (Beinert et al., 1997). Historically, Fe-S 
clusters were believed to assemble spontaneously on proteins (Malkin and Rabinowitz, 
1966), but later evidence confirmed that synthesis of these compounds is in fact a 
catalysed process (Johnson et al., 2005). Fe-S clusters are formed through 2 pathways 
in eukaryotic cells, though a third pathway has been identified in bacteria; 
mitochondria are the major site of iron-sulphur (Fe-S) cluster formation in eukaryotic 
cells (Lill et al., 1999). The system for Fe-S biosynthesis in the mitochondria involves 
the ISC assembly machinery, a major source of Fe-S cluster generation in bacteria and 
likely inherited during the endosymbiotic event which led to mitochondria. This is a 
two-step process, involving Fe-S assembly on scaffold proteins Isu1 and Isu2 by a 
currently unknown mechanism prior to trafficking of Fe-S clusters from Isu1 to the 
apoprotein for assembly into a functional protein (Lill, 2009). There are many assisting 
proteins involved in this complex mechanism, as outlined in Figure 1.2. 
 
Figure 1.2 - Fe-S biosynthesis 
A schematic representation of Fe-S cluster assembly on the Isu protein scaffolding, prior to inclusion into 
apoproteins to form functional proteins. 
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1.3.2 Calcium handling 
Calcium (Ca2+) is an important signalling molecule in eukaryotes, involved in major cell 
events including differentiation, cell signalling, apoptosis, and cellular proliferation. 
Different signals can be identified by the cell according to different intensities, 
frequencies, localisation or durations of Ca2+ signalling (Berridge et al., 2000). At rest, 
cytosolic concentrations of Ca2+ are maintained at a steady level by import into and 
export out of the cell through the plasma membrane (Rizzuto and Pozzan, 2006). 
Cytoplasmic Ca2+ signals can then be created in the cell through an influx of Ca2+ 
through the plasma membrane from the extracellular matrix, or a release of Ca2+ from 
intracellular stores. Ca2+ is stored in most organelles within the cell, though the 
endoplasmic reticulum is often the largest store of Ca2+(Saris and Carafoli, 2005).  
The ability of mitochondria to accumulate and store Ca2+ has been well documented 
since the 1960s (Chance, 1965), though investigations to elucidate the molecular 
mechanisms involved in mitochondrial Ca2+ handling continue to this day. 
Mitochondria are able to buffer cellular Ca2+ levels by uptaking potentially vast 
quantities of Ca2+ when levels in the cell peak too high - preventing potential cell 
damage from Ca2+ overload – or releasing Ca2+ into the cytoplasm when cellular levels 
drop (Collins and Meyer, 2010).  
Ca2+ was originally believed to move freely cross the mitochondrial outer membrane 
through the voltage dependent anion channel (VDAC), when this channel was shown 
to conduct Ca2+ in addition to its known role in conducting monovalent ions (Gincel et 
al., 2001). However, more recent data has shown VDAC to provide a barrier to  free 
diffusion of Ca2+, allowing for very tight regulation of Ca2+ movement across the OM 
(Rapizzi et al., 2002). Once across the OM, Ca2+ can then be imported across the 
mitochondrial IM by the mitochondrial Ca2+ uniporter (MCU), a non-MCU Ca2+ channel 
or a mitochondrial ryanodine receptor (mRyR) (Gunter and Sheu, 2009).  
Three separate mechanisms serve to efflux Ca2+ from the mitochondrial matrix. In 
excitable cells, including neurons and cardiomyocytes, efflux is Na+ dependent; the 
Na+/Ca2+ exchanger NCLX is responsible for the electrogenic exchange of 3Na+ with 
1Ca2+ (Palty et al., 2010). A Na+ independent mechanism for Ca2+ efflux exists 
predominantly in non-excitable cells, coupling Ca2+ export to the import of H+(Puskin et 
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al., 1976). Finally, the permeability transition pore (PTP) allows Ca2+ to pass out of the 
mitochondria under conditions of Ca2+ overload. In this case, mitochondrial stress - 
caused by excessive levels of Ca2+ in conjunction with other factors such as oxidative 
stress – can cause the PTP to open, allowing free movement of Ca2+ across the 
mitochondrial membranes into the less saturated cellular cytoplasm (Halestrap, 2009).  
 
1.3.3 The TCA cycle 
The tricarboxylic acid (TCA) cycle - also known as the citric acid cycle or the Krebs cycle 
- was discovered by Sir Hans Krebs, who won the Nobel prize “for his discovery of the 
citric acid cycle” in 1953 (Krebs, 1953). The TCA cycle is the first stage in cellular 
respiration, where NADH and FADH2 are generated through the processing of carbon 
fuels. Both NADH and FADH2 are important downstream of the TCA cycle in oxidative 
phosphorylation (see 1.3.5), to reduce O2 in order to generate the proton gradient 
used in ATP synthesis.  
Under aerobic conditions in the cell, pyruvate - generated from glucose by glycolysis - 
is transported into the mitochondrial matrix, where it forms acetyl CoA under the 
action of the pyruvate dehydrogenase complex: 
Pyruvate + CoA + NAD+ → acetyl CoA + CO2 + NADH +H
+ 
Acetyl CoA can then enter the citric acid cycle, where it reacts with oxaloacetate under 
catalysis by citrate synthase to form citrate; the by-product of this reaction is CoA, 
which is then free to react with a new molecule of pyruvate to initiate a new beginning 
to the citric acid cycle. The citric acid cycle then continues, with seven further 
enzymatic steps bringing the set of reactions full circle back to oxaloacetate (Thauer, 
1988), as outlined in Figure 1.3. Importantly for downstream ATP production by 
oxidative phosphorylation, NADH is produced as a by-product from 3 stages of the TCA 
cycle and FADH2 is produced as the by-product of a further reaction, as outlined below: 
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 Isocitrate + NAD+ → α-ketoglutarate + NADH + CO2 
(catalysed by isocitrate dehydrogenase) 
 α-ketoglutarate + NAD+ + CoA → succinyl CoA + NADH + CO2 
(catalysed by α-ketoglutarate dehydrogenase complex) 
 Malate + NAD+ → oxaloacetate + NADH + H+ 
(catalysed by malate dehydrogenase) 
 Succinate + FAD → fumerate + FADH2 
(catalysed by succinate dehydrogenase)
 
Figure 1.3 Outline of the TCA cycle 
A brief overview of the citric acid cycle within the mitochondrial matrix; this process is the first stage of 
cellular respiration, generating NADH and FADH2, both of which play important roles in oxidative 
phosphorylation. 
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1.3.4 Apoptosis 
Programmed cell death, a highly regulated process distinct from cellular necrosis, was 
first investigated in the 1960’s, and given the term apoptosis (Kerr et al., 1972). 
Apoptosis is identified by a consistent pattern of changes to cell morphology prior to 
death, including cell shrinkage, nuclear fragmentation and condensation of chromatin, 
as opposed the characteristic cellular swelling and lysis of necrosis (Pollack and 
Leeuwenburgh, 2001). Unlike necrosis, which occurs following cellular insult such as 
infection or acute injury, apoptosis is an advantageous cellular mechanism for 
multicellular eukaryotic organisms, allowing fine control of cell numbers, tissue 
remodelling, homeostasis and disposal of dysfunctional cells. 
Two major apoptotic pathways exist in eukaryotic cells - the extrinsic and the intrinsic 
pathways - both of which respond to different cellular signals. The extrinsic apoptosis 
pathway is activated by extracellular, proapoptotic ligands binding to and hence 
activating transmembrane death receptors. When active, the death receptors form a 
cell death inducing signalling complex, which in turn activates caspases 8 and 10. These 
active caspases then stimulate the activity of caspases 3, 6 and 7, which carry out 
apoptosis (Ashkenazi, 2008). 
The intrinsic pathway, which is also referred to as the mitochondrial pathway due to 
heavy involvement of mitochondria in this signalling pathway, acts in response to cell 
death stimuli including DNA damage and UV radiation. This pathway is activated by the 
BH3 family of proteins (a heterogeneous group of proteins,  including Puma, Bmf and 
Bad, which share a BH3 motif), which are capable of binding to and inhibiting anti-
apoptotic Bcl-2 proteins and hence acting as pro-apoptotic proteins (Youle and 
Strasser, 2008). The inhibition of the anti-apoptotic Bcl-2 proteins allows the pro-
apoptotic proteins Bak and Bax to permeabilise the outer mitochondrial membrane, 
releasing cytochrome c (Suen et al., 2008). As apoptosis is initiated, Bax is translocated 
from the cytosol to the mitochondria, where it forms oligomers that appear as foci on 
the mitochondria (Antonsson et al., 2001); Bak is already located at the mitochondria, 
but undergoes conformational changes to form oligomers during apoptosis (Griffiths et 
al., 1999). The three-dimensional structures of Bcl-2 family proteins, including Bax, 
have been shown to resemble the structure of bacterial toxins capable of creating 
holes in cellular membranes (Muchmore et al., 1996). It is now widely believed that 
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the oligomerisation of Bax is fundamental to the release of cytochrome c (Eskes et al., 
2000), following the demonstration of Bax involvement in the formation of openings in 
the OMM in cell-free systems (Kuwana et al., 2002).  
When released from the mitochondria, cytochrome c binds to Apaf-1; until this point, 
Apaf-1 exists is autoinhibited by the closed, compact state it exists in (Bao et al., 2005). 
Binding of cytochrome c causes Apaf-1 to undergo a conformational change, moving 
into an open formation and freeing the N-terminal caspase recruitment domain 
(CARD). This allows for seven molecules of Apaf-1 to bind together in a wheel-like 
structure to form the apoptosome (Acehan et al., 2002), which can then recruit, bind 
and activate procaspase 9 (Shi, 2006). The now active caspase 9 remains associated 
with the Apaf-1 apoptosome, forming a complex known as a holoenzyme (Rodriguez 
and Lazebnik, 1999) , increasing the activity of the apoptosome and initiating apoptosis 
by stimulating the activity of caspases 3, 6 and 7 (Wang and Youle, 2009). 
 
1.3.5 Oxidative Phosphorylation 
The oxidative phosphorylation (OXPHOS) system is regarded as one of the most 
essential mitochondrial functions, being responsible for the majority of ATP synthesis 
within a eukaryotic cell. The OXPHOS system is made up of five multi-subunit protein 
complexes and two electron carriers (coenzyme Q and cytochrome c); together, this 
group of proteins link together cellular respiration and ATP synthesis. The electron 
transport chain (ETC) is made up from four protein complexes: Complex I (NADH 
dehydrogenase), complex II (succinate dehydrogenase), complex III (cytochrome c 
reductase) and complex IV (cytochrome c oxidase).  Electrons flow through the ETC 
from NADH or FADH2 to O2 during a series of oxidoreductase reactions, releasing 
energy at each stage; the energy released from this electron transfer is used to sustain 
a proton (H+) gradient across the IMM (Smeitink et al., 2001). This H+ gradient, which is 
generated by the pumping of H+ from the mitochondrial matrix into the inter-
membrane space through complexes I, III and IV, is then utilised by ATP synthase to 
catalyse the production of ATP from ADP and inorganic phosphate (Mitchell, 1961). 
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1.3.5.1  Complex I 
Complex I, also known as NADH or ubiquinone oxidoreductase, is the first complex of 
the ETC and oxidative phosphorylation; this is one of two entrances to the OXPHOS 
system, the other being Complex II. Complex I is also the largest and most complicated 
protein complex of the OXPHOS system, consisting of forty-five subunits with a 
combined mass of 980kDa in mammals (as assed in Bos Taurus heart mitochondria – 
closely related to human mitochondria for modelling purposes) (Carroll et al., 2006). Of 
these subunits, seven are encoded within the mitochondrial DNA (ND1, ND2, ND3, 
ND4, ND4L, ND5 and ND6), while the remaining thirty-eight are nuclear encoded (Hirst 
et al., 2003).  In bacteria, Complex I (NDH-1) consists of fourteen subunits, all of which 
are evolutionarily conserved from bacteria to mammals; these fourteen subunits of 
mammalian Complex I are known as the ‘core subunits’, and are essential to the 
enzymatic activity of the complex. The other thirty-one subunits are known as 
‘accessory subunits’ (Friedrich and Scheide, 2000) or ‘supernumerary subunits’ (Hirst, 
2013) – though these are not required for catalysis, they are known to be involved in 
normal Complex I function due to the pathogenic nature of mutations in these 
subunits (Valsecchi et al., 2010; Koene et al., 2012).  
Mitochondrial Complex I is believed, based upon structural and phylogenetic studies, 
to structurally consist of three sectors – the peripheral arm which protrudes into the 
matrix is comprised of a dehydrogenase domain and a hydrogenase-like domain, while 
the H+ transporter is embedded in the IMM (Mathiesen and Hägerhäll, 2002). An 
alternative interpretation of Complex I structure, based upon analysis of the intact 
complex and it’s subunit composition from bovine heart mitochondria, defines four 
subcomplexes of Complex I (Iα, Iβ, Iγ, and Iλ) (Carroll et al., 2003). Subcomplex Iλ 
consists of 15 subunits, including the seven nuclear-encoded ‘core’ subunits, the flavin 
mononucleotide (FMN, the primary electron acceptor of Complex I), and nine Fe-S 
clusters. Subcomplex Iλ forms the hydrophilic peripheral arm of Complex I, with only 
one of its constituent eight subunits containing a transmembrane helix. Subcomplex Iα 
consists of all of the subunits which comprise subcomplex Iλ, plus eight more subunits 
which serve to anchor the subcomplex to the IMM. Subcomplex Iβ predominantly 
consists of twelve subunits, with a thirteenth present at a sub-stoichiometric level, and 
has a high level of transmembrane helices spread across its constituent subunits; this 
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subcomplex makes up the majority of the IMM embedded arm of Complex I. The five 
remaining subunits not involved in subcomplexes Iα or Iβ are collectively regarded as 
subcomplex Iγ (Janssen et al., 2006). 
Complex I catalyses the oxidation of NADH to NAD+ + H+ releasing two electrons that 
are transferred to FMN, the primary electron acceptor of Complex I, reducing FMN to 
FMNH2. These two electrons are then transferred through a series of seven of the total 
nine Fe-S clusters present in Complex I to a membrane bound ubiquinone molecule 
(Sazanov and Hinchliffe, 2006) (Figure 1.5)- the remaining two Fe-S clusters are 
believed to be an anti-oxidant centre (Yagi and Matsuno-Yagi, 2003) and a functionless 
evolutionary remnant (Sazanov and Hinchliffe, 2006). Cluster N2 (4Fe-4S) acts as the 
terminal electron donor; this iron sulphur cluster transfers both electrons to a single 
molecule of ubiquinone, reducing Q to QH2.  
  
Figure 1.5 - Transport of electrons through Complex I. 
Complex I is also known as NADH-ubiquinone oxidoreductase or NADH dehydrogenase I. This protein 
complex catalyses the reaction NADH + Q + 5H
+
 → NAD
+ 
+QH2 + 5H
+
, releasing two electrons which are 
collected by FMN, the primary electron acceptor of Complex I. The electrons are passed through seven 
Fe-S clusters to a membrane-bound ubiquinone molecule, catalysing its reduction to ubiquinol. Four 
protons are translocated across the mitochondrial inner membrane during this process. 
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1.3.5.2  Complex II 
Mitochondrial complex II – succinate dehydrogenase, SDH – is the smallest protein 
complex of the OXPHOS system, consisting of only four subunits with a total mass of 
124kDa which make up a catalytic heterodimer and an integral membrane region 
(Hägerhäll, 1997). Uniquely within the respiratory chain, complex II is entirely nuclear 
encoded, with no subunits encoded by mitochondrial DNA.  
Complex II can also be classified within a family of proteins known as succinate: 
ubiquinone oxidoreductases; these proteins are classified into five types (A-E) 
according to their structural and biochemical properties. Mitochondrial complex II falls 
into category C, with one heme molecule and two transmembrane proteins (Lemos et 
al., 2002).  Among mitochondrial succinate: ubiquinone oxidoreductases, two subunits 
are highly conserved among bacteria, archaea and eukaryotic, known as the two ‘core’ 
subunits. These two subunits – A and B – form the hydrophilic domain of the protein 
complex. 
Subunits A and B of Complex II form a catalytic heterodimer, located on the matrix side 
of the IMM. Subunit A contains a covalently bound flavin adenine dinucleotide (FAD) 
cofactor (an electron acceptor), while subunit B contains 3 Fe-s clusters, 2Fe-2S, 4Fe-4S, 
3Fe-4S (Hägerhäll, 1997). FAD is responsible for catalysing the succinate to fumerate 
step of the Krebs cycle, transferring the two electrons released from this reaction into 
the respiratory chain via the Fe-S clusters of subunit B and the membrane domain of 
the complex, where electron acceptor coenzyme Q is located (Lancaster et al., 1999). 
This is the second and final access point for electrons to enter the respiratory chain. 
The remaining two subunits of Complex II are transmembrane proteins responsible for 
anchoring the complex to the IMM; the large cytochrome b binding protein (CybL, 
subunit C), and the small cytochrome b binding subunit (CybS, subunit D). Both of 
these hydrophobic subunits form α-helices (subunit C forms 5, while subunit D forms 
four); a heme group is located between the helices of the heterodimer formed by 
these two subunits (Sun et al., 2005).  
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Figure 1.6 - Transport of electrons through Complex II. 
Complex II is also known as succinate : ubiquinone oxidoreductase. This protein complex is unique in the 
oxidative phosphorylation system in being entirely nuclear encoded. Complex II is a second entrance 
point to the oxidative phosphorylation system, the alternative entry point being Complex I; Complex II 
catalyses the reaction succinate + Q → fumerate + QH2, releasing two electrons into the respiratory 
chain via electron acceptor coenzyme Q. 
 
1.3.5.3  Complex III 
Mitochondrial Complex III, also known as ubiquinone-cytochrome c oxidoreductase  or 
the bc1 complex, was initially discovered in 1961 by Hafterfi et al (Hatefi et al., 1961) 
from work in bovine heart. Mammalian Complex III consists of eleven subunits (Hatefi, 
1985)and four prosthetic groups]), at a total mass of approximately 240kDa. The 
prosthetic groups are made up of one 2Fe-2S Rieske centre in subunit V and a total of 
three heme groups; two heme groups within cytochrome b - bL (low affinity) and bH 
(high affinity) - and a heme in cytochrome c1. The heme groups present in cytochromes 
b (subunit III) and c1 (subunit IV) are iron-protoporphyrin IX – the same heme group 
present in myoglobin and haemoglobin (Berry et al., 2000). The three subunits 
containing these prosthetic groups (subunits III, IV and V) are the essential subunits, 
conserved across all species and constituting the minimal functional core of the 
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complex (Xia et al., 1997), while the remaining eight subunits are termed the 
supernumerary subunits. 
With the exception of cytochrome b, which is mitochondrially-encoded, Complex III is 
entirely encoded by the nuclear genome. The ten nuclear-encoded subunits of 
Complex III interact together with cytochrome b to form a bc1 monomer; these eleven 
subunit structures dimerise symmetrically into a pear-shaped structure to form a 
complete Complex III (Berry et al., 2000).   
Complex III can be split into three functional regions; the intermembrane space region, 
the matrix region and the transmembrane helix region. Each bc1 monomer contains 
thirteen membrane-spanning helices in the transmembrane domain, with eight of 
these belonging to cytochrome b and one more belonging to cytochrome c1, Fe-S, and 
subunits VII, X, XI respectively. Over half of the molecular mass of Complex III is located in 
the matrix region, consisting of subunits I, II, VI, and IX, as well as part of subunit VII, the N-
terminal region of the Fe-S cluster, and the C-terminal region of cytochrome c1. The 
transmembrane domain, containing the transmembrane region of cytochrome b, also 
house heme groups bL and bH, and the Qi and Qo pockets. The intermembrane space 
region of Complex III houses the functional domains of cytochrome c1, the 2Fe-2S Rieske 
centre and subunit VIII. The extramembrane regions of the Fe-S clusters in the two bc1 
monomers of Complex III interact when a dimer is formed. (Yu et al., 1999).  
As the third complex in the electron transport chain, ubiquinone-cytochrome c 
oxidoreductase, serves to transfer electrons from the pool of QH2 produced by 
Complexes I and II to oxidised cytochrome c, and to pump protons from the 
mitochondrial matrix into the intermembrane space. These processes are believed to 
occur via the Q cycle, as first proposed by Peter Mitchell in 1976 (Mitchell, 1976), 
which involves the oxidation of ubiquinol at the Qo site and the reduction of 
ubiquinone at the Qi site. First, two QH2 molecules consecutively bind to Complex III, each 
donating two electrons to the complex and releasing two H+ into the intermembrane 
space. The first QH2 molecule to binds to the Qo site; the electrons released here travel 
through the complex via two distinct pathways. One electron travels, via the 2Fe-2S 
Rieske centre and cytochrome c1, to a molecule of oxidised cytochrome c, which is 
then converted to its reduced form. A second electron travels to the second Q binding 
site (Qi) via bL and bH; this reduces the oxidised ubiquinone present at this site to a 
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semi-quinone radical anion (Q·-). Now fully oxidised, the Q molecule at the initial Qo 
site re-enters the Q pool, leaving the Qo site free for a second molecule of QH2 to bind. 
This molecule of QH2 reacts in the same manner as the first molecule, transferring one 
electron to cytochrome c and one electron to fully reduce the partly reduced 
ubiquinone at Qi. This quinone radical anion then takes up two protons from the 
mitochondrial matrix to form a molecule of QH2. In total during this cycle, two protons 
are taken from the mitochondrial matrix and four are released into the inner 
membrane space - contributing to the proton gradient across the IMM – two molecules 
of QH2 are oxidised to Q molecules, and one Q molecule is reduced to QH2 (Yu et al., 
1999; Gao et al., 2003; Papa et al., 2012). 
 
Figure 1.7 - Electron transport system of Complex III. 
Complex III is also known as ubiquinone-cytochrome c oxidoreductase or the bc1 complex. This protein 
complex transfers electrons from the pool of QH2 produced by Complexes I and II to oxidised 
cytochrome c, and to pump protons from the mitochondrial matrix into the intermembrane space. 
These processes occur via the Q cycle, which involves the oxidation of ubiquinol at the Qo site and the 
reduction of ubiquinone at the Qi site.  
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1.3.5.4  Complex IV 
Mitochondrial Complex IV, also known as cytochrome c oxidase, is the final complex of 
the electron transport chain, and the third proton pump involved in OXPHOS. The final 
step of the electron transport chain – the transfer of electrons from reduced 
cytochrome c to molecular oxygen, the final electron acceptor – is catalysed by 
Complex IV.  
Mammalian Complex IV is made up of thirteen subunits and six prosthetic groups, with 
a total molecular mass of ~200kDa; ten of these subunits are nuclear encoded, with 
the remaining three being encoded by the mitochondrial genome. The three highly 
conserved mitochondrial subunits (CO1, CO2 and CO3) are the largest and most 
hydrophobic of the subunits, and form the catalytic core of the complex (Lazarou et al., 
2009), while the nuclear-encoded subunits serve structural and regulatory roles. The 
crystal structure of bovine Complex IV was resolved in 1996 by Tsukihara et al, showing 
that the active enzyme exists as a dimer (Tsukihara et al., 1996).  
The six prosthetic groups of cytochrome c oxidase consist of two heme groups, two 
copper centres, and additional metal centres of Zn and Mg. The copper centres 
present in the complex are able to act as electron acceptors/donors by alternating 
between the reduced Cu+ and oxidised Cu2+ form. Copper centre A (CuA), containing 
two copper ions linked by cysteine residues, is the entry point for electrons into 
Complex IV – electrons are initially passed here following the reduction of cytochrome 
c at the outer membrane of the complex. This copper centre is located in the 
extramembrane domain of subunit II. Copper centre B (CuB) consists of a single copper 
ion coordinated by three histidine residues. CuB is located at the transmembrane 
region of subunit I, as are heme groups a and a3. Heme a3 is located directly adjacent 
to CuB, together forming the active centre for reduction of O2 to H2O (Tsukihara et al., 
1996).  
The initial step at Complex IV involves the consecutive binding of four individual 
molecules of cytochrome c to the enzyme, each releasing a single electron as the 
molecule is reduced. Electrons from two molecules of cytochrome c are sequentially 
passed through CuA and heme a, one electron then stopping at heme a3 while the 
second electron continues on to CuB. The reduced heme a3 and CuB centres are then 
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capable of recruiting and binding a molecule of O2, which takes an electron from each 
of the ions present in the active centre to form a peroxide (O2
2-) bridge between Fe3+ 
and Cu2+. This process is repeated with 2 more electrons donated by the remaining two 
molecules of cytochrome c involved in this process, resulting in the addition of an 
electron and an H+ ion from the mitochondrial matrix to each oxygen atom present at 
the active centre. This reduction of the peroxide bridge forms Fe3+ -OH and Cu2+ -OH. 
The reaction of each of these molecules with a further H+ ion from the mitochondrial 
matrix allows the release of two molecules of H2O, oxidising the a3 and CuB centres 
back to their original state.  
In addition to the uptake of four H+ ions from the mitochondrial matrix to reduce O2 to 
two molecules of H2O, four further H
+ ions are directly transported through Complex IV 
from the mitochondrial matrix out into the intermembrane space. The energy for this 
translocation comes from the reduction of O2 to H2O. This proton pump is believed to 
work simultaneously with H+ uptake to the active site of Complex IV (Faxen et al., 
2005). 
 
Figure 1.8 - Electron transport in Complex IV. 
Complex IV is also known as cytochrome c oxidase; as the fourth and final respiratory chain complex, 
Complex IV is responsible for the transfer of electrons from reduced cytochrome c to molecular oxygen, 
the final electron acceptor. Complex IV takes up four H
+
 ions from the matrix to reduce O2 to H2O, as 
well as transporting four more H
+
 ions from the mitochondrial matrix out into the intermembrane space. 
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1.3.5.5   ATP Synthase 
Mitochondrial ATP synthase, also referred to as FOF1-ATPase, catalyses the final step of 
oxidative phosphorylation – the synthesis of ATP from ADP and inorganic phosphate 
(Pi). This reaction is fuelled by the energy released by the transport of H
+ ions through 
ATP synthase down the electrochemical gradient across the IMM (Mitchell, 1961); this 
electrochemical gradient is produced by the movement of H+ from the mitochondrial 
matrix into the intermembrane space by Complex I, III and IV. Mammalian ATP 
synthase is comprised of sixteen subunits, two of which are mitochondrially encoded 
(ATPase 6 and 8), at a total molecular weight of approximately 550kDa (Boyer, 1997). 
Fourteen of the sixteen ATP synthase subunits form the two domains of the complex; 
the hydrophobic FO transmembrane domain, and the hydrophilic F1 domain which 
protrudes into the mitochondrial matrix. The remaining two subunits of ATP synthase 
are the oligomycin-sensitivity-conferring protein (OSCP), and the IF2 inhibitor protein 
which plays a key role in ATP hydrolase regulation (Gaballo and Papa, 2007). The F1 
domain is made up from five subunits, in the following proportions: 3α subunits, 3β 
subunits, and 1 each of subunits γ, δ and ε (Abrahams et al., 1994). The α and β 
subunits directly interact with one another, forming a hexameric ring, while the γ and ε 
subunits form the central stalk of the subunit. A long helical coiled coil domain of the γ 
subunit protrudes into the centre of the α3β3 hexamer, linking it to the γε stalk. The 
area of the γ subunit bound to each of the β subunits serves to distinguish these 
otherwise identical molecules. Finally, the δ subunit forms part of the exterior column 
of the molecule; the δ subunit is bound to the α3β3 hexamer, while two b subunits 
form the long stretch of the column bound at one end to the δ subunit, and at the 
other end bound to an a subunit on the periphery of the FO domain.  
The mitochondrial FO has three highly conserved ‘core’ subunits – a, b and c, which are 
present in a ratio of 1:1:10-12 – plus six additional subunits with currently unknown 
function (d, e, f, g, F6 and 8).  Ten to fourteen c subunits form a ring embedded in the 
IMM; the single a subunit is bound to the outside of this ring, while two b subunits 
form the exterior column attaching the a subunit of the FO domain to the δ subunit of 
the F1 domain (Collinson et al., 1994).  
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The proton gradient established by complexes I, III and IV of the electron transport 
chain allows for the movement of H+ protons through the FO proton channel, causing 
the rotation of the ring of c subunits in the FO domain (Cox et al., 1984). The rotation of 
the c-ring subsequently causes the rotation of the F1 domain subunits γ, δ and ε, 
providing energy for the production of ATP by a mechanism known as rotary catalysis 
(Devenish et al., 2008). This energy is utilised by the β subunits, which act as the 
catalytic sites for the synthesis of ATP. At any one time, each β subunit exists in one of 
three states; the β subunits cycle through these three states, moving from one to the 
next with each 120° turn of the γ subunit.  In the ‘loose state’, ADP and Pi are bound to 
the subunit, ATP synthesised from is ADP and Pi but remains bound to the subunit in 
the ‘tight’ state, and in the ‘open’ state of a β subunit ATP is released,  allowing ADP 
and Pi to bind (Jonckheere et al., 2012). This is known as the ‘binding-change’ 
mechanism, as was first proposed by Boyer in 1975 (Boyer, 1975). 
 
Figure 1.9 - ATP synthase structure. 
ATP synthase, also known as FOF1-ATPase, is the final protein complex involved in oxidative 
phosphorylation. ATP synthase catalyses the ATP synthesis from ADP and inorganic phosphate. This 
reaction is fuelled by the energy released from the transport of H
+
 ions through ATP synthase, down the 
electrochemical gradient across the inner mitochondrial membrane generated by the other protein 
complexes involved in oxidative phosphorylation. 
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1.4 Mitochondrial DNA 
1.4.1 Human Mitochondrial Genome 
Mitochondrial are unique organelles within eukaryotic cells in that they contain their 
own DNA, separate from the nuclear DNA of the cell – the only other organelles 
containing their own genetic material are chloroplasts (Borst, 1977). This genetic 
material results from the ancestral history of the mitochondria as a free-living 
primitive bacteria-like organism, prior to the symbiosis event with a eukaryotic cell 
(Kurland and Andersson, 2000).  
The mitochondrial genome was first discovered in chick embryos in 1966, later being 
confirmed to exist in chick liver cells (Borst and Ruttenberg, 1966). The mitochondrial 
genome is comprised of double stranded DNA – the two strands being identified as the 
guanine-rich heavy (H) strand and cytosine-rich light (L) stand –  and a short three-
strand region of the genome known as the displacement loop (D-loop) (Kasamats.H et 
al., 1971). In humans, the mitochondrial genome has been confirmed as a circular 
16,569 base pair molecule, with the first complete sequence being published in 1981 
(Anderson et al., 1981b). This sequence - derived from the genetic information from a 
single human, bovine cells and HeLa cells - became known as the Cambridge Reference 
Sequence, though further work which widened the resources used to best sequence 
the mitochondrial genome has led to the formation of the Revised Cambridge 
Reference Sequence (Andrews et al., 1999). 
The mitochondrial DNA is very condensed, with no introns within the DNA and very 
few non-coding regions – the only lengthy non-coding region contains control 
elements for mtDNA transcription and translation (Shadel and Clayton, 1997).  The 
16,569bp human mitochondrial genome encodes thirty-nine genes; 22tRNAs, 2 rRNAs, 
and 13 proteins essential for the respiratory chain and ATP production, including 7 
subunits of complex I (NADH dehydrogenase-ubiquinone oxidoreductase), 1 subunit of 
complex III (ubiquinone cytochrome c oxidoreductase), 3 subunits of complex IV 
(cytochrome c oxidase), and 2 subunits of complex V (ATP synthetase) (Schon et al., 
1997). The remaining proteins required for normal mitochondrial function are encoded 
for by the nuclear DNA, and are imported into the mitochondria from the cytoplasm. 
Many of these protein encoding genes are proposed to have originally been present in 
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the mitochondrial genome, but have since been transferred to the ‘host’ nuclear 
genome during early eukaryote evolution (Sagan, 1967). 
The mitochondrial genome is organised within the cell into structures known as 
nucleoids; stable protein-DNA complexes within the mitochondria, each containing 5-7 
mitochondrial genomes (Gilkerson et al., 2008). Studies of nucleoid dynamics suggest 
these structures to be immobile within the mitochondria, with no interaction between 
individual nucleoids. Investigation into the segregation of mitochondrial DNA (mtDNA) 
between nucleoids was carried out in a cybrid cell line created by the fusion of two 
homoplasmic cell lines carrying non-overlapping mitochondrial DNA deletions. Probes 
specific to each mtDNA deletion type were developed, and used to visualise the 
presence of the two deletion species in nucleoids within the cybrid cell line, but no 
fusion of separate nucleoids or exchange of genomic information was observed 
(Gilkerson et al., 2008). 
Most proteins known to be involved in mtDNA maintenance (including TFAM, POLG, 
mtSSB and TWINKLE) have been found to be contained within the nucleoids (Wang and 
Bogenhagen, 2006; Bogenhagen et al., 2008). A layered model of nucleoid structure 
has been proposed following extensive analysis of the proteins involved in nucleoid 
formation and structure, suggesting that a core central region of the nucleoid is 
responsible for the replication and transcription of the mtDNA, while mtDNA 
translation and assembly of the mitochondrial complexes takes place in a peripheral 
outer region of the nucleoid structure (Bogenhagen et al., 2008). This proposed model 
demonstrates the importance of nucleoid structure to mtDNA replication and 
processing, as indicated by the presence of many mitochondrial DNA maintenance 
proteins, but could also support a previous hypothesis put forward by Capaldi et al 
that nucleoid formation may play an important role in cellular respiration. This 
hypothesis suggests that binding several mtDNA molecules together may facilitate the 
pooling of the peptide products from each genome, supporting efficient assembly of 
the respiratory complexes (Capaldi et al., 2002).  
Chapter One 
24 
 
Figure 1.10 – The mitochondrial genome. 
The mitochondrial genome is comprised of double stranded DNA – the two strands being identified as 
the guanine-rich heavy (H) strand and cytosine-rich light (L) stand – and a short three-strand region of 
the genome known as the displacement loop (D-loop). In humans, the mitochondrial genome has been 
confirmed as a circular 16,569 base pair molecule. The human mitochondrial genome encodes thirty-
nine genes; 22tRNAs, 2 rRNAs, and 13 proteins essential for the respiratory chain and ATP production. 
 
1.4.2 Transcription 
The two major transcription initiation sites in the mitochondrial genome, ITH1 and ITL, 
are both located within the D-loop, within a 150bp region. Surrounding both of these 
initiation site is a promoter with a 15bp consensus sequence, 5′-
CANACC(G)CC(A)AAAGAYA-3’, crucial to transcription. The adenine positioned 7 bases 
from the 3’ end of this promoter sequence represents the transcription initiation site 
(Hixson and Clayton, 1985). ITH1, at nucleotide position 561 within the heavy strand 
promoter, is where the majority of H-strand transcription begins, while L-strand 
transcription begins at nucleotide position 407 at ITL within the light strand promoter. 
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Upstream enhancer elements, including binding sites for mitochondrial transcription 
activator A TFAM, are required for optimal transcription from these sites. A second 
heavy strand site for transcription initiation, ITH2 is located at nucleotide position 638 
in the gene for tRNAPhe, though the promoter for this initiation site shows little 
similarity to the 15bp consensus sequence; this initiation site is less frequently used 
than ITH1 (Chang and Clayton, 1984). 
Mitochondrial RNA polymerase (POLRMT), mitochondrial transcription factors B1 and 
B2 (TFB1M and 2M), and TFAM are all required for successful mitochondrial 
transcription in mammals. POLRMT, a single-subunit RNA polymerase, is responsible 
for the transcription of DNA to RNA, but is unable to initiate transcription without the 
aid of TFAM and one of TFB1M or 2M. Prior to transcription initiation, either TFB1M or 
2M forms a heterodimeric complex with POLRMT; this heterodimer has the capacity to 
recognise mitochondrial promoters, allowing the heterodimer to bind to the mtDNA 
and begin the process of transcription. TFAM, a 25kDa protein containing two High 
Mobility Group (HMG) box domains, is responsible for regulating the activity of the 
POLRMT-TFB1M/2M heterodimers, and hence regulates mtDNA transcription in vitro. 
TFAM binds directly to mtDNA in a sequence-specific manner, upstream of the light 
and heavy-strand promoters. This causes structural alterations to the mtDNA at the 
region, partially unwinding the transcription initiation sites to allow for binding of 
POLRMT-TFB1M/2M (Falkenberg et al., 2007).  
Once transcription of the L-strand has begun, the whole light strand is transcribed as a 
single polycistronic RNA (Aloni and Attardi, 1971). H-strand replication may occur in 
the same way, although an alternative mechanism has been proposed to account for 
the two initiation sites, and the different transcription rates of rRNAs and mRNAs 
encoded on the heavy strand (Gelfand and Attardi, 1981). This ‘dual H-strand 
transcription model’ proposes that most transcription begins at ITH1  and terminates 
just after the 16S rRNA; the model proposes that this is responsible for most of the 
transcription of the 2 rRNA genes contained on the heavy strand, and as this accounts 
for the majority of H-strand replication, this explains the higher rates of rRNA 
transcription seen in HeLa cells (Gelfand and Attardi, 1981). Transcription initiation at 
ITH2, conversely, occurs much less frequently but leads to the transcription of 
polycistronic molecules almost the entire length of the heavy strand, including all of 
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the mRNAs and tRNAs encoded on the heavy strand. Evidence for both heavy chain 
transcripts have been found in vivo, supporting this method of transcription (Gelfand 
and Attardi, 1981).  
Of the three mitochondrial transcripts produced - from transcription beginning at 
HSP2, HSP2, and LSP – the termination site for transcription has only been identified 
for the H1 transcript. This termination site is a tridecamer DNA sequence (5'-
TGGCAGAGCCCGG-3') located at the 3’ end of the 16S rRNA gene (Christianson and 
Clayton, 1988). Termination at this site is dependent upon the binding of 
mitochondrial transcription termination factor (mTERF), a 39kDa protein known to 
bind specifically to a 28-bp sequence at the 3’ end of tRNALeu(UUR) (Falkenberg et al., 
2007). Due to the evidence that mTERF functions bi-directionally, and exhibits 
increased activity during POLRMT transcription of the light strand, it is believed that 
mTERF is key to the termination of transcripts from all three initiation sites (Guja and 
Garcia-Diaz, 2012).  
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Figure 1.11 - mtDNA transcription. 
MtDNA transcription is initiated from three promoters in the D-loop; one of these promoters is on the 
light strand (LSP1), while two are on the heavy strand (HSP1 and HSP2). The light strand of the mtDNA is 
transcribed as a single polycistronic RNA transcript; the heavy strand may also be transcribed this way 
from HSP1, while initiation from HSP2 results in transcription of only 2rRNAs and 2 tRNAs. TFAM is 
responsible for mtDNA transcription, but requires interaction with a POLRMT-TFBM1 or 2 heterodimer 
to initiate transcription. mTERF is responsible for the termination of transcription from all three 
initiation sites. 
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1.4.3 Translation 
Mitochondrial translation displays a number of significant differences from the very 
well-characterised nuclear translation of both eukaryotes and prokaryotes. The most 
distinctive difference is perhaps the divergence in coding; in mitochondria arginine 
codons AGG and AGA serve as markers for termination, while UGA codes for 
tryptophan rather than termination, and AUA codes for methionine as opposed to 
isoleucine (Osawa et al., 1992). The mRNAs also display some unusual characteristics; 
they either do not contain a 5’ untranslated region or it is very small (Montoya et al., 
1981), they are uncapped (Grohmann et al., 1978), and the poly(A)-tail immediately 
follows or even forms part of the stop codon (Ojala et al., 1981). Also unusual is the 
translation mechanism itself, using only 22 tRNAs to translate all codons rather than 31 
(Barrell et al., 1980).  
Mechanistically, mitochondrial translation takes place following the same three steps 
familiar from nuclear translation –initiation, elongation and termination. Mitochondrial 
translation factor IF3 initiates the separation of the two subunits – 28S and 39S – of 
the mitoribosome, before helping correctly orient the mRNA to bind the small subunit 
of the mitoribosome by placing the AUG start codon adjacent to the peptidyl site (P-
site) of the mitoribosome (Liao and Spremulli, 1989). fMet-tRNAMet binds to the 28S 
small subunit with the aid of mitochondrial translation factor IF2 (Ma and Spremulli, 
1996). The two mitoribosome subunits subsequently recombine, causing the 
dissociation of mtIF3 (Haque et al., 2008), while GTP-hydrolysis of mtIF2 stimulates its 
dissociation from the complex (Ma and Spremulli, 1996); elongation can now begin.  
Elongation factor mtEFTu is the main protein involved with the elongation process; 
mtEFTu forms a complex with a molecule of GTP and an aminoacylated tRNA, 
protecting the tRNA from hydrolysis (Nagao and Suzuki, 2007). MtEFTu carries the 
tRNA to the acceptor site (A-site) of the mitoribosome, where codon-anticodon 
recognition causes binding of the tRNA; mtEFTu is released as mtEFTu-GDP following 
the hydrolysis of the GTP molecule in the complex. The 3’ end of the aminoacyl-tRA is 
then moved into the peptidyl transferase centre of the mitoribosome, adding the 
amino acid carried by the tRNA to the peptide being formed; this reaction is catalysed 
conformational changes in the mitoribosome induced by mtEFG1. This also causes 
tRNAs to move along one site within the mitoribosome. After amino transferral, tRNA 
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leaves the mitoribosome via an exit site allowing a new cycle of elongation to begin 
(Van Den Heuvel et al., 2010). 
Termination of the translation process begins when a stop codon binds to the 
mitoribosome. The stop codon is recognised by a mitochondrial release factor 
mtRF1/mtRF1a, causing the protein attached to the last tRNA in the P site to be 
released by hydrolysis of the ester bond between the tRNA and polypeptide. MtRF1 
and mtEFG2 are then responsible for dissociation of all translational components in 
readiness for a new round of synthesis to begin (Van Den Heuvel et al., 2010). 
 
Figure 1.12 - mtDNA translation. 
Schematic representation of the three stages of mtDNA translation - initiation, elongation and 
termination - taken with permission from (Smits et al., 2010).  
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1.4.4 Replication 
Mitochondria use their own unique DNA replication machinery, completely separate 
from that of the nuclear DNA. Each component of this machinery is encoded by the 
nuclear DNA, translated in the cytoplasm and transported into the mitochondria across 
the OMM and IMM (Wanrooij and Falkenberg, 2010). The mitochondrial replication 
machinery is much simpler than that contained in the nucleus, being much more 
closely related to the replication machinery of bacteriophages (Shutt and Gray, 2006). 
Mitochondrial DNA replication has been shown to occur independently of the cell 
cycle; this work was originally carried out in mouse L cells, where mtDNA molecules 
were labelled with 3H-thymidine for two hours prior to incubation with 5-
bromodeoxyuridine after varying time periods. The results following mtDNA isolation 
showed that the mtDNA molecules originally labelled with 3H-thymidine began to 
incorporate 5-bromodeoxyuridine during replication after only 1.5 – 2 hours, 
demonstrating that replication of the mtDNA continues to occur throughout the cell 
cycle (Bogenhagen and Clayton, 1977). 
Mitochondrial DNA replication is carried out by a single DNA polymerase, POLγ. In vitro 
construction of the mitochondrial replication machinery requires only five proteins: 
the DNA polymerase gamma catalytic subunit (POLγA) and processivity subunit 
(POLγB), the DNA helicase TWINKLE, mitochondrial single-stranded DNA-binding 
protein (mtSSB), and mitochondrial RNA polymerase (POLRMT) (Gray and Tai Wai, 
1992). POLRMT is required to initiate replication of the mtDNA, which it does by 
providing a primer at the origin sites. Following this initiation step, mtSSB stimulates 
the helicase activity of TWINKLE, allowing the enzyme to unwind short sections of 
double stranded DNA in a 5’-3’ direction. POLγ and TWINKLE together form the main 
body of the replication machinery, which is capable of using double-stranded DNA to 
synthesise DNA molecules of around 2kb in length. MtSSB also stimulates greater 
exonuclease activity from POLγ, allowing the generation of full mitochondrial genome 
length products (Falkenberg et al., 2007). At the observed replication rate of 180 base 
pairs per minute, a genome would be replicated in ~90 minutes (Korhonen et al., 
2004). 
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Although the mitochondrial replication machinery has been well characterised, the 
mechanism by which replication occurs is still highly debated. Two main models have 
been proposed to characterise mitochondrial DNA replication; the strand a-
synchronous replication model (Robberso.Dl and Clayton, 1972; Clayton, 1982), and 
the coupled leading-lagging strand DNA replication model (Holt et al., 2000). 
 
1.4.4.1 Strand asynchronous model of mtDNA replication 
The strand a-synchronous model of replication, also known as the strand displacement 
model, was considered to be the method of mtDNA replication for decades after being 
originally put forward in 1972. This model, based upon the visualisation of replicating 
mtDNA molecules by electron microscopy, proposes that the leading and lagging 
strands are synthesised asynchronously from their respective origins OH and OL  
(Clayton, 1982), in a manner similar to plasmid replication (Masukata and Tomizawa, 
1990). According to this model, mtDNA replication begins at OH in the only large non-
coding region of the mitochondrial genome, and proceeds uni-directionally in a 
clockwise manner (SEE FIGURE). Replication of the heavy strand of the mtDNA 
progresses until OL is exposed on the heavy strand, allowing light strand replication to 
be initiated in the opposite direction. Both strands of replication are continuous, 
proceeding to completion of two daughter mtDNA molecules; these molecules are 
closed to form circular molecules, and undergo dissociation to form two distinct new 
copies of the genome. This model is characterised by a lack of short Okazaki lagging 
strand fragments,  and the presence of single strand regions in all replicating mtDNA 
molecules (Clayton, 1982).  
 
1.4.4.2 Coupled leading-lagging strand model of mtDNA replication 
The long-held acceptance of the strand asynchronous model of mtDNA replication was 
challenged in 2000 by the emergence of a new model put forward by Holt, Lorimer and 
Jacobs (Holt et al., 2000). As opposed to the microscopy techniques used in the 
development of the strand asynchronous model, the new coupled leading-lagging 
strand model was proposed based upon replication studies using neutral/neutral 2D 
agarose gel electrophoresis (2D-NAGE). 2D-NAGE is used to separate DNA molecules 
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based upon both size and shape, and as such is a useful method by which to analyse 
the quantity and structure of replication intermediates (Brewer and Fangman, 1987; 
Brewer and Fangman, 1988). 2D-NAGE was used to compare replication intermediates 
from two distinct scenarios; cultured human cells undergoing mtDNA amplification due 
to induced mtDNA depletion, and human cells undergoing low levels of mtDNA 
synthesis to maintain mtDNA copy number. Interestingly, different types of replication 
intermediates were observed in these two cell types; this implies that there is more 
than one mode of mtDNA replication which can occur in different cell conditions. 
Partially single-stranded replication intermediates were observed where DNA synthesis 
was exclusively responsible for mtDNA maintenance, in keeping with Clayton’s 
asynchronous strand replication model, but where large levels of mtDNA amplification 
was necessary the replication intermediates observed were double stranded. These 
double-stranded intermediates were proposed to be the product of leading-lagging 
strand replication, suggesting that amplification of high levels of mtDNA are carried 
out by a similar mode of replication to that of nuclear DNA (Holt et al., 2000). 
As in the asynchronous model of replication, DNA synthesis is believed to be initiated 
at OH in coupled strand mtDNA replication. Again, the synthesis of the leading strand 
proceeds in a clockwise direction around the genome. Shortly after synthesis of the 
heavy strand begins, replication of the light lagging strand begins in the opposite 
direction. Short sections of the light strand known as Okazaki fragments are generated 
as sections of the heavy strand become displaced – these fragments must be ligated to 
form a complete DNA strand. Two daughter molecules are produced by this method of 
replication, but as light strand synthesis begins much closer to the initiation of heavy 
strand synthesis than in asynchronous replication, all observed replication 
intermediates are double stranded (Holt et al., 2000). 
Additional to the coupled strand replication model, it has since been proposed that the 
lagging strand fragments generated during replication are initially composed of RNA – 
this is known as the RITOLS model (RNA incorporation throughout the lagging strand) 
(Yasukawa et al., 2006). These RNA intermediates are later converted to DNA, starting 
at defined loci including the OL. This model is based upon 2D-NAGE evidence that 
mtDNA replication intermediates often contain RNA as well as DNA. The RITOLS model 
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is in all other ways consistent with the coupled strand model of replication (Yasukawa 
et al., 2006). 
 
Figure 1.13 - mtDNA replication machinery. 
The mtDNA replication machinery is made up of five proteins; the DNA polymerase gamma catalytic 
subunit (POLγA) and processivity subunit (POLγB), the DNA helicase TWINKLE, mitochondrial single-
stranded DNA-binding protein (mtSSB), and mitochondrial RNA polymerase (POLRMT). POLRMT initiates 
replication, while mtSSB stimulates the helicase activity of TWINKLE, allowing the enzyme to unwind 
short sections of double stranded DNA in a 5’-3’ direction. POLγ and TWINKLE together form the main 
body of the replication machinery, which uses double stranded DNA as a template to synthesise 
daughter DNA.  
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Figure 1.14 – Two proposed mtDNA replication models. 
Both proposed models of mtDNA replication begin with strand displacement of the mtDNA beginning at 
the origin of heavy strand replication (OH), but the models diverge from this point.  
a) Strand asynchronous replication 
Replication begins at the OH, proceeding until the origin of light chain replication, OL, is exposed. From 
this point, replication commences in the other direction, with replication of both strands continuing to 
completion. 
b) Coupled leading-lagging strand replication 
Replication also begins from OH, but replication of the light strand begins soon after this initiation event. 
Sections of the light strand known as Okazaki fragments are generated as sections of the heavy strand 
become displaced – these fragments must be ligated to form a complete DNA strand. 
 
 
 
 
 
 
Chapter One 
35 
1.4.5 Mitochondrial DNA Repair 
Mitochondria were long believed to have no mechanism of DNA repair, following 
evidence presented in 1974 that no pyrimidine dimer repair mechanism existed in 
mammalian mitochondria (Clayton et al., 1974). However, later worked showed that 
mitochondria were indeed capable of repairing some types of DNA damage, despite 
having no mechanism for the removal of large DNA lesions (Bogenhagen, 1999). The 
first evidence of mtDNA repair was put forward in 1991, showing that DNA lesions 
formed by exposure to an alkylating antibiotic, streptozotocin (Pettepher et al., 1991). 
Soon after this, a study carried out in Chinese hamster ovary cells compared repair of a 
variety of DNA lesions in nuclear and mitochondrial DNA, conclusively showing that the 
capacity for repair of mtDNA is lesion type dependant (LeDoux et al., 1992). As well as 
being lesion-specific, mtDNA repair also seems to be cell type dependant, being much 
less effective in certain cell types such as glia and neurons (LeDoux et al., 1999). 
Base excision repair (BER) has been confirmed to occur in mitochondria in a very 
similar fashion to BER in the nucleus, to repair alkylation and oxidative DNA lesions, 
although the mitochondria do have BER machinery independent to that of the nucleus. 
Most importantly, BER is used to repair damage caused by reactive oxygen species 
(ROS), including 8-oxoguanine (8-oxoG) and thymine glycol (TG) lesions. BER is initiated 
by DNA glycosylases, which recognises and removes the damaged base by cleaving the 
N-glycolytic bond, leaving behind an abasic (AP) site. The lysate activity of the 
glycosylase then creates a single strand break 3’ to the AP site, and an apurinic or 
apyramidic endonuclease cleaves the phosphodiester backbone of the DNA 5’ to the 
AP site; together these activities cause excision of the single baseless sugar, creating a 
gap in the DNA. POLγ is recruited to fill the space left by the base excision mechanism, 
before the final step of repair – the ligation of the new base into the DNA by DNA 
ligase III – is carried out.  (Bohr, 2002).  
While BER is now relatively well characterised in mitochondria, other repair 
mechanisms are still undergoing study. Mismatch repair has been clearly identified in 
yeast (Reenan and Kolodner, 1992), but has yet to be identified in eukaryotic cells. The 
ability of mitochondria to repair mtDNA cross-linking by recombinational repair is an 
area of heated debate, with much contradictory evidence having been put forward 
regarding its existence. Recombination intermediates thought to be formed by 
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homologous recombination have been identified in Kearns-Sayre syndrome (KSS) and 
chronic external ophthalmoplegia (CPEO) patients (Poulton et al., 1993) and in vitro 
studies have provided some evidence for the presence of homologous recombination 
activity in mammalian mitochondrial extracts (Thyagarajan et al., 1996). However, no 
evidence of homologous recombination has been found in cell lines taken from 
patients with KSS or CPEO, where homologous recombination is thought to occur 
(Poulton et al., 1993). Finally, while it has been conclusively shown that no nucleotide 
excision repair (NER) occurs to remove UV-induced pyrimidine dimers from mtDNA 
(Clayton et al., 1974), evidence has emerged to support the involvement of NER in 
removing 4NQO (Snyderwine and Bohr, 1992) and possibly interstrand (but not 
intrastrand) cisplatin adducts (LeDoux et al., 1992).  
 
1.5 mtDNA Mutations 
The mitochondrial genome is known to be very prone to mutagenesis, with a mutation 
rate approximately ten times that of nuclear DNA (Brown et al., 1979). This high 
mutation rate can be contributed to a combination of factors, but is often primarily 
associated with the close proximity of mtDNA and the respiratory complexes within 
the mitochondria. mtDNA is therefore highly exposed to reactive oxygen species (ROS) 
such as superoxide (O2
-) produced during OXPHOS, which are highly mutagenic. The 
high level of ROS exposure is made more problematic by the lack of protective histones 
in mtDNA – the naked DNA is much more susceptible to mutation. 
A secondary probable cause of the high mutation rate of mtDNA is the accuracy of the 
mitochondrial DNA polymerase – POLγ is has been shown to have a much lower level 
of accuracy than its nuclear counterpart polymerase α (Kunkel and Loeb, 1981). This 
issue of lower polymerase fidelity is compounded by a high rate of turnover of mtDNA 
compared to nuclear DNA (Rabinowi.M and Swift, 1970).  
The issues associated with a high mutation rate are exacerbated by the gene-dense 
nature of the mtDNA (as discussed in section 1.4.1), which means that any mtDNA 
mutation is highly likely to occur within a coding region of the genome and so has a 
high probability of becoming pathogenic. 
Chapter One 
37 
1.5.1 Point mutations 
Point mutations in DNA are the substitution of one base pair for another in the genetic 
code. Point mutations in tRNA genes are the most common mitochondrial defects, 
with over 50% of mitochondrial disease cases with a known genetic defect  accounted 
for by this mutation type (Schaefer et al., 2008). Point mutations in mtDNA can be 
harmless or pathogenic, depending upon where in a three-base amino acid codon they 
fall; if an amino acid change is caused – known as a non-synonymous base change - 
downstream disruption in the production of the gene’s encoded protein is caused, and 
the mutation becomes pathogenic. Non-pathogenic point mutations occur in 
unconserved base positions – if no gene disruption is caused by the base change, no 
further effects are caused by the point mutation – known as a synonymous base 
change. Due to the complexity of determining how a point mutation will affect the 
protein product of the gene that the mutation has arisen in, scoring systems have been 
proposed to determine the likely pathogenicity of newly discovered point mutations, 
to aid in diagnosis of mitochondrial disease and predicting patient outcome (Montoya 
et al., 2009; Yarham et al., 2012).  
Pathogenic point mutations are known to cause mitochondrial encephalomyopathy, 
lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red 
fibres (MERRF), Leigh syndrome, and Leber’s hereditary optic neuropathy (LHON) (Wu 
et al., 2010). The first identified pathogenic point mutation was the m.11778G>A 
modification – this base change in codon 340 in the ND4 gene changes a highly 
conserved amino acid (converting an arginine to a histidine), and was associated with 
LHON. This finding, as well as demonstrating that mtDNA mutations could be 
pathogenic, created a Diagnostic test for LHON, as the m.11778G>A mutation knocks 
out an Sfa NI restriction site (Wallace et al., 1988). 
The most common, and hence best characterised point mutations are the 8344 A to G 
substitution in the tRNALys gene, and the 3243 A to G substitution in the tRNALeu gene 
in the mitochondrial genome – which has been estimated to have a carrier rate of 1 in 
400 in the general population (Manwaring et al., 2007). The m.8344A>G point 
mutation is known to cause 80 -90% of all known cases of MERRF, a mitochondrial 
disease characterised by muscle weakness and exercise intolerance, myoclonic 
twitches, cerebellar ataxia, heart conduction block, deafness and dementia (Wu et al., 
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2010). Studies conducted in skin fibroblasts have shown a strong correlation between 
m.8344A>G and reduced function of Complex I and IV of the OXPHOS chain, meaning a 
much lower ATP-production in individuals with this mutation and hence organ 
dysfunction where tissues have a high energy demand (James et al., 1996). More 
recent studies have shown, by microarray comparison of DNA expression in MERRF 
patients and age matched controls, the up-regulation of ~350 genes and the down-
regulation of ~300 more in MERRF patients (Ma et al., 2005). 
The m.3243A>G transition is the mutation most commonly associated with MELAS, 
accounting for ~80% of all MELAS cases (Urata et al., 2004), though patients with this 
mutation can present at different ages with an array of phenotypes ranging from 
MELAS to other multisystem syndromes (maternally inherited deafness and diabetes 
(MIDD), progressive external ophthalmoplegia (PEO), and Leigh syndrome ) or isolated 
symptoms such as myopathy, cardiomyopathy, seizures, migraine, ataxia, cognitive 
impairment, bowel dysmotility or short stature. (Manwaring et al., 2007; Nesbitt et al., 
2013). It is thought that severity of disease presentation with the m.3243A>G point 
mutation is dependent upon heteroplasmy levels – the highest percentages of 
mutation causing the most severe disease phenotypes, and vice versa (Koga et al., 
2000).  
Point mutations, as well as being inherited, occur naturally within the cell with 
progressing age. A fibroblast study found high copy numbers of point mutations are in 
the control region (D-loop) of mtDNA in older individuals, with some high copy number 
point mutations not present at all in younger individuals, even at low level. Of 
particular interest was the study of the T414G transversion, present in no younger 
individuals, but with a heteroplasmy level of over 50% in 8/14 aging controls over 65 
years of age (Michikawa et al., 1999). 
 
1.5.2 Large-scale Duplications 
Large-scale duplications have been found to occur in mtDNA but there is some 
uncertainty over their pathogenicity. Duplications have been identified in some cases 
of sporadic Kearns-Sayre syndrome (KSS), though not as frequently as mtDNA 
deletions. KSS is a mitochondrial disease with an age of onset below 20, with a 
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presentation of chronic progressive external ophthalmoplegia (CPEO) and pigmentary 
retinopathy, with additional symptoms including cerebellar ataxia, cardiac conduction 
block hearing loss, endocrinopathies, muscle weakness and renal tube dysfunction. 
Duplicated mtDNA molecules can be found in tandem with deleted molecules, and 
these are structurally related (i.e. the duplicated mtDNA could be viewed as a wild-
type mtDNA molecule into which a deleted mtDNA genome has been inserted). It is 
possible that a sizable number of KSS patients thought only to have mtDNA deletion 
may contain the equivalent duplicated mtDNA also, as duplications are detectable only 
by Southern blot and PCR specifically designed to amplify a duplication and these are 
not routine tests. (Schon et al., 1997)    
It is not currently clear whether duplications are pathogenic as no genes are missing in 
mtDNA molecules with duplicated sections, though it is possible that by duplicating 
only some genes, unbalanced levels of tRNA could affect turnover or translation as a 
whole. Alternatively, the expression of a fusion gene created by insertion of a 
duplicated section of the mitochondrial genome could be included into the respiratory 
complexes, having a detrimental effect on OXPHOS function. (Schon et al., 1997) 
Duplications have also been proposed to exist as an intermediate step in the formation 
of mtDNA deletions (Poulton et al., 1993). This hypothesis was proposed following a 
molecular study carried out on three patients with KSS and diabetes mellitus or 
hypoparathyroidism who had previously been identified as carrying identified mtDNA 
duplications. Upon investigation, four mtDNA types were found to be present in each 
of these patients; one of these represents the wildtype DNA, while the remaining three 
were rearranged mtDNA forms. Of these three rearrangements, a large molecule was 
identified as carrying the previously characterised duplication in each patient, while 
two other molecule types represented an mtDNA deletion monomer and dimer. In 
each case, the deletion breakpoints were found to correspond to the junction regions 
of the duplication. In muscle sections taken ten years apart, a noticeable drop in 
duplication levels and rise in deletion monomer and dimer levels was found; this final 
piece of evidence led to the proposal that the two deletion rearrangement types arose 
from an original duplication rearrangement (Poulton et al., 1993). 
 
Chapter One 
40 
 
Figure 1.15 - Mitochondrial DNA duplications as a precursor to mtDNA deletions and further 
rearrangements. 
A molecular study carried out on three mitochondrial disease patients, each carrying four mtDNA types - 
one representing the wildtype DNA, and three rearranged mtDNA forms comprised of an mtDNA 
duplication as well as a deletion monomer and dimer – found that in each patient the deletion 
breakpoints were found to correspond to the junction regions of the duplication. This led to the 
proposal that mtDNA duplications exist as a precursor to mtDNA deletions and further rearrangements, 
following the scheme depicted above. 
 
1.5.3 Large-scale Deletions 
Large-scale deletions occur when a portion of the mitochondrial genome is lost, 
causing the loss of protein-encoding genes. These re-arrangements have been 
documented to be disease causing for many years, with the first evidence of mtDNA 
deletion pathogenicity coming to light in 1988 (Holt et al., 1988). Deletions most often 
occur within the major arc of the mitochondrial genome, between the light and heavy 
strand origins of replication and are usually - in approximately 85% of cases - flanked 
by short repeat regions (Bua et al., 2006) (Samuels et al., 2004). The highest levels of 
mtDNA deletions are often seen in post-mitotic tissues, including neurons and muscle 
fibres, in cases of mitochondrial disease and in aging individuals (Wang et al., 1997); 
this accounts for the predominant neuromuscular symptoms of mitochondrial disease, 
and the onset of sarcopenia and neurodegeneration with progressing age. The size of 
mtDNA deletions, occurrence of repeat regions and length of repeats appears to be 
unrelated to disease type, with no significant differences found between neurons from 
individuals with Parkinson’s disease or multiple mtDNA deletion disorders, or indeed 
from aging brain, suggesting the same mechanism for mtDNA  deletion formation 
occurs in all cases (Reeve et al., 2008a). 
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Figure 1.16 - Location of mtDNA deletions within the mitochondrial genome. 
The majority of mtDNA deletions have been found to lie within the so-called ‘major arc’ of the 
mitochondrial genome, between the heavy and light strand origins of replication as depicted above (A). 
Example B depicts the 13bp direct repeat, typical of the 4977bp common deletion. 
 
 
 
 
 
 
A 
B 
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1.5.4 Mitochondrial DNA Deletions, Disease and Aging 
Large-scale deletions within mitochondrial DNA are a primary cause of mitochondrial 
disease, accounting for ~18% of all mitochondrial disease cases (Schaefer et al., 2008). 
However, the group of patients presenting with mitochondrial disease caused by 
mtDNA deletions is highly heterogeneous; mtDNA deletion patients display a large 
spectrum of phenotypes and disease severities, but can broadly be separated into two 
major categories. One group of patients present with sporadic single mtDNA deletions; 
in these cases,  a single mitochondrial DNA deletion is present in all affected cells 
throughout the tissues of a patient causing a disease phenotype (Schaefer et al., 2008).  
A second group of patients present with multiple mtDNA deletions, due to a primary 
defect in a nuclear gene involved in mtDNA maintenance. Nuclear genes involved in 
mtDNA maintenance include those for mitochondrial DNA replication and repair, or 
mitochondrial nucleotide metabolism; a prime example of this is seen in patients with 
defects in the POLG or POLG2 nuclear genes, which encode the single mitochondrial 
polymerase used in mtDNA replication (Hudson and Chinnery, 2006). In this patient 
group, multiple mtDNA deletions are seen in all affected cells, particularly in the post-
mitotic muscle and CNS system tissues.  
Patients presenting  with multiple mtDNA  deletions often present with CPEO, while 
sporadic single mtDNA deletions are primarily responsible for KSS (as outlined for 
duplications), CPEO and Pearson’s syndrome, an early-onset disorder presenting with 
pancreatic dysfunction and anaemia (Schon et al., 1997). Few patients survive 
Pearson’s syndrome; those who do go on to develop KSS (McShane et al., 1991). With 
a high enough level of heteroplasmy, mtDNA deletions can go on to be responsible for 
two scenarios in which the cell’s respiratory function is altered. The deleted region 
itself may be the cause of the mutant cellular phenotype (i.e. too few copies of a 
protein-encoding gene may prevent one of the respiratory complexes being formed 
correctly), or alternatively none of the polypeptide-encoding mRNAs may be translated 
if an essential tRNA gene is located within the deleted genome region. (Nakase et al., 
1990b; Hayashi et al., 1991). 
MtDNA deletions are found in aged post-mitotic tissues in normal ageing and in 
patients with neurodegenerative diseases as well as in cases of mitochondrial disease, 
however the mtDNA deletion levels are often much lower (Bender et al., 2006; 
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Kraytsberg et al., 2006). Until a 2006 study of the substantia nigra, mtDNA deletions 
identified in aging and neurodegeneration were only detected at low levels, and 
certainly not approaching a heteroplasmy threshold level that could cause clinical 
significance (Cortopassi and Arnheim, 1990). However, two independent studies 
carried out in 2006 shed new light on the accumulation of mtDNA deletions in aging.  
In one study, carried out by Bender et al, COX-normal neurons of patients with 
Parkinson disease and age matched controls were found to contain high levels of 
mtDNA deletions (an average of 52.3% and 43.3% respectively). As a comparison, COX-
normal neurons of the hippocampus from the same experimental subjects were 
investigated, but similarly high levels of mtDNA deletion were not found (17.8% and 
14.3% respectively) (Bender et al., 2006). In substantia nigra COX-deficient neurons of 
aged controls, the mutation load was measured at 66.9% (compared to 47.7% in 
normal neurons), demonstrating that the COX-deficiency is due to increased mtDNA 
deletion levels. The results of this study led the authors to propose that high levels of 
neuronal loss in the substantia nigra with age (Fearnley and Lees, 1991) are due to the 
levels of deleted mtDNA within the neurons – this being much higher than in other 
investigated areas of the brain – and the resultant respiratory deficiency (Bender et al., 
2006).  
A similar study carried out independently by Kraytsberg et al in Boston showed very 
similar results to those obtained by Bender et al, confirming a high level of mtDNA 
deletion in neurons of the substantia nigra (Kraytsberg et al., 2006). These 
observations of high mtDNA deletion levels in substantia nigra neurons were very 
much in keeping with a previous study carried out in 2004 by Trifunovic et al, where 
real-time PCR investigations revealed a linear increase of mtDNA deletion levels in the 
substantia nigra with age, in a similar manner to increasing mutation load over time in 
an animal model of aging (Trifunovic et al., 2004). This has led to speculation that, as 
well as respiratory dysfunction, the accumulation of mitochondrial DNA deletions may 
influence cell loss, primarily of muscle fibres, and neurons from the substantia nigra 
(Bender et al., 2006; Herbst et al., 2007). 
Fibre loss can be as pronounced in muscle as neuronal loss in the substantia nigra with 
age - loss of muscle fibres and fibre atrophy are major contributing factors to the loss 
of muscle seen in aging adults and in sarcopenia (Evans, 1997), while muscle weakness 
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and atrophy are major clinical features seen in mitochondrial disease. MtDNA 
deletions were strongly linked to fibre loss by single fibre analysis in a study of aged rat 
muscle, comparing mitochondrial genotype to cellular phenotype (Herbst et al., 2007). 
COX-deficient fibre areas were identified by histochemistry, with a selection of fibres 
containing respiratory abnormal areas being shown to display normal morphology, 
atrophy or fibre splitting. Subsequent analysis of mtDNA by breakpoint and real-time 
PCR analysis of mtDNA deletion  level in multiple areas of each fibre showed the 
broken ends of atrophic fibres to have the highest measured levels of mtDNA 
deletions, 3x105 mutant genomes, with a strong COX-deficient phenotype (Herbst et 
al., 2007). Also, even in areas where fibre splitting did not overlap with COX-deficiency 
in fibres, deletion levels were higher in split fibre areas - though not high enough to 
cause COX-deficiency. It is postulated that fibre splitting may be a precursor to fibre 
atrophy as mtDNA deletion levels rise (Herbst et al., 2007). In conjunction with 
previous studies showing 25% of COX-deficient fibres to be associated with fibre 
atrophy and 7% with fibre breakage (Wanagat et al., 2001), these results implicate 
expansion of mtDNA deletions as the cause of fibre dysfunction and atrophy. 
 
1.5.5 Common mtDNA deletions 
In the majority of cases, the breakpoints of the mtDNA deletions found to be disease-
causing in single mtDNA deletion patients are unique to each patient; however, there 
are exceptions to this trend. There are two mtDNA deletion types seen relatively often, 
the most prominent being the 4977bp ‘common deletion’ which removes 6 protein 
encoding genes and five genes for tRNAs between nucleotides 8470 and 13447, with 
13bp sequence repeats on either side of the breakpoint. The common deletion is 
estimated to occur in ~25% of single mtDNA deletion patients, and ~33% of KSS 
patients, as well as commonly accumulating with age (Taylor, 2005). Another 
commonly occurring mutation often found in CPEO and KSS patients is the larger 
7435bp deletion, which occurs between nucleotides 8649 and 16084 of the 
mitochondrial genome removing genes from ATPase6 to tRNA proline (Taylor 2005). 
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1.5.6 Mitochondrial DNA Deletion Formation 
Mitochondrial DNA deletions are very well characterised in terms of deletion location 
and pathogenicity, but the mechanism by which these deletions arise is still unknown. 
Two main methods have been proposed to be involved in the formation of mtDNA 
deletions, with replication being the most long-standing and widely accepted 
hypothetical model. The ‘slipped-strand’ replication mechanism of mtDNA deletion 
formation relies upon replication occurring by a strand-asynchronous mechanism (see 
1.4.4.1), with a slipped strand between two direct repeats during replication causing 
the loss of a large section of the genome (Shoffner et al., 1989).   If strand slippage 
were to occur between two direct repeats, the displaced single stranded light strand 
DNA could misalign so that the 3’ repeat of the light strand would anneal to the 5’ 
repeat of the heavy strand. This would cause a single stranded loop to form 
downstream in the light chain, susceptible to strand breaks and so damaged and 
degraded, forming the mtDNA deletion in the light strand. Replication continues from 
here, creating a mtDNA wildtype molecule from the undamaged heavy chain and a 
deleted mtDNA molecule type from the light chain, where part of the genome was 
degraded during replication (Shoffner et al., 1989). 
Concerns have been raised about the replicative mechanism for mtDNA deletion 
formation, such as the need for mtDNA to be replicating at the point that the 3’ and 5’ 
repeats anneal to form a single strand loop that can be degraded (Krishnan et al., 
2008). However, the biggest question mark left hanging over the replicative 
mechanism is mitochondrial turnover; in both diseased tissue and aged controls, some 
of the highest mtDNA deletions levels are seen in post-mitotic tissues such as muscle 
and the CNS where the rate of turnover is thought to be very low (Wang et al., 1997). If 
deletions do occur during replication, it would be expected that mtDNA deletion levels 
would be higher in cells with a rapid mitochondrial turnover where there would be a 
greater chance of an mtDNA deletion occurring. A study to this effect was carried out 
on human colonic tissue, but though no suggestion was found of selection against 
deleted mtDNA molecules in these rapidly dividing cells, no deleted molecules have 
been detected in this tissue (Taylor et al., 2003). The high turnover of mitochondria in 
these cells with no evidence of deleted mtDNA molecules, and the high mtDNA 
deletion levels in post-mitotic tissue, would suggest that a mechanism other than 
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replication may be responsible for the formation of mtDNA deletions in human tissues 
(Krishnan et al., 2008). 
Such a mechanism was proposed by Krishnan et al in 2008, suggesting that mtDNA 
deletions may be formed during repair of damaged mtDNA molecules. This mechanism 
proposes that double stranded breaks occurring between direct repeats are 
responsible for mtDNA deletion generation; the DNA on either side of the break is 
susceptible to 3’ to 5’ exonuclease activity, creating single stranded DNA on either side 
of the break (Krishnan et al., 2008). The single strands then anneal, the 3’ repeat on 
one strand annealing to the 5’ repeat of the other strand; the unbound single strands 
are then degraded, leaving an mtDNA molecule with a large deletion (Haber, 2000). 
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1.6 Mitochondrial DNA copy number 
1.6.1 Copy number regulation 
Studies of mouse and of human cells in vitro have shown that most cells contain 1000 
– 5000 copies of the mitochondrial genome; this number is made up from the multiple 
copies of mtDNA in each of the hundreds of mitochondria present in most cell types 
(Bogenhagen and Clayton, 1974; Shmookler Reis and Goldstein, 1983). Interestingly, 
control of mtDNA copy number seems to be regulated by total mtDNA mass within the 
cell rather than genome copy, as first proposed by Tang et al in 2000 (Tang et al., 
2000a). This group carried out an analysis of mtDNA copy number in cybrids created by 
the fusion of ρ0 cells (human cells lacking in mtDNA) and cytoplasts derived from KSS 
patient fibroblasts with 10% duplicated mtDNA, 20% deleted mtDNA and 70% wild 
type mtDNA. 27 resultant clones contained a mixture of wild type and rearranged 
mtDNA; ethidium bromide treatment was used to generate 3 cell lines which were 
homoplasmic for wild type mtDNA, deleted mtDNA or duplicated mtDNA. The mtDNA 
mass was found to be identical in each of these three cell lines, despite the presence of 
different numbers of replication origins and large variances in genome size in each cell 
line (Tang et al., 2000a). 
Though it seems clear from this evidence that mtDNA regulation occurs via control of 
total mtDNA mass, the actual mechanism for mtDNA copy number regulation remains 
unknown. Following their discovery that a constant total mtDNA mass seems to be 
maintained within the cell, rather than a specific number of mtDNA copies, Tang et al 
hypothesised that copy number may be regulated by controlling the size of the 
mitochondrial dNTP pools (Tang et al., 2000a). However, a number of other 
hypotheses have also been proposed to explain mtDNA copy number regulation (Clay 
Montier et al., 2009). These proposed mechanisms include regulation of mtDNA copy 
number by number of replication origins, where genomes with multiple replication 
origins are preferentially amplified regardless of molecule size (Tang et al., 2000b); 
TFAM mediated copy number control, where the mode of mtDNA replication can be 
influenced by TFAM to change mtDNA copy number, as evidenced by mtDNA depletion 
in instances of TFAM knockdown (Pohjoismaki et al., 2006). Although no data has been 
put forward to support this model, another widely accepted model is that the current 
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ATP requirements of a cell can influence the mtDNA copy number (Clay Montier et al., 
2009). 
 
1.6.2  Mitochondrial DNA Heteroplasmy, Homoplasmy and Threshold 
Due to the multi-copy nature of mtDNA in all cells with mitochondria, the mtDNA is 
able to exist in a number of states with regards to the presence of mutations. In 
healthy cells which harbour no mtDNA mutations, the mitochondrial DNA exists in a 
state where each copy is wildtype –each mtDNA molecule is therefore identical, and 
this state is known as homoplasmy. When mutations of the mtDNA do occur, if the 
mutation affects each copy of the genome within the cell, this too is known as 
homoplasmy – so a cell can be wildtype homoplasmic (0% mutation level) or mutant 
homoplasmic (100% mutation level). If a mutation co-exists within a cell with copies of 
wildtype DNA – as was observed with the first finding of a mitochondrial DNA mutation 
(Holt et al., 1988) – the cell is known as heteroplasmic. Heteroplasmy can refer to any 
level of mutation above 0% and below 100%, and also includes scenarios where more 
than one mtDNA mutation is present within a single cell (Figure 1.18).  
 
Figure 1.18 - Heteroplasmy and homoplasmy of mitochondria in single cells. 
Cells containing mitochondria may be homoplasmic in two distinct scenarios, containing 100% wildtype 
or mutant mtDNA, or may be heteroplasmic, containing a mixture of wildtype and mutated mtDNA. 
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The potential for mitochondrial DNA mutations to exist in a heteroplasmic state gives 
rise to the mitochondrial ‘threshold effect’ (Rossignol et al., 2004). Low level 
heteroplasmy, particularly in cases where mtDNA deletion heteroplasmy is so low as to 
be undetectable, does not affect the cell’s phenotype due to the compensatory effect 
of the remaining wild-type molecules functioning normally within the cell. To affect the 
cell’s respiratory chain function a significant level of mtDNA heteroplasmy must be 
established within the cell; i.e. the balance of mutant and wildtype mitochondrial DNA 
molecules must shift significantly in favour of the deleted genome type. The 
‘phenotypic threshold level’ is the point at which the mtDNA mutation can no longer 
be compensated for by the remaining wildtype DNA, causing a functional defect and 
respiratory deficiency of the cell (Rossignol et al., 2004).  
The threshold level at which a biochemical defect is caused in the cell varies between 
different tissues and different mutation types. Mitochondrial DNA deletions in muscle 
have been reported to have phenotypic threshold values varying from 50% (Porteous 
et al., 1998) to 90% (Sciacco et al., 1994), though the average threshold level for 
mtDNA deletions has been determined to be approximately 60% (Hayashi et al., 1991) 
(Figure 1.19). Point mutations of mtDNA show huge variations in phenotypic threshold 
level between mutation types; the tRNALys 8344 A to G substitution associated with 
MERRF has been shown to have a very high threshold level, as high as 97% in muscle 
fibres in some patients (Moslemi et al., 1997), while other point mutations such as the 
3243 A to G substitution show much lower phenotypic threshold levels – a mutation 
load above 50% was shown to be associated with abnormal VO2 max and muscle 
morphology, while mutation loads of 65% or higher were also associated with 
symptoms in other tissues, such as diabetes mellitus and hearing impairment 
(Jeppesen et al., 2006).  
Following the proposal of the phenotypic threshold effect (Howell et al., 1983) two 
further mitochondrial threshold limits have been proposed; a biochemical threshold 
level, and a translational threshold level. The biochemical threshold limit is the level to 
which a single mitochondrial complex can be inhibited or decreased before a decrease 
is total respiratory activity of the cell is observed. This was initially observed in relation 
to cytochrome c oxidase (Complex IV) (Letellier et al., 1994), but has since been 
investigated in other mitochondrial proteins and complexes; biochemical threshold 
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levels have been found for respiratory Complexes I, III and IV as well as the adenine 
nucleotide translocator, phosphate carrier and pyruvate carrier (Rossignol et al., 2004). 
A translational threshold effect is observed when a threshold percentage of mutant 
mRNA or tRNA is exceeded, causing a decrease in the rate of mitochondrial protein 
synthesis.  This translational threshold can be reached by increased RNA instability, 
meaning insufficient total RNA amounts are maintained within the mitochondria. 
Secondarily, the level of mtDNA mutation may rise to such a level that sufficient 
wildtype RNA cannot be produced to meet cellular requirements (Helm et al., 1999). 
 
 
Figure 1.19 - Threshold of mitochondrial mutations 
The potential for mitochondrial DNA mutations to exist in a heteroplasmic state gives rise to the 
mitochondrial threshold effect. Low levels of heteroplasmy can be tolerated within a cell due to 
wildtype compensation, but increasing levels of heteroplasmy can lead to reduced mitochondrial 
enzyme activity. As heteroplasmy levels rise, more mitochondria contain a level of mutant DNA 
incompatible with normal mitochondrial function, and insufficient ATP is produced for normal cellular 
function. The threshold level, which varies between different mutations and tissue types, is the point at 
which the mtDNA mutation can no longer be compensated for by the remaining wildtype DNA, causing a 
functional defect and respiratory deficiency of the cell. 
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Interestingly, it has been shown that mtDNA mutation heteroplasmy levels alone may 
not account for the severity of patient phenotypes, with no direct correlation between 
patient phenotype and genotype having been found (Morgan-Hughes et al., 1995; 
Chinnery et al., 2001). Not only is there no link between disease severity and mutation 
load, but identical mutations can cause vastly different patient phenotypes – the 
common deletion, for example, is present is a spectrum of patients with mtDNA 
deletion disorders ranging from PEO and KSS through to the much more severe 
Pearson’s syndrome in children (Bernes et al., 1993) – and mutations present 
homoplasmically in all tissues may still phenotypically present in a tissue-specific 
manner (Fischel-Ghodsian, 2000).  
1.7 Clonal Expansion 
Mitochondrial DNA mutations only become detrimental to the cell once a specific 
mutation threshold level has been passed (see 1.6.2); a mutation must originally be 
formed in only a single mtDNA molecule, and so this mutation must accumulate within 
the cell in order to reach a detrimental level. This increase in mutant mtDNA 
heteroplasmy over time, and the associated decline in mitochondrial function, was first 
proposed to be a major cause of mitochondrial disease and human aging in 1989 
(Linnane et al., 1989). This ‘ageing mitochondria’ hypothesis was supported by 
experimental evidence that mitochondrial respiratory activity declined with  age 
(Trounce et al., 1989). Originally, the accumulation of mutant mtDNA with time was 
attributed to high mutation levels of mtDNA paired with a perceived lack of mtDNA 
repair mechanisms (Linnane et al., 1989), but later evidence of mitochondrial DNA 
repair mechanisms (see 
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Figure 1.14 – Two proposed mtDNA replication models. 
Both proposed models of mtDNA replication begin with strand displacement of the mtDNA beginning at 
the origin of heavy strand replication (OH), but the models diverge from this point.  
c) Strand asynchronous replication 
Replication begins at the OH, proceeding until the origin of light chain replication, OL, is exposed. From 
this point, replication commences in the other direction, with replication of both strands continuing to 
completion. 
d) Coupled leading-lagging strand replication 
Replication also begins from OH, but replication of the light strand begins soon after this initiation 
event. Sections of the light strand known as Okazaki fragments are generated as sections of the heavy 
strand become displaced – these fragments must be ligated to form a complete DNA strand. 
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1.4.5 Mitochondrial DNA Repair) is in strong opposition to this hypothesis. Since this 
first proposal of mutant mtDNA accumulation contributing to disease and aging, much 
work has been carried out in this field to try to understand how a single point mutation 
or mtDNA deletion could accumulate within the cell to cause pathology. This process 
of increasing heteroplasmy levels of a specific mutation has become known as clonal 
expansion.  
For a considerable period of time, the only evidence of clonal expansion was found for 
mtDNA deletions. In the same year that Linnane et al first proposed the importance of 
the accumulation of mtDNA mutations, research began to show that at the cellular 
level, high deletion heteroplasmy levels were associated specifically with areas of 
muscle fibres showing evidence of respiratory deficiency in mitochondrial disease – 
specifically KSS in this first study (Mita et al., 1989). More recent work has successfully 
linked the accumulation of mtDNA deletions to human aging  - PCR amplification of 
whole mitochondrial genomes from single cells has shown high levels of single mtDNA 
deletions in individual cardiomyocytes, with each different cell carrying a different 
deletion (Khrapko et al., 1999), while high levels of mtDNA deletions have been found 
in substantia nigra neurons in aged subjects (Trifunovic et al., 2004; Bender et al., 
2006; Kraytsberg et al., 2006) (see 1.5.3 for further details). Interestingly, identical sets 
of deletion types were found to be present in the substantia nigra neurons of 
Parkinson disease patients, multiple mtDNA deletion patients and aging controls, 
suggesting that a similar mechanism for clonal expansion of mtDNA deletions is 
present in each of these cases (Reeve et al., 2008a). 
Evidence for the clonal expansion of mtDNA point mutations began to emerge much 
later than for large-scale mtDNA deletions. The first identification of the accumulation 
of point mutations came from work in tumours, where it was suggested that clonal 
expansion was the cause of high levels of point mutations of the mitochondrial 
genome found in colorectal and gastric tumours (Alonso et al., 1997). The investigation 
into whether clonal expansion is indeed responsible for high heteroplasmy levels of 
point mutations has since been carried over into healthy human tissue, where a cell-
by-cell analysis of buccal epithelium and cardiomyocytes has revealed that 
approximately one third of cells (13 cells from 36 for both buccal epithelium cells and 
cardiomyocytes) in aged individuals (over 76 in this particular study) has clonally 
expanded point mutations at a high level of heteroplasmy. In most cases a single 
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mutation has undergone clonal expansion to accumulate to a high degree within the 
cell, though in rare cases two separate point mutations have both gone on to clonally 
expand (Nekhaeva et al., 2002).  
Though strong evidence has now been put forward for the clonal expansion of large-
scale mtDNA deletions and pathogenic mtDNA point mutations, the mechanism by 
which these mutations accumulate within the cell has yet to be discovered. However, 
three main hypotheses have been put forward, as described below. 
 
1.7.1 Survival of the smallest 
The ‘survival of the smallest’ mechanism was first proposed by Wallace et al (Wallace, 
1992), suggesting that deleted mtDNA molecules are clonally expanded due to a 
selective advantage of smaller mtDNA molecules. It was proposed that replication of 
mitochondrial DNA molecules harbouring mtDNA deletions occurs faster due to the 
smaller size of the molecules. This would allow for more frequent replication, causing 
the deleted mtDNA to outcompete wildtype DNA within the cell and the percentage of 
mutant DNA to rise within the cell to exceed the threshold level (Figure 1.20).  
Since the initial proposition of the ‘survival of the smallest’ mechanism a number of 
papers have since questioned its validity, one of the main arguments being that an 
accumulation of point mutations is also seen in patients with mitochondrial disease; as 
point mutations do not change the mitochondrial genome size there can be no 
selective advantage for these molecules based on the length of time taken for 
replication, which brings into question whether a selective advantage is seen based on 
size in deleted molecules (Weber et al., 1997). Also, a 1997 study of replicative 
dynamics showed that all mitochondrial molecules, including wildtype molecules, 
replicate in under 90 minutes – a much shorter period of time than that between 
replications – meaning the time taken to replicate the mitochondrial genome is not 
rate-limiting for mitochondrial turnover (Shadel and Clayton, 1997). The shorter time 
span for replication of deleted mtDNA molecules, taking this into account, should not 
influence the individual turnover rates of wildtype and deleted mtDNA molecules and 
so percentage heteroplasmy should not change. 
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Despite these criticisms of the ‘survival of the smallest’ model of clonal expansion, a 
study of cell repopulation was performed to investigate whether smaller, deleted 
mtDNA molecules do have a replicative advantage in cells in 2002 (Diaz et al., 2002). 
Under tight copy number control – i.e. during normal, non-selective cell conditions – it 
was demonstrated that over time deleted molecules actually show a small decrease 
(10 – 20%), believed to be due to better growth of cells containing higher levels of 
wildtype DNA. This is in keeping with other studies that have shown cells with the 
highest percentage of deleted mtDNA molecules to have the longest population 
doubling time (Hayashi et al., 1991). Significantly different results, however, were seen 
under relaxed copy number control following mitochondrial DNA depletion by 
treatment with ethidium bromide. Seven days after treatment, cell lines undergoing 
repopulation displayed a higher percentage deleted mtDNA molecules – deleted 
mtDNA molecules repopulated the cell 2-3 times faster than the wildtype molecules 
(Diaz et al., 2002). This suggests that deleted molecules may have a replicative 
advantage within the cell, which could be the cause of clonal expansion of deleted 
mtDNA molecules. Experimental evidence with regards to the ‘survival of the smallest’ 
hypothesis is therefore inconclusive, with different cellular conditions yielding very 
different results in terms of a replicative advantage for mitochondrial genomes with 
large-scale DNA deletions. Further work has been done to try to further elucidate the 
likelihood of a replicative advantage for mtDNA deletions, as discussed in further detail 
in Chapter 3, but no conclusive evidence has yet proven whether or not this hypothesis 
is correct. 
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Figure 1.20 - Survival of the smallest mechanism for the clonal expansion of mtDNA 
deletions. 
This proposed mechanism for the clonal expansion of mtDNA deletions suggests that the smaller size of 
mitochondrial genomes with DNA deletions confers a selective advantage over wildtype genomes due to 
a faster rate of replication. It was proposed that replication of the smaller mitochondrial DNA molecules 
harbouring mtDNA deletions occurs faster than that of wildtype genomes, allowing for more frequent 
replication. This would result in the deleted mtDNA outcompeting wildtype mtDNA within the cell, 
leading to a rise in the percentage of mutant mtDNA. 
1.7.2 Survival of the slowest 
An alternative model proposing an advantage for mtDNA mutations within the cell, the 
‘survival of the slowest’ mechanism, was proposed by De Grey (1997). This 
hypothetical model for clonal expansion stated that the inherent dysfunction of 
mutated mitochondrial DNA molecules gave them a selective advantage in the cell, 
proposing that mitochondrial genomes within dysfunctional mitochondria (i.e. 
mitochondria with no, or limited, respiratory function) would be preferentially 
amplified within a cell. The main rationalisation of this hypothesis was that 
mitochondria with no respiratory function do not produce as great a level of damaging 
free radicals as normally functioning mitochondria (reactive oxygen species being a 
common by-product of oxidative phosphorylation), meaning the mitochondrial 
membranes undergo less damage. As a result of this, non-functional mitochondria are 
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less likely to be targeted for mitophagy, as mitochondrial membrane damage by ROS in 
otherwise healthy mitochondria causes membrane depolarisation, leading to selective 
mitophagy (Kim et al., 2007). If normally functioning mitochondria with predominantly 
wildtype DNA are targeted for mitophagy more often than dysfunctional mitochondria 
carrying mtDNA mutations then wildtype mtDNA molecules must be destroyed more 
often, increasing the percentage of deleted molecules within the cell and making it 
more likely that deleted mtDNA molecules will be replicated to a higher level of 
heteroplasmy (De Grey, 1997) (Figure 1.21). 
 
 
 
 
Figure 1.21 - Survival of the slowest mechanism for clonal expansion of mtDNA deletions. 
This proposed mechanism for the clonal expansion of mtDNA deletions suggests that the inherent 
dysfunction of mutated mitochondrial DNA molecules provides a selective advantage in the cell, as a 
reduced capacity to carry out oxidative phosphorylation reduces the quantity of ROS produced by the 
mitochondria. The reduced level of damage to the mitochondrial membrane by harmful free radicals in 
this case could reduce the potential for dysfunctional mitochondria to be targeted by mitophagy, 
increasing the chances of mutant DNA within the dysfunction mitochondria being replicated. 
 
1.7.3 Random Drift 
Both of the mechanisms discussed above suggest that deleted mitochondrial DNA 
molecules are preferentially amplified due to an inherent selective advantage, but 
another school of thought suggests that this may not be the case, and that clonal 
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expansion can occur by random genetic drift - as proposed by Elson et al (2001). This 
mechanism of clonal expansion is based on the theory of relaxed replication within 
cells, which explains the constant turnover of mtDNA independent of the cell cycle and 
replication of nuclear DNA (Bogenhagen and Clayton, 1977). Elson et al set up a model 
based on mitochondrial replicative dynamics demonstrated previously (Shadel and 
Clayton, 1997), and showed that relaxed replication alone can cause the clonal 
expansion of deleted mtDNA molecules without any necessary replicative advantage in 
post mitotic tissue (Figure 1.22). However, large clonal expansions were shown to be 
the result of a lengthy process; results for simulated cells equivalent to 80 years old 
showed that 78% of the original mtDNA deletion formation events occurred before 30 
years, and 46% before 15 years. The model showed that mutations acquired later in 
life would not have sufficient time to reach significant levels of heteroplasmy by 
random genetic drift alone (Elson et al., 2001), suggesting that any mtDNA deletions 
observed to have clonally expanded to a significant level of heteroplasmy in aged 
tissue (Bender et al., 2006; Bua et al., 2006; Kraytsberg et al., 2006) must have formed 
early in development. This raises the question of how early-onset disease phenotypes 
such as Leigh syndrome could arise if clonal expansion occurs by this mechanism alone 
as, by extension of this finding, there would have been insufficient time for clonal 
expansion of an mtDNA mutation to have occurred to a degree that could cause 
pathology. A further question raised by the ‘random drift’ mechanism of clonal 
expansion is the number of cells predicted to become COX-deficient within a human 
lifespan. The prediction by Elson et al was that ~4% of post-mitotic cells would become 
COX-deficient over the course of 80 years, but this does not correlate with the high 
levels of mtDNA deletions observed in aged substantia nigra neurons (Reeve et al., 
2008). 
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Figure 1.22 – Random drift mechanism for the clonal expansion of mtDNA deletions. 
Taken with permission from (Elson et al., 2001). Proportion of mutant mtDNA in single simulated cells. 
Each simulated cell contained 1,000 mtDNAs and had a half-life, T1/2, of 10 d and a copy-error (mutation) 
probability of 10
−5
 (measurements taken monthly for 30 years). For illustration, we have shown the 
results of 24 simulations from a total of 600. In the 600 cells, one mutant event went to fixation (trace at 
the back) and three others showed a significant expansion (one shown), but, in most, the mutations 
were rapidly lost. When these simulations were continued for a full 120 years (not shown on the graph), 
a mean of only 31.27 mutations occurred per cell, corresponding to the value predicted by the equation 
Nmut=[NmtDNAPmutt ln(2)]/T1/2, where Nmut is the number of mutation events and t is the duration of the 
simulation in d. Many of these mutations were lost almost instantaneously (41% were lost within 
one T1/2, and 88% were lost within 10 T1/2), but, in some cells, the proportion of mutant mtDNA 
increased. 
1.8 Mitochondrial inheritance 
Mitochondrial DNA is inherited in a non-Mendelian fashion, being inherited from only 
one parent. In humans, the mother is the only parent to pass on mtDNA to the 
offspring; this was first demonstrated by screening for single nucleotide 
polymorphisms (SNPs) in blood platelets from individuals across three generations of 
several families. Of these families, seven were found to have informative, easily 
traceable polymorphisms – 5 families with a polymorphism disrupting the Hae II 
restriction enzyme cleavage site, a family with a polymorphism disrupting the Hae III  
restriction site and a family with a polymorphism disrupting the Hine II restriction site – 
all of which were found to segregate maternally (Giles et al., 1980).  
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Despite discovering the maternal mode of mtDNA inheritance over three decades ago, 
the mechanism by which paternal mtDNA is prevented from being passed on to the 
offspring in humans remains unclear. One method by which the paternal mtDNA may 
be destroyed was discovered in fertilized cow and monkey eggs by Sutovsky et al in 
1999. This group found that the sperm mitochondria donated to an egg following 
fertilisation – which can number up to approximately 100 – are ubiquitin-tagged, and 
are therefore targeted for degradation within the embryo. It was proposed that this 
degradation may occur at the embryo pre-implantation stage (Sutovsky et al., 1999). 
Recent work carried out in Drosophila melanogaster has revealed an alternative 
method by which paternal mitochondrial DNA transmission may be prevented, as 
mature Drosophila sperm contain little to no mtDNA due to the loss of mitochondrial 
genetic material during spermatogenesis. This removal of mtDNA from the sperm is 
carried out in two ways - mitochondrial endonuclease EndoG is responsible for the 
removal of mtDNA nucleoids from spermatids, while any remaining nucleoids are 
removed along with any other debris by cellular remodelling. This remodelling occurs 
after the accumulation of any remaining nucleoids and cellular debris into a structure 
known as the ‘cystic bulge’, which travels the length of the spermatid before being 
extruded from the end of the tail (Chan and Schon, 2012; DeLuca and O'Farrell, 2012). 
A third method preventing the paternal transmission of mtDNA has been identified in 
mice (Al Rawi et al., 2011) and in Caenorhabditis elegans (Sato and Sato, 2011), where 
autophagy has been shown to destroy paternal mitochondria in the zygote. In both C 
elegans and mouse embryos, LC3-dependent autophagy markers were detected; it was 
found that sperm mitochondria could be selectively degraded by this mechanism with 
no detriment to the cytoplasmic major sperm proteins (Al Rawi et al., 2011; Sato and 
Sato, 2011). 
Only one isolated case of paternal mtDNA transmission has been discovered in 
humans.  A male patient, 28 years of age at the time of investigation, presented with 
extreme exercise intolerance due to severe lactic acidosis, suspected to be due to a 
mitochondrial defect. This patient was indeed found to have a short, pathogenic 2 
base pair deletion (5132delAA) in the mitochondrial ND2 gene at approximately 90% 
heteroplasmy in muscle. This discovery of this deletion and a 1303G-A point mutation 
led to extensive sequencing analysis of mtDNA from the patient’s skeletal muscle 
tissue blood and hair, as well as cultured fibroblasts; this revealed the presence of two 
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distinct mtDNA sequences present in the patient’s skeletal muscle. These two mtDNA 
sequences, which showed variations at 18 different nucleotide positions, were 
assigned to different European haplogroups. Subsequent sequencing analysis of 
mtDNA from the blood of the patient’s parents and paternal uncle revealed that the 
patient’s 2bp deletion had occurred in a mitochondrial DNA sequence identical to the 
paternal line – i.e. the patient had inherited paternal DNA which had segregated to a 
high proportion in skeletal muscle. Maternal mtDNA only was present in the patient’s 
blood, hair and fibroblast samples (Schwartz and Vissing, 2002). 
 
1.8.1 The mtDNA Bottleneck 
The mtDNA bottleneck theory pertains to the transmission of mtDNA from mother to 
offspring; at a currently undetermined point during oogenesis, a small number of 
maternal mtDNA molecules undergo a high level of amplification to form the total 
mtDNA pool to be passed on to an offspring. Evolutionarily, this mechanism is believed 
to function to limit the inheritance of mutations by offspring – limiting the number of 
mtDNA molecules involved in transmission limits the chances of passing on a maternal 
mutation. The rapid genetic drift then created by the amplification of a small number 
of mitochondrial genomes to a full oocyte complement of mtDNA is also likely to cause 
either the loss or fixation of an mtDNA mutation, which has been said to allow for 
natural selection at the level of the individual organism to come into effect (Bergstrom 
and Pritchard, 1998; Chinnery et al., 2000b). 
The mtDNA bottleneck does serve to limit the transmission of mtDNA mutations and 
to preserve genome integrity in the healthy population, but there are complications in 
the case of mitochondrial disease – specifically for point mutations, as cases of 
transmitted rearrangements are much rarer (risk of transmission is approximately 1 in 
24 according to a cohort study of 226 families, (Chinnery et al.)). Due to the effects of 
the genetic bottleneck there is no link between the level of mutation heteroplasmy of 
a mother and her offspring, and siblings sharing a mother may have vastly different 
heteroplasmy levels (Figure 1.23).  
Evidence for the existence of an mtDNA bottleneck first emerged in a 1982 study of 
maternal transmission of an mtDNA polymorphism in cows. One maternal lineage of 
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Holstein cows was found to carry two distinct mitochondrial genotypes which could be 
tracked through consecutive generations – a wildtype genome, and a genome carrying 
a polymorphism in the form of an A to G transition which created a new HaeIII 
restriction site. Large genotype shifts were observed in this maternal lineage between 
generations, leading to the suggestion that large levels of mtDNA amplification from a 
small starting pool of mtDNA in oocytes may be responsible for rapid, inter-
generational variations in mtDNA (Hauswirth and Laipis, 1982). Since then, the 
presence of a bottleneck in mtDNA transmission has become widely accepted, though 
at what point the bottleneck lies is still a point of contention.  
In 2007, it was proposed by Cao et al that an mtDNA bottleneck could exist without 
any overall changes to mtDNA copy number in the developing oocyte; a study carried 
out in the C57BL/6 mouse model by this group showed no decrease in mtDNA copy 
number in primordial germ cells (PGCs) during development. With no mass decline in 
mtDNA copy numbers at this point in oogenesis, the genetic bottleneck cannot purely 
be due to amplification from very small number of starting mtDNA molecules. Instead, 
Cao et al hypothesised that the mtDNA aggregates into a small number of 
homoplasmic nucleoids, which then act as the segregation units in the germ cells (Cao 
et al., 2007). 
This finding was almost immediately thrown into contention, as the following year 
Cree et al presented evidence that the alkaline phosphatase staining of PGCs used by 
Cao et al disrupts the detection of mtDNA copy number, due to the sensitivity of qPCR.  
The data put forward in the mouse study completed by this group showed that mtDNA 
copy number is in fact reduced in  mouse PGCs, backing the original hypothesis of 
Hauswirth and Laipis that a reduced number of mitochondrial genomes during 
oogenesis is responsible for the genetic bottleneck (Cree et al., 2008). 
The same finding – a reduction in mtDNA copy number in the PGCs of mice – was also 
presented in 2008 by Wai et al, though this study was extended with a follow-up 
analysis of mtDNA heteroplasmy in the PGCs. Interestingly, in direct contrast to the 
expected results if reduced mtDNA levels were responsible for the genetic bottleneck, 
no great variation in heteroplasmy levels was found in the PGCs immediately following 
copy number reduction. This led the group to hypothesise that, although mtDNA copy 
number is indeed reduced in the PGCs, this is not necessarily where the genetic 
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bottleneck lies.  An alternative mechanism was proposed to explain the genetic 
bottleneck, involving the selective replication of a subpopulation of mtDNA genomes 
at the later developmental stage of postnatal folliculogenesis (Wai et al., 2008). 
 
 
 
 
 
Figure 1.23 - The mtDNA bottleneck 
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The mtDNA bottleneck theory pertains to the transmission of mtDNA from mother to offspring; at a 
currently undetermined point during oogenesis, a small number of maternal mtDNA molecules undergo 
a high level of amplification to form the total mtDNA pool to be passed on to an offspring. This 
bottleneck is designed to limit the inheritance of mutations by offspring – limiting the number of mtDNA 
molecules involved in transmission limits the chances of passing on a maternal mutation. A rapid 
accumulation of mtDNA follows this bottleneck stage. However, in instances where an oocyte is 
heteroplasmic for a mutation following the bottleneck stage, the rapid genetic drift then created by the 
amplification of a small number of mitochondrial genomes to a full oocyte complement of mtDNA is also 
likely to cause either the loss or fixation of an mtDNA mutation. 
1.9 Mitochondrial Dynamics 
Mitochondrial structure has been well characterised since the original electron 
microscopy work carried out by Palade et al  uncovered the presence of the double 
mitochondrial membrane (Palade, 1953). However, mitochondria are still typically 
depicted as single, oval-shaped organelles when in fact they exist in a much more 
dynamic state. The size and shape of individual mitochondria are dynamic, varying in 
different cellular conditions, while the internal mitochondrial structure can change 
from a characteristic morphology of narrow cristae and few cristae junctions in low 
ADP conditions to large cristae with many more cristae junctions in the presence of 
high levels of ADP (Detmer and Chan, 2007). The dynamic interactions between 
individual mitochondria are perhaps the most important for maintenance of normal 
mitochondrial function. Mitochondria are now known to exist within a dynamic 
network undergoing fusion, where two mitochondria merge to become a single 
organelle and fission events where individual mitochondria divide into two separate 
structures. This allows for the exchanging of mitochondrial contents, as well as 
regulating mitochondrial size, number and morphology. Fission and fusion are also 
integral in maintaining the correct mitochondrial membrane potential in healthy 
organelles, and decreasing membrane potential in organelles to be targeted for 
mitophagy (Chan, 2006).  
 
1.9.1 Mitochondrial Fusion 
Membrane fusion is an important cellular event in many circumstances - including the 
merging of gametes during fertilisation, the fusion of transport vesicles with other 
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organelles, or the fusion of lysosomes with vacuoles to facilitate the digestion of the 
enclosed cellular debris – but is particularly complex in the case of mitochondrial 
fusion, requiring the simultaneous management of four membranes due to the 
mitochondrial double membrane. Outer membrane fusion is coordinated with inner 
membrane fusion, as opposed to occurring as separate sequential events, although 
outer membrane fusion can still occur normally in instances where inner membrane 
fusion is impaired (Westermann, 2010). 
Mitochondrial fusion is carried out by mitofusins, a subset of dynamin-related proteins 
(DRPs), which are a specific class of GTPases conserved across yeast, worms, flies and 
mammals (Escobar-Henriques and Anton, 2012). The first protein found to be involved 
in mitochondrial fusion was fuzzy onions (FZO), discovered in Drosophila melanogaster 
in 1997, which is expressed during spermatogenesis (Hales and Fuller, 1997). FZO is 
unusual in being expressed so specifically; in all other known cases, mitochondrial 
fusion proteins are expressed constitutively. In mammals, the DRPs known to mediate 
outer membrane fusion are mitofusin 1 and 2 (Mfn1 and Mfn2), which are both 
nuclear encoded proteins. Mfn1 and Mfn2 each contain two hydrophobic coiled coil 
heptad repeat region - HR1 and 2 - which sit on either side of two transmembrane 
domains, and an N terminal GTPase domain (Escobar-Henriques and Anton, 2012). 
These two large GTPases are arranged with the two hydrophobic transmembrane 
regions located in the OMM, a short loop in the intermembrane space, and the large 
functional portions of the protein protruding into the cytosol. Both Mfn1 and Mfn2 are 
involved in mitochondrial docking, as the cytosolic regions of the proteins from 
adjacent mitochondria interact with each other, allowing for lipid bilayer mixing. 
GTPase activity then provides the biomechanical energy required for full outer 
membrane fusion (Figure 1.24) (Westermann, 2010). 
Fusion of the IMM is controlled separately from the OMM, mediated by nuclear 
encoded DRP protein OPA1 in mammals (Cipolat et al., 2004). OPA1 is present in the 
IMM in multiple forms; several long, membrane-anchored isoforms are formed by 
alternate splicing, and these are processed to form several shorter, soluble isoforms. 
Each OPA1 isoform contains a mitochondrial targeting sequence, which is cleaved after 
import into the mitochondria. Long OPA1 isoforms contain a transmembrane region to 
anchor the protein to the IMM, while the rest of the protein protrudes into the 
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intermembrane space. Not all of the long OPA1 isoforms undergo cleavage – only 
some of these proteins undergo processing at the S2 cleavage site to create equimolar 
quantities of each long and short isoform; both types of OPA1 are required for fusion 
to proceed normally. Long isoforms of  OPA1 promote the tethering of the two inner 
mitochondrial membranes following OMM fusion, promoting the direct contact of the 
two inner membranes, while the GTPase activity which is believed to trigger 
membrane conformational changes and lead to membrane fusion is provided by the 
short OPA1 isoforms (Figure 1.24) (Escobar-Henriques and Anton, 2012).  
Though the Mfn1, Mfn2 and OPA1 are the main proteins directly responsible for 
mitochondrial fusion in mammals, accessory proteins are also involved in the 
regulation of this process. These accessory proteins include YME1L, which is 
responsible for the cleavage of the long OPA1 isoform, MitoPLD for OMM fusion 
promotion, the pro-apoptotic protein BAX for both positive and negative regulation of 
mitochondrial fusion, and MIB1, which negatively regulates mitochondrial fusion 
through physical interaction with Mfn1 and Mfn2 (Westermann, 2010).  
 
 
Figure 1.24 – Mitochondrial Fusion 
Mitochondrial fusion is a complex process, requiring the coordination of inner and outer mitochondrial 
membrane fusion. This process allows for the dynamic interaction of individual mitochondria, permitting 
the free exchange of mitochondrial matrix components as well as playing a role in the regulation of 
mitochondrial size, number and morphology In mammals, mitochondrial fusion is regulated by three 
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major dynamin-related proteins – Mitofusin 1 and 2 are responsible for mitochondrial docking and outer 
mitochondrial membrane fusion, while OPA1 is the key component of inner mitochondrial membrane 
tethering and fusion. 
 
 
 
 
1.9.2 Mitochondrial Fission 
The first identification of a protein involved in mitochondrial fission was that of Dnm1 
in yeast - a dynamin-related GTPase similar to those involved in mitochondrial fusion 
(as discussed above in section 1.9.1). Dnm1 was initially discovered through yeast 
genetic screens, and was subsequently found to be localised to the OMM; its 
importance in mitochondrial dynamics is highlighted in Dnm1-knockout strains of 
yeast, where the mitochondria are observed to form a single interconnected web of 
tubules in each cell due to normal mitochondrial fusion but a lack of fission events 
(Bleazard et al., 1999). A study in the same year in C elegans found a protein called 
Drp1 to be responsible for a similar role in OMM fission. Studies carried out in a C 
elegans Drp1 knockout model demonstrated separation of the mitochondrial matrix 
into distinct blebs contained within a single tubular network, indicating that IMM 
fission can still occur in the absence of Drp1 and that Drp1 must therefore responsible 
only for OMM fission events  in C elegans (Labrousse et al., 1999). Subsequent studies 
in mammalian cells have identified the two major components of the fission machinery 
as dynamin-related protein 1 (Drp1, the mammalian homolog of C elegans Drp1) 
(Smirnova et al., 2001) and Fis1 (James et al., 2003).  
Drp1 is a classic dynamin related protein, with a structure comprised of a GTPase 
domain, a central domain and a GTPase effector domain (Chan, 2006). A second 
isoform of Drp1 is present specifically in human brain; this tissue-specific isoform has a 
insertion between the central domain and GTPase effector domain caused by 
alternative splicing (Westermann, 2010). Drp1 resides primarily in the cytoplasm in 
mammalian cells, but a proportion of this protein is recruited to the mitochondrial 
outer membrane by Fis1 to carry out fission. It is still unclear at this point whether 
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Drp1 directly interacts with the OMM following recruitment.  
Fis1 is a small protein anchored to the OMM by a C-terminal transmembrane domain; 
the remainder of the protein, which is comprised of six antiparallel helices, protrudes 
into the cytoplasm (Chan, 2006). The importance of Fis1 in Drp1 recruitment to the 
OMM has been demonstrated in overexpression models, where fission rates are 
greatly increased leading to a fragmented mitochondrial network, and in instances of 
Fis1 depletion where tubular networks deficient in mitochondrial fission are observed 
(Westermann, 2010). 
Following recruitment to the OMM, Drp1 is believed to behave in a manner similar to 
dynamin during the mediation of endocytic vesicle membrane scission. Multiple Drp1 
molecules are thought to self-assemble to form a helical oligomer capable of wrapping 
around the mitochondrial membrane. The Drp1 oligomer is then believed to constrict 
around specific mitochondrial fission sites, this process being driven by the energy 
released during GTP hydrolysis (Westermann, 2011). The constriction of Drp1 at these 
regions is thought to sever both the inner and outer mitochondrial membranes, 
leading to a complete fission event (Youle and van der Bliek, 2012), though this differs 
from the OMM-only fission events mediated by Drp1 in C elegans (Labrousse et al., 
1999). 
 
 
Figure 1.25 – Mitochondrial Fission 
Mitochondrial fission, as well as being involved in the regulation of mitochondrial size, number and 
morphology, is key in maintaining the correct mitochondrial membrane potential in healthy organelles, 
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and decreasing membrane potential in organelles to be segregated from the mitochondrial network and 
targeted for mitophagy. This process is regulated by a dynamin-related GTPase, Drp1, which is recruited 
to the mitochondria by a small protein located at the outer mitochondrial membrane, Fis1. Following 
recruitment, Drp1 self-assembles to form a helical oligomer which then restricts around a specific fission 
site to cause membrane scission, creating two separate daughter mitochondria. 
 
 
 
1.9.3 Mitophagy 
Mitophagy is a type of cargo-specific autophagy employed to remove selected 
mitochondria from the cell. More specifically, mitophagy refers to the engulfment of 
mitochondria by vesicles coated with MAP1 light chain 3, an autophagosome marker. 
The ability to remove selected mitochondria is important in mitochondrial quality 
control, preventing an accumulation of dysfunctional mitochondria damaged by 
oxidative stress, but is also crucial in the degradation of mitochondria during 
erythrocyte development, steady-state turnover of mitochondria, and the adjustment 
of mitochondrial numbers in response to cellular energetic demands (Youle and 
Narendra, 2011). The sequestration of mitochondria into lysosomes was first observed 
in early electron microscopy studies of mitochondria, though the term mitophagy was 
not coined until many years later following the study of selective mitochondrial 
degradation in instances of cellular stress induced by starvation and UV damage (Kim 
et al., 2007). 
More than one mechanism for mitophagy exists in mammalian cells, allowing for a 
distinction to be made between mitophagy of undamaged and damaged mitochondria. 
Undamaged mitochondria may be selected for degradation during key developmental 
processes such as red blood cell maturation – mature erythrocytes contain no 
mitochondria – or to control the number of individual mitochondria in relation to 
changing metabolic demands. In these scenarios, a protein located on the OMM 
known as NIP3-like protein X (NIX) is believed to mediate mitophagy. It is thought that 
the WXXL-like motif located in the cytosolic region of NIX directly binds LC3 (a 
ubiquitin-like protein required for the formation of autophagosomal membranes) and 
the LC3 homolog GABA receptor-associated protein (GABARAP). This binding allows 
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mitophagy induction via the direct recruitment of isolation membranes (Youle and 
Narendra, 2011). 
An alternate pathway for the selective degradation of damaged mitochondria during 
normal aging or in disease relies upon the segregation of dysfunctional mitochondria 
from the dynamic network before the induction of mitophagy by two main proteins – 
PTEN-induced putative kinase 1 (PINK1) and Parkin. Damaged mitochondria become 
isolated from the mitochondrial network via a fission event which leaves the damaged 
daughter mitochondria with a reduced membrane potential. This depolarisation event 
prevents the damaged mitochondria from re-entering the network, as a reduced 
membrane potential inhibits the capacity of mitochondria to undergo fusion, in 
addition to initiating mitophagy (Twig et al., 2008). Under normal conditions PINK1 is a 
constitutively expressed kinase which is constantly imported into all mitochondria, but 
is subjected to high rate of proteolysis and so maintained at a very low level in the 
mitochondria. However, the depolarisation of the mitochondrial membrane allows the 
stabilisation of PINK1 at the OMM, with its kinase domain facing into the cytosol. This 
increase in expression at the OMM allows PINK1 to recruit Parkin, cytosolic E3 
ubiquitin ligase, to the mitochondria via a direct physical interaction between the two 
proteins. Parkin is bound and phosphorylated by PARK1 at the OMM before beginning 
to mediate the ubiquitination of Mfn1, Mfn2 and voltage-dependent anion-selective 
channel protein 1 (VDAC1), all of which are embedded in the OMM (Youle and 
Narendra, 2011).  Following Parkin-mediated ubiquitination, p62 has been found to 
accumulate on the mitochondria; this ubiquitin-binding adapter is able to recruit 
autophagosomes to the mitochondria through its capacity to bind LC3 (Pankiv et al., 
2007; Youle and Narendra, 2011) (Figure 1.26). 
 
 
 
 
 
 
Chapter One 
72 
 
 
 
 
 
 
 
 
 
Chapter One 
73 
 
1.10 Mitochondrial Disease 
Many diseases are known to be associated with mitochondrial abnormalities and 
dysfunction of the oxidative phosphorylation system; these disorders are grouped 
together under the umbrella term of ‘mitochondrial disorders’. This range of disorders 
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can present at any age, and can clinically affect almost any tissue due to the universal 
need for ATP production throughout the body and the presence of mitochondria in 
almost every cell type to fulfil this energy demand. Due to the wide variety of potential 
symptoms of mitochondrial diseases, patients can present in a number of ways – with 
a single organ or tissue type being clinically affected (a tissue specific disorder), with 
clinical symptoms spread throughout the nervous system and skeletal muscle (a 
neuromuscular disorder), or with neuromuscular symptoms alongside further clinical 
pathology (multisystem disorders) (Di Donato, 2009).  
 
1.10.1 Prevalence of mitochondrial disease 
Correctly diagnosing patients with mitochondrial disease presents difficulties for 
clinicians, with the diverse symptoms of the mitochondrial disorder spectrum making it 
difficult to establish a diagnosis for many patients; this has consistently led to an 
under-estimation of mitochondrial disease prevalence. However, as understanding of 
mitochondrial disease continues to improve, more patients are receiving the correct 
diagnosis, care and advice, leading to an ever-increasing estimation of the prevalence 
of the disease in the general population (Schaefer et al., 2004; Schaefer et al., 2008).  
A study by Elliot et al in 2008 set out to determine the prevalence of ten separate 
mtDNA point mutations in the general population, through the analysis of neonatal-
cord blood samples from 3168 live births in Cumbria, England. This study, determined 
to be representative of the whole of the UK through haplotype analysis, found point 
mutations to be present in 0.54% of samples (Elliott et al., 2008) – a huge increase 
from previous estimates of  12.48 in 100,000 (Chinnery et al., 2000a) or 13.1in 100,000 
live births (Skladal et al., 2003). Fortunately, though this study determined that point 
mutations may be present in up to 1 of every 200 members of the general population, 
these mutations do not seem in be pathogenic in every case, meaning the prevalence 
of mitochondrial disease remains much lower than this. 
A study in 2008 carried out in the North East of England followed the diagnosis of 
adults with suspected mitochondrial disease at a single specialised neurology centre, 
and found that 9.2 of every 100,000 people had clinical symptoms of mitochondrial 
disease. This high level in the general population makes mitochondrial disease one of 
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the most common inherited neuromuscular disorders; correctly diagnosing 
mitochondrial disease, in order to best advise patients on potential disease 
progression paths and the risks of disease transmission to children, is therefore of 
paramount importance (Schaefer et al., 2008). As our understanding of mitochondrial 
disease progresses and more pathogenic mutations are discovered, it seems likely that 
the prevalence of mitochondrial disease will continue to rise.  
 
1.10.2 Mitochondrial disorders 
Though the spectrum of mitochondrial disorder presentation is wide, certain 
symptoms are strongly linked to specific mutations, and some sets of symptoms often 
segregate together. On this basis, mitochondrial disorders can be considered as a 
number of different conditions. 
 
1.10.2.1 Chronic Progressive External Ophthalmoplegia (CPEO) 
Chronic progressive external ophthalmoplegia is a progressive eye movement disorder, 
typically involving ptosis (a characteristic drooping of the eyelids) and weakness of the 
extraocular muscles. Patients are often found to move the entire head to compensate 
for the loss of peripheral vision caused by the inability to correctly move the eye. Both 
eyes are usually affected in CPEO, though it is common for symptoms to occur only on 
one side before eventually affecting both. CPEO is one of the most common symptoms 
of mitochondrial disease and is a relatively mild disorder, though can be a secondary 
symptom of some multisystem syndromes such as KSS. As a stand-alone syndrome 
CPEO can present at any age, though it usually presents in the third or fourth decade 
of a patient’s life (Laforêt et al., 1995; McFarland et al., 2002).  In later life, some CPEO 
patients may begin to suffer from more general muscle weakness and/or wasting, and 
exercise intolerance as symptoms of more general myopathy (Zeviani and Di Donato, 
2004). CPEO is most commonly caused by sporadic single mtDNA deletions, but has 
also been linked by multiple mtDNA deletions resulting from nuclear mutations and 
mtDNA point mutations.  
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1.10.2.2 Kearns-Sayre Syndrome (KSS) 
Kearns-Sayre syndrome (MIM 530000) is a multisystem disorder typically caused by 
sporadic single mtDNA deletions but, as for CPEO, this disorder has also been linked to 
mtDNA point mutations and nuclear mutations.  Onset of KSS typically occurs before 
20 years of age, and is clinically characterised by the presence of CPEO and pigmentary 
retinopathy (Kearns and Sayre, 1958) – these symptoms may be combined with one or 
more of cerebellar syndrome, diabetes, short stature, increased cerebrospinal fluid 
protein levels, and heart block (Zeviani and Di Donato, 2004). Histochemically ,this 
syndrome is associated with high levels  of COX-deficiency and ragged red fibres in the 
muscle (Mita et al., 1989). Interestingly, though the same large-scale mtDNA deletions 
are capable of causing either CPEO or KSS, evidence has recently come to light that the 
time at which the deletion is formed may determine the final clinical outcome and 
which tissues are affected by affecting the final deletion load and tissue distribution of 
the mtDNA deletion (López-Gallardo et al., 2009). 
 
1.10.2.3 Pearson Syndrome 
Pearson marrow-pancreas syndrome (MIM 557000) is the most severe of the three 
syndromes associated with sporadic single mtDNA deletions, with onset commonly 
occurring in early infancy. First described in 1979 in four children in the USA by 
Pearson et al, this mitochondrial disorder is characterised by the presence of 
transfusion-dependent sideroblastic anaemia and exocrine pancreatic dysfunction 
(Pearson et al., 1979). These two characteristic symptoms are often combined with 
lactic acidosis, poor growth and neutropaenia, thrombocytopaenia, or pancytopaenia. 
Clinical symptoms may also include enteropathy and severe renal tubulopathy. 
Pearson syndrome is often fatal  - a combination of early childhood onset and high 
risks of liver failure or overwhelming lactic acidosis gives a poor patient prognosis – but 
in cases where patients survive early infancy, a much milder KSS phenotype is often 
developed (Pitceathly et al., 2012).  
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1.10.2.4 Myoclonic Epilepsy with Ragged Red Fibres (MERRF) 
MERRF is a multisystem disorder brought about by the presence of an mtDNA point 
mutation. MERRF usually presents in the 2nd or 3rd decade of a patient’s life, 
characteristically developing a combination of symptoms including myoclonic epilepsy, 
and ragged red fibres in muscle. Additional symptoms include dementia, the 
development of lipomas, neuropathy, cardiomyopathy, optic nerve atrophy and 
deafness. The mutation most commonly associated with MERRF, present 
heteroplasmically in approximately 80 to 90% of all clinical cases,  is the A to G 
transversion at nucleotide 8344 in the tRNALys gene (Wu et al., 2010). The remaining 
clinical cases of MERRF are made up of cases of the much rarer m.8356T>C (Silvestri et 
al., 1992) and m.8363G>A (Ozawa et al., 1997) point mutations. These tRNA mutations 
cause multiple complex deficiency of the respiratory chain, most strongly affecting 
complexes I and IV, due to defective mtDNA translation (Bindoff et al., 1991) .  
 
1.10.2.5 Mitochondrial myopathy, encephalomyopathy, lactic acidosis and 
stroke-like episodes (MELAS) 
MELAS is one of the most commonly occurring mitochondrial diseases, caused by the 
m.3243A>G point mutation in the tRNALeu(UUR) gene. First described in 1984 in two 
children, MELAS was characterised by the presence of ragged red fibres in a muscle 
biopsy, short stature, seizures, hemiparesis or hemiplegia, visual impairment and lactic 
acidosis (Pavlakis et al., 1984). Later in the study of this syndrome – following the 
discovery of the m.3243A>G mutation in 1990 (Goto et al., 1990b) – it was found that 
the stroke-like episodes which are a prominent feature of MELAS are often preceded 
by a mild clinical prodrome and are associated with good recovery (Sue et al., 1998). 
Early in the study of MELAS, prevalence was estimated to be as low as 0.06% (Gerbitz 
et al., 1995), but more recent studies have shown this to be a much more commons 
syndrome, present in 0.24% of the Caucasian population (Manwaring et al., 2007). 
Molecular analyses following the discovery of the m.3243A>G point mutation have 
also shown that clinical symptoms due to this nucleotide transition may present at any 
age, and can be responsible for a range of syndromes beyond MELAS, including CPEO, 
diabetes and deafness, diabetes mellitus or isolated hearing loss . A recent overview of 
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the clinical phenotypes in 129 patients (from 83 families) suggested that the classical 
MELAS phenotype associated with the m.3243A>G transition is not actually the most 
common clinical phenotype to result from this point mutation; 10% of patients 
exhibited a classical MELAS phenotype, while 30% had MIDD, 6% MELAS/MIDD, 2% 
MELAS/chronic PEO (CPEO) and 5% MIDD/CPEO overlap syndromes. 6% had PEO and 
other features of mitochondrial disease not consistent with another recognised 
syndrome. Isolated sensorineural hearing loss occurred in 3%. Interestingly, 28% of 
patients presented with clinical features that were not consistent with any of the 
classical syndromes associated with the m.3243A>G mutation, while 9% of individuals 
harbouring the mutation were clinically asymptomatic (Nesbitt et al., 2013). 
 
1.10.2.6 MERRF/MELAS overlap syndrome 
In rare cases, members of a family can be affected with a syndrome featuring 
characteristics of both MERRF and MELAS , as first described in 1993 in a three-
generation Sardinian family (Zeviani et al., 1993). This disease was found to be caused 
by a heteroplasmic T to C transition at nucleotide 8356 in the tRNALys gene – a 
mutation which had previously been associated purely with MERRF (Silvestri et al., 
1992). Other cases have been identified where two distinct point mutations have been 
carried by a single family with mitochondrial encephalopathy where symptoms of both 
MERRF and MELAS may be displayed in individual family members. One notable case 
followed a family carrying both the common MERRF and MELAS mutations (the 8344 
and 3243 point mutations), where the MERRF/MELAS overlap syndrome was clearly 
displayed (Nakamura et al., 2010).  
 
1.10.2.7 Leber’s Hereditary Optic Neuropathy (LHON) 
LHON, first described by German ophthalmologist Theodor Leber in 1871 (Leber, 
1871a), is a syndrome characterised by severe visual loss, most frequently presenting 
between the ages of 15 and 55 – though the average age of onset is slightly higher in 
females (31.3) than males (24.3) (Huoponen, 2001). LHON presents with a marked 
gender bias, with over 80% of patients being male (Newman et al., 1991), though the 
reason for this pattern of male predominance remains unknown (Abu-Amero, 2011). 
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with acute visual loss in one eye. Vision in the second eye is most often affected within 
one year of the initial presentation, though this can occur within weeks, with most 
patients progressing to a visual acuity lower than 20/200 in both eyes. In some cases, 
there may be some visual recovery within a year of the onset of LHON symptoms, and 
in some rare cases a profound improvement in vision has occurred after many years of 
impaired vision. While visual loss is the only symptom in most LHON cases, some 
patients may have cardiac defects or major neurological defects; this more severe 
clinical presentation is called Leber Plus. Leber Plus may present with basal ganglionic 
degeneration, spasticity, movement disorders, psychiatric disturbances or 
encephalopathy (Fraser et al., 2010). First described in 1871, LHON was originally 
thought to be an X-linked disease (Leber, 1871b), but became linked to mitochondrial 
dysfunction following the discovery that a point mutation at nucleotide 11778 in the 
mitochondrial genome resulting in a change of a histidine to an arginine in the ND4 
subunit of Complex I was a primary cause of LHON (Wallace et al., 1988). 
Subsequently, point mutations at nucleotide 3460 in the ND1 gene and nucleotide 
14484 in the ND6 gene were also found to cause LHON (Howell et al., 1991; Johns et 
al., 1992). These three mutations are involved in approximately 90 - 95% of clinical 
LHON cases, with many other mutations responsible for one or two cases each in the 
remaining 5 - 10% of cases (Yu-Wai-Man et al., 2009; Fraser et al., 2010). In most 
cases, individuals with LHON are homoplasmic for the pathogenic mutation, though 10 
-15% are heteroplasmic – in these cases, level of heteroplasmy and variances in tissue 
segregation may be responsible for some of the phenotypic variation between 
patients.  Interestingly, the three primary LHON mutations which usually cause optic 
atrophy have been found to be responsible for Leber Plus syndrome in some families, 
demonstrating that specific mutations are not necessarily associated with disease 
severity (Fraser et al., 2010). 
1.10.2.8 Leigh Syndrome 
Leigh syndrome was first described in 1951 as a subacute necrotizing encephalopathy 
– a neurological disorder with striking neuropathological features including necrotic 
lesions in the basal ganglia, cerebellum or cerebral white matter causing 
demyelination, vascular proliferation and gliosis (Leigh, 1951). Leigh syndrome 
presents in a particularly varied clinical manner; while necrotic neural lesions are the 
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neuropathological hallmark of Leigh disease, clinical symptoms often include – but are 
not restricted to - psychomotor delay, weakness, hypotonia, truncal ataxia, intention 
tremor and lactic acidosis (Finsterer, 2008). While Leigh syndrome usually occurs in the 
first two years of life, rare cases with presentation in youth or young adulthood have 
been found (Arii and Tanabe, 2000). Leigh syndrome was first linked to mitochondrial 
dysfunction through an association with COX-deficiency 26 years after its initial 
discovery (Willems et al., 1977), prior to being associated with a the T to G point 
mutation at nucleotide 8993 of the ATPase6 gene in maternally inherited  cases of 
Leigh syndrome (Tatuch et al., 1992). Many more pathogenic mutations have since 
been discovered to cause Leigh syndrome – both in mitochondrial and nuclear genes – 
with point mutations in the genes coding for subunits of the respiratory chain or 
assembly factors of respiratory chain complexes being the most common cause of 
Leigh syndrome or Leigh-like syndrome (a condition which presents with neurological 
problems atypical of Leigh syndrome) (Finsterer, 2008).  
 
1.10.2.9 Neuropathy, ataxia and Pigmentary Retinopathy (NARP) 
Axonal neuropathy characterised by cerebellar and olivopontocerebellar atrophy, gait 
and limb ataxia and pigmentary retinopathy are the classic hallmarks of NARP, though 
additional symptoms may include dementia and seizures. As with Leigh syndrome, 
lactic acid is also found to be elevated in the blood and cerebrospinal fluid. NARP 
typically manifests in the 2nd decade of life, with slow progression throughout the 
patient’s life. Though NARP is a much less severe syndrome than Leigh disease, these 
two disorders have been shown to share the same common point mutation, the 
m.8993T>G transversion in the ATPase 6 gene. Mutation loads of over 90% result in 
Leigh syndrome, while mutation heteroplasmy levels between 70 and 90% tend to lead 
to the development of NARP; an individual with less than 70% heteroplasmy for the 
m.8993T>G point mutation tends to be asymptomatic (Schmiedel et al., 2003). 
 
1.10.2.10 Mitochondrial neurogastrointestinal encephalopathy (MNGIE) 
MNGIE is caused by a recessive mutation in the nuclear TYMP gene, encoding 
thymidine phosphorylase – for MNGIE to occur in an individual, both parents must be 
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heterozygous for the TYMP mutation and each parent must pass on the mutated gene 
copy to the offspring. TYMP mutations are known to knock out thymidine kinase 
activity, allowing a build-up of thymidine to occur in the body, which is disruptive to 
the normal maintenance and repair of mtDNA. This creates a cellular environment 
conducive to a build-up of harmful mtDNA mutations, and can also result in mtDNA 
depletion. MNGIE is characterised by severe gastrointestinal dysmotility and cachexia, 
ptosis, PEO, sensorimotor neuropathy and asymptomatic leukoencephalopathy, 
though other symptoms may include hearing loss and demyelinating peripheral 
neuropathy. Age of onset is very variable in MNGIE, typically occurring between the 2nd 
and 5th decades of life, and the order in which symptoms manifest and speed at which 
they progress may also vary between patients (Nishino et al., 2000). 
 
1.10.3  Diagnosis of Mitochondrial Disease 
The wide range of symptoms with which mitochondrial disease can present 
complicates the diagnosis process for patients. Patients with suspected mitochondrial 
disease first undergo an extensive clinical assessment, discussing family history and the 
extent of any clinical symptoms with a clinician. If it does seem that mitochondrial 
disease could fit the patient’s symptoms, diagnostic tests can be performed to 
measure blood levels of creatine kinase, lactate and glucose – all potential indicators 
of mitochondrial function – and blood counts. At this stage, a positive diagnosis of 
mitochondrial disease may be made, though negative results do not necessarily 
exclude the possibility of a mitochondrial disorder (Munnich and Rustin, 2001).  
Following these initial tests, if a definitive diagnosis of mitochondrial disease has not 
been found, a muscle biopsy must be taken for analysis. This ‘gold standard’ of 
diagnosis allows for histological, biochemical and molecular analyses to be carried out 
to diagnose respiratory chain deficiency (Taylor et al., 2004). Two major histochemical 
protocols have been established as a starting point to determine the presence of any 
mitochondrial dysfunction. The modified Gomori one-step trichrome stain (Engel and 
Cunningham, 1963) is used to visualise any accumulation of mitochondria at the outer 
edges of the cell; the red component of the trichrome stain is selectively taken up by 
these subsarcollemal mitochondria, which gave rise to the term ‘ragged red fibres’ as 
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in MERRF. Possibly the most important histochemical diagnostic test is the dual-stain 
for cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) (Old and Johnson, 
1989a) – COX/SDH dual staining is explained in full in chapter 2. This two-part 
histochemical protocol begins with the application of the COX reagent solution, which 
creates a brown precipitate where cytochrome c (a subunit of complex IV in the 
electron transport chain, involved in ATP production) is active within the muscle fibres, 
and therefore where the mitochondria are functional. A secondary histochemical assay 
for SDH (succinate dehydrogenase subunits A and B - fully nuclear-encoded subunits of 
complex II of the electron transport chain unaffected by mitochondrial DNA mutations) 
activity is then applied, highlighting any COX-deficient areas with a blue precipitate 
where they have previously remained unstained for cytochrome c activity. When 
muscle fibres are affected by respiratory chain deficiency, a characteristic mosaic 
pattern will often be observed throughout the tissue section – there will be COX-
deficient and COX-positive fibres present, as well as some fibres classed as ‘COX-
intermediate’, where partial respiratory activity remains (Murphy et al., 2008). The 
results from the COX/SDH histochemistry, particularly in cases which demonstrate low 
levels of COX-deficiency, must be interpreted with consideration to the patient’s age, 
as low levels of COX-deficient fibres are known to accumulate with age (Brierley et al., 
1998; Bodyak et al., 2001). However, a lack of COX-deficient fibres does not necessarily 
rule out respiratory chain dysfunction, as only defects affecting Complex IV activity will 
be picked up by this assay. 
Biochemical assessment of mitochondrial function can be carried out following the 
isolation of mitochondria from biopsy tissue. A fresh muscle biopsy sample is 
preferable to frozen - where the IMM will be damaged, meaning no information 
regarding overall OXPHOS capacity can be obtained - as a wider series of assays can be 
carried out using functionally intact mitochondria isolated from fresh tissue (Janssen et 
al., 2003). In this case, levels of enzyme activity, oxidation, ATP production and flux 
rates can all be measured; this is of particular use in the diagnosis of paediatric cases, 
though can narrow down the diagnosis of a specific mitochondrial syndrome for many 
patients (Taylor et al., 2004; Rodenburg, 2011). However, measurement of PDH 
complex and individual respiratory chain enzyme activities can still be carried out using 
mitochondria isolated from frozen tissue (Janssen et al., 2003). 
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Once a diagnosis of mitochondrial disease has been confirmed, and the potential range 
of conditions has been narrowed down based upon clinical presentation, family 
history, and histochemical and biochemical findings, molecular work can begin in order 
to determine a specific genetic defect. Rearrangements of the mitochondrial genome 
may be identified via Southern blotting or long-range PCR of the mtDNA, while genetic 
sequencing may be used to identify point mutations of the mtDNA or nuclear defects 
(Chinnery and Turnbull, 1997). 
 
1.10.4  Mitochondrial Disease Therapy 
Despite huge recent advances in understanding the pathological mechanisms 
underlying mitochondrial disease and in diagnosing these syndromes, the availability 
of therapy for these disorders remains small. A cure is yet to be found for any 
mitochondrial disorder, while therapy has retained a focus upon symptomatic relief 
(DiMauro et al., 2006). However, opportunities for prevention of transmission are now 
becoming available to patients, and research is still continuing into potential 
treatments and further therapies to offer to patients. 
 
1.10.4.1 Early Therapies for Mitochondrial Disease 
Early therapies for mitochondrial disease focussed on attempting to restore 
respiratory function through the application of patient supplementation with 
substrates, vitamins or electron carriers. These supplements included carnitine, 
coenzyme Q10, thiamine, succinate, folate and methylene blue (Schon et al., 2010). L-
arginine has been used in the treatment of MELAS due to its vasodilatory effects, and 
treatment of the thymidine phosphorylase defect in MNGIE may be treated 
temporarily with platelet infusions or permanently with a bone marrow transplant 
(Schapira, 2012).  
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1.10.4.2 Symptomatic Relief of Mitochondrial Disease Symptoms 
In many cases of mitochondrial disease, surgical intervention is one option which may 
be considered to alleviate a patient’s symptoms. Ptosis, which may be obstructive to 
vision, can be managed through brow suspension surgery or a levator resection, while 
cochlear implants have been deemed appropriate for implantation in cases of hearing 
loss. Tendon release surgery can be used to improve joint mobility in children suffering 
from progressive neuromuscular disorders, and a tracheotomy or mechanical 
ventilation may be considered in cases of chronic respiratory failure. In patients 
displaying a failure to thrive, a gastrostomy tube may be necessary to ensure the 
intake of a sufficient number of calories (Edmonds, 2004). In patients with MERRF, 
lipomas may be surgically excised due to patient discomfort but in many cases these 
will grow back following surgery, often to such a degree that further excisions may be 
deemed necessary (Holme et al., 1993). With more severe complications, such as acute 
cardiomyopathy, organ transplant may be considered – this is becoming more 
accepted in cases of individual organ failure, but remains controversial in cases of 
multisystem disorder (DiMauro et al., 2006). Other, non-invasive methods of 
symptomatic relief are available for different manifestations of mitochondrial disease. 
Examples include diabetes mellitus commonly occurs in patients with MELAS and KSS, 
and can be managed with dietary intervention and insulin, while anticonvulsants are 
effective in most cases in controlling the seizures associated with many mitochondrial 
disorders  (DiMauro et al., 2006).  
 
1.10.4.3 Genetic Manipulation 
A number of possible approaches to influence the level of mutant mtDNA 
heteroplasmy have been investigated as potential treatments for mitochondrial 
disease. In terms of gene therapy, a variety of methods to import wildtype mtDNA into 
the mitochondria are under investigation; allotopic expression of mitochondrial genes 
introduced to the nucleus has shown some promise in cultured cells, while xenotopic 
expression of single subunit enzymes from other species shows some promise in 
rescuing phenotypes caused by OXPHOS complex defects. Some success has also been 
had in targeting mtDNA molecules harbouring a mutation with restriction 
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endonucleases, following nuclear transfection with a specific restriction endonuclease 
gene. However, these gene therapy treatments are all in very early stages of 
development, and require research to be carried out in animal models in order to scale 
up the treatment from single cells in culture to the tissue level in living organisms 
(Kyriakouli et al., 2008).  
Aside from gene therapy approaches, attempts to combat mitochondrial disease via 
genetic manipulation have focussed upon affecting heteroplasmy, in an attempt to 
shift the balance of mtDNA in favour of wildtype over mutant copies. Methods to 
achieve this heteroplasmy shift include inhibiting the replication of mutant mtDNA 
with peptide nucleic acids without affecting wildtype mtDNA replication, importing 
RNAs into mitochondria to restore normal function, importing polypeptides into the 
mitochondria, or selecting for respiratory function by selectively placing 
pharmacological or metabolic stress on mitochondria with high mutation levels 
(DiMauro et al., 2006). The induction of muscle regeneration is thought to be a 
potential method to decrease mutant heteroplasmy specifically in patient muscle. This 
can be achieved through the recruitment of muscle satellite cells due to stress placed 
on the muscle via resistance training (Gardner et al., 2007). Finally, the induction of 
increased amounts of mitochondrial fusion is thought to be one more way of 
addressing the issue of heteroplasmy. This should encourage a more even distribution 
of mutant mtDNA molecules, rather than discreet populations of normally functioning 
mitochondria with low levels of mutation and dysfunctional mitochondria with high 
levels of mutation. A more even mutation load distribution should ensure that more 
organelles within the cell remain below the mutation threshold, maintaining normal 
function, despite no overall decrease in mitochondrial mutation load (DiMauro et al., 
2006). 
 
1.10.4.4 Genetic Counselling 
Genetic counselling is an important option for mitochondrial disease patients 
considering having children, as well as providing important information regarding 
disease progression and prognosis to all affected individuals. However, as 
mitochondrial disorders are so heterogeneous, giving accurate advice to all patients 
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concerning the risk of disease for any offspring remains challenging (DiMauro et al., 
2006). It has been proposed that, for the purposes of counselling, patients are split 
into three groups; patients with identified nuclear gene mutations, patients with a 
respiratory chain defect but no identified mutation, and patients with a known 
pathogenic mutation in a mitochondrial gene. Counselling is most straightforward in 
the case of patients with known nuclear mutations, though this group only represent 
approximately 10% of mitochondrial disease diagnoses (Thorburn and Dahl, 2001; Zhu 
et al., 2009), as there is a clear pattern of Mendelian inheritance for nuclear mutations. 
Prenatal diagnosis (PND) can be reliably carried out in the case of known nuclear 
mutations, reducing the risk of having an affected child (Thorburn and Dahl, 2001). 
Where a genetic defect has not been identified but a respiratory gene defect has, 
genetic counselling becomes more difficult. In these cases, family history may imply a 
mode of inheritance, or risk of transmission may be inferred from a specific clinical 
presentation or enzymatic defect, but prenatal diagnosis is less likely to be an option, 
and may be unreliable (Thorburn and Dahl, 2001). Genetic counselling is most difficult 
for the final patient group, where a pathogenic mutation has been identified in the 
mitochondrial DNA. Patients with single large-scale deletions can be advised that it is 
unlikely that this defect will be transmitted to an offspring as these defects tend to be 
sporadic rather than maternally inherited, though they should be made aware that 
there are rare circumstances where the mtDNA deletion may still be passed on 
(DiMauro et al., 2006). Advice is harder to give in the case of mtDNA point mutations; 
the mutation load in each of the patient’s oocytes may be different, and the level of 
heteroplasmy passed on to a child need bear no relation to the mother’s mutation 
load because of the genetic bottleneck (as discussed in 1.8.1), so the disease severity 
with which any offspring may be affected is hard to predict. It is also important to 
stress to families that having had one unaffected child does not necessarily mean that 
that mutation may not be passed onto a second child at a much higher level (Thorburn 
and Dahl, 2001).  
1.10.4.5 Prevention of Transmission 
Though a cure for mitochondrial disease remains elusive, much progress has been 
made in preventing the transmission of pathogenic mutations from generation to 
generation. Prenatal diagnosis can be safely carried out where a nuclear defect is 
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known to be the cause of disease but is less informative for other causes of 
mitochondrial disorders, where the lack of correlation between mtDNA deletion 
heteroplasmy and disease severity restricts predictions of disease presentation or 
clinical severity (Sallevelt et al., 2013).  A more recent alternative, pre-implantation 
genetic diagnosis (PGD) can now safely be carried out for many mitochondrial disease 
patients. PGD involves patients undergoing a round of IVF and removing one or two 
single cells from each successful embryo to test for the genetic defect before selecting 
embryos with the lowest mutation loads for implantation. Though there is no 
guarantee that offspring with low levels of mutation will be unaffected, this does 
reduce the risk of parents having a severely affected child (Bredenoord et al., 2008). 
The most recent method under investigation to prevent the transmission of mtDNA 
mutations is pronuclear transfer (Craven et al., 2010). This technique involves the 
transfer of the pronucleus from a fertilised zygote into an enucleated donor zygote 
with normally functioning mitochondria. This prevents transmission of maternal 
mtDNA mutations to the offspring, as only wildtype donor mtDNA will be present in 
the reconstituted zygote. This technique does however require further research to 
ensure that the zygote manipulations cause no chromosomal or epigenetic 
abnormalities, and that the resultant embryo is able to develop normally (Craven et al., 
2010).   
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Chapter 2 
Materials and Methods 
2.1 Reagents, equipment, solutions and consumables 
2.1.1 Equipment and consumables 
2.1.1.1 Equipment 
ABI 3130xl genetic analyser     Applied Biosystems 
ABI Gene Amp 9700 Thermal Cycler    Applied Biosystems 
ABI Veriti 96 well Thermal Cycler    Applied Biosystems 
ABI Step-one Plus Real Time PCR system   Applied Biosystems 
ABI Prism 7000 sequence detection system   Applied Biosystems 
ABI Step one software v2.0     Applied Biosystems 
Autoclave       Astell 
Balance EK-120A      Salter 
Balance: Sartorius Basic     Sartorius 
Bench-top Microcentrifuge     Sigma 
Bench-top Centrifuge 3-15     Sigma 
Binder General Purpose Incubator    Phillip Harris 
Cryostat (Cryostar HM 560M)    Microm International 
Dry Heat Block      Techne 
Electrophoresis power supply model 250EX   Life Technologies 
Horizontal Agarose Gel Electrophoresis Systems  Amersham 
Laminar Flow hood      Jencons-PLS 
Leica Laser-microdissection system    Leica 
Nanodrop ND-1000 Spectrophotometer   Labtech International 
ND-1000 Software      Labtech International 
NANOpureII Water Purification System   Barnstead 
OFT 5000 Cryostat      Bright 
PALM MicroBeam      Zeiss 
PURELAB flex       Elga 
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UV Gel Documentation System    Flowgen 
with AlphaImage series 2200 Software   Flowgen 
Vortex Genie 1 Touch Mixer     Wolf Laboratories 
Vortex Genie       Scientific Industries 
 
2.1.1.2 Consumables 
0.2ml Thin-walled PCR tubes     Biogene 
0.5ml Thin-walled PCR tubes     Biogene 
1.5ml Eppendorph tubes     Biogene 
2.0ml Eppendorf tubes     Biogene 
96 Well semi-skirted Plate, with Raised Rim   Starlabs 
96 Well Fast Optical Reaction Plates    Applied Biosystems 
Aerosol Resistant Pipette Tips    Starlabs 
Bioclean Pipette Tips      Rainin 
Capstrips, domed      Eppendorph 
Coverslips (37 x 58m)      Cellpath 
Destaining Bags      Amresco 
Electronic Pipettes      Rainin 
Expand Long Template PCR system kit   Roche 
Falcon Tubes (15ml ad 50ml)     Costar 
Gel Extraction Kit      Qiagen 
Gilson Pipetteman (P2, P20, P200, P1000)   Anachem 
Gloves        Ultrasense 
Medical Wipes      Kimberly Clarke 
MicroAmp Fast Optical 96 Well Reaction plates  ABI 
Microscope Slides (76x26x1.0-1.2mm)   Cellpath 
Parafilm       Pechiney plastic packaging 
Polyethylenenaphthalate (PEN) Slides   Leica 
QIAamp DNA micro kit     Qiagen 
Scalpels       Swann Morton 
SlideRite 5 Mailer      Cellpath 
Slide tray and box      Thermo Scientific 
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Starseal Advanced Polylefin Film    Thermo Scientific 
Superfrost microscope slides     Starlabs 
Tissue Extraction Kit      Qiagen 
Thermo-Fast 96 Well Plates, Non-skirted   Thermo Scientific 
Weigh boats       Heathrow Scientific 
Whatman Grade IV filter      Merck 
 
2.1.2 Solutions and Chemicals 
2.1.2.1 Solutions 
Buffers and solutions were prepared with NANOpure (18 Mega Ohms activity) water.  
DNA loading buffer: 
 0.25% (w/v) Bromophenol Blue 
 0.25% (w/v) Xylene Cyanol 
 30% (v/v) Glucerol 
Gel Buffer (1l) 
 100ml 10x TAE 
 900ml NANOpure water 
Electrophoresis buffer (1l) 
 100ml 10x TAE 
 900ml NANOpure water 
Lysis buffer for single molecule PCR (1ml) 
 5ml SDS 
 945ml 10mM EDTA 
 50µl proteinase K 
Lysis buffer (standard, 500µl) 
 250µl 1% Tween 20 
 50µl 0.5M TrisHCl pH8.5 
 195µl dH2O 
5µl proteinase K 
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0.5M TrisHCl pH8.5 
 30.275g Trisma base in 500ml dH20 
Phosphate Buffered Saline 
 Prepared from tablets; 1 tablet in 100ml dH20 
 
2.1.2.2   Chemicals  
2.1.2.2.1  Tissue Preparation 
Iso-pentane       Merck 
Liquid Nitrogen      BOC 
OCT-embedding matrix     Raymond Lamb 
 
2.1.2.2.2  Histological and histochemical reagents 
Catalase       Sigma 
Cytochrome c       Sigma 
3.3’ Diaminobenzidine Tetrahydrochloride   Sigma 
DPX™ Mount       BDH 
Ethanol Analar      Merck 
Histoclear™       National Diagnostics 
Nitro Blue Tetrazolium     Sigma 
Phenazine Methosulphate     Sigma 
Phosphate Buffered Saline Tablets    Sigma 
Sodium Dodecyl Sulohate (SDS)    BDH 
Sodium Azide       Sigma 
Sodium Succinate      Sigma 
Trizma base       Sigma 
Tween-20       Sigma 
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2.1.2.2.3 DNA extraction, amplification and sequencing reagents 
Betaine       Sigma 
BigDye Terminator v3.1 cycle sequencing kit   Applied Biosystems 
DNA Oligonuleotide synthesis    MWG BioTech UK Ltd 
DNA Oligonuleotide synthesis IDT 
Dioxynucleotide triphosphates    Roche 
dNTPs (pre-prepared, for use with LA Taq)   TaKaRa 
ExoSAP-IT       GE Healthcare 
Expand Long Template PCR system    Roche 
HiDi        Applied Biosystems 
LA Taq        TaKaRa 
LA buffer       TaKaRa 
Phusion polymerase      Fisher Scientific 
 with HF buffer 
Primers for real time PCR     Applied Biosystems 
Proteinase K solution      Fisher Scientific 
Restriction Enzymes (XhoI, BamHI, XcmI, DraI)  New England Biolabs 
Tamra labelled probes (18S, ND1, ND4)   Applied Biosystems 
Taqman mastermix      Applied Biosystems 
 
2.1.2.2.4 Gel Electrophoresis reagents 
1kb DNA ladder       New England BioLabs 
Agarose MP        Roche 
Bromophenol Blue       Sigma 
Ethidium bromide       Merck 
GelRed nucleic acid stain      Biotium 
Glycerol        Sigma 
Tris acetate EDTA (TAE:10X)      Sigma 
Xylene cyanol        Sigma 
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2.1.2.3 Histochemical Solutions 
COX stock solutions 
 Diaminobenzidine 
  5mM DAB in 0.2M phosphate buffer pH 7.0 
  Stored in 800µl aliquots 
 Cytochorome c 
  500µM cytochrome c in 0.2M phosphate buffer pH 7.0 
  Stored in 200µl aliquots 
 
SDH stock solutions 
 Sodium succinate 
  1.3M sodium succinate in 0.2M phosphate buffer pH 7.0 
  Stored in 300µl aliquots 
 NitroBlue Tetrazolium 
  1.875mM NBT in 0.2M phosphate buffer pH 7.0 
  Stored in 800µl aliquots 
 Phenazine methosulphate 
  2mM PMS in 0.2M phosphate buffer pH 7.0 
  Stored in 150µl aliquots 
 Sodium azide 
  100mM sodium azide in 0.2M phosphate buffer pH 7.0 
  Stored in 50µl aliquots 
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2.2 Methods 
2.2.1 Patient samples 
The majority of patient samples used are from patients referred to the NCG 
Mitochondrial Diagnostic Laboratory, Newcastle Upon Tyne. All samples were taken 
with informed consent, and patient anonymity was maintained at all times.  
 
2.2.1.1 Patient DNA samples   
Patient DNA samples were extracted from tissue by the NCG Mitochondrial Diagnostic 
Laboratory, Newcastle Upon Tyne. The majority of patient DNA samples were 
extracted from skeletal muscle samples, though a small proportion of DNA samples 
were extracted from blood or urine. Samples were requested in volumes of 5 – 10µl 
and stored at -20⁰C until needed.  
 
2.2.1.2  Patient tissue samples 
All tissue used in this study was skeletal muscle tissue, isolated from the mid-portion of 
the Vastus Lateralis, apart from patients 2 and 3 in Chapter 3 (see 3.3.3), where 
skeletal muscle tissue was isolated by open biopsy from the biceps brachii muscle. 
Tissue blocks were mounted onto Whatmen grade IV filter paper using OCR adhesive 
and snap-frozen by immersion into iso-pentane which had been pre-cooled to -160⁰C 
in liquid nitrogen. Mounted tissue blocks were stored at -80⁰C. 
Tissue was sectioned at -19⁰C using the OFT 5000 Cryostat or the Cryo-star HM 560M 
cryostat, with the blade set at -21⁰C. Muscle sections were taken at a thickness of 
20µm and mounted on SuperFrost glass slides or Polyethylenenaphthalate (PEN) 
membrane slides. Sections were air-dried for an hour before being stored in airtight 
containers at -20⁰C until required. 
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2.2.2 Dual cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) 
histochemistry 
COX/SDH histochemistry (Old and Johnson, 1989b) was performed on frozen muscle 
sections to assess complex II and IV activity.  Muscle sections were defrosted in slide 
mailers for 30 minutes, then air dried for one hour. The COX incubation medium was 
prepared by adding 200µl of 500µM cytochrome c to 800µl of 5mM diaminobenzidine 
and approximately 20µg of catalase. This solution was mixed well using a bench-top 
vortex, and then applied in sufficient volume (approximately 200µl) to each section to 
ensure the entire tissue section is covered. The slides were incubated for 45 minutes at 
37⁰C in a humidified chamber, and then washed twice with PBS to remove any excess 
COX incubation medium. 
The SDH incubation medium was prepared by adding 100µl of sodium succinate, 100µl 
of PMS and 10µl of sodium azide to 800µl of NBT. This solution was mixed well using a 
bench-top vortex, and then applied in sufficient volume (approximately 200µl) to each 
section to ensure the entire tissue section is covered. Again, the slides were incubated 
for 45 minutes at 37⁰C in a humidified chamber, and then washed twice with PBS to 
remove any excess COX incubation medium. 
The sections were dehydrated by passing the slides through a graded ethanol series – 
75%, 95%, 2 x 100% - and were left in the final 100% ethanol bath for 10 minutes. PEN-
membrane slides were left at this stage to air-dry for 1 hour before being stored in an 
airtight container at -20⁰C until required for use. Glass slides were cleared through two 
stages of Histoclear™ and then mounted in DPX™ before the addition of a coverslip. 
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2.2.2.1. Dual cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) 
histochemistry in serial sections 
Where single muscle fibres were to be isolated from tissue sections for mtDNA 
analysis, a minimum of 3 slides of serial sections would be cut and stained as below 
(Table 2.1). 
Slide type Number of tissue sections Histochemical stain 
Glass, Superfrost 1 COX/SDH 
PEN-membrane 3 SDH only 
Glass, Superfrost 1 COX/SDH 
Table 2.1 – Histochemical assessment of COX/SDH activity in serial sections 
 
Evidence suggests that the COX histochemical stain may affect mtDNA copy number, 
while the SDH histochemical stain has no such effect, so sections from which single 
muscle fibres were to be isolated for mtDNA analysis were assessed for SDH activity 
only (Murphy et al., 2012). Sections which had been assessed for dual COX/SDH 
histochemistry were then used as maps of biochemical activity for serial sections 
treated only with the SDH histochemical stain in order to allow an assessment of COX-
activity in individual fibres. 
 
2.2.3 DNA extraction 
2.2.3.1  Extraction of DNA from homogenate tissue.  
DNA was extracted from homogenate muscle tissue samples using the QIAGEN DNeasy 
blood and tissue extraction kit. Samples of frozen tissue were added to 180μl Buffer 
ATL and equilibrated to room temperature. 20μl proteinase K was then added, and 
mixed thoroughly by vortexing for 15 seconds. This mixture was then incubated at 
56°C, with occasional agitation, until the tissue was completely lysed. (Lysis was usually 
complete in 1–3 hours.) The sample was then mixed thoroughly by vortexing for 15 
seconds, before adding 200μl Buffer AL to the sample and thoroughly vortexing again. 
200μl of 100% ethanol was added to the sample next, before mixing again thoroughly 
by vortexing. The resulting lysate, including any precipitate, was then transferred by 
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pipette into a DNeasy Mini spin column which was placed in a 2 ml collection tube. The 
lysate was passed through the spin column membrane by centrifugation 6000 x g; the 
collection tube and any flow-through it contained was discarded after this step. The 
DNeasy Mini spin column was subsequently placed in a new 2 ml collection tube. 500μl 
Buffer AW1 was added to the spin column membrane, and this underwent 
centrifugation for 1 minute at 6000 x g. The collection tube and any flow-through were 
again discarded at this point, and the DNeasy Mini spin column was placed in another 
new 2 ml collection tube. 500μl Buffer AW2 was added to the spin column membrane, 
and this underwent centrifugation for 3 minutes at 20,000 x g to dry the DNeasy spin 
column membrane. Discard flow-through and collection tube. The collection tube and 
flow-through were again discarded at this point, and the DNeasy Mini spin column 
placed in a clean 1.5 ml or 2 ml microcentrifuge tube. 200μl Buffer AE was added onto 
the DNeasy membrane, and the spin column allowed to incubate at room temperature 
for 1 minute before undergoing centrifugation for 1 minute at 6000 x g to elute the 
DNA into the microcentrifuge tube. This was then stored at -20⁰C until required. 
 
2.2.3.2  Single fibre isolation and lysis 
2.2.3.2.1 Single cell isolation and lysis, standard method 
Individual cells were captured by laser microdissection into the caps of 0.5ml 
eppendorph tubes.  15μl of lysis buffer containing 1%Tween-20, 0.5M Tris-HCl pH8.5 
and proteinase K was then added to the cap of each tube, before mixing vigorously for 
20 to 30 seconds using a bench-top vortex. In a bench-top centrifuge, these single cells 
were then spun at 16,000 x g for 5 minutes to accumulate the isolated cell and lysis 
buffer at the bottom of the eppendorph tube. The isolated cells were incubated at 
55°C in a humidified chamber for 2 hour to complete cell lysis, before denaturing the 
proteinase K with a single 10 minute incubation at 95⁰C. 
 
2.2.3.2.2 Single cell isolation and lysis for smPCR, using Leica AS-LMD 
Individual cells were captured by laser microdissection into the caps of 0.5ml 
eppendorph tubes.  5μl of lysis buffer (0.5% SDS, 10mM EDTA, 5% proteinase K) was 
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then added to the cap of each tube, before mixing vigorously for 20 to 30 seconds 
using a bench-top vortex. In a bench-top centrifuge, these single cells were then spun 
at 16,000 x g for 5 minutes to accumulate the isolated cell and lysis buffer at the 
bottom of the eppendorph tube. The isolated cells were incubated at 37°C in a 
humidified chamber for 1 hour, prior to the addition of 5μl of dH2O; this was gently 
mixed into the lysate solution by pipetting up and down. The fibres were then returned 
to 37°C in a humidified chamber for 1 further hour, before the addition of 10μl of TE. 
This was the 10^-1 dilution. This was mixed well using a bench-top vortex, and stored 
at -80°C until needed. 
 
2.2.3.2.3 Single cell isolation and lysis for smPCR, using Zeiss PALM LMD 
Individual cells were captured by laser microdissection into 20µl of lysis buffer (0.5% 
SDS, 10mM EDTA, 5% proteinase K) in the cap of a 0.5ml eppendorph tube. In a bench-
top centrifuge, these single cells were spun at 16,000 x g for 5 minutes to accumulate 
the isolated cell and lysis buffer at the bottom of the eppendorph tube. The isolated 
cells were incubated at 37°C in a humidified chamber for 2 hours. Due to capture into a 
larger volume of lysis buffer, no further dilution was required at this stage. The cell 
lysate was mixed well using a bench-top vortex, and stored at -80°C until needed. 
 
2.2.4 Polymerase Chain Reaction (PCR) based methods 
Polymerase chain reactions (PCRs) were used to amplify target areas of the 
mitochondrial genome. Specific primers were designed to flank each area of interest; 
cycling conditions were then designed to be appropriate for the oligonucleotides, 
length of template DNA required to be amplified, and the polymerase used. Long 
range and single molecule PCRs used a Gene Amp 9700 Thermal Cycler or a Veriti 96 
well Thermal Cycler, while real-time PCR was carried out using a Step-one Plus Real 
Time PCR system. 
2.2.4.1  Primer design 
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All primers were designed according to the revised Cambridge Reference Sequence 
(rCRS- GenBank No. NC_012920), and were obtained from MWG BioTech or Integrated 
DNA technologies. Primers were designed to avoid hairpin structures and dimer 
formation, as these could limit PCR efficiency, and primer pairs were designed 
together to limit Tm differences. All primers were re-suspended in sterile water to a 
stock concentration of 200µl, and stored at -20⁰C until required. 
 
2.2.4.2 Long range PCR 
2.2.4.2.1 TaKaRa LATaq long range PCR 
Homogenate DNA isolated from tissue, by myself or the NCG Mitochondrial Diagnostic 
Laboratory, was amplified using this technique. All reactions were set-up on the bench-
top, as the assay is relatively insensitive to contamination. The primers were situated 
approximately 10kb apart (NC_012920.1, 5875 – 15896bp), and were designed to flank 
a majority of the major arc of the mitochondrial genome. For the PCR reaction ~100ng 
of DNA was added to PCR mastermix (dH2O, LA Taq buffer (TaKaRa), 10mM dNTPs, 
20mM forward and reverse primers and LA Taq enzyme (TaKaRa), to a total volume of 
50μl. Amplifications were carried out using a thermal cycler (GeneAmp® PCR System 
9600, Applied Biosystems) with the following cycling conditions: 94°C for 1 minute; 35 
cycles of 94°C for 30 seconds, 58°C for 30 seconds and 68°C for 11 minutes; final 
extension of 72°C for 10 minutes.  
 
2.2.4.2.2 Roche expand long template PCR 
Long range PCR of mtDNA extracted from single fibres was accomplished using a two-
step protocol (Expand Long Template PCR system®) to amplify regions of the major arc 
of the mitochondrial genome. A two-step protocol is used to increase the efficiency of 
the assay when using only small amounts of DNA. All reactions were set up in a UV 
hood and a prior 20 minute UV exposure to materials was carried out to prevent 
contamination. The first round amplification used 1µl of DNA as a template, and the 
reaction mix comprised 1x reaction buffer (Roche), 0.35mM dNTPs, 1mg/ml BSA 0.75µl 
enzyme mix and 30pmol of each primer set in a total volume of 50µl. Amplifications 
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were carried out using a thermal cycler (GeneAmp® PCR System 9600, Applied 
Biosystems) with the following cycling conditions: 3 minutes as 93˚C; 10 cycles of 93˚C 
for 30 seconds, 58˚C for 30 seconds and 68˚C for 12 minutes; 20 cycles of 93˚C for 30 
seconds, 58˚C for 30 seconds and 68˚C for 12 minutes + 5 seconds per additional cycle; 
and a final extension of 11 minutes at 68˚C.  
The PCR product was then diluted 1:20 and 1µl was used as a template in the second 
round PCR which again, was set up in the UV hood. Identical reaction buffer mix was 
used as in the first round PCR with identical cycle conditions. 
 
2.2.4.2.3 AmpliTaq Gold PCR 
Standard PCR reactions using AmpliTaq Gold were carried out to amplify mtDNA 
fragments for sequencing, and to generate ND1 and ND4 templates for copy number 
analysis with real-time PCR. The two-step protocol, used to increase the efficiency of 
the assay, was carried out on the bench-top. Each reaction was performed in a volume 
of 25µl.  
The first round amplification used 1µl of DNA as a template, and the reaction mix 
consisted of 16.87μl of autoclaved water, 2.5μl of 10 x dNTP’s (ROVALAB), 2.5μl of 10 x 
PCR buffer (10mM Tris-HCl pH8.3 15mM MgCl2, 50mM KCL, 0.001% w/v gelatine), 
0.13μl of AmpliTaq Gold® DNA polymerase (Applied Biosystems), and 1μl of both 
forward and reverse primer at 20μM (Table 2.2, Table 2.3). 1μl of wild type (WT) blood 
DNA was used as a positive control, while 1μl of dH2O was used as a negative control. 
Reactions were carried out using a thermal cycler (GeneAmp® PCR System 9600, 
Applied Biosystems) with the following cycling conditions: 95⁰C for ten minutes, thirty 
cycles of: 94⁰C for forty five seconds (denaturing), 58⁰C for forty five seconds 
(annealing), and 72⁰C for one minute (extension), with a final extension of 72⁰C for 
eight minutes. 
1µl of the first round PCR product was then used as a template in the second round 
PCR.  An almost identical reaction buffer mix was used as in the first round PCR, with 
only adjustment being a different primer pair nested inside the first pair(Table 2.4, 
Table 2.5), with identical cycle conditions. 
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First round primers 
Primers Primer position Size (incl primer) 
 Forward Reverse  
A  627-646  3087-3068  2460  
B  2395-2415  4653-4633  2258  
C  4489-4508  6468-6450  1979  
D  6113-6133  8437-8417  2324  
E  8128-8147  10516-10487  2388  
F  9821-9841  12101-12080  2280  
G  11866-11887  13924-13904  2038  
H  13721-13742  15997-15978  2276  
I  15659-15680  868-847  1778  
Table 2.2 - First round primer positions 
 
 
First round primers 
Primer Sequence 
A Forward  
A Reverse  
GCTCACATCACCCCATAAAC  
GATTACTCCGGTCTGAACTC  
B Forward  
B Reverse  
ACCAACAAGTCATTATTACCC  
TGAGGAAATACTTGATGGCAG  
C Forward  
C Reverse  
CCGTCATCTACTCTACCATC  
GGACGGATCAGACGAAGAG  
D Forward  
D Reverse  
AATACCCATCATAATCGGAGG  
GGTGATGAGGAATAGTGTAAG  
E Forward  
E Reverse  
AACCACTTTCACCGCTACAC  
AGTGAGATGGTAAATGCTAG  
F Forward  
F Reverse  
ACTTCACGTCATTATTGGCTC  
ATAGGAGGAGAATGGGGGATAG  
G Forward  
G Reverse  
ACCCCCCACTATTAACCTACTG  
GGTAGAATCCGAGTATGTTGG  
H Forward  
H Reverse  
TATTCGCAGGATTTCTCATTAC  
AGCTTTGGGTGCTAATGGTG  
I Forward  
I Reverse  
CCCATCCTCCATATATCCAAAC  
GGTTAGTATAGCTTAGTTAAAC  
Table 2.3 - First round primer sequences 
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Second Round Primers  
Primers  Primer Position  Size (incl primer)  
 Forward Reverse  
1  721-740  1268-1248  548  
2  1157-1177  1709-1689  553  
3  1650-1671  2193-2175  544  
4  2091-2111  2644-2625  536  
5  2549-2569  3087-3068  539  
6  3017-3036  3374- 3356  558  
7  3533-3351  4057-4037  558  
8  4005-4025  4577-4556  573  
9  4518-4537  5003-4983  486  
10  4950-4969  5481-5462  532  
11  5367-5386  5924-5906  558  
12  5875-5895  6430-6410  556  
13  6378-6398  6944-6924  567  
14  6863-6882  7396-7376  534  
15  7272-7293  7791-7773  520  
16  7744-7763  8301-8283  558  
17  8196-8215  8740-8720  545  
18  8656-8676  9201-9183  546  
19  9127-9146  9661-9641  535  
20  9607-9627  10147-10128  541  
21  10085-10104  10649-10629  565  
22  10534-10553  11109-11089  576  
23  11054-11074  11605-11586  552  
24  11541-11561  12054-12034  514  
25  12001-12019  12545-12527  545  
26  12498-12517  13009-12991  538  
27  12940-12959  13453-13435  514  
28  13365-13383  13859-13839  495  
29  13790-13809  14374-14356  585  
30  14331-14350  14857-14838  527  
31  14797-14815  15368-15349  572  
32  15316-15334  15896-15877  581  
D1  15758-15777  16294-16274  537  
D2  16223-16244  129-110  476  
D3  15-34  389-370  375  
D4  323-343  771-752  449  
Table 2.4 - Second round primer positions 
 
 
 
 
 
 
Chapter Two 
101 
 
Second Round Primers  
Primer  Sequence  
1 Forward  
1 Reverse  
TGTAAAACGACGGCCAGTTCACCCTCTAAATCACCAG  
CAGGAAACAGCTATGACCGATGGCGGTATATAGGCTGAG  
2 Forward  
2 Reverse  
TGTAAAACGACGGCCAGTTTAAAACTCAAAGGACCTGGC  
CAGGAAACAGCTATGACCCTGGTAGTAAGGTGGAGTGGG  
3 Forward  
3 Reverse  
TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG  
TGTAAAACGACGGCCAGTAACTTAACTTGACCGCTCTGAG  
4 Forward  
4 Reverse  
TGTAAAACGACGGCCAGTACTGTTAGTCCAAAGAGGAAC  
CAGGAAACAGCTATGACCTCGTGGAGCCATTCATACAG  
5 Forward  
5 Reverse  
TGTAAAACGACGGCCAGTCAGTGACACATGTTTAACGGC  
CAGGAAACAGCTATGACCGATTACTCCGGTCTGAACTC  
6 Forward  
6 Reverse  
TGTAAAACGACGGCCAGTCAGCCGCTATTAAAGGTTCG  
CAGGAAACAGCTATGACCGGAGGGGGGTTCATAGTAG  
7 Forward  
7 Reverse  
TGTAAAACGACGGCCAGTCCTTAGCTCTCACCATCGC  
CAGGAAACAGCTATGACCAGAGTGCGTCATATGTTGTTC  
8 Forward  
8 Reverse  
TGTAAAACGACGGCCAGTAATAAACACCCTCACCACTAC  
CAGGAAACAGCTATGACCGTTTATTTCTAGGCCTACTCAG  
9 Forward  
9 Reverse  
TGTAAAACGACGGCCAGTACACTCATCACAGCGCTAAG  
CAGGAAACAGCTATGACCGATTTTGCGTAGCTGGGTTTG  
10 Forward  
10 Reverse  
TGTAAAACGACGGCCAGTTCCATCATAGCAGGCAGTTG  
CAGGAAACAGCTATGACCTGTAGGAGTAGCGTGGTAAGG  
11 Forward  
11 Reverse  
TGTAAAACGACGGCCAGTACCTCAATCACACTACTCCC  
CAGGAAACAGCTATGACCTAGTCAACGGTCGGCGAAC  
12 Forward  
12 Reverse  
TGTAAAACGACGGCCAGTCACTCAGCCATTTTACCTCAC  
CAGGAAACAGCTATGACCATGGCAGGGGGTTTTATATTG  
13 Forward  
13 Reverse  
TGTAAAACGACGGCCAGTTTAGGGGCCATCAATTTCATC  
CAGGAAACAGCTATGACCAAGAAAGATGAATCCTAGGGC  
14 Forward  
14 Reverse  
TGTAAAACGACGGCCAGTATTTAGCTGACTCGCCACAC  
CAGGAAACAGCTATGACCCATCCATATAGTCACTCCAGG  
15 Forward  
15 Reverse  
TGTAAAACGACGGCCAGTGGCTCATTCATTTCTCTAACAG  
CAGGAAACAGCTATGACCGGCAGGATAGTTCAGACGG  
16 Forward  
16 Reverse  
TGTAAAACGACGGCCAGTTAACATCTCAGACGCTCAGG  
CAGGAAACAGCTATGACCTACAGTGGGCTCTAGAGGG  
17 Forward  
17 Reverse  
TGTAAAACGACGGCCAGTACAGTTTCATGCCCATCGTC  
CAGGAAACAGCTATGACCGTATAAGAGATCAGGTTCGTC  
18 Forward  
18 Reverse  
TGTAAAACGACGGCCAGTACCACCCAACAATGACTAATC  
CAGGAAACAGCTATGACCGTTGTCGTGCAGGTAGAGG  
19 Forward  
19 Reverse  
TGTAAAACGACGGCCAGTATCCTAGAAATCGCTGTCGC  
CAGGAAACAGCTATGACCATTAGACTATGGTGAGCTCAG  
20 Forward  
20 Reverse  
TGTAAAACGACGGCCAGTCATCCGTATTACTCGCATCAG  
CAGGAAACAGCTATGACCTAGCCGTTGAGTTGTGGTAG  
21 Forward  
21 Reverse  
TGTAAAACGACGGCCAGTCAACACCCTCCTAGCCTTAC  
CAGGAAACAGCTATGACCAGGCACAATATTGGCTAAGAG  
22 Forward  
22 Reverse  
TGTAAAACGACGGCCAGTATCGCTCACACCTCATATCC  
CAGGAAACAGCTATGACCATGATTAGTTCTGTGGCTGTG  
23 Forward  
23 Reverse  
TGTAAAACGACGGCCAGTCTAATCTCCCTACAAATCTCC  
CAGGAAACAGCTATGACCTAGGTCTGTTTGTCGTAGGC  
24 Forward  
24 Reverse  
TGTAAAACGACGGCCAGTTCCTTGTACTATCCCTATGAG  
CAGGAAACAGCTATGACCCGTGTGAATGAGGGTTTTATG  
25 Forward  
25 Reverse  
TGTAAAACGACGGCCAGTACAATGGGGCTCACTCACC  
CAGGAAACAGCTATGACCGTGGCTCAGTGTCAGTTCG  
26 Forward  TGTAAAACGACGGCCAGTCATGTGCCTAGACCAAGAAG  
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26 Reverse  CAGGAAACAGCTATGACCCTGATTTGCCTGCTGCTGC  
27 Forward  
27 Reverse  
TGTAAAACGACGGCCAGTGCCCTTCTAAACGCTAATCC  
CAGGAAACAGCTATGACCGGGAGGTTGAAGTGAGAGG  
28 Forward  
28 Reverse  
TGTAAAACGACGGCCAGTCGGGTCCATCATCCACAAC  
CAGGAAACAGCTATGACCGTTAGGTAGTTGAGGTCTAGG  
29 Forward  
29 Reverse  
TGTAAAACGACGGCCAGTACCTAAAACTCACAGCCCTC  
CAGGAAACAGCTATGACCAGGATTGGTGCTGTGGGTG  
30 Forward  
30 Reverse  
TGTAAAACGACGGCCAGTCAACCACCACCCCATCATAC  
CAGGAAACAGCTATGACCAAGGAGTGAGCCGAAGTTTC  
31 Forward  
31 Reverse  
TGTAAAACGACGGCCAGTATTCATCGACCTCCCCACC  
CAGGAAACAGCTATGACCGGTTGTTTGATCCCGTTTCG  
32 Forward  
32 Reverse  
TGTAAAACGACGGCCAGTAGCCCTAGCAACACTCCAC  
CAGGAAACAGCTATGACCTACAAGGACAGGCCCATTTG  
D1 Forward  
D1 Reverse  
TGTAAAACGACGGCCAGTATCGGAGGACAACCAGTAAG  
CAGGAAACAGCTATGACCGTGGGTAGGTTTGTTGGTATC  
D2 Forward  
D2 Reverse  
TGTAAAACGACGGCCAGTCTCAACTATCACACATCAACTG  
CAGGAAACAGCTATGACCAGATACTGCGACATAGGGTG  
D3 Forward  
D3 Reverse  
TGTAAAACGACGGCCAGTCACCCTATTAACCACTCACG  
CAGGAAACAGCTATGACCCTGGTTAGGCTGGTGTTAGG  
D4 Forward  
D4 Reverse  
TGTAAAACGACGGCCAGTGCCACAGCACTTAAACACATC  
CAGGAAACAGCTATGACCTGCTGCGTGCTTGATGCTTG  
Table 2.5 - Second round primer sequences 
 
 
2.2.4.3 Agarose gel electrophoresis 
Agarose was dissolved in a 1x TAE buffer by heating in a microwave until boiling – the 
concentration of agarose was varied according to the level of PCR product separation 
that was required. 4µl of GelRed per 100mls agarose gel was then added to the 
solution, for DNA visualisation. The solution was poured into a cast, with a 20-prong 
comb insert to form loading wells, and allowed to set before use.  
Approximately 1µl loading dye was added to each PCR product and mixed thoroughly 
by pipetting. 5µl of each PCR product/loading dye solution was then subsequently 
loaded into an agarose gel well. An appropriate commercially available base pair 
ladder was also loaded onto the gel to allow for sizing of the separated PCR products. 
Gels were electrophoresed in a tank containing 1x TAE buffer at 70 volts until products 
were sufficiently separated. PCR products were visualised using UV light.  
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2.2.4.4 Single molecule PCR 
2.2.4.4.1 First round PCR 
For single molecule PCR, the cell lysates from the above stage needed to be diluted – 
initial dilutions of 1:10 and 1:100 were made, to give concentrations of 10-2 and 10-3. 
Dilutions were made in Tris-EDTA (TE) buffer - 5μl template: 45μl TE for 1:10, and 5μl 
(1:10): 45μl TE for 1:100. 
Once the serial dilutions of template mtDNA had been performed, the first round PCR 
mastermix was made up (100x master-mix for a 96 well plate - 200μl buffer, 200μl 
betaine, 150μl dNTPs, 50μl primer 2999F, 50μl primer 2949R, 10μl bromophenol blue, 
4μl Phusion™ polymerase, and 243.6μl dH20) (Table 2.6). This mastermix was split into 
aliquots of 150µl in six 0.5ml eppendorph tubes. 14.4μl of 10-2 template DNA was 
added to into each ‘mini-mix’ and mixed well using a bench-top vortex giving a 
template DNA concentration of 9 x 10-2 for the first round of smPCR. 10µl of mini-
mix/template DNA solution was then distributed into each well of a 96-well plate, 
touching the bottom of each well with the pipette tip (2 x 8-well-rows per sample, 6 
samples per plate). A drop of oil was then added to each well. The plate was sealed, 
pulse spun down using a centrifuge, and then kept on ice until a PCR machine was up 
to temperature to start the first-round PCR run. First round smPCR cycle conditions 
were: 94°C for 1 minute, then 35 cycles of 94°C for 20 seconds, 68°C for 16 minutes; 
hold at 4°C. 
 
2.2.4.4.2 Second round PCR 
Using a multi-channel pipette, 1.6μl first round smPCR product from each well was 
transferred to a clean 96-well plate; a drop of oil was then added on top of the PCR 
product in each well of the new plate while the second round master-mix was made. 
The plate was pulse spun down the plate using a centrifuge. The plate was kept on ice 
while the second round smPCR master-mix was made up (100x master-mix for a 96 
well plate – 530μl dH20, 100μl LA Buffer, 150μl dNTPs, 100μl primer 3160F, 100μl 
primer 2494R, 10μl bromophenol blue, 10μl LA Taq)(Table 2.6). 10μl second round 
smPCR master-mix was added into each well, on top of the oil, and then the plate was 
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pulse spun down using a centrifuge. The plate was kept on ice until a PCR machine was 
up to temperature to start the second-round PCR run. Second round smPCR cycle 
conditions were: 94°C for 1 minute, then 20 cycles of 94°C for 20 seconds, 68°C for 16 
minutes; hold at 4°C. 
 
 Single molecule PCR primers 
Primer Primer 
position 
Sequence Size (inc. 
primers) 
2999F 2999 – 3028 GTCCTGTAGGGCTACCACGTCGGCGATAAT 16,519 
2949R 2918 - 2949 GGATTGCGCTGTTATCCCTAGGGTAACTTGTT 
3160F 3160 - 3191 TCGCGGAAGGGGGCATTTACTATAGTAGAGTT 15,903 
2494R 2462 - 2494 GCGGGGTAAGATTTGCCGAGTTCCTTTTACTT 
Table 2.6 - Single molecule PCR primer positions and sequences 
 
2.2.4.4.3 Agarose gel electrophoresis 
Agarose was dissolved in a 1x TAE buffer by heating in a microwave until boiling – the 
concentration of agarose was varied according to the level of PCR product separation 
that was required. 4µl of GelRed per 100mls agarose gel was then added to the 
solution, for DNA visualisation. The solution was poured into a cast, with a 20-prong 
comb insert to form loading wells, and allowed to set before use.  
Using a multi-channel pipette, approximately 1µl loading dye was added to each well 
of the smPCR plate and mixed with the PCR products. 5µl of this mixture from each 
well was then subsequently loaded into an agarose gel well. An appropriate 
commercially available base pair ladder was also loaded onto the gel to allow for sizing 
of the separated PCR products. Gels were electrophoresed in a tank containing 1x TAE 
buffer at 70 volts until products were sufficiently separated. PCR products were 
visualised using UV light.  
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2.2.4.4.4 Result interpretation 
To ensure that there were enough smPCR product bands to analyse, while at a low 
enough quantity to be sure that each well started with s single mtDNA molecule to 
amplify, the aim was to have ~¼ wells successfully amplify a PCR product. If no bands, 
or too few product bands were obtained, the DNA concentration per well for first 
round PCR needed to be increased, 2 rows total per DNA sample as below: 
4 wells of 5 x 10-2/well, + 15μl MM (total 20μl/well) 
4 wells of 3 x 10-2/well, + 17μl MM (total 20μl/well) 
8 wells of 1 x 10-2/well; make a 90μl MM + 9μl of 10-2 template, aliquot 10μl/well (total 
10μl/well) 
If a higher proportion of wells produced product bands, the starting DNA 
concentration needed to be diluted according to calculations from the Poisson 
distribution table (Table 2.7) and the smPCR protocol repeated. The level of dilution 
required involved working out the fraction of positive well results from a sample (e.g. 8 
wells out of 16 would be 0.5), and from this obtain the ‘true number’ of copies per 
sample from Table 2.7 (working fraction of 0.5 would gave a ‘true number’ of copies of 
0.69). To ensure that the PCR is being run at single molecule level, 1/4 successful gel 
lanes should be aimed for (i.e. a 0.25 success rate, with a ‘true’ success rate of 0.29). 
This gives the ratio of observed to desired success rate (0.69/0.29, or 2.4, in this 
example). The original quantity of template DNA per well was then divided by the 
observed: desired ratio, to calculate the optimal concentration to run smPCR with this 
sample.  
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Fraction of 
positives 1-p(0) 
True no of copies 
per sample 
fraction of doublets 
p(2) 
fraction of 
multiplets 1-p(0)-
p(1) 
0 - - - 
0.05 0.05 0 0 
0.1 0.11 0 0.01 
0.15 0.16 0.01 0.01 
0.2 0.22 0.02 0.02 
0.25 0.29 0.03 0.03 
0.3 0.36 0.04 0.05 
0.35 0.43 0.06 0.07 
0.4 0.51 0.08 0.09 
0.45 0.6 0.1 0.12 
0.5 0.69 0.12 0.15 
0.55 0.8 0.14 0.19 
0.6 0.92 0.17 0.23 
0.65 1.05 0.19 0.28 
0.7 1.2 0.22 0.34 
0.74 1.35 0.24 0.39 
0.75 1.39 0.24 0.4 
0.8 1.61 0.26 0.48 
0.85 1.9 0.27 0.57 
0.9 2.3 0.27 0.67 
0.925 2.59 0.25 0.73 
0.9333 2.71 0.24 0.75 
0.95 3 0.22 0.8 
Table 2.7 – Poisson distribution table 
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2.2.4.5 Real-time PCR (qPCR) 
2.2.4.5.1 Detection of mtDNA deletions by real-time PCR 
Deletions in the mitochondrial genome were detected and quantified using a multiplex 
real-time PCR method, MTND1/MTND4 qPCR, as described by Krishnan et al. (Krishnan 
et al., 2007). The ND1 gene (MTND1) lies within the minor arc of the mitochondrial 
genome, an area rarely involved in deletions, while the ND4 gene (MTND4) is encoded 
within an area of the major arc of the mitochondrial genome taken out in almost every 
large-scale mtDNA deletion.  The difference in the relative proportions of these genes, 
as measured by quantitative PCR, can then be used as an accurate indication of mtDNA 
deletions present in tissue samples or lysed single cells.   
Primers were designed to flank the MTND1 and MTND4 regions of the genome, in 
order to specifically amplify these two regions. Fluorescently-tagged (VIC and FAM) 
probes were also designed to bind to these specific areas (Table 2.8, Table 2.9); the 
fluorescent dye was inactivated using a TAMRA quencher. The quencher is removed 
from the fluorescently-tagged probe by the 5’nuclease of the DNA polymerase once 
the probe has annealed, allowing a fluorescent signal to be emitted to indicate specific 
amplification. The intensity of this fluorescent signal was measured throughout the 
real-time PCR run to quantify levels of DNA amplification, and was compared to the 
fluorescent signal of a passive reference dye for normalization.  
Real-time PCR reactions were all set up in the UV-hood in 96-well plates, and all 
samples were run in triplicate. Each plate was run with 6 wells of no-template control, 
and triplicates of a blood sample and 3 deletion standards. No-template control wells 
were to ensure that there was no DNA contamination in any reagents or consumables, 
and the deletion standards were to check that the deletion levels calculated from the 
relative levels of ND1 and ND4 were accurate on each run. Any deletion level detected 
in the blood sample was subtracted from all other sample results. Each well contained 
1µl of template DNA and 24µl of reaction mastermix containing 12.5µl TaqMan 
Universal mastermix, 0.5µl ND1 probe (5µM stock), 0.5µl ND4 probe (5µM stock), 0.75 
ND1 forward primer (10µM working stock), 0.75 ND1 reverse primer (10µM working 
stock), 0.75 ND4 forward primer (10µM working stock), 0.75 ND4 reverse primer 
(10µM working stock) and 7.5µl dH20. The plate was sealed using a MicroAmp™ 
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Optical Adhesive Film and centrifuged down. Real-time PCR plates were run on an ABI 
Step-one Plus Real Time PCR system. Reaction cycle conditions were: 2 minutes at 
50⁰C, 10 minutes at 95⁰C, and then 40 cycles of 15 seconds at 95⁰C and 1 minute at 
60⁰C. 
When the plate had been completely processed by the ABI Step-one Plus Real Time 
PCR system, results were exported from the machine into a spread sheet format, and 
analysed using Microsoft Excel. Average Ct values were calculated from the triplicate 
runs of each sample, where Ct is the cycle threshold (the cycle number at which the 
level of DNA amplification exceeded a pre-determined threshold), and a ∆Ct was 
calculated by subtracting the average ND1 Ct value from the average ND4 Ct value. The 
∆Ct is indicative of the difference between wildtype (ND4) and total (ND1) mtDNA 
levels, and so mtDNA deletion heteroplasmy can be calculated from this value. First, 
the ∆Ct of the blood sample was subtracted from all other data sets, to increase 
accuracy of calculated deletion levels. The percentage mtDNA deletion heteroplasmy 
level was then calculated with the equation:  
%deletion = (1-(2^-∆Ct))*100.  
 
2.2.4.5.2 Detection of relative mtDNA copy number by real-time PCR 
The multiplex qPCR assay outlined above can be run in conjunction with one further 
assay, to amplify and detect 18S rRNA, to measure depletion of mitochondrial DNA. 
18S rRNA is a nuclear gene, so amplification of MTND1 alongside this allows for 
calculation of the number of mtDNA copies relative to nuclear DNA. As 18S rRNA is a 
multi-copy gene present in an unknown quantity in each sample, it is not possible to 
accurately quantify absolute mtDNA copy number using this method. However, 
relative copy number can be compared to an appropriate control to determine 
whether there is evidence of mtDNA depletion. This assay is only appropriate for use 
with tissue samples, as 18S rRNA is not present in a sufficient quantity for detection by 
qPCR in single lysed cells. 
Amplification of 18S rRNA was run alongside the ND1/ND4 assay to allow for 
simultaneous screening of mtDNA deletion level and depletion in a single real-time 
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PCR run.  Primers were designed to specifically flank to 18S rRNA region, and a 
fluorescent FAM-tagged probe – inactivated by a TAMRA quencher until bound - was 
designed to specifically bind to amplified 18S rRNA (Table 2.8, Table 2.9). 3 extra 
standards with known mtDNA copy number were run in triplicate alongside samples 
when running the 18S rRNA assay, to ensure that all results were as accurate as 
possible. 
As for the ND1/ND4 qPCR assay, all 18S rRNA real-time PCR reactions were all set up in 
the UV-hood in 96-well plates, and all samples were run in triplicate. Each well for the 
18S rRNA qPCR assay contained 1µl of template DNA and 24µl of reaction mastermix 
containing 12.5µl TaqMan Universal mastermix, 0.75µl 18S rRNA probe (5µM stock), 
0.13 18S rRNA forward primer (10µM working stock), 0.75 18S rRNA reverse primer 
(10µM working stock) and 9.87µl dH20. The plate was sealed using a MicroAmp™ 
Optical Adhesive Film and centrifuged down. Real-time PCR plates were run on an ABI 
Step-one Plus Real Time PCR system. Reaction cycle conditions were: 2 minutes at 
50⁰C, 10 minutes at 95⁰C, and then 40 cycles of 15 seconds at 95⁰C and 1 minute at 
60⁰C. 
To quantify the amount of MTND1 present in a sample compared to 18S rRNA, average 
Ct values were first calculated from the triplicate runs of each sample. A ∆Ct for each 
sample was then calculated by subtracting the average 18S rRNA Ct value from the 
average ND1 Ct value. The samples were normalised to the blood control by 
subtracting the blood ∆Ct from all other sample ∆Ct values. Relative mtDNA copy 
number could then be calculated using the equation R = 2-∆Ct. The ∆Ct is indicative of 
the difference between wildtype (ND4) and total (ND1) mtDNA levels, and so mtDNA 
deletion heteroplasmy can be calculated from this value. First, the ∆Ct of the blood 
sample was subtracted from all other data sets, to increase accuracy of calculated 
deletion levels. The percentage mtDNA deletion heteroplasmy level was then 
calculated with the equation %deletion = (1-(2^-∆Ct))*100.  
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Real time PCR primers  
Primer Primer position 
 Forward Reverse 
ND1 L 3485 – 3504 H 3506 – 3553 
ND4 L 12087 - 12109 H 12170 - 12140 
18S L 1050 - 1071 H 1115 - 1135 
Table 2.8 - Real time PCR primer and probe positions 
 
Real time PCR primers and probes  
Primer Sequence 
ND1 F CCCTAAAACCCGCCACATCT 
ND1 R GAGCGATGGTGAGAGCTAAGGT 
ND1 VIC probe VIC-5’-CCATCACCCTCTACATCACCGCCC-3’-TAMRA 
ND4 F CCATTCTCCTCCTATCCCTCAAC 
ND4 R CACAATCTGATGTTTTGGTTAAACTATATTT 
ND4 FAM probe FAM-5’-CCGACATCATTACCGGGTTTTCCTCTTG-3’-
TAMRA 
18S F GCCGCTAGAGGTGAAATTCTTG 
18S R CATTCTTGGCAAATGCTTTCG 
18S FAM probe FAM-5’-CCGGCGCAAGACGGACCAGA-3’-TAMRA 
Table 2.9 - Real time PCR primer and probe sequences 
 
2.2.4.5.3 Generation of DNA templates for copy number standard curves 
ND1 and ND4 template DNA was isolated from wildtype DNA using  standard long 
range PCR (primers 6F and 7R for ND1, 25F and 26R for ND4) to give approximately 1kb 
PCR products. PCR products were run out on a 0.7% agarose gel at 70 volts for 1 hour; 
products were then excised from the gel with a scalpel, and collected into a 1.5ml 
eppendorph tube. The amplified DNA templates were then extracted from the gel 
using a QIAGEN gel extraction kit (quick spin protocol).  The gel slice was weighed by 
comparing the weight of the eppendorph containing the excised gel to an empty 
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eppendorph; 3 volumes of Buffer QG were then added to one volume of gel (i.e. 300µl 
of Buffer QG to each 100mg of gel. The eppendorph containing the gel slice and buffer 
was then incubated at 50⁰C for 10 minutes, and mixed by vortexing every 2-3 minutes 
during the incubation. After the gel slice was completely dissolved, the gel slice should 
have been yellow, indicating that the solution is at pH7.5 and appropriate for use with 
the QIAquick membrane. If orange or violet, indicating a higher pH, 10µl of 3M sodium 
acetate pH 5 was added and mixed thoroughly by vortexing, to correct the pH.  
When an appropriate pH was achieved, 1 gel volume of isopropanol was added to the 
sample and mixed. The sample was then applied to a QIAquick column, placed in a 2ml 
collection tube, and centrifuged for 1 min at 16,000 x g. Flow through was discarded 
from the collection tube, and the spin column placed back into the same 2ml collection 
tube. 0.5ml of Buffer QG was then applied to the QIAquick column and centrifuged for 
1 minute at 16,000 x g, to remove all traces of agarose from the solution. 0.75ml of 
Buffer PE was then added to the QIAquick column and centrifuged at 16,000 x g for 1 
minute to wash the membrane. All flow-through was then discarded, and the QIAquick 
spin column was placed back into the same 2ml collection tube. The QIAquick column 
was then centrifuged for an additional minute at 17.900 x g to remove all residual 
ethanol from buffer PE. The collection tube and any flow through were then discarded, 
and the QIAquick column was placed into a clean 1.5ml microcentrifuge tube. To elute 
the DNA from the membrane in the QIAquick spin column, 50µl of Buffer EB (10mM 
Tris-Cl, pH 8.5) was added to the QIAquick membrane, and the column was centrifuged 
for 1 minute at 16,000 x g. DNA is collected in approximately 48µl of elution in the 
1.5ml microcentrifuge tube; the spin column was discarded after this step. 
The DNA content of the purified DNA was measured using the Nanodrop ND-1000 
Spectrophotometer. Isolated template DNA was then sequentially diluted 1 in 10 a 
total of ten times to create a serially diluted standard curve with known DNA content. 
The two sets of serial dilutions were then run on a plate of real time PCR, using ND1 or 
ND4 primers and probe respectively, to assess the levels of template DNA present in 
each dilution. The resulting Ct values were plotted against log known copy number to 
obtain a standard curve, from which copy number (total copy number from ND1, 
wildtype copy number from ND4) for single cells could be estimated.  
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2.2.4.5.4  Quantification of mtDNA copy number by standard curve in single cells 
The ND1/ND4 multiplex qPCR is carried out as standard (2.2.4.5.1), including wells for 
both sets of serial dilutions (2.2.4.5.3) to obtain ND1 and ND4 Ct values for all samples. 
Average Ct values were then calculated for both ND1 and ND4 from each sample. A 
standard curve was then plotted from each serial dilution - Ct values were plotted 
against log known copy number - and the equation for this standard curve was 
calculated. The equation for this standard curve was determined to be y = x * (Ct + z), 
where y represents log10 of absolute copy number (ND1 Ct value) or absolute wildtype 
mtDNA copy number (ND4 Ct value) present in 1µl of cell lysate, x is the slope of the 
standard curve, and z is the value at which the standard curve crosses the y axis. Copy 
number per unit area of the cell could then be calculated using the equation cu = (y x 
15)/cell area, where cu is the copy number per unit area of the cell, and 15 is the total 
quantity of lysate obtained per cell. Copy number per unit area of the cell, as derived 
from these two equations, is then a value comparable across all copy number results 
from single fibres on this ND1/ND4 qPCR run. 
 
2.2.4.5.5 Generation of a universal standard curve for ND1 and ND4 copy number 
Through the method outlined above, a new standard curve was required to be 
generated and run with the samples through the ND1/ND4 qPCR assay for each new 
set of samples. This was both time-consuming and inefficient, and meant that samples 
from different batches (i.e. run with separately generated standard curves) did not 
have comparable results. To resolve this, a universal standard curve needed to be 
generated. A set of serial dilutions of wildtype mtDNA of known concentration and 
copy number was prepared by Dr Kim Krishnan. This was run through the ND1/ND4 
qPCR assay, as standard (2.2.4.5.1) to obtain Ct values for both ND1 and ND4 from 
each lysed fibre. Average Ct values were calculated for both ND1 and ND4 from each 
sample. The resulting Ct values were plotted against log known copy number to obtain 
a standard curve. The equation for this standard curve was determined to be y = -
3.0024 x (Ct + 40), where y represents log10 absolute copy number (ND1 Ct value) or 
absolute wildtype mtDNA copy number (ND4 Ct value) present in 1µl of cell lysate. 
Copy number per unit area of the cell could then be calculated using the equation cu = 
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(y x 15)/cell area, where cu is the copy number per unit area of the cell, and 15 is the 
total quantity of lysate obtained per cell. Copy number per unit area of the cell, as 
derived from these two equations, is then a value comparable across all copy number 
results from single fibres analysed through the ND1/ND4 qPCR assay. Three samples 
from the original set of serial dilutions, stored in aliquots at -80⁰C, were then included 
as copy number standard controls with every plate of real-time PCR for copy number 
analysis, to ensure that the results from each plate were accurate. 
 
2.2.5  Cycle Sequencing 
2.2.5.1  Generation of DNA templates for sequencing 
Samples for sequencing were primarily amplified using TaKaRa LA Taq, as outlined in 
2.2.4.2.1. This generated 50µl of PCR product from which to work from throughout the 
rest of this protocol, and almost every mtDNA deletion for which sequencing was 
required was captured in the 10kb region of the mitochondrial genome that was 
amplified by this technique. PCR products were separated by gel electrophoresis, as 
outlined in 2.2.4.3, alongside a suitable DNA ladder. As the size of the wildtype PCR 
product was known to be 10kb, the size of the PCR product obtained from each sample 
was indicative of the expected mtDNA deletion size (i.e. a 6kb PCR product would 
indicate a 4kb mtDNA deletion). 
 
2.2.5.2  Restriction endonuclease digest 
To more accurately determine where in the amplified 10kb region of the mitochondrial 
genome the mtDNA deletion was located, a restriction endonuclease digest was 
performed. In a 200µl thin-walled PCR tube, 5µl ddH20, 2µl NE Buffer2, 1µl 10 x BSA, 
0.25µl Xho1, 0.25µl Bam H1, 0.25µl Xcm1, and 0.25µl Dra1 were mixed thoroughly by 
vortexing. 2µl of PCR product were then added to the restriction digest buffer, and 
mixed thoroughly by vortexing. The restriction digest was incubated in a humidified 
chamber for 1 hour at 37⁰C. The products from this digest were then separated by gel 
electrophoresis (2.2.4.3), to assess fragment size.  
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There were predicted sizes for each of the 6 fragments created from this digest of a 
wildtype mtDNA molecule, and each of these fragment sizes was associated with a 
section of the mitochondrial genome (Table 2.10, Table 2.11). By determining which of 
these fragments were present or absent, a predication could be made as to where the 
mtDNA deletion lay in the genome. A table was consulted, based upon which of these 
restriction fragments were successfully identified when separated by gel 
electrophoresis, in order to identify which reverse primer would be most likely to 
amplify across the mtDNA deletion breakpoint for identification by sequencing (Table 
2.11). If this primer was then unsuccessful, a nested primer would then be used, 
continuing until the deletion breakpoints were identified.  
 
2.2.5.3  Purification of PCR products 
Before cycle sequencing, 5µl of each PCR product was transferred to a 96-well plate on 
ice; 2µl ExoSAP-IT was then added to each sample. ExoSAP-IT, which contains alkaline 
phosphatase and Exonuclease I, removes any excess primers or deoxynucleotides from 
the PCR product to prevent interference with downstream sequencing. The plate was 
then sealed with capstrips, and placed in a GenAmp PCR system 9700. The plate was 
incubated at 37⁰C for 15 minutes, to digest primers and dNTPs, followed by 15 minutes 
at 80⁰C to denature the components of ExoSAP-IT. The plate was then removed from 
the thermal cycler and placed back on ice. 
 
2.2.5.4  Cycle Sequencing 
BigDye amplification of the purified PCR products was carried out next; 7µl of dH20, 3µl 
of 5 x sequencing buffer, 1µl of an appropriate primer (10mM) and 2µl of BigDye® v3.1 
were added to each well of the 96-well plate that contained a sample. The plate was 
re-sealed with capstrips after this step. The plate was then placed back into a GenAmp 
PCR system 9700 under the following conditions: 1 minute at 96⁰C, then 25 cycles of 
96⁰C for 10 seconds, 50⁰C for 5 seconds and 60⁰C for 4 minutes. At this point the plate 
could be carried forward straight into the precipitation step, or stored at -20⁰C until 
required. 
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2.2.5.5  Precipitation and sequencing 
For the precipitation step, 2µl of 3M sodium acetate, 2µl of 125mM of EDTA and 50µl 
of 100% Analar ethanol were added to each sample in the 96-well plate. The plate was 
then sealed with capstrips, inverted 4 times to mix the contents of each individual well, 
and allowed to incubate for 15 minutes at room temperature. Following this, the plate 
was spun in a centrifuge at 2090g for 30 minutes, before being unsealed, inverted onto 
white tissue paper and spun in a centrifuge at 100g for 2 minutes to remove 
supernatants. 70µl of 70% Analar ethanol was added to each well to wash the sample, 
and the plate was then sealed and spun at 1650g for 15 minutes. The supernatant was 
then removed from each well by unsealing the plate, inverting it onto white tissue 
paper and spinning in a centrifuge at 100g for 2 minutes. The plate was then left to air-
dry in the dark for 15 minutes. 
Once the plate of samples had been left to dry, 10µl of HiDi formamide was added to 
each sample, and the plate was heated to 95⁰C for 2 minutes in a GenAmp PCR system 
9700. This incubation was designed to separate the DNA strands for each sample, and 
HiDi aids this process by lowering the melting point of the DNA. The plate was then 
placed in an ABI 3130xl Automated DNA Sequencer to run. Using SeqScape software, 
the fragments were aligned and compared to the Cambridge Reference Sequence 
(Anderson et al., 1981a).  
 
Position Expected band size 
10416 – 12270 1854 
12270 – 135700 1430 
13700 – 14257 557 
14257 – 14954 697 
14954 – 16009 1055 
16009 - 16450 441 
Table 2.10 - Predicted bands from restriction digest of wildtype mtDNA 
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441bp 1055bp 697bp 557bp 1430bp 1854bp Primer 
√      16450R 
X √     PINK25R 
X X √    31R 
X X X √   29R 
X X X X √  28R 
X X X X X √ 25R 
Table 2.11 - Sequencing primer to use, as predicted by restiction digest 
 
2.2.6  Statistical analysis 
Unless stated otherwise, all statistical analysis was carried out using GraphPad Prism 
v.4 statistical software. Both parametric and non-parametric tests were used and 
individual tests are stated in the relevant chapters. 
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Chapter 3 
Analysis of the accumulation of mtDNA deletions longitudinally 
through skeletal muscle fibres. 
3.1 Introduction 
3.1.1 Proposed mechanisms of clonal expansion of mtDNA deletions 
Elucidating the mechanism by which mtDNA deletions clonally expand is key to 
understanding how these DNA defects reach pathogenic levels to cause biochemical 
defects in mitochondrial disease and in aging; a number of hypothetical mechanisms 
have been proposed. These can be split broadly into three categories. Firstly, 
hypothetical “mtDNA structure” mechanisms suggest that an advantage is gained by 
the direct change to the mtDNA imparted by a mutation; this advantage is not 
necessarily associated with any functional change to mtDNA encoded proteins. The 
most prominent and widely studied of these is the ‘survival of the smallest’ 
mechanism, as discussed section 1.7.1, (Figure 1.20). An alternative mtDNA structure-
based mechanism, proposed by Shoubridge et al in 1990, suggests that mutations 
which go on to clonally expand may eliminate or inactivate negative cis-acting 
proliferative control elements (Shoubridge et al., 1990). This would provide a 
proliferative advantage over wild-type mtDNA, allowing mutant mtDNA to replicate 
independent of metabolic demands and resulting in an accumulation of higher levels 
of mutant mtDNA. This particular mechanism is attractive in that it is able to 
simultaneously account for the accumulation of both mtDNA deletions and mtDNA 
point mutations over time; both of these mutation types have the capacity to affect a 
control sequence, while mtDNA point mutations do not alter mtDNA size in the same 
manner as mtDNA deletions.  
The second group of proposed mechanisms for clonal expansion can be described as 
“phenotype-based” hypotheses, due to their assertion that the propagative advantage 
which allows for the accumulation of mutant mtDNA over wildtype is due to the 
mutation’s downstream effect on mitochondrial enzyme activity rather than the 
primary change to the mtDNA molecule.  The ‘survival of the slowest’ hypothesis (see 
section 1.7.2, Figure 1.21), is the most well-known example of a phenotype-based 
hypothesis, though an earlier phenotype-based hypothesis had been proposed by  
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Shoubridge et al as an alternative to the inactivated cis-acting control elements model 
– also suggesting that the impaired ability of mitochondria carrying mtDNA mutations 
to synthesise cellular ATP is the driving force behind the accumulation of mutant 
mtDNA (Shoubridge et al., 1990). The decline in ATP production could trigger a 
metabolic feedback loop where declining levels of ATP drive increased mitochondrial 
biogenesis, potentially increasing the level of mutant mtDNA and dysfunctional 
mitochondria. This hypothesis was based on earlier evidence in skeletal muscle that 
increased oxidative demand leads to an increase in mitochondria proliferation 
(Salmons and Henriksson, 1981; Williams et al., 1986). This hypothesis was later 
adopted by another research group as a mechanism that could drive the clonal 
expansion of both mtDNA point mutations and deletions, being applicable to known 
mtDNA point mutations which affected no known proliferative control sequence, and 
was dubbed the ‘crippled mitochondria’ theory (Yoneda et al., 1992). 
More recently, it was proposed that a selective advantage may not be required for the 
clonal expansion of mtDNA deletions – proposed mechanisms which fall under this 
category can be widely termed “random segregation” hypotheses. These suggest that 
random genetic drift during mtDNA replication could be sufficient to allow clonal 
expansion of a single mtDNA mutation within a cell (Chinnery and Samuels, 1999; Elson 
et al., 2001) due to relaxed mtDNA replication (Bogenhagen and Clayton, 1977) (see 
section 1.7.3, Figure 1.22) . Random genetic drift is supported by mathematical models 
based on previously demonstrated principles of mitochondrial replicative dynamics 
(Shadel and Clayton, 1997), but the presence of high levels of deleted mtDNA in all 
substantia nigra neurons from aged individuals (Bender et al., 2006; Reeve et al., 
2008a) is challenging to explain based on an accumulation of mtDNA deletions by 
random genetic drift. 
 
3.1.2 Recent amendment to the ‘survival of the smallest’ theory of clonal expansion 
In the same year that the ‘survival of the slowest’ mechanism for the clonal expansion 
of mtDNA deletions was put forward, the identification of pathogenic point mutations 
able to accumulate  over time in patient cells caused the ‘survival of the smallest’ 
hypothesis to fall out of favour within the scientific community. Point mutations 
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maintain an identical genome size to wild-type mtDNA molecules, meaning that the 
accumulation of pathogenic mtDNA point mutations over time cannot be driven by a 
replicative advantage based on size (Weber et al., 1997). Furthermore, a study of 
replicative dynamics found that all mitochondrial DNA molecules are replicated in 
under two hours (Davis and Clayton, 1996); this fast rate of replication is much quicker 
than the rate of mitochondrial turnover in any cell types in which the clonal expansion 
of mtDNA deletions normally occurs. This would suggest that replication of the DNA is 
not a rate-limiting step during mitochondrial biogenesis, making it unlikely that the 
smaller genome size of mitochondrial genomes with deletions confers a selective 
advantage (Weber et al., 1997). 
An amendment to the ‘survival of the smallest’ mechanism was proposed in 2001, 
suggesting that the shorter size of mtDNA deletions may confer a selective advantage 
without influencing the speed at which the genome is replicated (Birky, 2001). This 
hypothesis, which was designed to address the issues that had been raised in 
opposition to the ‘survival of the smallest’ mechanism, was heavily influenced by the 
finding that mtDNA copy number control is based upon total mtDNA content within 
the cell in terms of mass as opposed to control of the number of individual mtDNA 
molecules (Tang et al., 2000a). Based upon this finding, Birky suggested that short 
deleted genomes would have to undergo more rounds of replication than longer wild-
type genomes to reach a prescribed mtDNA mass within the cell, leading to an increase 
in the proportion of short genomes (Birky, 2001). However, further analysis of this 
model determined that equilibrium would be reached when the ratio of deleted 
mtDNA:wildtype molecules was equal to the reciprocal ratio of the genome lengths. In 
this case, the common deletion would not rise above 60%, which is not in keeping with 
the high heteroplasmy levels seen in patient cells. While this mechanism may 
therefore not play a role in the clonal expansion of mtDNA deletions - due to the 
predicted slow accumulation of mutant mtDNA and the inability of the mechanism to 
account for high heteroplasmy levels for most mtDNA deletions -  it has been 
suggested that this copy number control mechanism may stabilise mtDNA deletion 
heteroplasmy levels (De Grey, 2003). 
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3.1.3 Recent evidence supporting the ‘survival of the smallest’ theory of clonal 
expansion. 
New evidence in support of the ‘survival of the smallest’ mechanism of clonal 
expansion emerged from a 2002 study of cellular mtDNA, contradicting the evidence 
which had been amassing in opposition to this hypothesis in previous years.  This work 
was carried out in cytoplasts derived from fibroblasts of patients with mtDNA disease 
to investigate whether smaller, deleted mtDNA molecules do have a replicative 
advantage in cells (Diaz et al., 2002). Two groups of cytoplasts were derived – one 
group with heteroplasmic large-scale mtDNA deletions and a second group with 
heteroplasmic mtDNA point mutations – both of which were first investigated during 
normal, non-selective cell conditions under the exertion of tight copy number control. 
After 45 days in culture, mtDNA deletion levels had dropped by 10 to 20% in the 
heteroplasmic deletion cybrids lines, while mtDNA point mutations had also shown a 
small decrease in mutation heteroplasmy levels in the cybrids carrying point mutations 
(Diaz et al., 2002). This initial finding was in keeping with previous work which has 
shown cells with the highest percentage of deleted mtDNA molecules to have the 
longest population doubling time (Hayashi et al., 1991).  
Following analysis in normal cellular conditions, both sets of cytoplasts underwent 
treatment with ethidium bromide (EtBr) to deplete the mtDNA, inducing mtDNA 
repopulation and hence allowing the investigation of mtDNA replication under relaxed 
copy number control.  Following the EtBr treatment, no increase in point mutation 
heteroplasmy levels was observed in the set of cytoplasts harbouring pathogenic point 
mutations, showing no difference in repopulation rate compared to wild-type mtDNA. 
However, a much greater mtDNA deletion heteroplasmy was observed following EtBr 
mitochondrial depletion and repopulation in the cytoplast lines containing deleted 
mtDNA molecules – in these lines, deleted mtDNA molecules were shown to 
repopulate the cell 2-3 times faster than wild-type molecules. These results clearly 
demonstrated a replicative advantage for deleted mtDNA over wild-type molecules in 
the same cell under relaxed copy number control conditions; the authors concluded 
that the stimulation of defective mitochondria to proliferate in muscle may relax copy 
number control, allowing for a replicative advantage for deleted mtDNA molecules as 
witnessed in the cytoplasts cell lines (Diaz et al., 2002).  
Chapter Three 
121 
In addition to the cytoplast-based evidence for the existence of a replicative advantage 
for deleted mtDNA molecules, a 2009 study by Fukui and Moraes presented evidence 
that smaller mitochondrial genomes accumulate more rapidly in vivo in a  mitoPst1 
mouse model (Fukui and Moraes, 2009). This mouse model was developed to express 
an inducible mitochondria-targeted restriction endonuclease (mitoPst1), causing the 
generation of double-strand breaks in adult neurons and the subsequent  formation of 
deleted mtDNA molecules which mimicked as closely as possible the range of 
naturally-occurring mtDNA deletions found in aging neurons. MitoPst1 was regulated 
by the presence of doxycycline (Dox) in the diet of the mice, and was induced for a 
short time period by removal of Dox from the diet for 3 days at four weeks of age; DNA 
from cortical tissues of the mitoPst1 induced mice was then analysed alongside age-
matched controls at 5 and 14 weeks of age. DNA analysis by semi-quantitative PCR 
found mtDNA deletions to be present in tissue from 5 week old mitoPst1 induced 
mice, but present at a much greater level at 14 weeks, demonstrating the 
accumulation of mtDNA deletions over time. It was inferred that, if the smaller size of 
deleted mtDNA molecules compared to wild-type mtDNA conferred a replicative 
advantage, small mitochondrial genomes carrying large mtDNA deletions should also 
have a replicative advantage within the cell over larger mtDNA molecules with small 
deletions. 
The combined evidence from the cytoplast and mitoPst1 mouse models strongly 
support the ‘survival of the smallest’ mechanism of clonal expansion, with a replicative 
advantage for smaller mtDNA molecules having been observed in both cases. 
However, it is important to take into consideration that both of these studies 
modelling clonal expansion of mtDNA deletions have been carried out in modified 
systems; no conclusive evidence has yet been presented to suggest that mtDNA 
deletions species have a replicative advantage in human tissue. 
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3.2 Aims and hypothesis 
The aim of this study was to investigate the presence of a replicative advantage for 
mtDNA deletions in human tissue, following on from evidence presented in cytoplast 
and mouse model studies in favour if the ‘survival of the smallest’ theory.  
The ‘survival of the smallest’ hypothesis that mtDNA deletions have a replicative 
advantage over wild-type mtDNA molecules due to a smaller genome size was further 
extrapolated, suggesting that the largest mtDNA deletions would also display a 
replicative advantage over smaller mtDNA deletions due to a smaller genome size. In 
this case, the most sizeable mtDNA deletions would be subject to the greatest rate of 
replication and rate of accumulation within the cell.  Due to this replicative advantage, 
it would be reasonable to expect that in muscle fibres, the largest mtDNA deletions 
would spread more quickly and generate larger segments of COX-deficiency than 
smaller mtDNA deletions.  
Based upon the above hypotheses, it was decided to focus this study on determining 
whether the largest mtDNA deletions spread the furthest longitudinally through 
muscle fibres, demonstrating a greater rate of accumulation within the muscle than 
smaller mtDNA deletion species. Previous assessments of COX-deficiency in muscle 
fibres have identified a large range in the length of COX-deficient fibre segments from 
just 10µm to in excess of 1.2mm within single patients (Elson et al., 2002), in keeping 
with previous observations of COX-deficient muscle fibre segments in excess of 1.6mm 
in model organisms (Lopez et al., 2000). A large spectrum of COX-deficient fibre 
segment lengths should be available within individual biopsies from multiple mtDNA 
deletion patients to allow the identification of any correlation with mtDNA deletion 
size. Interestingly, prior studies have identified a strong relationship between the 
length of COX-deficient segments of muscle and disease severity (Elson et al., 2002), 
though no work has so far been carried out to identify a link between mtDNA deletion 
size and COX-deficient fibre segment length. The presence of a positive relationship 
between these two variables would demonstrate that a smaller genome size does 
confer a replicative advantage within the cell, fulfilling the project aim of determining 
whether mtDNA deletions display a replicative advantage based upon genome size in 
human tissue.  
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3.3 Methods 
3.3.1 Patient Biopsies 
Skeletal muscle samples (vastus lateralis) were obtained by open muscle biopsy from 6 
patients with multiple mtDNA deletions. All patients presented with chronic 
progressive external ophthalmoplegia and had a mosaic pattern of respiratory chain 
deficiency in muscle.   These biopsies were taken either for diagnostic purposes 
(patients 2 and 3) or at post-mortem. Five patients harboured pathogenic mutations in 
the POLG gene, as outlined in 3.3.2, while the underlying nuclear genetic defect 
remains unknown in one patient (screened for mutations in POLG, POLG2, PEO1, 
SLC25A4, RRM2B and TK2 with no mutations identified). Large muscle biopsies were 
available from each of these patients, allowing longitudinal sections to be cut for 
analysis along the length of each skeletal muscle fibre. Samples were frozen in 
isopentane cooled by liquid nitrogen for histological and histochemical analysis. Ethical 
approval was obtained from Newcastle and North Tyneside LREC. 
 
3.3.2 Mitochondrial enzyme histochemistry 
20µm thick skeletal muscle sections were taken from each of the biopsies outlined 
above. Dual cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) 
histochemistry was carried out to identify muscle fibres areas displaying a biochemical 
defect. Due to the nature of the patients from which tissue was obtained, all 
biochemically deficient fibre areas could be attributed to the presence of high levels of 
mtDNA deletions. An initial stain for COX activity creates a brown precipitate where 
cytochrome c is active within the muscle fibres, and therefore where the mitochondria 
are functional. The application of a second histochemical stain for SDH activity creates 
a blue precipitate in the presence of succinate dehydrogenase subunits SDHA and 
SDHB, both of which are entirely nuclear encoded and are therefore unaffected by the 
presence of mtDNA deletions. This creates a stain which is only visible in areas 
unstained, or weakly stained, for COX activity, highlighting COX-deficient muscle fibre 
areas in blue (Figure 3.27).  
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Figure 3.27 – 20µm thick longitudinal sections of vastus lateralis skeletal muscle tissue dual-
stained for COX and SDH histochemistry. 
Starred fibres demonstrate COX-deficiency, with no detectable brown precipitate from the applied COX 
histochemical assay present, but very visible blue precipitate from the SDH histochemical assay which 
was subsequently applied.  
All other fibres positively demonstrate normal COX activity, with visible brown precipitate forming 
following the application of the COX histochemical assay. 
 
3.3.3 Single fibre isolation  
Two categories of fibres were selected for investigation from the COX/SDH stained 
longitudinal muscle biopsy sections; for the purposes of this study, they were termed 
‘long’ and ‘short’ regions of COX-deficiency. Short COX-deficient regions were those 
under 200μm in length, while long COX-deficient regions were over 500μm in length. 
These values were chosen based upon the maximum cutting length on our 
microscope/LMD system of 650μm.   
It was initially decided to compare two discrete groups of fibres in order to maximise 
the power of the statistical tests available to determine whether any relationship 
existed between mtDNA deletion size and COX-deficient fibre area. Selecting only 
fibres >500µm or <200µm in length ensured that there was no overlap between the 
two fibre groups, with a buffer of 300µm in length of COX-deficient fibre area 
separating the two data sets. 
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3.3.4 Long-extension PCR, gel electrophoresis and mtDNA deletion detection 
To detect mtDNA deletions in individual COX-deficient muscle fibres, long-extension 
PCR was performed on DNA from isolated single COX-deficient fibre regions alongside 
wild-type homogenate DNA. Over the course of the study two sets of primer pairs 
were used; one set amplified a 13.5kb region of the major arc of the mitochondrial 
genome (NC_012920.1, 2999 – 16450bp), while the other set amplified a smaller 10kb 
region within the same section of the major arc (NC_012920.1, 6240 – 16132bp). After 
running the 13.5kb long-range PCR on ~30 isolated muscle fibres with few successful 
DNA amplifications, a more efficient 10kb primer pair was designed for the long-range 
assay to increase the PCR success rate. Both sets of data were used. PCR product sizes 
were read from agarose gels following gel electrophoresis using the accompanying 
DNA ladder; the size of the mtDNA deletion present in a sample was determined by 
the difference in size between sample and wild-type DNA products.   
 
3.3.5 Restriction endonuclease digest and sequencing analysis 
A restriction endonuclease digest using 4 restriction enzymes - Xho1, BamH1, Xcm1 
and Dra1 - was used to fine map the location of the mtDNA deletion breakpoints 
(Khrapko et al., 1999). The restriction sites for these enzymes in wild-type mtDNA 
produce a pattern of restriction fragments, ranging between 441 and 4474bp in length, 
which can be clearly visualised following separation by gel electrophoresis in 2% 
agarose gel (Figure 3.28, Table 3.14). The mtDNA deletion present in sample DNA from 
individual isolated COX-deficient muscle fibre regions could then be roughly mapped 
by identifying which restriction fragments were missing following the restriction 
endonuclease digest. PCR products were then sequenced using appropriate PCR 
primers close to the predicted mtDNA deletion breakpoint to identify the mtDNA 
deletion breakpoint sequences (Figure 3.29), and accurately determine the size of the 
deleted region of mtDNA.  
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3.3.6 Statistical Analysis 
All statistical analysis was carried out using GraphPad Prism v.4 statistical software. 
Relevant t-tests we chosen to carry out dataset comparisons according to whether 
data was paired, and whether the data followed a normal distribution (Table 3.13). 
Similarly, data correlation was assessed using a 2-tailed Spearman or Pearson 
correlation test at 95% confidence, dependent upon data distribution (these are non-
parametric and parametric tests, respectively). To assess data distribution a battery of 
normality tests were carried out: the Kolmogorov-Smirnov test, where samples are 
standardized and compared with a standard normal distribution; the Shapiro-Wilk 
normality test, which compares low sample numbers (<50) to a standard normal 
distribution with higher accuracy; and the D’Agostino and Pearson omnibus normality 
test, which identifies data skewness and kurtosis. Normality was assumed when at 
least two of these three tests identified a normal distribution. 
 
 
 Normal data distribution Non-normal data distribution 
Paired data Paired t-test Wilcoxon matched pairs test 
Unpaired data Unpaired t-test Mann-Whitney u-test 
Table 3.13 Selection of appropriate tests to carry out data group comparisons. 
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Figure 3.28 – Restriction digest products from one wildtype mtDNA sample and 3 long-range 
PCR amplimers from single COX-deficient fibre DNA samples; products separated on a 2% 
agarose gel by gel elctrophoresis. 
1 - 1kb ladder; 2 - Digested wildtype mtDNA, all 8 expected digest bands present; 3 - Long-range PCR 
amplimer 1; 5kb deletion (8kb product from a 13kb long-range PCR); 4 - Digested products of long-range 
PCR amplimer 1; expected bands present at 441bp, 557bp, 697bp, 1854bp and 2943bp; expected bands 
at 4474bp, 1430bp and 1055bp missing. Sequencing initiated with primers 28R and 21F; 5 - Long-range 
PCR amplimer 2; 5kb deletion (8kb product from a 13kb long-range PCR); 6 - Digested products of long-
range PCR amplimer 2; expected bands present at 441bp, 557bp, 697bp and 1854bp; expected bands at 
2943bp, 4474bp, 1430bp and 1055bp missing, unexpected band at approximately 2kb. Sequencing 
initiated with primers 28R and 19F; 7 - Long-range PCR amplimer 3; 6kb deletion (7kb product from a 
13kb long-range PCR); 8 - Digested products of long-range PCR amplimer 1; expected bands present at 
4447bp and 1854bp only. Sequencing initiated with primers 16540R and 23F. 
All relevant primer locations and sequences are listed in section 2.2.4.2.2, Tables 2.4 and 2.5 
respectively. 
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Table 3.14- Predicted sequencing primers to use, as determined by restiction endonuclease 
digest. 
The presence of expected restriction digest bands, of a range of sizes from 441bp to 4474bp, was 
assessed following separation of restriction di gest products by gel electrophoresis (Figure 3.28). The 
most appropriate reverse primer to utilise for breakpoint sequencing was determined by the first 
missing band from the restriction digest, reading left-to-right from the above table; i.e. if the 441bp and 
1845bp bands were present, but the 697bp band was found to be absent, primer 31R was used for 
breakpoint sequencing analysis. The most appropriate forward primer to use as a starting point for 
breakpoint sequencing was determined either by the first band to appear after a break in the restriction 
digest sequence (i.e. if the 441bp band is present, 1854bp, 697bp and 557bp bands are absent, but the 
1055bp bands is present, forward primer 25F would be used), or by the estimated deletion size (i.e. 
using a forward primer located xkb after the determined reverse primer, where x is the deletion size 
predicted by long-range PCR).  
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3.4 Results 
3.4.1 COX-deficient fibre segment length. 
Two categories of fibres were selected for investigation from longitudinal sections of 
skeletal muscle biopsy, identified as ‘long’ and ‘short’ regions of COX-deficiency. Short 
fibres were under 200μm in length and long fibres over 500μm in length; these values 
were chosen based on a maximum cutting length of our microscope/LMD system of 
650μm (Figure 3.30). Previous measurements of COX-deficient fibre segments found 
regions of biochemical defect to range in length from 10µm to over 1.2mm (Shadel and 
Clayton, 1997), meaning the categories of <200µm and >500µm in length fell within an 
acceptable range. The area (µm2) of individual muscle fibre regions isolated by laser 
microdissection was determined and was found to be a more variable measurement 
than fibre length when extracting fibres, but analysis showed no overlap between the 
two groups of COX-deficient fibre areas, with a maximum area of 12800µm2 for short 
COX-deficient fibre regions, and a minimum area of 19412µm2 for long COX-deficient 
fibre regions. 
 The mean fibre area for short COX-deficient regions under 200µm in length was 
5725µm2, with a standard deviation in area of 3194µm2 and a total range in size of 
11498µm2, from 1302µm2 to 12800µm2. The mean fibre area for long COX-deficient 
regions over 500µm in length was 32120µm2, with a standard deviation in area of 
10536µm2 and a total range in size of 45800µm2, from 19412µm2 to 57289µm2 (Figure 
3.31). A Mann-Whitney u-test, chosen because the spread of data did not follow a 
normal distribution, performed on the 2 fibre area data sets gave a p-value <0.0001, 
showing a significant difference in area of COX-deficiency between the long and short 
fibres. 
Although long and short COX-deficient muscle fibre regions were selected based upon 
the length of the fibre region affected by the biochemical defect, it became apparent 
that total fibre area (µm2) isolated by laser microdissection would be a more 
appropriate measure for any statistical analyses within this study. The area affected by 
the biochemical defect is a better measure of the spread and accumulation of the 
mtDNA deletion species responsible for the COX-deficiency, as basing measurements 
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purely on the length over which the biochemical defect has spread fails to take into 
consideration variable fibre width. 
 
Figure 3.30 - Example images of COX-deficient skeletal muscle fibre areas to be extracted by 
laser capture micro-dissection. 
A – E: Long COX-deficient regions, over 500µm in length. 
F – J: Short COX-deficient regions, under 200µm in length. 
COX-deficient fibres region to be captured by laser microdissection in each example is outlined in red. 
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Figure 3.31 – COX-deficient fibre areas,  measured in µm2, captured by laser microdissection. 
‘Short fibres’ are short COX-deficient fibre regions isolated by laser microdissection, and ‘long fibres’ are 
long COX-deficient fibre regions isolated by laser microdissection.  
The mean fibre area for short COX-deficient regions under 200µm in length was 5725µm
2
, with a 
standard deviation in area of 3194µm
2
 and a total range in size of 11498µm
2
, from 1302µm
2
 to 
12800µm
2
.  
The mean fibre area for long COX-deficient regions over 500µm in length was 32120µm
2
, with a 
standard deviation in area of 10536µm
2
 and a total range in size of 45800µm
2
, from 19412µm
2
 to 
57289µm
2
. 
The two groups of COX-deficient muscle fibre areas were found to be significantly different using a 
Mann-Whitney u-test (P<0.0001). 
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3.4.2 Assessing mtDNA deletion size in individual COX-deficient SKM fibre regions 
Long range TaKaRa LA Taq PCR was successfully performed on total cell lysate from 62 
short COX-deficient fibres (under 200μm in length) and 60 individual long (over 500μm 
in length) COX-deficient fibre regions, from a total of 6 patients with multiple mtDNA 
deletion disorders. Following amplification of the mtDNA, PCR products were 
separated and analysed by gel electrophoresis – the size of the amplified PCR product 
from each sample could then be compared to the product size from wild-type mtDNA, 
allowing an assessment of mtDNA deletion size. In most cases, a single PCR product 
representing one mtDNA deletion was seen per muscle fibre – these were the 
successful samples, which were then used for analysis of the relationship between 
mtDNA deletion size and the length of the COX-deficient fibre area (Figure 3.32). 
Interestingly, multiple mtDNA deletion bands were evident in mtDNA samples from 
approximately 20% of successfully amplified COX-deficient fibre regions. While this in 
itself was a thought-provoking finding, as clonal expansion is usually considered in 
terms of the accumulation of a single mtDNA deletion species, these results could not 
be included in this particular study; there was no way of distinguishing how the 
multiple mtDNA deletions were distributed through the biochemically affected muscle 
fibre area, and so no length of COX-deficiency could be attributed to a specific mtDNA 
deletions size. The presence of multiple mtDNA deletions in single COX-deficient 
muscle fibre areas was, however, investigated in a later study (see Chapter 7).  
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Figure 3.32 - Example gel: mtDNA deletions amplified by a 10kb long-range PCR from 6 
'short' and 6 'long' COX-deficient fibres. 
10kb PCR, using primer pair 1, of 5 short and 5 long COX-deficient fibre regions, bands separated by gel 
electrophoresis on a 0.7% agarose gel.   
1 – 1 kb ladder; 2 – short fibre, 6kb PCR product, 4kb deletion; 3 - short fibre, 6kb PCR product, 4kb 
deletion;  4 – short fibre, 9kb PCR product band, 1kb deletion;  5 - short fibre, 9kb PCR product band, 
1kb deletion;  6 – short fibre, 8kb PCR product band, 2kb deletion;  7 - long fibre, 7kb PCR product band, 
3kb deletion;  8 - long fibre, 10kb wildtype PCR product plus 4.5kb PCR product, 5.5kb deletion;  9 – 2kb 
and 1.25kb PCR products, multiple deletions of 8kb and 8.75kb, discarded from study;  10  - long fibre, 
6.5kb PCR product band, 3.5kb deletion;  11 - long fibre, 6.5kb PCR product band, 3.5kb deletion;  12 – 
1kb ladder. 
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3.4.3 Validation of long-range PCR analysis of mtDNA deletion size 
In total, mtDNA deletion sizes from 122 COX-deficient muscle fibre regions were 
analysed by long-range PCR, as described above. To ensure that the mtDNA deletion 
sizes estimated by this method were accurate to the true mtDNA deletion size, a 
stratified sample of 10 random short and 10 random long COX-deficient fibre regions 
were also analysed through mtDNA deletions breakpoint sequencing.  All sequenced 
samples revealed a deletion size within a 0.5kb range of accuracy of the mtDNA 
deletion size predicted by the long-range PCR products. The mean deviation from 
mtDNA deletion size as estimated by long-range PCR analysis to true mtDNA deletion 
size as measured by breakpoint sequencing was only 229bp, ±191bp, demonstrating 
that long-rage PCR can be used to assess mtDNA deletion size to a high degree of 
accuracy (Table 3.15). The 20 mtDNA deletions analysed by both long-range PCR and 
breakpoint sequencing were determined to be normally distributed in terms of 
deletion size following analysis by a battery of normality tests (see section 3.3.6). Due 
to the normal distribution of these data, a two-tailed paired t test at 95% confidence 
was carried out to determine how tight the relationship between the two 
measurements of deletion size was; there was found to be no significant difference 
between the paired measurements of mtDNA deletion size (P= 0.3792), and the pairing 
was determined to be significantly effective (r = 0.9922, P<0.0001). This allowed the 
confident use of data from long-range PCR analysis to compare mtDNA deletion sizes 
between long and short COX-deficient muscle fibre regions. 
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Table 3.15 – Table of results for the validation of long-range PCR as an appropriate method 
to investigate mtDNA deletion size. 
A stratified sample of 10 short (COX-deficient fibres 1 – 10) and 10 short (COX-deficient fibres 11 – 20) 
muscle fibre areas displaying COX-deficiency were fully analysed for mtDNA deletion size; first by long-
range PCR, and subsequently by breakpoint sequencing. mtDNA deletion size estimated by long-range 
PCR differed from actual deletion size, as determined by successful breakpoint sequencing, by no more 
than 0.5kb (mean difference of 229bp ± 191bp between results). A paired t-test at 95% confidence was 
used to assess the similarity of the two readings of mtDNA deletion size; there was found to be no 
significant difference between mtDNA deletion size as determined by long-range PCR or by breakpoint 
sequencing (P = 0.3792), with a correlation coefficient (r) of 0.9922 demonstrating the similarity of the 
reading for each individual fibre.   
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3.4.4 Assessing differences in mtDNA deletion size between long and short COX-
deficient skeletal muscle fibre areas. 
A total of 62 short and 60 long COX-deficient muscle fibre areas were successfully 
isolated, lysed and analysed by long-range PCR to assess the size of the mtDNA to 
which the biochemical defect is attributable. mtDNA deletions detected in short skm 
fibre areas of COX-deficiency ranged in size from 0.5kb to 12kb, with a mean mtDNA 
deletion size of 6589bp (±2788bp), while mtDNA deletions detected in long muscle 
fibre areas of COX-deficiency ranged in size from 1kb to 12kb, with a mean mtDNA 
deletion size of 6508bp (±2478bp). A comparison of the two groups of deletion size 
data showed a similar data spread, with a difference in mean deletion size of only 
81bp. As the battery of normality tests used to assess the data (see section 3.3.6) 
found this dataset not to adhere to a normal distribution, a Mann-Whitney u-test was 
deemed the most appropriate test to determine if the two groups of deletion size data 
were significantly different. This 2-tailed Mann-Whitney u-test, carried out at a 95% 
confidence level, showed the set of mtDNA deletion sizes found in long and in short 
COX-deficient muscle fibre areas were not significantly different (P = 0.5506) (Figure 
3.33).  
In order to ensure that no trends linking mtDNA deletion size and affected COX-
deficient muscle fibre area in individual patients being masked by inclusion into the 
total dataset, data from individual cases were also independently analysed. No 
significant difference between mtDNA deletion sizes in long and in short COX-deficient 
muscle fibre areas was identified in any of the 6 cases included in this study (Figure 
3.34, Table 3.16), in keeping with the total dataset. 
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Figure 3.33 - mtDNA deletion sizes present in the total investigated long and short COX-
deficient skeletal muscle fibre areas. 
A total of 62 short muscle fibre areas displaying COX-deficiency were investigated, with a mean mtDNA 
deletion size of 6589bp (±2788bp). The mtDNA deletion size range was 11.5kb, with a data spread 
between 0.5kb and 12kb. 
A total of 60 long muscle fibre areas displaying COX-deficiency were investigated, with a mean mtDNA 
deletion size of 6508bp (±2478bp). The mtDNA deletion size range was 11kb, with a data spread 
between 1kb and 12kb. 
Both long and short regions of COX-deficiency displayed a similar range of mtDNA deletion sizes, with 
mean mtDNA deletions size values differing by only 81bp. No significant difference was found to exist 
between the two data sets by Mann-Whitney u-test (P = 0.5506). 
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Figure 3.34 - mtDNA deletions sizes in long and short COX-deficient skm fibre regions from 6 
investigated patients. 
A (Patient 1) - Mean mtDNA deletion size of 5714bp (±2658bp, N = 14) in short fibres and 6682bp 
(±1210bp, n = 11) in long fibres (no significant difference, P = 0.7009). B (Patient 2) – Mean mtDNA 
deletion size of 4357bp (±2911bp, N = 7) in short fibres and 3700bp (±3094bp, N = 5) in long fibres (no 
significant difference, P = 0.7751). C (Patient 3) – Mean mtDNA deletion size of 6300bp (±2462bpN = 15) 
in short fibres and 5583bp (±1940bp, N = 12) in long fibres (no significant difference, P = 0.4136). D 
(Patient 4) – Mean mtDNA deletion size of 9250bp (±2003bp, N = 10) in short a fibres and 9375bp 
(±1611bp, N = 12) in long fibres, (no significant difference, P = 0.8727). E (Patient 5) – Mean mtDNA 
deletion size of 7625bp (±946bp, N = 4) in short fibres and 6714bp (±2343bp, N = 7) in long fibres (no 
significant difference, P = 0.2303). F (Patient 6) – Mean mtDNA deletion size of 6708bp (±2832bp, N = 
12) in short fibres and 6077bp (±2060bp, N = 13) in long fibres (no significant difference, P = 0.3406). 
Data comparisons were carried out by Mann-Whitney u-test for A, B, E and F; C and D were assessed by 
unpaired t test.  
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Patient 
Short fibre, 
average 
mtDNA 
deletion size 
(kb) 
Long fibre, 
average 
mtDNA 
deletion size 
(kb) 
Fibre type 
carrying larger 
mtDNA 
deletions 
Average 
difference in 
mtDNA 
deletion size 
(kb) 
Significant 
difference? 
1 5.71±2.66 6.68±1.21 Long 0.97±0.86 No (P=0.7009) 
2 4.36±2.30 3.70±3.09 Short 0.66±1.75 No (P=0.7751) 
3 6.30±2.43 5.58±1.94 Short 0.72±0.86 No (P=0.4136) 
4 9.25±2.02 9.34±1.61 Long 0.13±0.77 No (P=0.8727) 
5 7.63±0.97 5.71±2.34 Short 1.91±1.25 No (P=0.2303) 
6 6.71±2.83 6.08±2.06 Short 0.63±0.98 No (P=0.3406) 
Table 3.16 – Average mtDNA deletion sizes in long and short COX-deficient fibres in 6 
patients with multiple mtDNA deletions in muscle.  
The average mtDNA deletion size and standard deviation were calculated for both long and short COX-
deficient fibres from each individual patient dataset. From this information, it was determined which 
COX-deficient fibre category the largest deletion species tended to be associated with; the average 
difference in mtDNA deletion size between the two fibre types was also calculated. Statistical tests were 
carried out to see if any of these associations were significant (Mann-Whitney u-test for patients 1, 2, 5 
and 6; unpaired t test for patients 3 and 4; all tests at 95% confidence intervals); mtDNA deletion sizes 
were not found to be significantly associated with long or short COX-deficient fibre regions in any of the 
6 individual datasets. 
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3.4.5 Correlating mtDNA deletion size with COX-deficient skeletal muscle fibre area 
Although no difference was found between mtDNA deletion size in long and short 
areas of COX-deficiency in muscle fibres, there was still potential for a correlation to 
exist between mtDNA deletion size and area (µm2) of biochemical defect; a trend could 
have existed within each of the two groups for the smallest deletion size to result in 
the smallest area of COX-deficiency.  To ensure that this was not the case – i.e. that the 
smallest area of COX-deficiency in both the long and short muscle fibre groups did not 
contain the smallest mtDNA deletions, and vice versa – correlation analyses were 
carried out between mtDNA deletion size and resultant area (µm2) of muscle fibre 
COX-deficiency.  
Total data for mtDNA deletion size and COX-deficient skeletal muscle fibre area were 
not normally distributed (analysis by a Kolmogorov-Smirnov normality test, a 
D’Agostino & Pearson omnibus normality test and a Shapiro-Wilk normality test), 
making a Spearman correlation analysis the most appropriate for this data set. No 
significant correlation was found to exist between mtDNA deletion size and COX-
deficient skm fibre area in the total 122 biochemically affected fibre regions 
successfully analysed for this study (P = 0.7792) (Figure 3.35). Individual analyses of the 
data for the short and the long regions of skm fibre COX-deficiency similarly revealed 
no significant correlation between mtDNA deletion size and area (µm2) of skm fibre 
biochemical defect (P = 0.8845 and 0.5827 respectively) (Figure 3.35).  
As for the assessment of differences in mtDNA deletion size between long and short 
COX-deficient skeletal muscle fibre areas (Section 3.4.4, page 138), data sets from 
individual patients were individually analysed in order to prevent any trend in a single 
patient becoming obscured when combined into the total data set. The spread of 
mtDNA deletion sizes and area (µm2) of COX-deficiency were analysed in each case to 
determine whether they followed a normal distribution, in order to carry out the most 
appropriate statistical analyses. Data were normally distributed for patients 3 and 4, 
making a Pearson correlation test the most appropriate, but data from patients 1, 2, 5 
or 6 did not follow a normal distribution, meaning the highest degree of statistical 
power would be gained by using a Spearman correlation test. No significant correlation 
was found to link mtDNA deletion size to the size of the area of COX-deficiency in 
muscle fibres in any of the 6 investigated cases (Figure 3.36). 
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Figure 3.35 - Correlation between the biochemically deficient skm fibre area and mtDNA 
deletion size. 
A - Spearman correlation analysis carried out on the total data set of 122 COX-deficient skeletal muscle 
fibre regions, to determine if any relationship exists between mtDNA deletion size and the size of the 
resulting area of biochemical deficiency. No significant correlation was found to exist between these 
two parameters (P = 0.7792).  
Subsequent Spearman correlation analyses carried out on the separate short (B) and long (C) COX-
deficient fibre area groups also revealed no significant correlation between mtDNA deletion size and 
area (µm
2
) of muscle fibre COX-deficiency (P = 0.8845 and 0.5827 respectively). 
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Figure 3.36 - Correlation between mtDNA deletion size and area of COX-deficiency  from 6 
investigated patients. 
A (Patient 1) – No significant correlation between mtDNA deletion size and COX-deficient fibre area 
identified in COX-deficient fibres (P = 0.2477, N = 25). B (Patient 2) – No significant correlation between 
mtDNA deletion size and COX-deficient fibre area identified in COX-deficient fibres (P = 0.8572, N = 12). 
C (Patient 3) – No significant correlation between mtDNA deletion size and COX-deficient fibre area 
identified in COX-deficient fibres (P = 0.2477, N = 27). D (Patient 4) - No significant correlation between 
mtDNA deletion size and COX-deficient fibre area identified in COX-deficient fibres (P = 0.4438, N = 22). 
E (Patient 5) – No significant correlation between mtDNA deletion size and COX-deficient fibre area 
identified in COX-deficient fibres (P = 0.4590, N = 11). F (Patient 6) – No significant correlation between 
mtDNA deletion size and COX-deficient fibre area identified in COX-deficient fibres (P = 0.8599, N = 25). 
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3.5 Discussion 
Previous studies carried out to assess the length of COX-deficient segments in skeletal 
muscle fibres have identified a range from 10µm to in excess of 1.2mm. While longer 
sections of COX-deficiency have been linked with more severe disease cases (Elson et 
al., 2002), no work has been carried out prior to this study to identify any link between 
the length of COX-deficient fibre segments and the size of mtDNA deletions. Following 
the hypothesis that the largest mtDNA deletions accumulate at the greatest rate in 
muscle, we would expect to see a strong correlation between COX-deficient segment 
length and mtDNA deletion size. However, in this study we see no significant 
difference in size of mtDNA deletion between ‘long’ and ‘short’ COX-deficient fibre 
areas, and no evidence of a correlation between mtDNA deletion size and the size of 
the resulting area of skm fibre COX-deficiency. The results from this study therefore do 
not support the hypothesis that a smaller genome size creates a replicative advantage 
that drives the clonal expansion of mtDNA deletions. 
The results of this study do not agree with the ‘survival of the smallest’ mechanism for 
the clonal expansion of mtDNA deletions, despite the emergence of strong evidence in 
support of this theory from studies carried out over the last decade in mouse models 
and cytoplasts. As discussed in the introduction to this chapter (see section 3.1.3, page 
120), the 2002 study of mtDNA deletion cytoplasts carried out by Diaz et al  
demonstrated a replicative advantage for deleted mtDNA over wildtype molecules 
under relaxed mtDNA copy number conditions (Diaz et al., 2002). Further evidence in 
favour of a replicative advantage for mtDNA deletions was gathered in the study of the 
mitoPst1 mouse model, where it was observed that smaller mitochondrial genomes 
accumulate more rapidly in vivo following the induction of a range of mtDNA deletions 
comparable to those found in ageing neurons. (Fukui and Moraes, 2009).  
The differences in experimental findings between this work and the studies carried out 
in the mtDNA deletion cytoplasts and the mitoPst1 mouse model could be due to the 
different models used. Firstly, it is possible that different mechanisms may be driving 
clonal expansion of mtDNA deletions in humans and in mice. While a strong similarity 
between mtDNA deletion accumulation in human and murine muscle has been 
documented in a number of independent studies (Bua et al., 2006; Herbst et al., 2007), 
more recent research has shown that mtDNA do not accumulate within mouse 
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neurons in a manner comparable to human neurons (Guo et al., 2010). When this is 
taken into considerations alongside other age-related differences, such as a reduced 
accumulation of neuromelanin in murine compared to human substantia nigra (Kim et 
al., 2006), it becomes clear that there are some significant and fundamental 
differences in ageing between humans and mice. This highlights the importance of 
choosing models carefully, as the relevance of age-related changes in mice to human 
cases seems to vary between tissue types. It is therefore plausible that mtDNA 
deletions have a replicative advantage in neurons from the mitoPst1 mouse but not 
necessarily in other tissue types from the same model; there is also no guarantee that 
comparable results would be observed in human cases.   
In comparing our findings to the reported observations in the mtDNA deletion 
cytoplasts, it is important to note that a replicative advantage for mtDNA deletions 
was only found under relaxed copy number control in the mtDNA deletion cytoplast 
study. In fact, Diaz et al reported no accumulation of or selective advantage for mtDNA 
deletions under normal cellular conditions (Diaz et al., 2002), in agreement with our 
own findings in patient tissue. The observation of a an accumulation of mtDNA 
deletions under relaxed copy number conditions has since been confirmed in human 
muscle, in a study of changes to the mitochondria following HIV treatment with 
nucleoside analog reverse transcriptase inhibitor anti-retroviral drugs (NRTIs) (Payne et 
al., 2011). NRTIs were known to inhibit the function of mitochondrial POLγ (Lim and 
Copeland, 2001), to cause a temporary but severe level of mtDNA depletion (Cote et 
al., 2002), and were reported to be associated with mtDNA deletions(Maagaard et al., 
2006); the study carried out by Payne et al successfully demonstrated an accelerated 
accumulation of mtDNA deletions associated with an increase in mtDNA turnover 
following the mtDNA depletion induced by the application of NRTIs (Payne et al., 
2011). The findings reported by Diaz et al in mtDNA deletion cytoplasts therefore seem 
to mimic current findings in human tissue remarkably well; no replicative advantage 
for mtDNA deletions is reported under normal cellular conditions (as in this study), but 
a selective advantage leading to accumulation of mtDNA deletions seems to be 
present under relaxed copy number control (as in the NRTI study carried out by Payne 
et al, 2011). 
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A subtle difference between the research aims of this study and those of the mitoPst1 
mouse study could also contribute to explaining the contradictory results we have 
gathered. While the mitoPst1 mouse study aimed to identify whether mtDNA deletion 
size affected the likelihood of the mutation undergoing clonal expansion, our work 
focussed upon how mtDNA deletion size affected the area through which the mutation 
spread by clonal expansion – with the implication that a greater spread of mtDNA 
deletion accumulation could be due to a more rapid rate of accumulation. Though no 
indication was found to suggest that larger mtDNA deletions were more prone to 
clonal expansion over greater distances through muscle fibres, with no distinction 
between the deletion sizes in ‘long’ and ‘short’ COX-deficient regions, the overall 
results are still in keeping with the mitoPst1 mouse model study. Analysis of the total 
122 mtDNA deletions in our study showed that larger mtDNA deletions were more 
prevalent than small (75% were >5kb and 50% were >6.75kb) which could either 
suggest that larger mtDNA deletions are formed more frequently, or that increasing 
mtDNA deletion size correlates with an increase in likelihood for clonal expansion to be 
initiated. In either scenario, our results would suggest that there is no further 
advantage for large mtDNA deletions sizes once clonal expansion of an mtDNA 
deletion has begun, as no observed correlation was found to exist between mtDNA 
deletion size and area of accumulation by clonal expansion.  
A potential drawback to the use of patient tissue for this study was the examination of 
each mtDNA deletion at only a single time point during clonal expansion, with no 
information on how much time has passed since the deletion formation event (i.e. how 
long each deletion has been accumulating for). As area of COX-deficiency caused by 
the clonal expansion of a specific mtDNA was being used as an indicator of clonal 
expansion rate – as rate could not be directly determined from examination of tissue 
from a single time point – this prompted a concern that we may simply observe the 
deletions which formed first accumulating the most to cause the largest regions of 
COX-deficiency. However, having carried out an a priori power analysis to calculate the 
minimum sample size required to observe a significant difference in deletion size 
between ‘long’ and ‘short’ COX-deficient regions, we are confident that sufficient 
analysis has been done to pick up any trend between mtDNA deletion size and rate of 
accumulation. The a priori power analysis was carried out using the highest standard 
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deviation seen experimentally (2.74kb), demonstrating a need for a minimum of 36 
samples per group to observe a difference in mtDNA deletion size of at least 2kb; our 
analysis of 60 ‘short’ and 62 ‘long’ COX-deficient muscle fibre regions would be more 
than sufficient to pick up any significant difference in mtDNA deletion size. 
The importance of clonal expansion in causing cellular pathology in ageing and disease 
is highlighted by the ability of cells to maintain normal function in the presence of low 
level mtDNA deletions; the initial deletion formation event could therefore never lead 
to a biochemical defect without the intercession of clonal expansion. It is consequently 
of paramount importance to understand the mechanism by which clonal expansion 
functions, in order to be able to intervene in the clinical progression of diseases 
involving mtDNA deletions. We have observed no variation in the ability of mtDNA 
deletions of different sizes to accumulate longitudinally through skeletal muscle fibres, 
leading us to the conclusion that smaller mtDNA molecules do not possess a replicative 
advantage to drive forward clonal expansion. While we have focussed upon the finding 
that smaller genome size is not an advantage, it is important to note that we have seen 
no trend toward a greater rate of clonal expansion for the smallest mtDNA deletions 
either, implying that there is no disadvantage associated with losing larger sections of 
the genome through a deletion event.  However, it remains possible that there may be 
an advantage for large mtDNA deletions at an early stage of clonal expansion. Though 
smaller mtDNA molecules do not seem to display an elevated rate of clonal expansion, 
the high proportion of large mtDNA deletions in the overall set of investigated 
deletions may indicate a preferential initiation of clonal expansion for large mtDNA 
deletions, as reported in the misoPst1 mouse model study (Fukui and Moraes, 2009). 
In short, our results suggest that, at least in terms of mtDNA deletion size, there is no 
selection taking place once the deletion has formed. In addition, if deleted mtDNA had 
a marked replication advantage over wild-type mtDNA then we would expect patients 
with large-scale single mtDNA deletions to show a marked increase in deletion levels 
over time. Whilst studies are limited in this area, there is little evidence that mtDNA 
deletion level changes over time; further evidence against the selective replication of 
smaller mtDNA species. Our results therefore indirectly support the hypothesis that 
random genetic drift is the likely mechanism driving the clonal expansion of mtDNA 
deletions in ageing and disease (Elson et al., 2001).  
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Chapter 4: 
Does the mtDNA deletion load increase over time in single mtDNA 
deletion patients? 
4.1 Introduction – Progression of mtDNA disease over time 
Mitochondrial disease is known to be highly heterogeneous in terms of disease 
presentation and progression, and single large-scale mtDNA deletion disease is no 
exception. Little is known about the disease progression, and research into this area is 
obfuscated by the different phenotypic presentations and rates of progression 
observed in patients. This creates a need for longitudinal studies of individual patients 
to study the phenotypic course of disease progression, as it is currently not possible for 
clinicians to predict a patient’s disease course - a topic explored further in Chapter 5.  
At a molecular level, there is an awareness of many changes which occur during 
progression in single mtDNA deletion disease, but not which factors actually drive 
progression. Respiratory chain dysfunction has clearly been shown to increase over 
time in cases of muscle myopathy, with decreasing respiratory function directly related 
to worsening muscle myopathy (Chinnery et al., 2003). MtDNA copy number has also 
been found to decrease over time in patients with single mtDNA deletions, with a 
reduction in absolute wildtype mtDNA number in single cells suggested as a cause for 
increasing levels of dysfunction over time in skeletal muscle (Durham et al., 2006). A 
marked reduction in wildtype mtDNA in COX-deficient fibres in extraocular muscle has 
also been identified in cases of CPEO (Greaves et al., 2010), suggesting similar tissue-
specific mechanisms of disease progression in extraocular and skeletal muscle.  
Due to decreasing levels of wildtype mtDNA copy number, an assumed accumulation 
of mtDNA deletion levels over time has been attributed to the progression of single 
mtDNA deletion disease over time. Findings that mtDNA deletions also accumulate in 
normal aging have strengthened this assumption, with a number of groups establishing 
a role for the formation and accumulation of mtDNA deletions in neuronal loss (Bender 
et al., 2006; Kraytsberg et al., 2006), COX-deficient muscle fibres occurring in normal 
aging (Bua et al., 2006), muscle fibre loss (Herbst et al., 2007) and many other 
hallmarks of ageing. Despite the mounting evidence in accumulation of age-related 
mtDNA deletions over time in the healthy population, little work has been undertaken 
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to investigate changing heteroplasmy levels over time in single mtDNA deletion 
patients. Evidence of a continuous increase in mtDNA levels over time in this patient 
group would strongly support the presence of an inherent advantage for mtDNA 
deletions driving clonal expansion.  
4.2 Aims and Hypotheses 
The aims of this case study of a patient with a single large-scale mtDNA deletion were 
twofold; to identify potential causes of patient progression at a molecular level, and to 
investigate the presence of a replicative advantage for mtDNA deletions in human 
tissue. This investigation was based upon a thorough genetic analysis of two muscle 
biopsies from a single patient, these samples having been acquired thirteen years 
apart.  
This study was driven primarily by the long-standing hypothesis of a replicative 
advantage for mtDNA deletions over wildtype mitochondrial genomes (Wallace, 1992), 
due to their smaller size and an inferred decrease in replication time. If this hypothesis 
were to hold true in cases of single large-scale mtDNA disease, we would expect to see 
a continuous increase in mtDNA deletion heteroplasmy levels, until homoplasmy was 
reached for the deleted mtDNA species. We therefore hypothesised that, where 
samples were available for analysis from different time-points in a single patient’s life-
course, the later sample(s) would display a higher level of mtDNA deletion 
heteroplasmy.  
At a cellular level, if the ‘survival of the smallest’ theory of a replicative advantage for 
deleted mtDNA species over wildtype mtDNA holds true, it would be predicted that 
individual COX-deficient fibres would also demonstrate an increase in deletion 
heteroplasmy levels over time, tending towards mutant homoplasmy. Other cellular 
developments which would hold true with the ‘survival of the smallest’ theory would 
be increasing levels of COX-deficient fibres; specifically where increased COX-
deficiency has been driven by increased mtDNA deletion levels (i.e. the single mtDNA 
deletion present in the muscle of this patient has increased above a threshold for 
normal biochemical activity in an increasing number of muscle fibres over time). 
Therefore it can be suggested that increased COX-deficiency, linked with a rise in 
mtDNA deletion heteroplasmy levels, should be apparent over time if deleted mtDNA 
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deletion species do display a replicative advantage over wildtype mtDNA molecules. If 
this is found to be the case, this would be indicative of rising mtDNA deletion levels 
over time driving phenotypic progression of single large-scale mtDNA deletion disease 
over time in patients.  
 
4.3 Methods 
4.3.1 Patient history 
The patient involved in this study had a classic presentation with CPEO and muscle 
weakness. He first presented with CPEO at 28 years of age; with was confirmed as a 
case of single large-scale mtDNA deletion disease following analysis of an initial 
diagnostic muscle biopsy. 35% of muscle fibres in this biopsy were reported to be COX-
deficient, while the mtDNA deletion heteroplasmy load in this biopsy was measured at 
75%. Despite this high mtDNA deletion load, disease progression was found to be slow 
in this patient, with an average increase of 1.2 NMDAS points per year. However, much 
of this progression is was due to increasing severity of the patient’s epileptic seizures - 
thought to be unrelated to his single deletion disease as epilepsy is not a common 
phenotype in patients with large-scale single mtDNA deletions, and the patient’s 
epileptic seizures were long-standing prior to onset of CPEO. Symptom progression 
was seen in exercise tolerance, gait stability, myopathy and ataxia, as well as vision and 
migraine. 
 
4.3.2 Patient biopsies, tissue sections and histochemistry 
Two skeletal muscle samples (vastus lateralis) were obtained by open biopsy from the 
single deletion patient discussed above; these were obtained from the same leg, but a 
different biopsy site. The initial biopsy was taken for diagnostic purposes, while a 
second biopsy was taken thirteen year later as part of an exercise trial (Exercise testing 
in patients with mitochondrial myopathy, 2003/21) and was consented for research 
use. These are henceforth to be referred to as Biopsy 1 (diagnostic) and Biopsy 2 (after 
13 years, exercise trial). Unfortunately, no information is available regarding changes 
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to the patient’s muscle mass over the 13 years between biopsies, these having been 
carried out at different hospitals. 
Multiple 20µm-thick sections were taken from each biopsy; an initial set of three 
sections were cut onto glass slides for total DNA extraction, while all further sections 
were mounted onto PEN-membrane slides for subsequent histochemical analysis and 
single fibre isolation.  
 
4.3.3 Histochemical analysis and tissue DNA extraction 
Sequential tissue sections of 20µm thickness mounted onto PEN-membrane slides 
were alternately assessed for dual COX and SDH histochemistry or SDH histochemistry 
only. The dual histochemical assay was carried out in order to identify muscle fibres 
displaying a biochemical defect, and served as a map of histochemical activity for 
sections assayed for only SDH activity from which individual muscle fibres were 
isolated for genetic analysis, as discussed in section 2.2.2.1.  
Tissue sections mounted onto glass slides were scraped into 1.5ml microcentrifuge 
tubes using a single-use scalpel, in preparation for DNA extraction. The DNA extraction 
was carried out using a Qiagen DNeasy blood and tissue kit, following the standard 
protocol for purification of total DNA from animal tissues (as described in 2.2.3.1).  
DNA was eluted into the minimum recommended amount of 100µl buffer AE (supplied 
with Qiagen DNeasy blood and tissue kit) to maximise DNA concentration; this was 
done twice per sample in order to maximise the total DNA yield from each sample. 
 
 4.3.4 Individual muscle fibre isolation and lysis 
Individual muscle fibres were identified as being deficient in COX activity, 
biochemically normal in terms of COX activity or COX-intermediate (Murphy et al., 
2012) from sections upon which the dual COX/SDH histochemical assay had been 
carried out. These sections were then used as a map of biochemical activity for serial 
sections assayed only for SDH activity, allowing accurate identification of COX-normal 
and COX-deficient fibres without the use of the histochemical assay for COX activity. 
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Individual muscle fibre isolation and DNA extraction were carried out as standard, 
following the method outlined in section 2.2.3.2.1. 
 
4.3.5 Real-time PCR analyses 
Quantitative assessments of mitochondrial DNA, including mtDNA copy number 
analysis and measurement of the mtDNA deletion heteroplasmy level, were carried 
our using real-time PCR. Total mtDNA copy number was determined by comparison of  
the number of mtDNA copies relative to nuclear DNA marker 18S (see section 
2.2.4.5.2), while both wildtype and total mtDNA copy numbers were assessed in single 
cell DNA samples using an established standard curve protocol (2.2.4.5.3-5); mtDNA 
deletion levels in both tissue homogenate and single cell DNA samples were 
determined by MTND1/MTND4 quantification (see section 2.2.4.5.1). 
 
4.3.6 Statistical Analysis 
All statistical analysis was carried out using GraphPad Prism v.4 statistical software. 
Group comparisons were made using unpaired t tests or Mann Whitney tests, and data 
correlation was assessed using a 2-tailed Spearman test at 95% confidence and simple 
(linear or non-linear) regression. In some cases, data transformation was required to 
allow for appropriate analysis by linear regression; a Box-Cox power transformation 
(Box and Cox, 1964) was carried out in each of these cases to identify the most 
appropriate data transformation to use. Relevant tests, as detailed in section 2.2.6, 
were chosen based upon data distribution (i.e. depending upon whether or not the 
spread of data followed a normal distribution, in order to maximise the power of each 
statistical analysis). 
 
 
 
Chapter Four 
154 
4.4 Results 
4.4.1 Initial repeat biopsy investigations 
Initial histochemical analysis of two vastus lateralis biopsies, taken either side of a 
thirteen year interval from a single large-scale mtDNA deletion disease patient, was 
carried out by the Newcastle Mitochondrial NCG Diagnostic Laboratory. COX, SDH, and 
COX/SDH histological stains were performed on serial sections of each biopsy, 
revealing a clear histological progression and large increase in COX-deficient muscle 
fibres in the patient tissue (Figure 4.37). 
 
 
Figure 4.37 - Histochemical activity assays. 
COX only, SDH only and dual COX/SDH histochemical assays carried out on serial 10µm thick sections of 
available patient tissue. Images courtesy of the Newcastle Mitochondrial NCG Diagnostics service.  
 
Initial estimates of COX-deficiency levels were carried out by the Newcastle 
Mitochondrial NCG Diagnostics service based upon these histochemical assays; 
approximately 35% of muscle fibres were reported to be COX-deficient in biopsy 1, 
compared to 80% of muscle fibres in biopsy 2. This constitutes a 2.28-fold rise in COX-
deficiency over the thirteen year period between these biopsies, or an increase of – on 
average – an extra 3.5% of muscle fibres becoming COX-deficient each year. The 
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presence of COX-intermediate fibres was not reported, not being part of the standard 
diagnostic assessment of patient samples. 
Following the reported increase in COX-deficiency over the 13 year period between 
these 2 muscle biopsies, in keeping with increasing severity of muscular symptoms, it 
was expected that a rise in mtDNA deletion heteroplasmy levels would be observed. 
However, Southern blot analysis carried out by the Newcastle Mitochondrial NCG 
Diagnostics service revealed no change to the mutation level in homogenate mtDNA; 
mtDNA deletion heteroplasmy remained stable at approximately 75%. 
 
4.4.2 Analysis of homogenate tissue DNA samples 
For each of the two biopsies, homogenate DNA extracted from biopsy tissue was 
available for analysis from the NCG Diagnostics Laboratory. 
To ensure that the previous deletion level analysis carried out by Southern blot was 
accurate, real-time PCR was used to measure mtDNA deletion heteroplasmy in DNA 
samples from both biopsies. The ND1/ND4 assay (He et al., 2002) was used to compare 
the ratios of total and wild-type mtDNA species present in each sample, as described in 
2.2.4.5.1, in order to quantify the level of mtDNA deletion present.  Biopsy 1 was found 
to have an mtDNA deletion heteroplasmy level of 75.1%, while Biopsy 2 had an mtDNA 
deletion level of 76.6% – a rise of only 1.5% over thirteen years. This was very much in 
keeping with the previous Southern blot results, though these results were surprising 
given the reported drastic increase in COX-deficiency from Biopsy 1 to 2. 
As it was found that increasing deletion levels could not be the cause of the 
histological progression between the two biopsies, mitochondrial DNA copy number 
was next investigated by real-time PCR. For these homogenate tissue DNA samples the 
18S/ND1 assay was employed to establish total mtDNA copy number relative to 
nuclear DNA copy number, determined by the measurement of 18S rRNA copy 
number, as described in 2.2.4.5.1.  Biopsy 1 was found to have approximately 385 
copies of the mitochondrial genome per copy of nuclear marker 18S rRNA, while 
Biopsy 2 had approximately 190. This shows a decrease in total mtDNA copy number 
of ~50% over the thirteen year period between biopsies.  
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Biopsy Year taken COX-deficiency 
level 
mtDNA deletion 
heteroplasmy level 
Total mtDNA 
copy number 
1 1993 35% 75.1% 385 
2 2006 80% 76.6% 190 
 13 year 
interval 
55% increase in 
COX-deficiency 
No significant increase 
in deletion level 
50% reduction in 
total mtDNA 
copy number 
Table 4.17 - Summary of initial repeat biopsy findings. 
Total mtDNA copy number is expressed as number of mitochondrial genome copies per copy of nuclear 
marker gene 18S rRNA. Results from the initial analysis of homogenate tissue DNA from Biopsy 1 and 2, 
taken thirteen years apart from the same single large-scale mtDNA deletion patient. No increase in 
mtDNA deletion level was observed over this time period, despite a large increase in observed COX-
deficient muscle fibres. However, mtDNA copy number was found to half - suggesting reduced copy 
number may be responsible for the observed biochemical progression. 
 
4.4.3 Single muscle fibre extraction 
The results from molecular analysis of homogenate tissue mtDNA from Biopsies 1 and 
2 were not in keeping with the reported histochemistry, making further investigation 
vital. A minimum of 25 individual COX-deficient muscle fibres, 25 individual COX-
positive muscle fibres and 25 COX-intermediate individual fibres were extracted from 
tissue sections assessed only for SDH histochemistry (as discussed in 2.2.2.1), from 
each biopsy. It was decided that it was as important to look for molecular changes in 
COX-normal and COX-intermediate fibres as in COX-deficient fibres, in order to identify 
on-going molecular changes. All fibres were lysed using the same single cell lysis 
method, as described in 2.2.3.2.1. 
Individual fibres were extracted by laser microdissection from sections upon which 
only the SDH histochemical assay had been carried out, using a serial section assessed 
for both COX and SDH activity as a map of COX-deficiency. In the examples 
demonstrated in Figure 4.38, 5 COX-deficient - highlighted with stars on a COX/SDH 
map - were selected for laser microdissection. Fibres are shown, having been drawn 
around, pre- and post- extraction. 
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4.4.4 Individual muscle fibre mtDNA deletion level analysis 
As for DNA extracted from homogenate tissue, the ND1/ND4 quantitative PCR assay 
(He et al., 2002) was carried out to determine deletion level for all isolated individual 
muscle fibres.  As in the homogenate tissue DNA study, mtDNA deletion levels were 
found to be stable at the single cell level between the two biopsies (Figure 4.39).  
In Biopsy 1, COX-positive fibres (N = 27) were found to have a low average mtDNA 
deletion load of 32% (± 22%), though the total range in mtDNA deletion heteroplasmy 
levels was high – from 0% up to a maximum observed mtDNA deletion load of 76%. 
COX-deficient fibres isolated from Biopsy 1 (N = 29) had, as would be expected, a much 
higher average mtDNA deletion level than that found in COX-normal fibres. In the COX-
deficient fibres, a mean mtDNA deletion load of 91% (± 14%) was found. For 28 of the 
total 29 COX-deficient fibres isolated from Biopsy 1 the spread of deletion load was 
quite small – particularly in comparison to the wide range of mtDNA deletion 
heteroplasmy found in COX-positive fibres – ranging from 83% to 98%. A single outlier 
had an unusually low deletion level of just 21% - this is discussed later, in 4.4.6. COX-
intermediate fibres (N = 28) isolated from Biopsy 1 were found to contain the largest 
range of mtDNA deletion levels, from 0% up to 84% deletion load, with a mean mtDNA 
deletion heteroplasmy level of 57% (±23%). An impairment of COX activity was 
observed in some fibres despite a low level of mtDNA deletion heteroplasmy where 
mtDNA copy number was subsequently found to be depleted (intermediate fibres with 
deletion levels 0, 11 and 23% had wildtype copy numbers of 13, 17 and 14 
respectively, compared to an average of 42 in wildtype fibres, see section 4.4.5.2). 
Similar results were found in individual fibres extracted from Biopsy 2. COX-positive 
fibres (N = 26) were again found to have a low average deletion load (28% ± 29%) but a 
high degree of spread, with a minimum deletion level of 0% and a maximum observed 
deletion level of 85%.  COX-intermediate fibres extracted from Biopsy 2 were also 
found to display a large spread of mtDNA deletion heteroplasmy level, ranging from 
0% to 87% deletion load (intermediate fibres with deletion levels 3, 14 and 16% had 
wildtype copy numbers of 19, 13 and 18 respectively, compared to an average of 42 in 
wildtype fibres, see section 4.4.5.2). However, the average heteroplasmy level was 
higher than that observed in COX-positive fibres, with a mean deletion level of 58% 
(+28%). COX-deficient muscle fibres isolated from Biopsy 2 (N = 25) displayed a smaller 
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range of spread than COX-normal fibres – ranging from 65% to 97%, excluding two 
outliers with mtDNA deletion loads of  0% and 13%  (to be discussed in 4.4.6) – and a 
much higher average mtDNA deletion level (81% ± 25%).  
Mann-Whitney tests, chosen as the data sets do not follow a normal distribution, were 
carried out at a 95% confidence interval to assess whether any significant differences 
were apparent between the 6 assessed groups of mtDNA deletion levels. As would be 
expected, mtDNA deletion heteroplasmy was significantly higher in COX-deficient than 
in COX-normal muscle fibres in both biopsies (P < 0.0001 in both cases). Also observed 
in both biopsies were the expected intermediary mtDNA deletion levels present in 
COX-intermediate fibres – significantly higher than the levels present in COX-positive 
fibres, but significantly lower than the observed mtDNA deletions loads in COX-
deficient fibres (Biopsy 1 COX-intermediate fibres vs COX-positive and vs COX-deficient 
P < 0.0001, Biopsy 2 COX-intermediate fibres vs COX-positive P = 0.0007, vs COX-
deficient P = 0.0003). No change in mtDNA deletion load was found to have occurred 
between the two biopsies in COX-positive muscle fibres (P = 0.3732) or in COX-
intermediate fibres (P = 0.3307), though the small decrease in average mtDNA deletion 
level in COX-deficient muscle fibres from Biopsy 1 to 2 was found to be significant (P = 
0.0480). However, when the outliers mentioned above (mtDNA deletion levels more 
than 2 standard deviation’s outside of the mean heteroplasmy levels observed in that 
fibre group) were excluded, no significant difference was found to exist between the 
deletion levels in COX-deficient muscle fibres from the two biopsies (P = 0.0678).  
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Figure 4.39 - mtDNA deletion heteroplasmy % measured in individual COX-positive, 
intermediate and deficient muscle fibres isolated from Biopsy 1 and 2. 
Individual COX-positive, intermediate and deficient fibres were isolated from each of two biopsies taken 
from a single large-scale deletion patient either side of a 13-year interval, and were assessed for mtDNA 
deletion heteroplasmy level (%) using the ND1/ND4 quantitative PCR assay. mtDNA deletion level was 
found to be significantly higher in COX-deficient fibres than in COX-positive fibres in both patient 
biopsies, with COX-intermediate fibres typically displaying an intermediate level of heteroplasmy. Mann-
Whitney t-tests were carried out to assess the similarity in mtDNA deletion heteroplasmy levels 
between groups; statistically significant differences in mtDNA deletion level are indicated with an 
asterisk, with relevant P values supplied. 
 
4.4.5 Individual muscle fibre mtDNA total copy number analysis 
Following the mtDNA deletion analysis, mitochondrial DNA copy number was assessed 
for each of the isolated individual COX-positive, intermediate or deficient muscle 
fibres. This was carried out using the universal standard curve method of absolute 
mtDNA copy number analysis, as described in 2.2.4.5.5. A universal standard curve was 
generated to allow results to be comparable between separate real-time PCR runs, and 
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validated by the inclusion of 3 copy number standards on each real-time run to ensure 
that the standard curve was generating accurate results. Copy number was, in all 
cases, expressed as copy number/µm2 to allow an accurate comparison of relative 
copy number between all extracted muscle fibres of different areas (Figure 4.40). 
 
4.4.5.1  Individual muscle fibre mtDNA total copy number analysis 
In Biopsy 1, COX-positive muscle fibres were found to have the lowest total mtDNA 
copy numbers, as measured by the quantity of MTND1 present by quantitative PCR. 
COX-positive fibres had a mean mtDNA copy number of 59 ± 53 copies/µm2, with a 
range from 6 to 197 copies/µm2. Both COX-intermediate and COX-deficient fibres 
displayed significantly higher levels of mtDNA (P = 0.0003 and 0.0022 respectively), 
with no significant difference existing in terms of total mtDNA copy number between 
these two groups (P = 0.8419). COX-deficient fibres displayed a much larger range of 
mtDNA copy number than that observed in COX-positive fibres, and a higher average 
total mtDNA copy number (range 6 – 399 copies/µm2, mean 142 ± 109 copies/µm2). 
The range in total mtDNA copy number observed in COX-intermediate fibres was 
slightly smaller than in COX-deficient fibres (range 36 – 314 copies/µm2, mean 121 ± 73 
copies/µm2). 
No significant differences were observed in any cell type between the 2 biopsies. A rise 
in total mtDNA copy number was observed in COX-positive fibres (from 59 ± 53 
copies/µm2 to 96 ± 95 copies/µm2), though this was found not to be a significant 
change (P = 0.1910). Total mtDNA copy number remained more clearly stable in both 
the COX-intermediate (from 121 ± 73 copies/µm2 in Biopsy 1 to 129 ± 109 copies/µm2 
in Biopsy 2) and COX-deficient fibre types (from 142 ± 109 copies/µm2 in Biopsy 1 to 
119 ± 106 copies/µm2 in Biopsy 2), with no significant change in total mtDNA copy 
number over time identified in either group (P = 0.5945 and 0.3144 respectively). 
However, no significant difference was found to exist between COX-positive and 
deficient fibres (P = 0.5529) or COX-intermediate and COX-positive or deficient fibres 
(P = 0.1481 and 0.5157 respectively) in Biopsy 2; the loss of significant difference 
between COX-positive and COX-intermediate or deficient fibres may be explained by 
the small rise of copy number in COX-positive fibres. The lower levels of total mtDNA 
Chapter Four 
162 
copy number observed remain static in all 3 fibre types (7 copies/µm2 for COX-
positive, 31 copies/µm2 for COX-intermediate fibres and 6 copies/µm2 for deficient 
fibres), while the range of copy numbers is increased in Biopsy 2 in both COX-positive 
and COX-intermediate fibres (7 – 409 copies/µm2 in COX-positive fibres, and 31 – 432 
copies/µm2 in COX-intermediate fibres). The range of total mtDNA copy numbers 
observed in COX-deficient fibres was found to remain similar from Biopsy 1 to 2 (6 – 
377 copies/µm2). 
 
 
Figure 4.40 - Total copy number/µm2 assessed in individual COX-positive, intermediate and 
deficient fibres from Biopsies 1 and 2. 
Individual COX-positive, intermediate and deficient fibres were isolated from each of two biopsies taken 
from a single large-scale deletion patient either side of a 13-year interval, and were assessed for total 
mtDNA deletion heteroplasmy level using MTND1 as a marker. Mann-Whitney t-tests were carried out 
to assess the similarity in mtDNA deletion heteroplasmy levels between groups; statistically significant 
differences in mtDNA deletion level are indicated with an asterisk, with relevant P values supplied. The 
only significant differences observed were between COX-positive and COX-intermediate and COX-
deficient fibres in patient biopsy 1; the similarity in total mtDNA copy number between most fibre 
categories may be due to the high degree of data spread.  
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4.4.5.2  Individual muscle fibre mtDNA wildtype copy number analysis 
Wildtype copy number, as measured using ND4 as a marker of wildtype mtDNA, was 
found to be exceptionally stable in all three investigated fibre types between the two 
biopsies, despite a thirteen year gap between biopsies and a drastic reported 
histological progression in the assessed tissue. COX-positive fibres from Biopsy 1 had a 
mean wildtype mtDNA copy number of 42 ± 37 copies/µm2, with a range of 5 - 155 
copies/µm2, while individual COX-positive fibres examined from Biopsy 2 were found 
to have a mean wildtype copy number of 43 ± 33 copies/µm2, with a range of 3 - 135 
copies/µm2. In both biopsies, COX-positive fibres had the highest observed range of 
wildtype mtDNA copy number. These two fibre sets were found to have no significant 
difference in wildtype copy number (2-tailed Mann-Whitney test at 95% confidence 
interval, P = 0.7827).  
COX-intermediate fibres also displayed a stable copy number over the 13 year period 
between the two patient biopsies. Individual COX-intermediate fibres extracted from 
Biopsy 1 had a mean wildtype copy number of 47 ± 21 copies/µm2, with a range  from 
13 – 102, while those isolated from Biopsy 2 had a mean wildtype copy number of 46 ± 
25 copies/µm2, with a range  from 9 – 97 copies/µm2. These two fibre sets were found 
to have no significant difference in wildtype copy number (2-tailed Mann-Whitney test 
at 95% confidence interval, P = 0.5210). COX-intermediate fibres seemed to have a 
higher average wildtype mtDNA copy number than COX-positive fibres in both 
biopsies, but this difference was found not to be statistically significant in either of the 
sample sets (2-tailed Mann-Whitney test at 95% confidence interval, P = 0.0786 in 
Biopsy 1, p = 0.4316 in Biopsy 2).  
COX-deficient fibres were found to display the same lack of variation in terms of 
wildtype mtDNA copy number between the 2 biopsies as was observed in both COX-
positive and intermediate fibres. COX-deficient fibres isolated from Biopsy 1 had a 
mean wildtype copy number of 9 ± 6 copies/µm2, with a range of 2 - 31 copies/µm2, 
while individual COX-deficient fibres examined from Biopsy 2 were found to have a 
mean wildtype copy number of 10 ± 7 copies/µm2, with a range of 3 - 34 copies/µm2. 
Both groups of COX-deficient fibres investigated were found to display the smallest 
range in wildtype mtDNA copy number. No significant difference in wildtype mtDNA 
copy number was found to exist between the two sets of COX-deficient fibre data (2-
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tailed Mann-Whitney test at 95% confidence interval, P = 0.8043). COX-deficient fibres 
were consistently found to contain the lowest levels of wildtype mtDNA. In Biopsy 1, 
wildtype mtDNA copy number was significantly lower in COX-deficient fibres than in 
COX-positive or intermediate fibres (2-tailed Mann-Whitney test at 95% confidence 
interval, P < 0.0001 for both comparisons); the same trend was found to exist in Biopsy 
2 (COX-deficient fibres found to have significantly lower wildtype mtDNA than COX-
positive or intermediate fibres by 2-tailed Mann-Whitney test at 95% confidence 
interval, P < 0.0001 for both comparisons).  
The high wildtype mtDNA copy number levels observed in COX-intermediate fibres was 
unexpected, especially in the light of reports highlighting the importance of absolute 
wildtype mtDNA copy number in determining cellular biochemical function (Durham et 
al., 2005). These high mtDNA copy levels were maintained due to a strong correlation 
between total mtDNA copy number and mtDNA deletion heteroplasmy level (see 
4.4.6.3, Figure 4.46 C - assessed by Spearman’s rho at 95% confidence, r = 0.5165, P = 
0.0001). This means that the fibres with the lowest total mtDNA copy number also 
tend to have the lowest mtDNA deletion heteroplasmy levels, hence maintaining a 
high wildtype mtDNA copy number. However, while this data makes sense in the 
context of the total mtDNA copy number and mtDNA deletion heteroplasmy data, the 
similarity of the observed wildtype mtDNA levels in COX-positive and intermediate 
fibres does not seem to fit with the difference in cellular biochemistry. One possibility 
is that we see a COX-intermediate phenotype in more energy demanding cells (i.e. a 
high proportion of COX-intermediate fibres not be Type IIa as opposed to Type I fibres) 
where a higher than average wildtype mtDNA copy number would be require to meet 
the cell’s ATP demands. This is something that could be investigated with further 
histochemical analysis of muscle tissue in the future, as muscle fibre type was not 
assessed as part of this study.   
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Figure 4.41 - Wildtype copy number/µm2 assessed in individual COX-positive, intermediate 
and deficient fibres from Biopsies 1 and 2. 
Individual COX-positive, intermediate and deficient fibres were isolated from each of two biopsies taken 
from a single large-scale deletion patient either side of a 13-year interval, and were assessed for total 
mtDNA deletion heteroplasmy level using MTND4 as a marker. Mann-Whitney t-tests were carried out 
to assess the similarity in mtDNA deletion heteroplasmy levels between groups; statistically significant 
differences in mtDNA deletion level are indicated with an asterisk, with relevant P values supplied. 
Wildtype mtDNA copy number was shown to be significantly lower in COX-deficient fibres than either 
COX-positive or COX-intermediate fibres in both patient biopsies, while COX-intermediate and positive 
fibres were found to be very similar in terms of wildtype mtDNA copy number.  
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4.4.6 Correlating mtDNA deletion level and copy number 
4.4.6.1 Analysis of total mtDNA and mtDNA deletion heteroplasmy level in total 
dataset. 
Total data from both biopsies was combined in order to assess whether deletion level 
tends to correlate with mtDNA copy number. Total mtDNA copy number was 
investigated first; correlation analysis by Spearman’s rank correlation identified a 
significant positive relationship between mtDNA deletion level and total mtDNA copy 
number/µm2 (P < 0.0001, r = 0.4732). The relationship between total mtDNA copy 
number and mtDNA deletion heteroplasmy was assessed for linearity – it was 
determined that this relationship could be better described by an exponential curve 
than by linear regression. The following curve was generated to fit the data:  
            
 
       
where γ = ND1 copy number/µm2 and χ = mtDNA heteroplasmy level (Figure 4.42). This 
relationship indicates that total copy number is likely to be higher where mtDNA 
deletion levels are also high, suggesting a compensatory increase in mtDNA copy 
number is triggered by rising levels of mtDNA deletion heteroplasmy. The exponential 
relationship between these two variables also indicates that any change at high 
heteroplasmy levels is likely to have more effect than at low levels. For example, 
following the exponential curve fitted to the data, total copy number at 20% 
heteroplasmy is likely to lie around 60 copies/µm2, increasing to 69 copies/µm2 at 30% 
heteroplasmy (a small increase of 15% in mtDNA copy number when mtDNA deletion 
heteroplasmy increases from 20% to 30%); however total copy number of 93 
copies/µm2 at 80% heteroplasmy is predicted to increase to 156 copies/µm2 following 
a 10% increase in mtDNA heteroplasmy level, to 90% (a large  increase of 69% in 
mtDNA copy number when mtDNA deletion heteroplasmy increases from 80% to 
90%). 
Although this curve seemed to fit the data quite well, analysis of the residuals showed 
a skew for data-points to lie further above than below the best-fit curve. To rectify this 
issue, a Box-Cox transformation was carried out to identify the best data form for 
analysis. This transformation gave a rounded λ-value of 0.246801, meaning that the 
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best linear relationship can be generated between mtDNA deletion level and (total 
mtDNA copy number/µm2)0.246801, or approximately√                           . 
The linear regression between these variables can then be described by the equation: 
                 
 where γ = √                     and χ = mtDNA heteroplasmy level (Figure 4.43). 
This analysis confirmed the presence of a strong positive relationship between mtDNA 
copy number and mtDNA deletion heteroplasmy level, accounting for approximately 
47% of variation in total mtDNA copy/µm2 (P < 0.0001, r = 0.4688). 
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Figure 4.42 – Exponential non-linear regression of mtDNA heteroplasmy level with total 
mtDNA copy number/µm2. 
A – The relationship between mtDNA deletion heteroplasmy level (%) and total (ND1) mtDNA copy 
number was assessed by non-linear regression, revealing the presence of an exponential relationship 
between these two variables. The trend line generated by this analysis is described by the equation y = 
46.04 x 2^(x/51.14), where y is total mtDNA copy number and x is mtDNA deletion heteroplasmy level. 
The positive, exponential relationship between mtDNA deletion level and total copy number was found 
to account for approximately 45% of the data spread (r = 0.4484) in this dataset. B – The residuals 
created by this data analysis were plotted and assessed for normality. The residuals were not found to 
follow a Gaussian distribution, meaning further analyses were required in order to accurately assess the 
relationship between total (ND1) copy number and mtDNA deletion heteroplasmy level in the most 
appropriate manner. 
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Figure 4.43 - Linear regression of the 4th root total mtDNA copy number/µm2 and mtDNA 
deletion heteroplasmy level in total dataset. 
A - A Box-Cox data transformation gave a rounded λ-value of 0.246801, suggesting the most appropriate 
data transformation to use to investigate a linear relationship is the 4
th
 root of the total mtDNA copy 
number/µm
2
. Linear regression was carried out to assess the relationship between the 4
th
 root of the 
total mtDNA copy number and mtDNA deletion heteroplasmy level, and identified a strong positive 
relationship between these variables (r
2
 = 0.2198, P < 0.0001). This relationship can be described by the 
equation y = -0.0103x + 2.4127, where y is the 4
th
 root total mtDNA copy number/µm
2
 and x is mtDNA 
deletion heteroplasmy level. B – Analysis of the residuals generated by this linear regression were found 
to follow a normal distribution, confirming that linear regression is an appropriate assessment of the 
relationship between mtDNA deletion heteroplasmy levels and the transformed total (ND1) mtDNA 
copy number dataset. 
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4.4.6.2  Analysis of wildtype mtDNA and mtDNA deletion heteroplasmy level in 
total dataset. 
Following identification of a positive relationship between mtDNA deletion 
heteroplasmy levels and total mtDNA copy number, heteroplasmy was similarly 
investigated with wildtype mtDNA copy number. Correlation analysis by Spearman’s 
rank correlation identified a significant negative relationship between mtDNA deletion 
level and wildtype mtDNA copy number/µm2 (P < 0.0001, r = - 0.4985). This is a 
stronger correlation than that with total copy number, and accounts for a greater level 
of data variance; this is to be expected, given that increasing deletion heteroplasmy by 
definition correlates to lower levels of wildtype mtDNA copy number. 
The relationship between wildtype mtDNA copy number and mtDNA deletion 
heteroplasmy was assessed first by linear regression, but this generated an uneven 
spread of residuals and was therefore an inappropriate analysis; however, the 
following non-linear, exponential regression generated a worse spread of data, 
suggesting this was a worse model to use (Figure 4.44). To rectify this issue, a Box-Cox 
transformation was carried out to identify the best model to use for analysis. This 
transformation gave a rounded λ-value of 0.165495, meaning that the best linear 
relationship can be generated between mtDNA deletion level and (wildtype mtDNA 
copy number/µm2) 0.165495, or approximately√                              . 
The linear regression between these variables can then be described by the equation: 
                 
 where γ = √                     and χ = mtDNA heteroplasmy level (Figure 4.45). 
This analysis confirmed the presence of a strong negative relationship between 
wildtype mtDNA copy number and mtDNA deletion heteroplasmy level, accounting for 
approximately 45% of variation in total mtDNA copy/µm2 (P < 0.0001, r = 0.4473). The 
residuals generated by this analysis were found to follow a Gaussian distribution, 
confirming this as the most appropriate data transformation to carry out. The most 
dramatic effects of heteroplasmy are, as for the relationship between total mtDNA 
copy number and mtDNA deletion heteroplasmy level, seen at higher levels of mtDNA 
deletion heteroplasmy.  
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For example, following the best fit of linear regression of the transformed data, 
wildtype copy number at 20% heteroplasmy is likely to lie around 36 copies/µm2, 
decreasing to 32 copies/µm2 at 30% heteroplasmy; however wildtype copy number of 
16 copies/µm2 at 80% heteroplasmy is predicted to decrease to 2 copies/µm2 following 
a 10% increase in mtDNA heteroplasmy level, to 90%. 
 
 
Figure 4.44 - Analysis of the relationship between wildtype mtDNA copy number and mtDNA 
deletion heteroplasmy level by linear and by non-linear regression. 
Neither linear regression analysis (A) nor non-linear regression analysis (B) were able to generate a 
model suitable to analyse the relationship between wildtype (ND4) mtDNA copy number and mtDNA 
deletion heteroplasmy level. This is demonstrated by the non-Gaussian distribution of the residuals 
generated by both of these models (C and D respectively). This identified a need for further analyses to 
accurately assess the relationship between total (ND1) copy number and mtDNA deletion heteroplasmy 
level in the most appropriate manner. 
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Figure 4.45 - Linear regression of 6th root wildtype mtDNA copy number/µm2 and mtDNA 
deletion heteroplasmy level in total dataset. 
A - A Box-Cox data transformation gave a rounded λ-value of 0.165495, suggesting the most appropriate 
data transformation to use to investigate a linear relationship is the 6
th
 root of the wildtype (ND4) 
mtDNA copy number/µm
2
. Linear regression was carried out to assess the relationship between the 6
th
 
root of the total mtDNA copy number and mtDNA deletion heteroplasmy level, and identified a strong 
negative relationship between these variables (P < 0.0001, r
2
 = 0.1995). This relationship can be 
described by the equation y = -0.0038x + 1.895, where y is the 6
th
 root wildtype mtDNA copy 
number/µm
2
 and x is mtDNA deletion heteroplasmy level. B – Analysis of the residuals generated by this 
linear regression were found to follow a normal distribution, confirming that linear regression is an 
appropriate assessment of the relationship between mtDNA deletion heteroplasmy levels and the 
transformed wildtype (ND1) mtDNA copy number dataset. 
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4.4.6.3 Relationship between mtDNA deletion heteroplasmy level and total 
mtDNA copy number in individual cell categories. 
Following the identification of a significant positive relationship between total mtDNA 
copy number and mtDNA deletion heteroplasmy in the total dataset (4.4.6.1, Figure 
4.43), this relationship was assessed in the three separate cell categories. This was 
done to determine whether the same positive relationship between total mtDNA copy 
number and mtDNA deletion heteroplasmy could be observed in COX-positive, COX-
intermediate and COX-deficient fibres; this would indicate a true relationship between 
these two variables. If this relationship was not observed in the individual data groups, 
the observed trend in the total dataset would be due to the concurrence, on average, 
of the lowest total mtDNA copy numbers and heteroplasmy levels in COX-positive 
fibres, and the highest total mtDNA copy numbers and heteroplasmy levels, on 
average, in COX-deficient fibres. 
Total mtDNA copy number (as measured by the presence of MTND1 by quantitative 
PCR) was found to correlate significantly with mtDNA deletion heteroplasmy level in all 
three investigated cell types – COX-positive, intermediate and deficient muscle fibres. 
Total mtDNA copy number and mtDNA deletion level were found to have a linear 
relationship in COX-positive fibres, meaning the data required no transformation to be 
appropriately analysed. As this data followed a Gaussian distribution, correlation of 
these 2 variables was first assessed using Pearson’s correlation coefficient; a significant 
positive correlation was found to exist (Pearson r = 0.4765, P = 0.0090). Linear 
regression was then used to further assess the relationship between mtDNA deletion 
heteroplasmy level and total mtDNA copy number (Figure 4.46A), again showing a 
significant positive relationship to exist (P = 0.0090). This relationship can be described 
using the equation                , where y represents total mtDNA copy 
number and x represents percentage mtDNA deletion heteroplasmy. However, the low 
r2 value associated with this best fit for the data suggests that this is quite a weak 
relationship, accounting for only 35% of the data spread.  
In COX-intermediate and COX-deficient fibres, where the highest levels of mtDNA 
deletion heteroplasmy tended to be detected, the total copy number data needed to 
be transformed in order to linearize the relationships between total copy number and 
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mtDNA heteroplasmy level for analysis. In both cases a Box-Cox analysis generated a λ-
value of 0, recommending a transformation of the data by Ln for analysis by linear 
regression. Ln total mtDNA copy number was therefore plotted against measured 
mtDNA deletion heteroplasmy level for both datasets (Figure 4.46 C & E). The total 
dataset from COX-intermediate fibres was first assessed using Spearman’s rank 
correlation coefficient, which indicated a significant positive relationship to exist 
between total copy number and mtDNA deletion heteroplasmy level (Spearman’s r = 
0.5165, P = 0.0001). The subsequent linear regression carried out on the transformed 
data set revealed a much stronger trend between the natural log of the total copy 
number and mtDNA deletion heteroplasmy levels than was observed in the linear 
regression analysis carried out in COX-positive fibres (Figure 4.46 C). This relationship is 
best described by the equation                      where y represents total 
mtDNA copy number and x represents percentage mtDNA deletion heteroplasmy. The 
r2 value of 0.3216 suggests that the relationship between copy number and deletion 
level is likely to account for approximately 57% of the total data spread. Finally, 
Spearman’s rho was carried out on the dataset from COX-deficient fibres, revealing a 
strong positive relationship to exist between total mtDNA copy number and mtDNA 
deletion level (Spearman’s r = 0.6023, P <0.0001). A linear regression analysis of the 
natural log of total copy number against mtDNA deletion load revealed the strongest 
positive relationship between these two variables in any of the three fibres categories 
(P < 0.0001), accounting for approximately 68% of the data variability (r2 = 0.4688). 
This relationship is best described by the equation                      where 
y represents total mtDNA copy number and x represents percentage mtDNA deletion 
heteroplasmy. 
 
4.4.6.4 Relationship between mtDNA deletion heteroplasmy level and wildtype 
mtDNA copy number in individual cell categories. 
Following the analysis above of total wildtype mtDNA copy number in relation to 
mtDNA heteroplasmy levels, wildtype mtDNA copy number was also investigated in 
the separate cell category data groups. A significant negative relationship between 
total mtDNA copy number and mtDNA deletion heteroplasmy was observed in the 
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total dataset (4.4.6.2, Figure 4.43); the presence of this relationship was therefore 
assessed in the three separate cell categories. This was done to determine whether the 
same negative relationship between wildtype mtDNA copy number and mtDNA 
deletion heteroplasmy could be observed in COX-positive, COX-intermediate and COX-
deficient fibres; this would indicate a true relationship between these two variables. If 
this relationship was not observed in the individual data groups, the observed trend in 
the total dataset would be due to the concurrence, on average, of the highest wildtype 
mtDNA copy numbers and lowest mtDNA heteroplasmy levels in COX-positive fibres, 
and vice versa in COX-deficient fibres. 
No relationship was found to exist between wildtype mtDNA copy number and mtDNA 
deletion levels, regardless of the biochemical fibre profile. This was confirmed by both 
correlation analysis (Pearson’s correlation assessment for COX-positive fibres, P = 
0.4765, Spearman’s correlation assessment of COX-intermediate and deficient fibres, P 
= 0.1188 and 0.3165 respectively) and linear regression (COX-positive, intermediate 
and deficient fibres, P = 0.4765, 0.9491 and 0.2793 respectively) (Figure 4.46 B, D and 
F). These analyses strongly suggest that the presence of either an mtDNA deletion, or 
the subsequent biochemical defect caused by the presence of an mtDNA deletion, may 
stimulate an increase in mtDNA copy number; however, this does not necessarily 
correlate to an increase in wildtype mtDNA and therefore may not be sufficient to 
rescue a biochemical phenotype.  
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Figure 4.46 – Relationship between mtDNA deletion heteroplasmy levels and total/wildtype 
mtDNA copy number in individual COX-positive, intermediate and deficient fibres.  
Linear regression was carried out on all datasets – to ensure that this analysis was appropriate, copy 
number data was transformed by Ln for the COX-intermediate and deficient fibre datasets, as 
recommended by a Box-Cox analysis. No significant correlation was found between mtDNA deletion 
heteroplasmy levels and wildtype mtDNA copy number in COX-positive (B), intermediate (D) or deficient 
(F) fibres. However, strong positive correlations were identified between mtDNA deletion heteroplasmy 
level and total mtDNA copy number in all 3 fibre types; this was stronger in COX-intermediate (C) than 
COX-positive (A) fibres, with the strongest relationship being identified in COX-deficient fibres (E). 
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4.4.6.5  Analysis of outlying data points. 
A selection of outlying data points were individually analysed for deletion level and 
both total and wildtype mtDNA copy number; these included COX-deficient fibres with 
unusually low levels of mtDNA deletion, and COX-positive fibres with high mtDNA 
heteroplasmy levels (Table 4.18). Three COX-deficient fibres were identified as 
potential outliers in the mtDNA deletion heteroplasmy level analysis (section 4.4.4), 
with low mtDNA deletion levels more than 2 standard deviations from the mean 
mtDNA deletion heteroplasmy in the remaining 51 COX-deficient fibres analysed from 
the two patient biopsies available. These were confirmed as outliers using Dixon’s Q 
test, as demonstrated here for 21% heteroplasmy: 
  
   
     
 
     
     
         
The Q-test limits for sample sizes of 10+ are 0.412, 0.466 and 0.568 for 90, 95 and 99% 
confidence intervals respectively; 0.5714>0.568, meaning we can be 99% sure that the 
21% heteroplasmy level is an outlier. Though these levels could have been due to 
experimental error, analysis was conducted to assess whether COX-deficiency in these 
cells may be attributable to something other than a high heteroplasmy level – i.e. low 
wildtype copy numbers or overall mtDNA depletion. In all 3 cases, these COX-deficient 
fibres were found to have low total and wildtype copy number – these were in fact 
some of the lowest copy numbers identified in the whole study. This suggests that low 
mtDNA copy number – and particularly low wildtype copy number – may be 
responsible for the cellular biochemical defect rather than the specific mtDNA 
deletion. With 94% of all assessed COX-deficient fibres presenting with a heteroplasmy 
level of >65%, it is possible that the only reason no COX-deficient fibres were detected 
with a deletion level between 21 and 65% is due to a small sample size. 
Conversely, 8 fibres identified as having normal COX biochemical activity were found 
to have mtDNA deletion levels exceeding 60%. In these cases, total mtDNA copy 
number tended to be high, while wildtype mtDNA copy number was higher than the 
range that was identified in COX-deficient fibres in either biopsy (Table 4.18). This 
again suggests that wildtype mtDNA copy number is playing a greater role in cellular 
function than mtDNA deletion heteroplasmy levels.  
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Following on from the outlier analysis, a further selection of individual COX-deficient 
fibres taken from Biopsy 2 were individually assessed. These 6 fibres were selected for 
further analysis due to their spectrum of mtDNA deletion heteroplasmy levels – above 
60%, the generally accepted mtDNA deletion threshold for skeletal muscle, but below 
80%, the lowest observed mtDNA deletion level in COX-deficient fibres isolated from 
Biopsy 1 (excluding 1 outlier). Sorting the M158 COX-deficient fibre data (N = 23, 
excluding 2 deletion level outliers) by total copy number revealed that the 6 COX-
deficient muscle fibres with mid-range mtDNA deletion heteroplasmy levels had the 
lowest levels of total mtDNA copy number (Table 4.19). In keeping with this, these 
fibres also displayed very low levels of wildtype mtDNA – 6 wildtype copies/µm2 at the 
highest, which still lies at the lower end of the normal range of wildtype mtDNA copy 
number found in COX-deficient fibres. This suggests that low levels of wildtype mtDNA 
alone may have been sufficient to cause a biochemical defect in these muscle fibres; 
however, a combination of a moderate level of mtDNA deletion heteroplasmy and a 
low mtDNA copy number is certainly sufficient to cause a state of COX-deficiency in an 
individual muscle fibre.  
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Muscle fibre identifier Deletion level (%) Total mtDNA copy 
number/µm
2
 
Wildtype mtDNA copy 
number/µm
2
 
1 - COX-deficient 29 21 41 6 
2 - COX-deficient 24 13 18 12 
2 - COX-deficient 25 0 6 6 
1 - COX-positive 1 80 180 50 
1 - COX-positive 2 69 105 36 
1 - COX-positive 3 62 210 79 
1 - COX-positive 4 61 79 34 
2 - COX-positive 1 85 145 21 
2 - COX-positive 2 84 408 49 
2 - COX-positive 3 74 149 48 
2 - COX-positive 4 66 80 27 
Mean COX-positive 
values (median and 
interquartile range) 
30 
1 – 45 
55 
19 – 104 
42 
14 - 57 
Mean COX-deficient 
values (median and 
interquartile range) 
86 
88 – 96 
101 
37 - 208 
9 
4 - 12 
Table 4.18 - mtDNA deletion level and copy number analysis for outlier data points. 
3 COX-deficient fibres were found to have deletion levels much lower than the norm for biochemically 
deficient fibres in the patient, while 8 COX-positive fibres contained relatively high deletion levels of 
more than 60%. The data for these samples were individually analysed, looking at mtDNA deletion load 
alongside total and wildtype mtDNA copy number. Total mtDNA copy number/µm
2
 and wildtype mtDNA 
copy number/µm
2
 were compared to the normal range of values for both COX-positive and deficient 
fibres (the normal range being defined between the 25% and 75% quartile of the total data). All 3 COX-
deficient fibres with low deletion levels were found to have low levels of wildtype mtDNA, in keeping 
with a COX-deficient fibre profile. Conversely, COX-positive fibres with higher than normal mtDNA 
deletion levels were found to have higher levels of wildtype mtDNA, in keeping with a COX-positive fibre 
profile. 
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Muscle fibre identifier Deletion level (%) 
Total mtDNA copy 
number/µm
2
 
Wildtype mtDNA copy 
number/µm
2
 
2 - COX-deficient 1 65.77456 6.049481 4.809915 
2 - COX-deficient 2 66.81219 9.308882 3.193685 
2 - COX-deficient 3 64.42739 12.19774 3.554521 
2 - COX-deficient 4 75.46981 24.15154 4.733096 
2 - COX-deficient 5 68.92391 24.85533 6.328166 
2 - COX-deficient 6 78.83015 31.74704 5.399714 
2 - COX-deficient 7 91.16354 37.92714 3.445369 
2 - COX-deficient 8 88.74969 47.62401 11.60864 
2 - COX-deficient 9 94.15784 53.16965 3.055765 
2 - COX-deficient 10 94.05193 72.19366 8.693602 
2 - COX-deficient 11 91.77197 114.3179 9.596667 
2 - COX-deficient 12 93.82996 114.7862 4.814649 
2 - COX-deficient 13 88.65739 118.8834 14.2358 
2 - COX-deficient 14 87.2738 132.7548 12.40535 
2 - COX-deficient 15 96.10166 144.0944 4.651978 
2 - COX-deficient 16 96.53834 183.9715 12.17113 
2 - COX-deficient 17 96.2478 207.9941 15.06114 
2 - COX-deficient 18 96.43901 208.6513 22.08622 
2 - COX-deficient 19 88.79622 229.7572 18.91965 
2 - COX-deficient 20 97.00394 239.1385 13.48394 
2 - COX-deficient 21 94.60243 269.2664 9.740551 
2 - COX-deficient 22 92.86837 289.5642 12.66709 
2 - COX-deficient 23 87.71744 376.6842 33.84432 
Mean COX-positive 
values (median 50 
percentile) 
30 
1 – 45 
55 
19 – 104 
42 
14 - 57 
Mean COX-deficient 
values (median 50 
percentile) 
86 
88 – 96 
101 
37 - 208 
9 
4 - 12 
Table 4.19 - mtDNA deletion level and copy number analysis for COX-deficient fibres 
extracted from biopsy 2. 
Total data for all COX-deficient fibres extracted from Biopsy 2 (excluding 2 outliers, 2 - COX-deficient24 
and 2 - COX-deficient25, Table 4.18). All data is sorted from lowest to highest total mtDNA copy 
number/µm
2
. Mean values and the median range (between the 25% and 75% data quartiles) for mtDNA 
deletion level, total copy number and wildtype copy number are also displayed for COX-positive and 
COX-deficient fibres, as a point of reference. 
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4.4.7  Further investigations of histochemistry and homogenate DNA genetics. 
Following the individual fibre investigations discussed in 4.4.3 – 4.4.6, it became 
evident that the two biopsies needed to be re-assessed; the initial report of a large 
increase in COX-deficiency and decrease in total mtDNA copy number between the 
two investigated biopsies did not tally with the observed lack of change in either 
mtDNA deletion heteroplasmy level or mtDNA copy number in individual muscle 
fibres.  
First, fresh tissue sections were taken from each of the two muscle biopsies for 
histochemical analysis. The initial analyses carried out by the NCG Mitochondrial 
Diagnostics Service were carried out independently as the samples arrived for 
assessment- it was thought that this may have contributed to skewing the COX-
deficiency data – so care was taken to investigate the set of freshly cut sections 
simultaneously, using the same batch of reagents. A new analysis also allowed for 
histochemical analysis to take into account the presence of COX-intermediate fibres, 
which are not assessed as part of the current diagnostic process with the NCG 
mitochondrial disease diagnostics service.  
Tissue sections of 20µm thickness from each biopsy were simultaneously investigated 
for COX and SDH activity, following the standard COX/SDH dual-histochemistry 
protocol. 6 tissue areas were chosen by random sampling from sections from each of 
the two biopsies for investigation (Figure 4.47); fibre counts were carried out in each 
of these areas in order to establish with as much accuracy as possible the level of 
biochemical deficiency in each biopsy. Individual fibres were assigned as being COX-
positive where the fibre was fully brown, as being COX-deficient where the fibre 
appeared fully blue, and COX-intermediate where a dull grey or purple colour was 
observed. The range of colours seen in COX-intermediate fibres is due to the presence 
of products from both the COX and SDH histochemical assays, where a low level 
biochemical deficiency has allowed some brown precipitate to be produced from the 
COX activity assay, but an insufficient amount to inhibit the SDH histochemical assay. 
Fibre counts in the 6 assessed areas from each biopsy were averaged to give an 
estimate of the percentage of each fibre type present in the whole biopsy (Table 4.20). 
These counts revealed no overall change in the level of biochemical deficiency from 
the first biopsy to the second biopsy taken 13 years later. Biopsy 1 gave observed 
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average values of 38.3% COX-positive fibres, 33.2% COX-intermediate fibres and 28.5% 
COX-deficient fibres, compared to 33.5% COX-positive fibres, 38.1% COX-intermediate 
fibres and 28.4% COX-deficient fibres observed in Biopsy 2. Although this was not the 
result we may have originally expected, this lack of histochemical progression over the 
13 year period between biopsies is in keeping with the stable genetics observed at the 
individual fibre level between the two biopsies. This finding also highlights the 
importance of maintaining identical experimental conditions to allow for comparable 
results, as the initial reported increase in COX-deficiency from biopsy 1 to 2 is likely to 
have been an artefact of a stronger reaction in the SDH histochemical assay in biopsy 2 
(due to different reagent batches, or different incubation conditions).  
 
 
Figure 4.47 - Images of 6 areas from each of two biopsies from a single patient, assessed by 
dual histochemical assays for COX and SDH activity. 
Tissue sections of 20µm thickness were taken from each biopsy and assessed for biochemical activity 
using a standard protocol for dual COX and SDH histochemistry. Images were taken at x10 magnification 
of 6 randomly sampled section areas from each biopsy for fibre counts and assessment of biochemical 
activity. 
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 Biopsy 1  Biopsy 2 
Area COX-pos COX-int COX-def Area COX-pos COX-int COX-def 
A 42 41 40 G 34 43 27 
B 28 12 14 H 26 46 23 
C 21 36 17 I 30 35 35 
D 29 27 16 J 27 22 11 
E 48 29 36 K 36 32 34 
F 45 40 36 L 36 37 30 
 
Average 
number 
%   
Average 
number 
%  
COX-pos 35.5 38.3  COX-pos 31.5 33.5 No 
change 
in fibre 
% 
COX-int 30.83 33.2  COX-int 35.8 38.1 
COX-def 26.5 28.5  COX-def 26.7 28.4 
Table 4.20 - Tallied fibre count of COX-positive, COX-intermediate and COX-deficient fibres in 
6 areas from each of two biopsies. 
Numbers of COX-positive, COX-intermediate and COX-deficient fibres were tallied in 6 randomly 
sampled section areas from each biopsy (Figure 4.47). The values from each of these sample areas were 
averaged for each biopsy, giving an estimate of the percentage of each fibre type present in the muscle 
as a whole. No significant change was observed between the two biopsies.  
 
Finally, to establish whether total mtDNA copy number from homogenate tissue DNA 
could be found to fit with the rest of the consistent data. To this end, fresh 
homogenate DNA was extracted from each biopsy. This was done in two ways: firstly, 
total DNA was extracted from a single unstained section from each biopsy; secondly, 4 
randomly sampled areas of known size (each contained ~20 muscle fibres) were 
extracted from a section from each biopsy assessed for SDH histochemistry only, and 
DNA was extracted from these. In both cases, the 18S/ND1 quantitative PCR assay was 
used to assess the quantity of total mtDNA present. As the mtDNA deletion levels from 
the first assessment were consistent with the Southern blot analysis carried out by the 
NGC Mitochondrial Disease Diagnostics service, it was decided that no further 
investigation of mtDNA deletion heteroplasmy was required.  
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Each of the DNA samples extracted from isolated regions of SDH-only assessed 
sections were run together on a single plate of ND1/18S quantitative PCR for analysis 
(3 wells per sample), while the two homogenate DNA samples extracted from a whole 
biopsy section were run as a pair (3 wells per sample) on 3 separate plates; average 
values were then taken for analysis. Both sets of analyses revealed no change in total 
copy number between the two biopsies (Table 4.21).  The isolated section areas from 
Biopsy 1 had a large range in total mtDNA copy number from 149 – 756 copies/18S, 
demonstrating the heterogeneity of the tissue as a whole, with an average mtDNA 
copy number per 18S rRNA of 342. A similar spread of copy number was observed in 
the areas extracted from Biopsy 2 sections, with a data spread of 127 – 601 copies/18S 
rRNA. This gave an average total mtDNA copy number of 331, with no significant 
difference observed between the two sets of data by Mann-Whitney test (P = 0.9814). 
Similarly, no difference was observed in total mtDNA copy number between the DNA 
samples extracted from whole tissue sections from Biopsies 1 and 2; the three runs for 
Biopsy 1 gave values of 235, 161 and 169 copies/18S rRNA (mean value 195 copies/18S 
rRNA) compared to 224, 198 and 241 copies/18S rRNA (mean value 221 copies/18S 
rRNA) in Biopsy 2. Again, no significant difference was observed in total mtDNA copy 
number between Biopsies 1 and 2 in this dataset Mann-Whitney test, P = 0.4001). 
Though no difference was found between the two biopsies in either analysis, total 
mtDNA copy numbers were, on average, higher in the analysis of laser micro-dissected 
sections areas. This may be due to the heterogeneity of the tissue in the whole tissue 
section – i.e. the presence of factors such as collagen and fatty infiltrate between 
muscle fibres in the tissue as a whole, which were not included in the small areas 
extracted by laser microdissection for copy number analysis. 
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 Sample Copy number/18S rRNA Average values  
Isolated section 
areas from 
Biopsy 1 
Area 1 156 
342 
No 
significant 
difference 
Area 2 307 
Area 3 756 
Area 4 149 
Isolated section 
areas from 
Biopsy 2 
Area 5 326 
331 
Area 6 601 
Area 7 270 
Area 8 127 
Biopsy 1 section 
homogenate 
DNA 
Run 1 235 
195 
No 
significant 
difference 
Run 2 161 
Run 3 169 
Biopsy 2 section 
homogenate 
DNA 
Run 1 224 
221 Run 2 198 
Run 3 241 
Table 4.21 - Total mtDNA copy number in homogenate DNA extracted from each biopsy. 
4 randomly selected areas from sections assessed for SDH activity only were isolated by laser 
microdissection from each biopsy; homogenate DNA was extracted from each of these areas for copy 
number analysis. A single unstained section from each biopsy was also used for total homogenate DNA 
extraction. All DNA samples were assessed for total mtDNA copy number, using the 18S/ND1 
quantitative PCR assay. No significant difference was found to exist between the two biopsies in terms 
of total mtDNA copy number. Lower measured copy numbers in the whole sections are likely to be an 
artefact; isolated section areas contained almost exclusively muscle fibre tissue, while sections are likely 
to have included a greater proportion of inter-fibre space/fatty infiltrate/etc . 
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4.5 Discussion 
Early work investigating mtDNA deletion disease suggested that the defect continued 
to accumulate over time (Larsson et al., 1990), which led to the initial proposal of a 
replicative advantage for deleted mtDNA species over wildtype mtDNA (Wallace, 
1992). More recent work in the field suggests that in single mtDNA deletion diseases 
the mtDNA deletion is amplified rapidly following formation in early development 
(Pitceathly et al., 2012); however, very little comment has been made in recent 
literature to suggest whether the level of mtDNA defect continues to change 
throughout a patient’s lifespan. Work carried out in a mouse model of single mtDNA 
deletion disease in 2007 has been proposed to support continuous accumulation of 
mtDNA deletion species in a tissue-specific manner. mtDNA deletion heteroplasmy 
was measured in a variety of tissues (tail, heart, skeletal muscle, kidney, liver, testis 
and ovaries) at set time-points throughout the lifespan. Heteroplasmy levels of the 
mtDNA deletion were found to rise over time in the tail, heart, skeletal muscle, kidney, 
liver, testis and ovaries, but not  the pancreas, spleen, brain or blood (Sato et al., 
2007).   
To determine if an increase in mtDNA deletion levels is seen in human tissue – 
specifically in muscle, this being a primary affected tissue in patients with single large –
scale mtDNA deletions, a case study was undertaken where two muscle biopsies taken 
thirteen years apart were available from a single patient, allowing analysis of 
molecular changes in this patient’s tissue over time. Initial histochemical and 
quantitative PCR analyses undertaken by the Newcastle Mitochondrial NCG 
Diagnostics service indicated a histochemical progression over the thirteen year period 
between these two biopsies and a dramatic loss of mtDNA (a drop in total mtDNA copy 
number of almost 50%). However, subsequent analysis was found to be required in 
order to ensure the results were accurate – histochemical analysis of the biopsies 
needed to be carried out simultaneously for comparisons to be appropriate, and 
homogenate DNA samples were extracted from fresh biopsy sections to ensure the 
best DNA quality possible for analysis. Following these safeguards, it became clear 
from the new analyses that there was no change in muscle histochemistry over the 13 
years between the two biopsies taken from this patient (Figure 4.47) and no change in 
total mtDNA copy number over time (Table 4.21). In stark disagreement with our 
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hypothesis, no increase in mtDNA deletion level was observed in the homogenate 
tissue DNA over the thirteen year period between the two biopsies. Southern blot 
analysis showed no change in deletion level between the two biopsies; this was 
subsequently confirmed by quantitative PCR, which showed stable mtDNA deletion 
heteroplasmy levels of approximately 75% between the two biopsies.  
Following the assessment of any molecular changes at the whole tissue level, 
investigations were carried out at the single cell level to identify any progression of 
molecular defects that may have taken place over the thirteen year period between 
these two biopsies. A minimum of 25 COX-positive, 25 COX-intermediate and 25 COX-
deficient fibres were isolated from tissue sections taken from each of the available 
muscle biopsies, and lysed to extract single muscle fibre DNA for genetic analysis. First, 
a deletion level analysis was carried out using the ND1/ND4 quantitative PCR assay. 
Deletion level was found, on average, to stay stable across the two biopsies in COX-
positive fibres (32% ± 22% for Biopsy 1 and 28% ± 29% for Biopsy 2) and COX-
intermediate fibres (57% ± 23% for Biopsy 1 and 58% ± 28% for Biopsy 2), although 
average deletion load dropped a small but statistically significant amount  in COX-
deficient fibres over time (91% ± 14% for Biopsy 1 and 85% ± 21% for Biopsy 2). 
However, the significance of this drop in average COX-deficient fibre deletion load can 
be attributed to a small number of outlying data points, suggesting that no true 
difference exists in mtDNA deletion level between COX-deficient fibres from Biopsy 1 
and from Biopsy 2. These outlying fibres are likely to be muscle fibres which were 
normally functioning at the time of the 1st muscle biopsy but have gone on to develop 
a biochemical deficiency by the time the 2nd muscle biopsy was taken from this 
patient. Either deletion load has risen in these muscle fibres to just above the 
threshold level up to which the cell can successfully tolerate the presence of the 
mtDNA deletion (Rossignol et al., 2004), or a drop in copy number has occurred in 
fibres with an already reasonably high level of mtDNA deletion heteroplasmy, these 
two parameters combining to deplete wildtype mtDNA below a functional threshold 
(Durham et al., 2005; Durham et al., 2007). If this is the case, this would suggest that 
some of the worst affected fibres have been lost over time in order for the proportion 
of COX-positive, intermediate and deficient fibres to remain stable over time (Herbst et 
al., 2007). These results fit with the findings in homogenate tissue; a stable level of 
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mtDNA deletion heteroplasmy in each of the three designated fibre types is consistent 
with a stable mtDNA deletion level and stable level of biochemical deficiency in the 
tissue as a whole.  
Following mtDNA heteroplasmy level analysis, wildtype and total mtDNA copy number 
were assessed in each of the individual isolated muscle fibres. Total wildtype copy 
number was found to be significantly higher in COX-deficient and intermediate fibres 
than COX-positive fibres in Biopsy 1 (P = 0.0022 and 0.0003 respectively), but this was 
no longer the case in Biopsy 2 (P = 0.5529 and 0.1481 respectively). Mean total copy 
number has remained very consistent in COX-intermediate fibres (121 copies/µm2 in 
Biopsy 1 and 129 copies/µm2 in Biopsy 2), while it has slightly risen over the 13 year 
period in COX-positive fibres (from 59 to 96 copies/µm2) and it has slightly decreased 
in COX-deficient fibres (from 142 to 119 copies/µm2). However, neither of these 
observed changes were statistically significant (P = 0.1910 and 0.3144 respectively).  
Wildtype mtDNA copy number was found to be even more consistent between the 
two biopsies than total copy number; no change was observed over time in COX-
positive (42 copies/µm2 in Biopsy 1 compared to 41 copies/µm2 in Biopsy 2, P = 
0.7827), intermediate (47 copies/µm2 in Biopsy 1 compared to 46 copies/µm2 in Biopsy 
2, P = 0.5210) or deficient fibres (9 copies/µm2 in Biopsy 1 compared to 10 copies/µm2 
in Biopsy 2, P = 0.8043). The difference between wildtype mtDNA copy number in COX-
positive and COX-deficient fibres was found to be highly statistically significant in both 
biopsies (P < 0.0001 in both cases), as was the difference between wildtype mtDNA 
copy number in COX-intermediate and COX-deficient fibres (P < 0.0001 in both cases). 
No significant difference was observed between COX-intermediate and COX-positive 
fibres in terms of wildtype mtDNA copy number in either biopsy (P = 0.0786 Biopsy 1, P 
= 0.4316 Biopsy 2).  
An investigation of the relationship between total mtDNA copy number and mtDNA 
deletion heteroplasmy levels revealed a strong positive trend between these two 
variables in the total dataset (P < 0.0001), as well as in each of the three defined fibre 
types. Interestingly, this relationship was found to be strongest in COX-deficient fibres 
(P < 0.0001), while COX-intermediate fibres (P = 0.0001) displayed a stronger positive 
trend than COX-positive fibres (P = 0.0090). The presence of higher mtDNA copy 
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numbers where high mtDNA deletion heteroplasmy levels are observed is indicative of 
a compensatory amplification of mtDNA in the presence of mtDNA deletion species in 
order to preserve a functional quantity of wildtype mtDNA (Wong and Bai, 2002; Bai et 
al., 2004). 
Wildtype mtDNA copy number was subsequently assessed against mtDNA deletion 
level in the same manner, revealing a significant negative correlation in the total 
dataset (P < 0.0001); this was expected given that increasing mtDNA deletion 
heteroplasmy is synonymous with a decreasing proportion of wildtype mtDNA in the 
cell. This correlation may have confounded previous studies in this area, many of 
which agreed that increasing levels of mtDNA deletion heteroplasmy above a 
determined threshold level (~60% in muscle (Hayashi et al., 1991))  was ultimately 
responsible for causing cellular biochemical defects (Porteous et al., 1998; Rossignol et 
al., 2004). However, the importance of mtDNA deletion heteroplasmy level, and 
indeed the presence of a deletion threshold in skeletal muscle, has previously been 
brought into question in studies of single mtDNA deletion disease patients (Schroder et 
al., 2000). This is perhaps reinforced by the lack of a relationship between wildtype 
mtDNA copy number and mtDNA deletion heteroplasmy levels in any of the three 
defined fibre types (Figure 4.46), which suggests that the combination of absolute 
wildtype mtDNA copy number and mtDNA deletion level is most likely to be 
responsible for defining the cell’s biochemical profile. 
The importance of absolute wildtype mtDNA copy number is further highlighted by the 
analysis of outliers in the individual cell study. 3 COX-deficient fibres found to have low 
deletion levels (21, 13 and 0% mtDNA deletion heteroplasmy) were all found to have 
unusually low wildtype copy numbers, suggesting that depletion of wildtype mtDNA 
past a functional threshold is responsible for the biochemical deficiency in these cells 
rather than the mtDNA deletion heteroplasmy level. Conversely, a number of COX-
positive fibres were found to have relatively high deletion levels – above the 60% 
mutation threshold for skeletal muscle proposed by Hayashi et al. However, these 
fibres all maintained a level of wildtype mtDNA within the normal range for COX-
positive muscle fibres, suggesting that the presence of sufficient wildtype genome 
copies is adequate to maintain normal biochemical function.  
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One of the most interesting subset of cells in the analysis were the COX-deficient fibres 
from Biopsy 2 which displayed a deletion level above the proposed skeletal muscle 
mtDNA deletion threshold of 60% but lower than 80%, the lowest level of 
heteroplasmy observed in COX-deficient fibres taken from Biopsy 1.  This subset of 
COX-deficient fibres had the lowest total mtDNA copy numbers observed in any fibres 
extracted from Biopsy 2, and lay among the lowest levels of wildtype mtDNA observed. 
This indicates that increasing mtDNA deletion level and mtDNA depletion have had a 
combined effect to cause a biochemical defect to occur in these muscle fibres – again 
suggesting that absolute wildtype mtDNA copy number is at least as important, if not 
more so, than mtDNA deletion heteroplasmy level.  
Overall, no evidence in support of the ‘survival of the smallest’ model for the clonal 
expansion of mtDNA deletions (Wallace, 1992) has been uncovered in this study. The 
presence of a replicative advantage for the mtDNA deletion species over wildtype 
mtDNA would lead to a continued increase in deletion heteroplasmy throughout the 
patient’s lifespan, until homoplasmy is reached; instead, we have observed a steady 
level of mtDNA deletion across the two biopsies and therefore across a thirteen year 
time-span. If a replicative advantage for mtDNA deletions over wildtype did exist, we 
would also expect to see an increase in COX-deficiency in a patient’s muscle over time 
driven by mtDNA deletion accumulation within single fibres. However, we have found 
the molecular defects present in this patient’s muscle to be exceptionally stable – the 
lack of change in mtDNA deletion levels or in total or wildtype mtDNA copy numbers 
have led to the maintenance of a similar level of biochemical deficiency over the 
thirteen years between these two biopsies.   
Results obtained from individual COX-positive fibres taken from each biopsy are 
arguably the most comparable datasets – all COX-positive fibres taken from biopsy 2 
must have been biochemically functional at the time of Biopsy 1, but COX-deficient 
fibres taken from the 2nd Biopsy could have become biochemically deficient at any 
time prior to the 2006 biopsy. In these fibre groups, there is no observed change in 
mtDNA deletion level or wildtype mtDNA copy number over time, and only a modest 
increase in total mtDNA copy number which was shown not to be statistically 
significant. This suggests no replicative advantage for mtDNA deletion species in these 
fibres, and lends no support to the ‘survival of the smallest’ hypothesis of clonal 
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expansion. As no advantage seems to be driving a continuous accumulation of mtDNA 
deletions over time, this work supports the hypothesis that random genetic drift is the 
likely mechanism driving the accumulation of mtDNA deletions by clonal expansion in 
aging and disease (Elson et al., 2001). 
A secondary aim of this study was to investigate the molecular changes that drive 
disease progression in single mtDNA deletions disease patients over time. This case has 
turned out to be a particularly interesting one, with no change in either molecular 
defects or biochemical deficiency in the muscle over the thirteen years between the 
two biopsies. This suggests that – at least in some patients – the mtDNA deletion 
accumulation responsible for disease symptoms may occur early in life before a 
plateau is reached. However, a wide patient cohort would have to be investigated to 
determine whether there are cases where mtDNA deletion level may continue to 
increase through a patient’s lifespan; this is perhaps the case where disease 
progression is more severe. The investigation of individual COX-deficient, COX-
intermediate and COX-normal fibres undertaken in this patient does suggest that 
wildtype mtDNA copy number as at least as important in determining cellular health as 
mtDNA deletion heteroplasmy – this was particularly evident in outlying data points 
from COX-positive and deficient fibres, where the effects of unusual mtDNA deletion 
levels were modified by more typical mtDNA wildtype copy numbers (see 4.4.6.5). This 
highlights the importance of mtDNA maintenance in the muscle, and lends support to 
the hypothesis that absolute wildtype copy number may be vital for maintaining 
normal biochemical function, superseding mtDNA deletion heteroplasmy level in 
determining cellular health (Durham et al., 2005). The results of the individual fibre 
studies, if extrapolated to whole tissue level, therefore indicate that decreasing levels 
of wildtype mtDNA below a threshold level may be the primary cause of patient 
progression in single mtDNA deletion disease. However, it is as yet unclear how strong 
a regulatory role mtDNA deletion heteroplasmy level has in modifying the effect of 
wildtype mtDNA copy number on cell fate. 
The variability in both the histochemical COX/SDH assay and the MTND1/18S 
quantitative PCR assay observed during the course of this study has led to an 
unexpected outcome for this study in the form of recommendations for future 
experimental design. Issues with both of these current experimental techniques have 
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been identified and, though these assays are both currently the best available 
techniques to assess COX-deficiency and mtDNA copy number respectively, this study 
highlights a need for improvement. Variability with the histochemical COX/SDH assay 
was shown to increase when samples were processed at different times – this could be 
due to unavoidable differences in reagent batches or experimental conditions such as 
room temperature. Consistency in measurements of biochemical deficiency can 
therefore be maximized by assessing relevant tissue sections concurrently, regardless 
of any previous analyses which may have taken place; any future studies involving the 
assessment of COX-deficiency levels in tissue should be designed to take this into 
account. Identifying an approach to increase the accuracy of mtDNA copy number 
measurements is more complicated. A need for a more reliable technique than the 
MTND1/18S TaqMan assay has been identified, though this technique remains best 
practice until an alternative measure can be established. The current assay is flawed 
due to the multi-copy nature of nuclear marker 18S rRNA, which can vary not only 
between individuals, but from cell to cell in any one individual. Ideally mtDNA copy 
number should be normalised to a single copy nuclear marker, but these are difficult to 
detect by quantitative PCR and, if detected, are likely to be read at an unreliably high 
Ct value. 18S rRNA therefore currently remains the most appropriate nuclear marker to 
use in real-time PCR quantification of mtDNA copy number, but the limitations in 
terms of accuracy of the 18S/ND1 assay should be taken into account in all future 
studies and research must be undertaken to identify a more reliable alternative. 
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Chapter 5: 
Investigating the impact of molecular mtDNA deletion characteristics on disease 
presentation and progression in single mtDNA deletion patients. 
5.1 Introduction 
5.1.1 Correlation of mtDNA deletion breakpoints/level/progression/phenotype 
Although the three main syndromes associated with single, large-scale mtDNA 
deletions – CPEO, KSS and Pearson syndrome – seem to be quite clearly defined, the 
reality is that a wide spectrum of disorders exists, from patients who may not be 
diagnosed until late in life with CPEO to onset of Pearson syndrome in very early 
infancy. The mid-range of this spectrum presents a serious problem for clinicians in 
that no genetic markers have been found to conclusively identify how severe a 
patient’s symptoms may become, or how quickly they will progress. In order to provide 
the best possible patient care and support, it is vital that we are able to better 
understand disease severity and progression. To date, many studies have been carried 
out with the aim of uncovering a link between the genetic defect present in cases of 
single large-scale mtDNA deletion disease, the resultant biochemical defect and the 
presented clinical phenotype – these have, however, met with mixed success, and 
many of the research findings have been contradictory. 
Early investigative efforts from a number of independent research groups uncovered 
no link between the mitochondrial genetics, biochemical defect and patient phenotype 
in heterogeneous groups of mitochondrial disease (Holt et al., 1988), a group of only 
KSS patients (Zeviani et al., 1988), a group of CPEO and KSS patients (Moraes et al., 
1989), or in a group of patients with Pearson syndrome (Rotig et al., 1995). No 
evidence was found in any of these studies to suggest a link between mtDNA deletion 
size and location, the resultant biochemical defect or clinical presentation. Further 
studies also brought mtDNA deletion heteroplasmy levels under scrutiny – findings 
from separate studies began to diverge at this point. Moraes et al had initially 
suggested that no link existed between heteroplasmy levels and clinical presentation 
(Moraes et al., 1989) – in keeping with contemporary work by Holt et al (Holt et al., 
1989) – but later found a strong relationship to exist between heteroplasmy levels and 
levels of COX-deficiency in muscle (Moraes et al., 1995). A similar relationship had 
Chapter Five 
194 
 
previously been identified by two other groups (Mita et al., 1989; Goto et al., 1990a), 
confirming a link between COX-deficiency and mtDNA deletion heteroplasmy levels. 
However, these papers were contradictory in many other aspects, leaving the field 
open to further study and interpretation. 
To date, controversy remains rife in this field of research. The most consistent 
indicator of disease severity and progression has been found to be age of symptom 
onset, with earlier symptom onset being indicative of a more severe and rapidly 
progressing clinical presentation (Goto et al., 1990a; Aure et al., 2007; Yamashita et al., 
2008). The presence and proportion of the mtDNA deletion in blood has also been 
associated with a more severe disease presentation (Aure et al., 2007), while 
assessment of urothelial cells has shown the presence of mtDNA deletions at higher 
levels in younger, more severely affected patients  (though  mtDNA deletion levels 
tend not to be representative of those seen in a clinically affected tissue) (Blackwood 
et al., 2010). Interestingly, mtDNA deletion size has been found to be predicative of 
age of onset (Yamashita et al., 2008; López-Gallardo et al., 2009), but has not been 
consistently found to correlate with disease phenotype or progression despite the 
predictive role of age of onset in determining these factors. Two studies of large 
groups of single large-scale mtDNA deletion disease patients presented conflicting 
evidence to suggest that mtDNA deletion size can (Yamashita et al., 2008) or cannot 
(López-Gallardo et al., 2009) be used to predict disease course.  
Some consistency has been achieved in that both the Yamashita and Lopez-Gallardo 
study have agreed that mtDNA deletion location is predictive of phenotype/age of 
onset. However, the studies disagree on which region of the mitochondrial genome 
plays the most vital role of determining the pathogenicity of the mtDNA deletion. 
Yamashita et al. found that deletions including COX (and ATP) subunit genes had 
significantly earlier onset, therefore correlating with a worse predicted disease 
phenotype and rate of disease progression (Bua et al., 2006); contradictorily, López-
Gallardo et al. found deletion of Cyt b to be associated with a severe KSS phenotype, 
and did not corroborate the findings of Yamashita et al. (López-Gallardo et al., 2009). A 
recent overview has suggested that the pathogenicity of mtDNA deletions is based 
upon the deletion of one or more tRNA genes (Schon et al., 2012) , on the basis that 
the loss of a single tRNA gene may have a global effect on the translation of all 
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mitochondrial-encoded genes (Nakase et al., 1990a). This review refutes the 
importance of mtDNA deletion size or location in determining pathogenicity.  
Overall, outside of the established relationship age of symptom onset shares with 
disease severity and rate of clinical progression, the presence of any relationships 
between the three major areas of mitochondrial genetics, biochemical defects and 
clinical presentation in cases of single large-scale mtDNA disease remains contentious. 
This area of research must become a focus for research in order to better understand 
the whole spectrum of mtDNA deletion disease, to allow for the most accurate 
diagnoses and most specialised care to be provided to patients.  
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5.2 Aims and Hypothesis 
This study aimed to investigate and thoroughly characterise mtDNA deletions in a large 
cohort of patients with single large-scale mtDNA deletions. Following assessment of 
mtDNA deletion heteroplasmy levels and mapping of mtDNA deletion breakpoints, we 
aimed to assess the presence of any correlation between deletion size and 
heteroplasmy levels, and evaluate the impact that specific deletion sites may have 
upon mtDNA heteroplasmy levels.   
The working hypothesis for this study once again rests upon the proposed ‘survival of 
the smallest’ mechanism of clonal expansion. The larger the mtDNA deletion, the 
smaller the remaining mtDNA genome and the greater its replicative advantage will 
therefore be. It would be reasonable to expect that a greater replicative advantage 
would lead to higher levels of mtDNA deletion heteroplasmy, due to a more rapid 
accumulation of the smaller mitochondrial genomes harbouring mtDNA deletions. 
Therefore, the hypothesis for this study is that a strong positive correlation will exist 
between mtDNA deletions size and heteroplasmy level in our patient cohort if a 
replicative advantage for smaller mtDNA molecules is driving the clonal expansion of 
mtDNA deletions.  
A secondary aim for this study was to identify if any correlation existed in this patient 
cohort between the mitochondrial genetic defect (including mtDNA deletion size, 
location and heteroplasmy level), cellular biochemical defect (COX-deficiency) and 
clinical presentation (NMDAS score). Due to the lack of consistent results so far in this 
field of study, it was also important to assess where results from this study lay in 
relation to previous investigations, and to assess whether any genetic markers could 
be identified to predict disease severity and/or rate of disease progression.  
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5.3 Methods 
5.3.1 Patient cohort 
All patients identified as having mitochondrial DNA disease caused by a single large-
scale mtDNA deletion within the MRC Mitochondrial Disease Patient Cohort Study (UK) 
were originally included in this study; a number of research-consented samples from 
patients with single, large-scale mtDNA deletion disease available through the NCG 
Mitochondrial Diagnostics Service were also included in this study. All DNA samples 
were accessed with appropriate consent through the NCG Mitochondrial Diagnostics 
service. From a total cohort of 150 patients, appropriate DNA samples were available 
from 113 individuals. These patients presented with varying degrees of disease 
severity and a spectrum of phenotypic presentations ranging from CPEO, through 
CPEO with muscular or multi-system involvement, to KSS. Samples included in this 
study are from patients from 2 main groups: those who have been clinically assessed 
at Newcastle (these patients have extensive clinical data available, including NMDAS 
rating scale data), and those assessed clinically elsewhere (DNA or muscle biopsy 
samples having subsequently been sent to the NCG Mitochondrial Diagnostics service; 
clinical information has been obtained from hospital records). 
 
5.3.2 Muscle biopsy and DNA extraction 
Information regarding muscle biopsy procedure and DNA extraction relates primarily 
to patients seen clinically at Newcastle – procedures may vary at other centres. 
Skeletal muscle samples (vastus lateralis) were obtained by muscle biopsy from all 
adult patients involved in this study – procedure varied between patients depending 
upon the required diagnostic analyses, with either a needle or open muscle biopsy 
being performed. Total homogenate DNA was extracted from a small quantity of 
biopsied muscle tissue by the NCG Mitochondrial Diagnostic Service. 3 paediatric cases 
presenting with Pearson Syndrome or KSS were included in this study; blood samples 
were taken from these patients rather than muscle biopsies due to the young age of 
clinical presentation. Genetic analysis was carried out on total extracted DNA from 
blood in these 3 cases only; mtDNA deletion heteroplasmy levels in blood have been 
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reported to accurately mirror deletion heteroplasmy in muscle in paediatric cases 
(McShane et al., 1991).  
 
5.3.3 Detection of mtDNA deletion level by quantitative PCR. 
Quantitative PCR analysis was used to assess the level of mtDNA deletion present in 
each homogenate DNA sample, employing the MTND1/MTND4 assay as discussed in 
section 4.3.5.1.  
 
5.3.4 Long-extension PCR, gel electrophoresis and mtDNA deletion detection 
Long-extension PCR was carried out on homogenate patient DNA samples alongside a 
homogenate wildtype DNA control sample, primarily to assess the size of mtDNA 
deletion present, but also to amplify sufficient mtDNA for breakpoint sequencing. 
MtDNA amplification was carried out as outlined in section 2.2.4.2.1, using primers 
approximately 10kb apart (NC_012920.1, 5875 – 15896bp) (primers 12F and 32R, 
section 2.2.4.2.3, Table 2.4), while mtDNA deletion detection and sizing were carried 
out as discussed in section 3.3.4. 
 
5.3.5  Restriction endonuclease digest and breakpoint sequencing 
A restriction endonuclease digest using 4 restriction enzymes - Xho1, BamH1, Xcm1 
and Dra1 - was used to fine map the location of the mtDNA deletion breakpoints 
(Khrapko et al., 1999), as outlined in section 2.2.5.2. A standard cycle sequencing 
protocol was then followed by determine mtDNA deletion breakpoint location, as 
outlined in sections 2.2.5.2 – 2.2.5.5. 
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5.3.6 Statistical analyses and modelling 
All basic statistical analysis was carried out using GraphPad Prism v.4 statistical 
software. Relevant tests were chosen based upon data distribution; each data set was 
analysed using a battery of tests (Kolmogorov-Smirnov, D’Agostino and Pearson, and 
Shapiro-Wilk normality tests) in order to assess whether the data conformed to a 
Gaussian distribution. This allowed the most appropriate analysis to be carried out for 
each dataset in order to maximise the power of each statistical test. Mann-Whitney u-
tests were carried out to compare data sets where data was non-parametric, while 
unpaired t-tests were utilised where data followed a parametric distribution; in both 
cases, two-tailed tests were carried out at 95% confidence. Correlation assessments 
were carried out using Spearman’s rho for non-parametric data and Pearson’s r for 
parametric data. All relationships were modelled using simple linear regression; in 
cases where the relationship between variables was not linear, Box-Cox analysis was 
used (through MiniTab 16 Statistical Software) to identify optimal transformations of 
data to enable parametric tests to be used (Box and Cox, 1964). All statistical modelling 
work was carried out by Dr John Grady.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
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5.4 Results 
5.4.1 Relationship between mtDNA deletion size and heteroplasmy level.  
A detailed genetic analysis was undertaken for all available DNA samples (total 
extracted DNA from blood in 3 paediatric cases, and from SKM in all other cases) from 
patients identified as having mitochondrial DNA disease caused by a single large-scale 
mtDNA deletion. In total, samples from 97 single mtDNA deletion patients were 
successfully analysed for mtDNA deletion heteroplasmy level, deletion size and 
breakpoint location. However, samples with a measured heteroplasmy percentage of 
20% or below could not be included in the final analysis; the ND1/ND4 mtDNA deletion 
level assay is not sufficiently accurate at low levels of heteroplasmy to include any 
measurements ≤20%. This led to the exclusion of data obtained from 11 patient 
samples, leading to a final sample number of 86. Future investigations could utilise 
Southern blotting in order to ensure accurate measurement of any samples with low 
levels of mtDNA deletion heteroplasmy. 
In the total dataset, a range of deletion sizes between 2300bp and 9123bp was 
identified, with the majority of deletion breakpoints occurring in only one individual 
patient. However, a small number of deletions occurred in 2 (NC_012920, 9486 – 
13723, 9349 – 11419, 7128 – 13992, 7128 – 13992, 7540 - 14012) or 4 (NC_012920, 
12112 – 14422) individuals, with the ‘common’ 4977bp deletion picked up in 22 cases 
– approximately a quarter of the total number of fully assessed patient samples, in 
keeping with earlier reports of ‘common deletion’ prevalence (Taylor and Turnbull, 
2005).  
Linear regression was used to identify whether a correlation existed between mtDNA 
deletion size and heteroplasmy level. This revealed a trend for lower heteroplasmy 
levels to be associated with larger deletions, and vice-versa; the best-fit given by linear 
regression was found to be y = -0.0041x + 77.679, where y is mtDNA deletion 
heteroplasmy level (%) and x is deletion size (bp). This negative correlation between 
deletion size and heteroplasmy was found to be statistically significant, with a P value 
of 0.0034 (Figure 5.48). Although this trend was shown to be significant, further 
analysis was required to ensure that the high level of data spread had not skewed the 
result in any way. A comparison was therefore made between the 10 largest and 10 
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smallest mtDNA deletion size found within this study, and the 10 highest and 10 lowest 
mtDNA heteroplasmy levels identified within this patient cohort (Table 5.22, Figure 
5.49). mtDNA deletion heteroplasmy levels were found to be significantly lower in the 
samples with the largest deletion sizes as compared to the 10 samples containing the 
smallest mtDNA deletion sizes (P = 0.0359), in keeping with the predicted inverse 
correlation between mtDNA deletion size and heteroplasmy predicted by analysis of 
the total dataset.  Assessment of the mtDNA deletion heteroplasmy levels found for 
each of the 22 patients with the 4977bp common deletion was also carried out (Figure 
5.49) – this revealed the largest spread of heteroplasmy data, suggesting that mid-
sized deletions show the greatest spread of heteroplasmy levels.  
 
Figure 5.48 – Assessing the relationship between mtDNA deletion size and heteroplasmy 
level. 
Correlation between mtDNA deletion size (as determined by breakpoint sequencing analysis) and 
heteroplasmy level (as determined by ND1/ND4 quantitative PCR analysis) revealed a negative 
correlation between these two factors. Linear regression carried out on this data found this correlation 
to be statistically significant (P = 0.0034) despite a high level of data spread. The trend between these 
two genetic measures is expressed by the equation y = -0.0041x + 77.679, where y is mtDNA deletion 
heteroplasmy level (%) and x is deletion size (bp). 
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The limitations of the relationship found to exist between mtDNA deletions size and 
heteroplasmy level is highlighted by the analysis of the 10 samples with the highest 
and lowest heteroplasmy levels assessed in this study (Table 5.22, Figure 5.49); no 
significant difference was found to exist between these two groups (P = 0.1395). This 
demonstrates the detrimental effect of the high level of data spread on the strength of 
the inverse relationship between mtDNA deletion size and heteroplasmy level, 
meaning one cannot necessarily be used as an accurate predictor of the other. Indeed, 
the inverse relationship observed between mtDNA deletion size and heteroplasmy 
levels may well simply be due to patient sampling bias – as discussed in section 5.5. 
 
10 smallest mtDNA 
deletions 
10 largest mtDNA deletion 10 lowest mtDNA 
heteroplasmy levels 
10 highest mtDNA 
heteroplasmy levels 
Size 
(bp) 
Heteroplasmy 
(%) 
Size 
(bp) 
Heteroplasmy 
(%) 
Heteroplasmy 
(%) 
Size 
(bp) 
Heteroplasmy 
(%) 
Size 
(bp) 
2297 55 7714 23 20 5906 83 4641 
2300 41 7768 39 22 4392 85 4500 
2300 55 7886 86 23 4963 85 4652 
2300 76 7958 44 23 7671 86 2549 
2308 87 7977 62 24 7355 86 7714 
2549 86 8039 32 25 5813 87 2308 
2803 72 8500 45 26 4978 88 4959 
3039 55 8560 36 28 7498 88 6472 
3527 55 8704 56 30 4978 90 6864 
3979 50 9120 37 32 7958 94 6036 
Average values: 
2740.2 63.2 8030.9 46 25.3 6151.2 87.2 5069.5 
Significantly higher het % in smallest deletions. No significant difference in average deletion size. 
Table 5.22 - Comparisons of 10 largest and smallest deletion sizes, and 10 highest and lowest 
heteroplasmy levels. 
Data from all patient samples with full genetic data were organised first by mtDNA deletion size, and 
secondly by heteroplasmy level; the 10 top and bottom data points were selected from each of these 
data-sets. A Mann-Whitney test carried out on the measured heteroplasmy levels of the 10 largest and 
smallest mtDNA deletions showed a significant difference, with larger deletions having a significantly 
lower heteroplasmy level (P = 0.0359). However, no significant difference in deletion size was observed 
between the samples with the 10 highest and 10 lowest heteroplasmy levels (P = 0.1395), highlighting 
the weakness of the deletion size/heteroplasmy relationship caused by the wide spread of data. 
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Figure 5.49 - Comparisons of heteroplasmy levels on the extreme mtDNA deletion sizes and 
the common deletion, and variance of deletion size in the extreme heteroplasmy level data. 
Representation of the heteroplasmy levels for the 10 largest and smallest mtDNA deletions, and 
deletion size for the 10 highest and lowest heteroplasmy levels (as described in Table 5.22). All 22 
instances of the 4977bp ‘common deletion’ were also assessed, and shown to have the highest spread 
of mtDNA deletion levels - implying that mid-sized deletions display the widest range of heteroplasmy 
%. 
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5.4.2 Relationship between mtDNA deletion breakpoints and heteroplasmy 
Breakpoint analysis was carried out on data from each of the 86 samples which had 
successfully undergone breakpoint sequencing as well as ND1/ND4 quantitative PCR 
analysis of mtDNA deletion heteroplasmy level. 3’ and 5’ breakpoint locations were 
both found to correlate well with mtDNA deletion size, with a high degree of 
significance and a reasonably low level of data spread. Correlation between breakpoint 
location and deletion size was in both cases determined using Spearman’s rank 
correlation coefficient, as the data does not follow a Gaussian distribution. 5’ mtDNA 
deletion breakpoint location was found to strongly correlate negatively with deletion 
size (Spearman r = -0.7679, P < 0.0001) – i.e. the further through the genome the 
mtDNA deletion begins, the smaller the total deletion size is likely to be. The opposite 
trend was observed for the 3’ deletion breakpoints, which correlated positively with 
deletion size, though this correlation was neither as strong nor as significant 
(Spearman r = 0.2083, P = 0.0463) (Figure 5.50). These results were expected, and 
make sense in the context that larger mtDNA deletions must cover a larger area of the 
mitochondrial genome; due to the tendency for mtDNA deletions to occur in the major 
arc of the genome, centred around the ND4 gene (rCRS 10760 – 12137), larger 
deletions are likely to have a 5’ breakpoint occurring further upstream and a 3’ 
breakpoint further downstream in the genome.  
Breakpoint location was assessed alongside mtDNA deletion heteroplasmy levels as 
well as deletion size. Correlation analysis using Spearman’s rank correlation coefficient 
showed that 5’ breakpoint location was found to correlate positively with mtDNA 
deletion level (Spearman r = 0.3029, P = 0.0035) – as would be expected, given that 
later 5’ breakpoints correlate with a smaller deletion size, and smaller deletion sizes 
have shown a trend for higher heteroplasmy levels of mtDNA deletions. However, 3’ 
breakpoint location was not found to have any significant relationship with 
heteroplasmy levels (Spearman r = -0.04084, P = 0.7007), despite the observed 
relationship between 3’ breakpoint location and deletion size, and the trend for larger 
deletions to accumulate to lower levels of mtDNA deletion heteroplasmy (Figure 5.50). 
This suggests that 5’ breakpoint location may be more important than deletion size in 
determining mtDNA heteroplasmy, while the trend for early 5’ deletion breakpoints to 
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lead to larger deletion sizes (and vice versa) creates the basis of the relationship 
between mtDNA deletion size and heteroplasmy. 
 
 
Figure 5.50 – Assessing the relationships between mtDNA deletion breakpoint and mtDNA 
deletion size and heteroplasmy level. 
Breakpoint location, as determined by breakpoint sequencing, was assessed for correlation with mtDNA 
deletion size and heteroplasmy level. Correlation analyses were carried out in all cases using Spearman’s 
rho, due to the non-Gaussian data spread. 5’ breakpoint location was found to have a very strong 
relationship with deletion size (Spearman r = -0.7679, P < 0.0001), and to correlate significantly with 
mtDNA deletion heteroplasmy levels (Spearman r = 0.3029, P = 0.0035). This correlation was stronger 
than that of deletion size with heteroplasmy. 3’ breakpoint location also correlated well with deletion 
size, though not as tightly as 5’ breakpoint location (Spearman r = 0.2083, P = 0.0463); however, 3’ 
breakpoint location showed no relationship with deletion heteroplasmy levels (Spearman r = -0.04084, P 
= 0.7007). 
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5.4.3.1  mtDNA deletion breakpoint distribution assessment 
The distribution of mtDNA deletion 3’ and 5’ breakpoints was investigated using 
information from all 92 cases where full breakpoint data was available. Breakpoint 
locations were grouped into 1000bp bins (based on the revised Cambridge reference 
sequence (Anderson et al., 1981a)) to assess breakpoint location frequency. 5’ 
breakpoint location was found to be bimodal, with a main peak of mtDNA breakpoint 
location frequency at 8-9kb and a minor peak at 6 – 7kb. The 5’ breakpoint location 
distribution was skewed in a 5’ direction, with a majority of 5’ breakpoints falling in the 
first 4 bin categories (5 – 9kb) compared to a lower level of mtDNA deletions with a 5’ 
breakpoint situated in the second 4 bin categories (9kb – 13kb). 3’ breakpoint location 
was found to follow a unimodal distribution, peaking at 13 – 14kb.  The 3’ breakpoint 
location distribution was skewed in a 3’ direction, with almost all 3’ mtDNA deletion 
breakpoint falling in the last 3 bin categories (13kb – 16kb) (Figure 5.51 A). A further 
investigation of mtDNA deletion breakpoint location was carried out using the same 
dataset minus the 22 occurrences of the 4977bp common deletion (5’ breakpoint at 
8482bp, 5’ breakpoint at 13447bp)m to ensure that the common deletion was not 
skewing the mtDNA deletion breakpoint distribution (Figure 5.51B). In this case the 5’ 
breakpoint location distribution skews further in the 5’ direction, with a major peak at 
6 -7kb and a minor peak at 9 – 10kb, while the 3’ breakpoint location distribution 
skews further in the 3’ direction with a single peak occurring at 14 – 15kb.   
The mtDNA deletion breakpoint distributions observed in this study, when the 
weighting of the common mtDNA deletion is removed (Figure 5.51Figure 5.51B), do 
not quite match up with those previously reported by Samuels et al  (2004). The major 
site of 5’ breakpoint locations in our dataset is shifted in a 5’ direction to 7 – 8kb 
(compared to 8 – 9kb in in the 2004 study by Samuels et al), while the majority of 3’ 
breakpoint lie in the 14 – 15kb region in our dataset (compared to 13 – 14kb in in the 
2004 study by Samuels et al). These distinctions suggest that the common mtDNA 
deletion breakpoints may not play as central a role in mtDNA deletion formation as 
previously thought, though further work would be required to clarify this issue. A 
limitation of our study compared to that of Samuel’s et al lies in the molecular 
techniques employed; we were unable to assess whether a peak occurred in 3’ 
breakpoint location in the genome 3’ of 16kb, as was shown by Samuels et al (2004). 
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Unfortunately, the assay used to detect mtDNA deletion in this patient cohort was not 
designed to detect mtDNA deletions occurring in this area. However, breakpoints were 
successfully identified in the majority of our patient cohort (92/113), suggesting it is 
unlikely that many 3’ mtDNA deletion breakpoints would fall in the 16000 – 16569bp 
region.  
 
Figure 5.51 – mtDNA deletion breakpoint distribution 
mtDNA deletion breakpoint position frequency calculated for A – all 96 successfully sequenced patient 
samples; B – 84 successfully sequenced patient samples (total dataset minus the 22 cases of the mtDNA 
‘common deletion’). Values were calculated based on a 1000bp bin size. Distributions are independently 
shown for 5’ and for 3’ breakpoint locations; all assessed distributions are non-uniform. 
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5.4.3.2  mtDNA deletion breakpoint sequence analysis 
Following the analysis of mtDNA deletion breakpoint distribution, an assessment of 
sequence homology at the 5’ and 3’ breakpoint locations of each mtDNA deletion was 
carried out. This assessment was carried out for all 92 cases where full breakpoint data 
was available, as outlined in section 5.4.3.1, following the protocol outlined by 
Sadikovic et al (2010) - involving the analysis of a total of 49 nucleotides surrounding 
the deletion junction (24 nucleotides either side of the breakpoint nucleotide, as 
recommended by McVey and Lee (2008)) at both the 5’ and 3’ end of the mtDNA 
deletion region. Sequence homology was evaluated using ClustalW software with 
default parameters (Thompson et al., 1994), and the presence of a Class I, or ‘direct’ 
repeat of 3 or more nucleotides was assessed. All relevant mtDNA deletion breakpoint 
data is presented in Chapter 8, Appendix B.  
A number of research questions were to be addressed by this analysis in order to best 
assess the potential impact of mtDNA deletion breakpoint sequences on deletion 
formation or propagation. Early reports suggested that different deletion formation 
mechanisms may account for mtDNA deletions displaying different breakpoint motifs 
(i.e. the presence or absence of a direct repeat) (Degoul et al., 1991); subsequent 
studies have found that a majority of mtDNA deletions (approximately 70%) are Class I, 
being flanked by two short direct repeats (Mita et al., 1990). However, these studies 
were undertaken with small numbers of patients, a high proportion of whom carried 
the common mtDNA deletion (known to be flanked by a 13bp direct repeat), meaning 
these results require verification. More recently, the mtDNA deletion breakpoint study 
conducted by Samuels et al reported that of 263 different human mtDNA deletions, 
143 were found to involve direct repeat sequences of 2bp or more (54%). Most 
recently, a study was conducted by Sadikovic et al to investigate the relationship 
between mtDNA deletion breakpoint sequences and clinical presentation in a group of 
67 patients; low levels of sequence homology at breakpoint regions were found, along 
with high mtDNA deletion heteroplasmy levels, to correlate with early symptom onset 
and more severe clinical presentations (Sadikovic et al., 2010).  
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5.4.3.2.1 mtDNA deletion breakpoint repeat sequence analysis 
The first stage of our breakpoint analysis involved assessing the presence of direct 
repeats of 2 or more base pairs at the 5’ and 3’ breakpoint regions of each mtDNA 
deletion (in keeping with the methods used by Sadikovic et al (2010)), to identify the 
number of Type I mtDNA deletions.  63 mtDNA deletions were found to present with 
direct repeat sequences at the 5’ and 3’ breakpoint regions – 68% of the total cohort of 
92 mtDNA deletions with fully characterised breakpoints (Appendix B). When the 
influence reoccurring mtDNA deletions was taken into consideration – with 22 
incidences of the common deletion, five mtDNA deletions picked up in two patients 
(NC_012920, 9486 – 13723, 9349 – 11419, 7128 – 13992, 7128 – 13992, 7540 - 14012) 
and a 2.3kb deletion occurring in four patients (NC_012920, 12112 – 14422) - 63 
unique mtDNA deletions were found to be appropriate for inclusion in this analysis. Of 
these, 34 were found to present with direct repeat sequences of a minimum of 2 
nucleotides – a total of 54% (Appendix B). An occurrence of direct repeats in 54% of 
unique mtDNA deletions is precisely in keeping with the findings of Samuels et al  
(2004), confirming this as an accurate representation of repeat sequences around 
mtDNA deletion breakpoints. Additionally, the study carried out by Sadikovic et al 
(2010) reported that approximately 70% of deletions presented with a direct repeat at 
the 3’ and 5’ breakpoints; when the re-occurrence of the common deletion (present in 
25 patients) and a 7436bp deletion (present in 6 patients) are taken into account, 20 
unique mtDNA deletions present with direct breakpoint repeats from a total of 40 
unique mtDNA deletions (50%). These findings are again consistent with the results of 
this study and the report by Samuels et al (2004), confirming that approximately 50% 
of mtDNA deletions occur with direct repeats at the 5’ and 3’ breakpoint regions, and 
suggesting that direct repeats may not be responsible for a common mtDNA deletion 
formation mechanism.  
 
 
 
Chapter Five 
210 
 
5.4.3.2.2 mtDNA deletion breakpoint repeat sequences; correlation with other 
molecular markers and with clinical presentation 
Following the analysis of repeat sequences at the 5’ and 3’ breakpoint regions of 
mtDNA deletions, the relationship between mtDNA deletion breakpoint characteristics 
and  clinical presentation was investigates, following the assertion by Sadikovic et al  
(Sadikovic et al., 2010) that low levels of sequence homology at breakpoint regions 
correlate with high mtDNA deletion heteroplasmy levels, early symptom onset and 
more severe clinical presentation. 
Full sets of appropriate data – breakpoint characterisation, mtDNA deletion 
heteroplasmy levels and clinical onset age – were available for a total of 48 patients. 
This dataset was divided into four age-at-symptom-onset categories for analysis 
following the methodology used by Sadikovic et al (2010), though the 10-year age 
ranges for our four groups (1 – 10, 11 – 20, 21 – 30 and 31+) differed from those used 
in the Sadikovic study in order to best reflect our spread of data (Table 5.23). The 
number of patients which fell into each of the onset-age brackets was recorded 
alongside mtDNA deletion size and heteroplasmy levels (mean, standard deviation and 
total range for both measurements), and the number of occurrences of type I 
breakpoints and the common mtDNA deletion (Table 5.23).   
 
Table 5.23 – mtDNA deletion breakpoint characteristics. 
A total of 48 patient datasets were available for analysis with mtDNA deletion size and heteroplasmy 
data in conjunction with complete breakpoint data; these were divided by patient age at symptom onset 
into four 10-year age categories for analysis. mtDNA deletion heteroplasmy levels were significantly 
higher in the youngest age group (0 – 10 years) than any other group, while Type I breakpoints were also 
most common in the youngest age category.  
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Significantly more mtDNA deletions were found to present with Type I breakpoints in 
the youngest age group, with a trend for lower numbers of Type I deletions as age at 
symptom onset increases, though no trend was found to exist in terms of incidence of 
the common mtDNA deletion. This contradicts the decrease in sequence homology 
reported in patients with earlier clinical onset ages by Sadikovic et al (2010), 
highlighting the need for a much larger dataset to clarify this relationship. Similarly, 
increased numbers of Type I breakpoints appear to correlate with higher levels of 
mtDNA deletions heteroplasmy in our dataset – in opposition to the inverse 
relationship between these two factors proposed by Sadikovic et al (2010).  
Unfortunately, the correlation between decreased breakpoint sequence homology and 
increased severity of clinical presentation described by Sadikovic et al (2010) could not 
be assessed in our patient cohort due to low numbers of patients with Pearson 
syndrome or multisystem involvement for whom all appropriate data was available. 
This is certainly an issue to be addressed in the future, to assess whether breakpoint 
homology is a factor which could improve mtDNA deletion disease progression 
modelling (discussed in section 5.4.5). The reduced range of clinical severity in this 48 
patient cohort compared to that assessed by Sadikovic et al (2010) could also account 
for the different outcomes in terms of the relationship between mtDNA deletion 
breakpoint sequence homology and onset age. If reduced sequence homology is 
associated with more severe clinical onset, the inclusion of more data from severely 
affected patients with early disease onset (i.e. those with Pearson syndrome) would 
likely bring down the percentage of early-onset patients with Type I breakpoints/high 
sequence homology.  
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5.4.4 Investigating the effect of specific gene involvement on mtDNA deletion 
characteristics. 
Following on from early indications that 5’ mtDNA deletion breakpoint location may 
play a role in determining heteroplasmy levels, further analysis was carried out to 
identify whether any 5’ specific genes could be linked to higher or lower levels of 
heteroplasmy. 
First, each of the 86 mtDNA deletions fully characterised by breakpoint sequencing and 
ND1/ND4 quantitative PCR analysis were organised by the gene location of the 5’ 
mtDNA deletion breakpoint (Figure 5.52, Table 5.24), with a view to identify whether 
any specific gene locations correlated with heteroplasmy. It became apparent that the 
5’ breakpoint positions were not distributed evenly throughout different genes; more 
5’ breakpoints tended to fall within genes of a larger size, while approximately a 
quarter of the total dataset has a 5’ breakpoint falling within ATPase8 due to the 
location of the common mtDNA deletion. This distribution prevented any reliable 
analysis of the relationship between mtDNA deletion gene location and heteroplasmy, 
meaning an alternative method of data analysis needed to be utilised. 
 
 
Figure 5.52 - mtDNA deletion heteroplasmy levels for deletions organised by gene location of 
3' deletion breakpoint. 
Representation of the spread of mtDNA deletion heteroplasmy levels for all 81 patient samples with 
fully characterised deletion breakpoints and heteroplasmy levels. All deletions were organised according 
which gene the 5’ deletion breakpoint occurs within; the visibly uneven distribution of 5’ breakpoint 
gene location prevented any further analysis based on this analysis. 
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Gene name Gene location 
(rCRS) 
Number of deletion with 5’ 
breakpoints in this region 
Average 
heteroplasmy level 
CO1 5904 – 7445 21 46.51±19.36 
TD 7518 – 7585 2 80.35±10.81 
CO2 7586 – 8269 3 48.93±11.39 
TK 8295 – 8364 2 35±21.21 
ATP8 8366 – 8572 22 61.94±18.16 
ATP6 8527 – 9207 5 51.71±18.38 
CO3 9207 – 9990 11 49.14±17.98 
ND3 10059 – 10404 2 54.30±44.83 
ND4L 10470 – 10766 1 65.18 
ND4 10760 – 12137 12 66.97±15.19 
Table 5.24 - mtDNA deletion heteroplasmy levels for deletions organised by gene location of 
5' deletion breakpoint. 
All 81 mtDNA deletions with fully characterised deletion breakpoints and heteroplasmy data were 
organised according to which gene the 5’ deletion breakpoint within. An uneven distribution of 5’ 
breakpoint locations was observed, which can largely be attributed to the variance in gene length – less 
mutations happen to occur with a 5’ breakpoint situated in the smallest genes. This distribution made it 
unreasonable to perform statistical analysis to assess the relationship between 5’ breakpoint location 
and heteroplasmy.  
 
As an alternative method of carrying out this analysis, and in order to ensure sufficient 
data points for statistical analysis to be reliably performed, gene locations of 3’ 
breakpoints were grouped together (Figure 5.53, Table 5.25). This allowed a clearer 
analysis of whether a deletion of one area of the mitochondrial genome could be 
tolerated at a higher heteroplasmy level than another. A sequential set of groups were 
set up for analysis, following the pattern set out in Table 5.25; two-tailed unpaired t-
tests were carried out at 95% confidence level, to determine if any significant 
difference existed between the two regions of 3’ breakpoint locations. Significant 
variations in heteroplasmy were identified in a number of groups (Table 5.25). Firstly, 
deletions with 3’ breakpoints occurring in CO1 have significantly lower heteroplasmy 
values than mtDNA deletions which occur after rCRS base number 7445 and therefore 
do not affect CO1 (P = 0.0150), suggesting that deletions which do not impact upon 
this complex 4 subunit can be tolerated at higher heteroplasmy levels. The next 
significant region appears to be the gene for tRNA lysine, as deletions occurring 
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between CO1 and TK appear to accumulate to lower heteroplasmy levels than those 
with 3’breakpoints within or beyond ATP8 (0.0179). However, few deletions in this 
study have been found to have 3’ breakpoints in TD, CO2 or TK, meaning this 
significance is likely to still depend on the apparent lower heteroplasmy levels of 
mtDNA deletions which affect CO1. The final gene region of interest highlighted by this 
analysis is CO3 – deletion occurring with a 3’ breakpoint within the region CO1 to CO3 
were found to have significantly lower heteroplasmy levels than those with 3’ 
breakpoint regions later in the genome (P = 0.0295) – again suggesting that deletions 
which affect CO3 are less likely to accumulate to high heteroplasmy levels than those 
which don’t. 
 
 
Figure 5.53 - mtDNA deletion heteroplasmy levels for deletions organised by grouped gene 
locations of 3' deletion breakpoints. 
As the uneven distribution of 5’ breakpoints made it unreasonable to analyse whether gene location of 
the 5’ deletion breakpoint correlated with heteroplasmy levels, an alternative approach was required. 
To this end, genes were combined into a series of groups, to determine which locations may be most 
significant in determining deletion heteroplasmy levels (results presented in Table 5.24). COI, TK and 
CO3 were highlighted by this analysis as areas with significant bearing on heteroplasmy. 
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 3’ deletion 
bp location 
group 1 
Average het 
% 
3’ deletion 
bp location 
group 2 
Average het 
% 
Mann-
Whitney 
test p-value 
Group het 
levels sig 
different? 
CO1 46.51±19.36 TD-ND4 58.61±19.14 0.0150 Yes 
CO1-TD 49.45±21.01 CO2-ND4 57.86±18.97 0.0849 No 
CO1-CO2 49.39±19.97 TK-ND4 58.35±19.25 0.0569 No 
CO1-TK 49.37±20.00 ATP8-ND4 59.23±18.82 0.0179 Yes 
CO1-ATP8 54.34±20.20 ATP6-ND4 57.31±19.34 0.5156 No 
CO1-ATP6 54.10±19.90 CO3-ND4 58.38±19.68 0.3669 No 
CO1-CO3 53.27±19.55 ND3-ND4 65.16±17.93 0.0295 Yes 
CO1-ND3 53.30±20.02 ND3-ND4L 66.83±14.55 0.0231 Yes 
CO1-ND4L 53.48±19,92 ND4 66.97±15.19 0.0285 Yes 
Table 5.25 - average heteroplasmy levels for mtDNA deletions grouped by gene location of 3' 
breakpoint. 
Average heteroplasmy data for mtDNA deletions grouped by 5’ deletion breakpoint location. Mann-
Whitney t-tests were carried out on appropriate groups (5’ breakpoints occurring within CO1 tested for 
significant difference from deletion occurring after CO1 in the TD – ND4 region, for example), in order to 
assess whether any regions appeared to have a significant impact on mtDNA deletion heteroplasmy 
levels. CO1 and CO3 were highlighted as being associated with lower mtDNA deletion levels, suggesting 
that deletion of these genes at a high level of heteroplasmy may not be tolerated. TK also appears to 
associate with lower levels of heteroplasmy, though it seems likely that this effect is maintained by CO1 
due to low levels of data with breakpoints occurring in TD, CO2 and TK.  
 
The analysis of the 5’ mtDNA deletion breakpoint data has suggested that deletions 
affecting Complex IV subunit genes – particularly CO1 and CO3 – may be less well 
tolerated in the cell, and may be less likely to accumulate to high levels of mtDNA 
deletion heteroplasmy. Further analysis was therefore undertaken to establish if the 
mitochondrial Complex IV (COX) genes are a major determinant of deletion 
heteroplasmy levels. COX subunit-encoding genes have been previously established as 
regions of interest, with mtDNA deletions affecting these (or genes encoding ATPase 
subunits) being found to potentially correlate with an earlier symptom onset age 
(Yamashita et al., 2008). Earlier symptom onset age has itself been found to correlate 
with a more severe disease phenotype (Aure et al., 2007), so a correlation between 
COX gene involvement in an mtDNA deletion and symptom onset makes this an 
attractive gene set for analysis. However, it is worth noting that the link between COX 
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genes deletion and earlier symptom onset has not been consistently reported; a later 
meta-study carried out by an independent group found no correlation between these 
two factors (López-Gallardo et al., 2009). 
Firstly, the relationship between the number of COX subunit genes deleted and total 
mtDNA deletion size was assessed; this was carried out using Spearman’s rho, due to 
the non-Gaussian data spread. As was expected, these were found to positively 
correlate (r = 0.7609, P < 0.0001); i.e. the bigger the mtDNA deletion, the more likely it 
is to affect more mitochondrial-encoded COX subunit genes (Figure 5.54 a). What was 
unexpected was the lack of any correlation found between the number of COX subunit 
genes disrupted by an mtDNA deletion and the respective mtDNA deletion 
heteroplasmy level (Figure 5.54 b & c). Following the grouping of deletion data into 
sets of mutations affecting 0, 1, 2 or all 3 of the mitochondrial COX genes, no 
significant difference was found in average heteroplasmy level between any groups. 
The biggest difference was found to exist between deletions disrupting 0 or 3 of these 
genes  - average heteroplasmy levels of 61.07 ± 20.33 and 49.45 ± 21.01 respectively – 
but even this was not found to be significant (P = 0.1005 by Mann-Whitney test). 
Correlation analysis using Spearman’s rho detected no significant relationship to exist 
between COX genes disrupted by an mtDNA deletion and the heteroplasmy level of the 
deletion (r = -0.1931, P = 0.0841). This was surprising given that the 5’ breakpoint data 
suggested these gene locations to be important in determining heteroplasmy, but 
particularly interesting in that the number of disrupted COX genes correlates well with 
mtDNA deletion size. This relationship with mtDNA deletion size – which displays a 
negative correlation with mtDNA deletion heteroplasmy levels - had suggested that 
mtDNA deletion levels would be lower for deletions with the largest involvement of 
COX genes. The lack of a significant relationship between number of COX genes 
deleted and mtDNA deletion heteroplasmy level therefore led to the conclusion that 
another set of genes may be influential in terms of determining mtDNA deletion 
heteroplasmy levels; insufficient data may have been collected with breakpoints in 
these genes regions for identification in the 5’ breakpoint analysis. The mitochondrial-
encoded tRNA genes were therefore assessed in the same manner as the Complex IV 
subunit genes to assess the influence of this gene set on mtDNA deletion heteroplasmy 
levels.  
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Figure 5.54 - Assessment of relationship of number of COX genes deleted with mtDNA 
deletion size and heteroplasmy level. 
A – Demonstration of the positive relationship between the number of COX genes deleted (0 – 3) and 
total mtDNA deletion size (bp). This correlation was determined to be significant using Spearman’s rank 
correlation coefficient (r = 0.7609, P < 0.0001). B – Average heteroplasmy levels demonstrated for 
deletions grouped by number of COX genes deleted. Average heteroplasmy levels: 0 = 61.07, 1 = 54.73, 
2 = 57.44, 3 = 49.45. No significant difference was identified between any of these groups. C – 
Demonstration of the examined relationship between the number of COX genes affected by an mtDNA 
deletion and the deletion heteroplasmy level. No significant correlation was found to exist between 
these measures (r = -0.1931, P = 0.0841). 
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The tRNA genes were chosen for examination due to their potentially important role in 
causing mtDNA mutation pathogenicity, as specified by in a recent review by Schon, 
DiMauro and Hirano (Schon et al., 2012). It was first noted that tRNA genes appeared 
to increase pathogenicity of mtDNA point mutations, with over 50% of total reported 
point mutations (over 270 since 1988, (Ruiz-Pesini, 2007))  occurring in tRNA genes, 
despite these comprising only approximately 10% of the coding regions of the 
mitochondrial genome. In comparison, only ~40% of point mutations occur in poly-
peptide encoding regions of the mitochondrial genome, which take up almost 70% of 
the total coding genome area; this irregular distribution highlights the potential 
importance of gene location of point mutations. While it is possible that mutations in 
the tRNA genes are less efficiently selected against during embryogenesis than those in 
polypeptide-encoding genes, Schon et al suggest that this skewed distribution is due to 
the increased pathogenicity of mutations present in tRNA genes due to the 
downstream effects upon all mitochondrial-encoded respiratory subunits if 
mitochondrial translation is compromised (Schon et al., 2012). This is then 
extrapolated to mtDNA deletions, where it is likely that at least one tRNA gene will be 
affected by any given mutation (in our study cohort alone, every mtDNA deletion 
affected 3 or more mitochondrial tRNA genes); reduced translation of all mt-mRNAs 
when an mtDNA deletion passes a threshold is therefore cited as a likely mechanism 
for mtDNA deletion pathogenicity (Schon et al., 2012). 
The number of tRNA genes disrupted by an mtDNA deletion was found to correlate 
strongly with deletion size (r = 0.8816, P < 0.0001) in a manner similar to the previously 
assessed COX genes; again, this is to be expected, with bigger deletions covering more 
of the genome and therefore being more likely to disrupt an increasing number of 
tRNA genes (Figure 5.55 a). An initial assessment of average heteroplasmy per number 
of tRNA genes disrupted by an mtDNA deletion revealed no single number of affected 
tRNAs to be significantly different to any other group (Figure 5.55 b). However, an 
overall trend for increasing numbers of deleted tRNAs to correlated with decreasing 
levels of mtDNA deletion heteroplasmy was found to be significant (Figure 5.55 c) (r = -
0.3797, P = 0.0005). The strength of this relationship – stronger than that between 
deletion size and heteroplasmy level – suggests that the number of tRNA genes 
affected by a deletion may be one of the major determinants of heteroplasmy. 
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Figure 5.55 - Assessment of relationship of number of tRNA genes deleted with mtDNA 
deletion size and heteroplasmy level. 
A – Demonstration of the strong positive relationship between the number of tRNA genes deleted (3 – 
10) and total mtDNA deletion size (bp). This correlation was determined to be significant using 
Spearman’s rank correlation coefficient (r = 0.8816, P < 0.0001). B – Average heteroplasmy levels 
demonstrated for deletions grouped by number of COX genes deleted. Average heteroplasmy levels 
ranged from 37% to 73%. C – Demonstration of the examined relationship between the number of COX 
genes affected by an mtDNA deletion and the deletion heteroplasmy level. A significant negative 
correlation was found to exist between these measures (r = -0.3797, P = 0.0005). 
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5.4.4.1 Limitations of assessing the effect of specific gene involvement on mtDNA 
deletion characteristics. 
A major limitation of assessing the involvement of specific gene sets is the strong 
relationship between many of the molecular features of each mtDNA deletion. This is 
demonstrated by the strong positive correlation between number of COX-subunit or 
tRNA encoding genes involved in an mtDNA deletion, and the total size of that deletion 
(r = 0.7609 and 0.8816 respectively, P < 0.0001 in both cases), both of which 
demonstrate a negative correlation with mtDNA deletion heteroplasmy levels. It is 
therefore difficult to establish for these two datasets whether the observed 
relationship between an increased number of tRNA/COX-subunit genes involved in an 
mtDNA deletion and lower levels of heteroplasmy is an artefact induced by the 
correlation between mtDNA deletion size and heteroplasmy levels, or whether the 
observed relationship between mtDNA deletion size and level is in fact due to  an 
increased chance of including specific genes at larger deletion sizes (i.e. the mtDNA 
deletion size is irrelevant other than altering the odds of the mtDNA deletion including 
more tRNA/COX-subunit genes). The difficulty of teasing out how the molecular 
characteristics of mtDNA deletions are linked, and the overlapping effects of many 
measures, is likely to be responsible for the contradictory nature of many reports 
published in this area (see Section 4.1.2, pages 193 - 5). It therefore became clear that 
a more sophisticated level of statistical analysis was necessary to interpret the 
molecular and clinical data in the best possible way, leading to the modelling work 
discussed in the remainder of this chapter. 
 
5.4.5 Modelling progression: can we predict mtDNA disease progression using 
molecular data? 
The initial analyses of the molecular data gathered for this study revealed a 
relationship to exist between mtDNA deletion size and level, and an observed potential 
importance for 5’ deletion breakpoint location and the number of tRNAs involved in 
the deletion. In order to identify how this data relates to patients’ clinical presentation, 
a modelling study was undertaken by Dr John Grady. This included the molecular 
profile for each patient, as examined in sections 4.4.1 – 3, the level of COX-deficiency 
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in muscle as measured by the NCG Mitochondrial Diagnostics service, and clinical data 
accessed via patient records including age at symptom onset and NMDAS scores. 
NMDAS is the Newcastle Mitochondrial Disease Adult Scale is a clinically validated, 
semi-quantitative rating scale used to measure mitochondrial disease (Schaefer et al., 
2006). Use of the NMDAS scale to measure disease burden allowed for a much less 
subjective measure of disease severity than separation of patients into phenotype 
categories as in previous studies, with the additional bonus of creating a more 
continuous spectrum of disease severity. Where NMDAS measurements were available 
from more than one clinical assessment, a rate of progression was calculated, allowing 
assessment of the impact of genetic and biochemical features on disease progression 
as well as severity. Multiple regression analysis was carried out to determine the 
relationship between heteroplasmy, deletion size and location and either disease 
severity or biochemical defects; we propose that analysis by multiple regression, in 
order to separate the individual effects of otherwise related deletion characteristics,  is 
necessary to properly understand these relationships. At each stage of analysis, the 
maximum number of patients for whom all appropriate data was available was 
included; a summary of the patient cohort numbers with available data is included 
below (Table 5.26). 
 With NMDAS Without NMDAS Total 
Patients with SKM 
heteroplasmy and deletion size 
49 37 86 
Of which have fully 
sequenced breakpoints 
46 36 82 
With onset age 42 12 54 
With COX-deficient fibre % 46 30 76 
Table 5.26 - Summary of patient cohort and available data at time of analysis. 
 
5.4.5.1 mtDNA deletion heteroplasmy and deletion location predict level of COX 
deficiency. 
The first stage of analysis was used to determine if the level of COX-deficiency in 
muscle was found to be related to any specific molecular features (Table 5.27). As in 
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previous studies (Mita et al., 1989; Moraes et al., 1989; Goto et al., 1990a), 
heteroplasmy levels were found to display a strong positive correlation with the level 
of COX-deficient fibres observed in muscle (P = 0.0001). However, neither deletion size 
nor location was found to have any significant relationship with COX-deficiency.  
Initial analysis of the deletion location showed no particular gene set to be predictive 
of COX-deficiency levels, with the presence of any COX genes within the deleted region 
coming the closest to showing any significant relationship with COX-deficiency (P = 
0.2405). However, when assessed by co-regression with the mtDNA deletion 
heteroplasmy level, the involvement of COX genes in an mtDNA deletion does become 
predictive of a higher level of COX-deficiency (P = 0.0010). Though the presence of COX 
genes in the deleted region was found to be the most predictive of COX-deficiency, 
other gene loci including ND3, ND4L and ATP6 were also found to be predictive 
markers for COX-deficiency.  
As COX genes tend to be involved in deletions of a larger size, it was expected that 
total mtDNA size would also be predictive of COX-deficiency. mtDNA deletion size was 
co-regressed with mtDNA deletion heteroplasmy level and the involvement of COX 
genes after finding that deletion size alone was not significantly predictive of COX-
deficiency (P = 0.1160), though did show a slight trend towards larger deletions 
predicting lower levels of COX-deficiency. Following co-regression, mtDNA deletion 
size was found to correlate less well with COX-deficiency levels (P = 0.3959), suggesting 
that the trend towards a negative relationship between mtDNA deletion size and level 
of COX-deficiency was likely to be due to the inherent nature of larger deletions to 
involve COX genes and to correlate to lower heteroplasmy levels. 
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 Predictive of 
COX-deficiency? 
Correlation with 
COX-deficiency? 
P value 
Heteroplasmy (%) Yes Positive <0.0001 
COX gene involvement No None 0.2405 
COX gene involvement 
 (co-regressed with het %) 
Yes Positive 0.0010 
Heteroplasmy (co-regressed with 
COX gene involvement) 
Yes Positive <0.0001 
Deletion size No None 0.1160 
Deletion size (co-regressed with 
COX gene involvement & het %) 
No None 0.3959 
Table 5.27 - Regression analysis to determine the predictive effect of mtDNA deletion size, 
heteroplasmy level and location for level of COX-deficiency (%). 
mtDNA deletion size and heteroplasmy level, as well as the involvement of COX genes in the deleted 
region, were selected as markers to check for potential correlation with COX-deficiency level. Each of 
these markers was assessed alone and subsequently co-regressed with other markers against COX-
deficiency level, to identify if any of these markers is predictive of COX-deficiency level in muscle. 
 
 
Figure 5.56 - Correlation of mtDNA deletion heteroplasmy and COX gene involvement with 
COX-deficiency level. 
COX-deficient fibre incidence is dependent on skeletal muscle heteroplasmy and deletion of COX genes. 
The y axis shows COX-deficient fibre incidence (COX-deficient fibre prevalence divided by age at biopsy). 
Data are from our cohort, N=76, r = 0.66. Heteroplasmy (p < 0.0001) and deletion of COX genes (p = 
0.0011) are both significant predictors. Separate regression lines are shown for those that delete one or 
more COX genes(N= 58, 95% confidence interval for regression line shown) and those that do not (N=8, 
gradient of regression line is not significantly non-zero, confidence interval not shown). 
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5.4.5.2 Clinical progression is determined by mtDNA deletion size and heteroplasmy. 
Age of symptom onset and rate of clinical progression (measured as number of points 
increase on the NMDAS scale per year) have both been found to correlate well with 
mtDNA deletion size and heteroplasmy level. In the MRC Mitochondrial Disease 
Patient Cohort Study (UK), patients had carried out an average of 4.5 NMDAS 
assessments over a median of 5.4 years – an average progression of approximately 0.8 
NMDAS points per year.  Two sets of analyses carried out in this patient cohort have 
confirmed these findings, as outlined below. 
First, all appropriate patient data sets were divided into four individual categories; 
mtDNA deletion size was determined to be ‘large’ or ‘small’ (above or below 5kb in 
size), while deletion heteroplasmy level was determined to be ‘higher’ or ‘lower’ 
(above or below 60%), leading to 4 data groups comprised of small deletions with low 
or high heteroplasmy levels and large deletions with low or high deletions levels. 
Statistical analysis of these data groups identified that small deletions lead to a 
significantly later age of onset and significantly slower rate of clinical progression, 
while lower heteroplasmy levels follow the same trend. No significant difference in age 
at onset of clinical symptoms and rate of clinical progression between large mtDNA 
deletions with low heteroplasmy levels and small mtDNA deletions with high levels of 
heteroplasmy (Figure 5.57). 
A second analysis was undertaken, using both mtDNA deletion size and heteroplasmy 
level as continuous predictors; the regression analysis undertaken is summarised in 
Table 5.28. Both deletion size and heteroplasmy were found to be predictive of 
symptom onset age and rate of NMDAS progression, though in both cases the 
predictive power of these markers was strengthened by co-regression – the 
implication of this being that each predictor modulates the effect of the other. 
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Dependent 
Variable 
N Deletion 
size alone 
Co-regressed 
with 
heteroplasmy 
level 
Heteroplasmy 
level alone 
Co-regressed 
with mtDNA 
deletion size 
R
2
 
(co-
regress) 
Onset age 54 0.0056 3x10
-6
 0.0113 5x10
-6
 39.7% 
NMDAS 
progression 
49 0.0010 1x10
-6
 2x10
-5
 2x10
-9
 66.3% 
Table 5.28 - Prediction of age at onset and NMDAS progression by mtDNA deletion size and 
heteroplasmy level. 
Table shows p-values for the regression of age of onset and progression of NMDAS score per year 
against predictors deletion size and SKM heteroplasmy. In all cases, co-regression of both predictors 
improves statistical significance. 
 
Figure 5.57 - Prediction of age at onset and NMDAS progression by mtDNA deletion size and 
heteroplasmy level. 
In both panels, low heteroplasmy is considered < 60%, and small deletion < 5kb. A - Age at onset is 
found to be predicted by both molecular markers, with lower heteroplasmy levels and smaller deletion 
sizes both leading to later onset of clinical symptoms. B – Both molecular markers are indicative of rate 
of disease progression, with smaller deletion sizes and lower deletion heteroplasmy levels leading to a 
lower increase in NMDAS per year following symptom onset. 
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5.4.5.3 Longitudinal clinical progression is predicted by mtDNA deletion size, 
heteroplasmy level and location. 
Longitudinal modelling has been carried out to determine the effect of mtDNA 
deletion size and heteroplasmy level on clinical progression; both of these molecular 
markers have been found to be strongly predictive of rate of NMDAS score increase 
(heteroplasmy, P < 0.0001; deletion size, P < 0.0001). A significant interaction between 
mtDNA deletion size and heteroplasmy level was also identified by longitudinal 
modelling (P = 0.0002) – a stronger relationship than was apparent when assessing 
deletion size and heteroplasmy level alone (see 5.4.1). The effect of this is clearly 
visible when comparing panels A and C of Figure 5.58 – at low heteroplasmy levels, 
mtDNA deletion size has a negligible impact on disease progression, but is found to 
highly modulate rate of progression at high heteroplasmy levels. Interestingly, the 
location of the deletion in the mitochondrial genome has also proven to impact upon 
rate of clinical progression. The most predictive gene locus is ND6, inclusion of which 
predicts faster progression (p = 0.0031); conversely, genes below ND4, from ND4L 
down to COX3, predict faster progression (p=0.0034). 
 
Figure 5.58 - Effect of mtDNA deletion size and level on NMDAS progression. 
A: The effect of deletion size for 20% heteroplasmy. Note that the size of deletion at this low level of 
heteroplasmy is minimal. B: The effect of deletion size at 50% heteroplasmy. C: The effect of deletion 
size at 80% heteroplasmy. D: The effect of heteroplasmy for a large (8kB) deletion. Graphs courtesy of 
Dr John Grady. 
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5.5 Discussion 
The primary aim of this study was to identify whether any evidence could be found to 
support the ‘survival of the smallest’ theory of clonal expansion in a large cohort of 
single large-scale mtDNA deletion patients. In order to test this hypothesis, a test for 
correlation between mtDNA deletion size and heteroplasmy levels was carried out. The 
expected positive correlation between mtDNA deletion size and heteroplasmy, which 
would have lent support to the replicative advantage model of mtDNA deletion clonal 
expansion, was not observed. This is in keeping with results from Chapters 3 and 4, 
suggesting that it is unlikely that a replicative advantage for mtDNA deletions species 
over wildtype mtDNA does exist.  
Interestingly, the relationship between mtDNA deletion size and heteroplasmy was not 
found to be neutral – a negative correlation was in fact found to exist between these 
two factors. Though this negative trend was found to be significant (P = 0.0034), the 
large range of data spread did raise questions about the relevance of this finding. 
However, further analysis of separate deletion groups did show the largest deletions to 
have significantly lower heteroplasmy levels than the smallest deletions (P = 0.0359), 
and mid-range deletions to account for a large proportion of the data spread. This 
negative trend between mtDNA deletion size and heteroplasmy level was also 
identified in a recent report by Lopez-Gallardo et al, though at a non-significant level (P 
= 0.0601). The relevance of this finding is minimally discussed in this report, suggesting 
that this is simply due to a lack of replicative advantage for mtDNA deletions (López-
Gallardo et al., 2009) However, I would suggest that this should lead to a neutral 
relationship between deletion size and heteroplasmy level rather than a negative 
correlation. I therefore propose that this negative trend is a result of the clinically 
observed phenotypes of patients from whom samples are available to access; 
individuals with small deletions at low heteroplasmy levels would not be likely to 
present clinically with symptoms, and large deletions at high heteroplasmy levels may 
be so deleterious as to be lethal early in development. An important implication of this 
is that the heteroplasmy threshold for pathogenicity of a deletion is likely to be 
dependent on deletion size and location. 
Following this observation, analysis of the role of mtDNA deletion breakpoint location 
was carried out. While breakpoint location was predictably found to dictate the 
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resulting mtDNA deletion size, it was interesting to observe that only 5’ breakpoint 
location and not 3’ deletion location forms a significant relationship with mtDNA 
deletion heteroplasmy level.  It was proposed that this may be due to specific genes 
affected at the 3’ mtDNA deletion breakpoint regions, so an analysis of affected genes 
was undertaken. Initial analyses suggested that the deletion of COX genes may 
ultimately affect mtDNA deletion heteroplasmy levels, but a more in depth study 
uncovered a closer link between the number of tRNA genes affected by an mtDNA 
deletion and the resultant heteroplasmy level. This is in keeping with the recent 
assertion by Schon et al  that the pathogenicity of mtDNA deletions is based upon the 
disruption of tRNA genes and the downstream effects of this on translation of all of the 
mitochondrial genes (Schon et al., 2012). The strong correlation between the total 
number of tRNA genes disrupted and mtDNA deletion size also observed therefore 
supports the importance of deletion size and location in determining the heteroplasmy 
threshold for pathogenicity of a deletion. 
Additional investigations were carried out using the available mtDNA deletion 
breakpoint data to assess breakpoint distribution and breakpoint repeat sequences. 5’ 
and 3’ mtDNA deletion breakpoint in this patient cohort were found to follow a similar 
distribution to that reported by Samuels et al (2004); both breakpoint sites followed 
unimodal distributions, with 5’ breakpoints most commonly occurring at 8 – 9kb and 3’ 
breakpoints most commonly occurring at 13 – 14kb (Revised Cambridge Reference 
Sequence, NC_012920.1 (Andrews et al., 1999)). However, when only unique mtDNA 
deletions were included in the analysis (removing the weighting of the 22 occurrences 
of the 4978bp common mtDNA deletion) the peaks of both the 5’ and 3’ breakpoint 
distributions shifted. In this re-analysis, the 5’ breakpoint distribution peaked at 6 – 
7kb while the 3’ breakpoint distribution peaked at 14 – 15kb. This shift away from the 
common deletion breakpoint regions (bp 8482 and 13460, NC_012920.1) suggests that 
the 13bp direct repeat present at the common mtDNA deletion breakpoints may not 
play as crucial a role in mtDNA deletion formation as originally suggested by Samuels 
et al (2004), though work must be done to further consider this. An assessment of 5’ 
and 3’ mtDNA deletion breakpoint sequences revealed that 68% of our total mtDNA 
deletion cohort with available breakpoint data present with direct (Type I) repeats of 2 
or more nucleotides. When only unique mtDNA deletions were included in this 
analysis, this figure reduced to 54%. These figures are consistent with previous findings 
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by both Samuels et al. (2004) and  Sadikovic et al. (2010), confirming that direct 
breakpoint repeats are found at the 5’ and 3’ breakpoint sites of approximately half of 
all mtDNA deletions. Breakpoint homology was further investigated to determine 
whether any correlation could be found to exist with mtDNA deletion heteroplasmy 
levels or age at disease onset (a strong predictor of disease severity (Aure et al., 
2007)), as was reported in a preliminary study by Sadikovic et al. (2010). The cohort of 
48 patient for whom all relevant information was available (breakpoint analysis, 
mtDNA deletion heteroplasmy levels and age at onset of clinical symptoms) was 
divided into four groups based upon age at symptom onset for analysis. High levels of 
breakpoint sequence homology were found to correlate with high mtDNA deletion 
heteroplasmy levels and an earlier age at onset; these results conflict with the original 
findings of Sadikovic et al. (2010), highlighting a need for further study in this area. 
Following these analyses, the collected molecular data was combined with clinical 
information and biochemical defect measures to be used in a modelling study. This 
was divided into three main areas, with the first investigation assessing the impact of 
genetic markers on the biochemical defect caused by a deletion. mtDNA deletion 
heteroplasmy was found to be highly predicative of COX-deficiency in muscle, which is 
in line with previous research by a number of independent groups (Mita et al., 1989; 
Moraes et al., 1989; Goto et al., 1990a). Initially, neither deletion size nor location 
showed any affinity with the level of observed biochemical defect in muscle. However 
a co-regression analysis with mtDNA deletion heteroplasmy level identified deletions 
involving COX genes to display a higher level of COX-deficiency than deletions located 
elsewhere in the genome. A correlation between the involvement of COX genes in an 
mtDNA deletion and the resulting level of cellular biochemical defect has been ruled 
out in previous studies (Goto et al., 1990a), highlighting the importance of analysis by 
co-regression in order to factor in the close relationship between many molecular 
features of mitochondrial DNA deletions. Interestingly, no significant relationship was 
identified between mtDNA deletion size and COX-deficiency – the probability of these 
being related actually decreased following co-regression with heteroplasmy level and 
the involvement on COX genes. This lies in agreement with early studies which found 
no relationship to exist between mtDNA deletion size and enzyme activity (Moraes et 
al., 1989; Goto et al., 1990a). 
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The next analysis undertaken demonstrated a predictive role for mtDNA deletion size 
and heteroplasmy level for disease severity. Both deletion size and heteroplasmy were 
found to be predictive of symptom onset age and rate of NMDAS progression, though 
in both cases the predictive power of these markers was strengthened by co-
regression – the implication of this is that each predictor modulates the effect of the 
other. In addition, deletion size is in all cases the stronger predictor. This finding ties 
together both the recent studies of single deletion disease (Yamashita et al., 2008; 
López-Gallardo et al., 2009) that found deletion size predictive (though these reports 
differed on the effect of heteroplasmy,) and the more seminal studies (Holt et al., 
1990). It is possible that, due to the intrinsic relationship between mtDNA deletion size 
and heteroplasmy level identified earlier in this study, our ability to observe a 
relationship between heteroplasmy level and age at symptom onset is confounded.  
Finally, a longitudinal modelling study was carried out, using change in NMDAS score 
over time as a measure of clinical progression. This is the first study of its kind and, 
though further verification of these results is required, is the first step towards 
providing clinicians with a better set of prognostic tools for patient analysis. Both 
mtDNA deletion size and location have been found to be highly predictive of patient 
progression, with larger deletion sizes and higher heteroplasmy levels indicating a 
more rapid disease course. These quantitative measures have the potential to be much 
more reliable indicators of a patient’s likely disease course than just age of onset and 
current clinical severity.  A number of gene loci have also been found to modulate 
disease progression – specifically ND6 involvement which predicts faster progression 
while the deletion of genes in the region ND4L to COX3 predict slower progression – 
though this analysis is currently at an early stage. 
In conclusion, this study has identified no evidence to support a replicative advantage 
for mtDNA deletions over wildtype genomes. A negative relationship was observed 
between mtDNA deletion size and level, but this is believed to be due to a sample bias 
– suggesting a true neutral relationship between these molecular characteristics, and 
therefore supporting the hypothesis that the clonal expansion of mtDNA deletions 
occurs by random intracellular drift (Elson et al., 2001). Evidence for a modulatory 
effect of deletion size and location on the heteroplasmy threshold for individual 
deletions has been presented, though a more comprehensive data set would be 
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required to fully determine the importance of specific tRNA and OXPHOS protein genes 
in regulating mtDNA heteroplasmy levels and the severity of any resulting biochemical 
defect. Statistical studies carries out by Dr John Grady have identified a role for mtDNA 
deletion heteroplasmy level and the involvement of COX genes in a deletion in 
determining the severity of the enzymatic defect caused by a deletion. Furthermore 
clinical severity can be predicted by mtDNA deletion size and heteroplasmy, while the 
combination of size, heteroplasmy and deletion location shows promise in predicting 
the course of disease progression over time.  
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Chapter 6 
Analysis of clonally-expanded mtDNA deletions in single muscle fibres 
by single molecule PCR. 
6.1 Introduction 
6.1.1 mtDNA deletions in ageing and disease 
Mitochondrial dysfunction has been implicated in human ageing since a very early 
stage in the study of mitochondria, beginning with the hypothesis that ageing is due to 
the accumulation of damage from ROS and other free-radicals produced during normal 
metabolism (Harman, 1955). The idea of mitochondria acting as a kind of ‘biological 
clock’ in human ageing was later proposed in 1972 (Harman, 1972); this theory has 
been developed over time as more was discovered about mitochondrial biology, with 
an ever-increasing set of evidence being collected that mitochondria play an integral 
role in ageing and disease (Reeve et al., 2008b). With free-radicals in the form of ROS 
being produced consistently during respiration – estimates suggesting that 0.1 to 4% of 
oxygen consumption leads to ROS production (Sanz and Stefanatos, 2008) – 
mitochondria are a primary source of free-radical generation in the cell, and were 
proposed to be the main target for their action (Harman, 1972). This proposition was 
refined to suggest that the respiratory complexes and mtDNA are the main targets for 
the harmful action of ROS produced during respiration, given the close proximity of the 
respiratory complexes to the mtDNA at the IMM (Fleming et al., 1982). This formed 
the basis of the ‘mitochondrial free radical theory of ageing’ (Linnane et al., 1989), 
which attributes ageing and age-related cellular pathology to a decline in 
mitochondrial ATP-production capacity over time due to an increase in mtDNA defects 
caused by free radicals. While debate continues to date regarding the accuracy of this 
hypothesis (De Grey, 1997; Sanz and Stefanatos, 2008) , it has certainly become 
accepted that accumulated mtDNA defects are an important contributor to the ageing 
process, and play an important role in age-related disease. mtDNA deletions are 
specifically associated with the ageing of post-mitotic tissues, and age-related 
neurodegenerative disorders (Taylor and Turnbull, 2005; Bender et al., 2006; 
Kraytsberg et al., 2006; Reeve et al., 2008b; Larsson, 2010).  
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As well as contributing to human ageing and age-related disease, mtDNA deletions are 
also a primary cause of a range of inherited and sporadic mitochondrial disorders. The 
role of single sporadic large-scale mtDNA deletions is more fully discussed in section 
4.1.1, while multiple mtDNA deletion disorders caused by inherited nuclear genetic 
defects are examined in section 1.5.4. 
  
6.1.2 Clonal expansion of mtDNA deletions 
The importance of clonal expansion was established early in the study of mtDNA 
deletions in human ageing (Brierley et al., 1998). While the identification of mtDNA 
deletions in a range of human tissues (Cortopassi and Arnheim, 1990; Zhang et al., 
1992; Horton et al., 1995; Melov et al., 1995) and an observed decrease in 
mitochondrial enzymatic activity over time (Cooper et al., 1992; Boffoli et al., 1994) 
supported a likely role for mtDNA deletions in human ageing, heteroplasmy analysis 
found individual mtDNA deletions to be present only at low levels in aged tissue 
samples. This was problematic for the field, with low mtDNA deletion heteroplasmy 
levels being unlikely to impair tissue function (Ozawa et al., 1990; Simonetti et al., 
1992) and complementation being likely to occur between different mtDNA deletion 
species as well as between mtDNA deletions and wildtype mtDNA (D'Aurelio et al., 
2006; Nakada et al., 2009). The discovery that mtDNA deletions did not occur 
heterogeneously throughout a given tissue, but rather accumulate to high 
heteroplasmy levels to cause a biochemical defect in a subset of cells, went some way 
to explaining the low level of deletions detected in tissue samples (Brierley et al., 
1998). This investigation, carried out in aged human muscle tissue, found mtDNA 
deletions to be present at high heteroplasmy levels in all investigated COX-deficient 
muscle fibres, while no COX-normal fibres harboured mtDNA deletions at 
heteroplasmy levels sufficient to cause a biochemical defect. Of equal importance was 
the discovery that different mtDNA deletions were found to have reached high 
heteroplasmy levels in different cells. This served both to explain the low level of any 
given mtDNA deletion in total mtDNA from tissue, and to emphasise the importance of 
clonal expansion; each of these individual mtDNA deletions has accumulated to a high 
level within a single cell over time to create a cellular biochemical defect (Brierley et 
al., 1998).  
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6.1.3 Single cell studies of mtDNA deletion mutants. 
Since the identification of different clonally expanded mtDNA deletions in separate 
single cells (Brierley et al., 1998), clonal expansion of mtDNA deletions has been 
considered to result in the accumulation of a single mtDNA deletion type within any 
given single cell. Early evidence did emerge that multiple mtDNA deletions may be 
present in biochemically deficient cells (Kopsidas et al., 1998). This study, carried out in 
single fibres isolated from human skeletal muscle, found all COX-deficient or 
intermediate fibres to contain a heterogeneous population of mtDNA deletion species, 
with no detectable levels of wildtype mtDNA (Kopsidas et al., 1998). The authors 
suggested that a degree of functional complementation was able to occur between the 
mtDNA deletion strains present in COX-intermediate fibres, while a lack of wildtype 
mtDNA with no complementation occurring between the remaining deleted strains of 
mtDNA was the cause of fully COX-deficient fibres (Kopsidas et al., 1998). However, 
subsequent studies have failed to replicate this finding. A study carried out in human 
cardiomyocytes, published just one year after the apparent discovery of multiple 
mtDNA deletions in single cells by Kopsidas et al, confirmed the presence of a trend for 
single mtDNA deletions to be present in individual cells. Myocytes from human 
autopsy heart samples (donors aged 31 to 109 years of age) which contained mtDNA 
deletions each harboured only one clonally expanded mtDNA deletion species 
(Khrapko et al., 1999). Of the 14 cells with detectable mtDNA deletions, 12 had unique 
breakpoints while 2 contained the same mtDNA deletion mutant. Interestingly, all 
mtDNA deletions were detected in centenarian samples while no mtDNA deletions 
were identified in samples from younger donors, highlighting the likely importance of 
increasing levels of mtDNA deletions in influencing the ageing of the heart. (Khrapko et 
al., 1999).  
In subsequent years, a number of single cell studies have been undertaken in model 
organisms, designed to characterise the distribution of mtDNA deletion mutants in 
tissues displaying mosaic COX-deficiency; these have served to confirm the presence of 
single, clonally expanded mtDNA deletions in post-mitotic cells displaying COX-
deficiency. One of the earliest single cell studies of mtDNA deletions, undertaken in 
rectus femoral muscle from aged rats, looked to characterise the mtDNA deletions 
present in age-associated ragged-red fibres (Cao et al., 2001). This investigation found 
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only one species of mtDNA deletion mutant to be present in each investigated ragged-
red fibre, though breakpoint sequencing found the mtDNA deletion type to be 
different in each case. Each of these single mtDNA deletions were found to have 
accumulated to a high heteroplasmy level, while only wildtype mtDNA was found to be 
present at a detectable level in biochemically-normal fibre areas (Cao et al., 2001). This 
was confirmed in aged muscle tissue in a 2007 study of rat quadriceps tissue, where 
single fibres were found to contain segmental, clonal expansions of unique mtDNA 
deletions (Herbst et al., 2007). Following on from the work of Cao et al, a 2004 study of 
laser micro-dissected ETS abnormal muscle fibres from aged rhesus monkeys found a 
similar pattern of mtDNA deletions in single cells. The clonal accumulation of single 
mtDNA deletion species in each single muscle fibre was supported by not only the 
identification of a single mtDNA deletion species in each ETS abnormal muscle fibre, 
but also the identification of the same single mtDNA deletion in different regions of 
the same ETS abnormal fibre (Gokey et al., 2004).  
More recently, studies have been carried out in human neuronal tissue to assess 
whether mtDNA deletions accumulate in human tissue with age in the same manner as 
had been observed in murine substantia nigra neurons (Trifunovic et al., 2004). mtDNA 
deletions were found to have accumulated in a clonal manner in individual substantia 
nigra neurons assessed in tissue from individuals with Parkinson disease and from 
healthy aged controls (Bender et al., 2006; Kraytsberg et al., 2006). Though substantia 
nigra neurons have been shown to display the highest observed levels of mtDNA 
deletions, and as such have been the most studied neuron type in terms of mtDNA 
deletions accumulation, other neurons have been shown to be susceptible to the 
accumulation of mtDNA deletions over time. A range of major-arc mtDNA deletions 
have been shown to be present in human cochlear spiral ganglion cells where COX-
deficiency has resulted in presbycusis (age-related hearing loss) (Markaryan et al., 
2010); again, different mtDNA deletion species were found to have independently 
accumulated in separate COX-deficient cells (Markaryan et al., 2010). Findings in the 
muscle of animal models (Cao et al., 2001; Gokey et al., 2004) were found to be 
reflective of the situation in aged human muscle, where unique mtDNA deletions were 
found to accumulate to detrimental levels (>90% of the total mtDNA) in a clonal 
manner within individual COX-deficient muscle fibres (Bua et al., 2006). 
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Barring one study in human skeletal muscle which identified multiple mtDNA deletions 
to have accumulated within a single muscle fibre (Kopsidas et al., 1998), each study 
outlined above has observed the clonal accumulation of  a single mtDNA deletions 
species within a single cell to be standard in both ageing and disease. This seems to 
suggest that the mtDNA deletion in each cell has accumulated due to some sort of 
selective pressure; if random drift was sufficient to allow for clonal expansion, it would 
be reasonable to expect the continuous state of flux within the cell’s mtDNA content 
to result in the presence of multiple mtDNA deletions in at least a subset of cells.  
 
6.2 Aims and Hypothesis 
The aim of this study was to investigate the presence of multiple clonally expanded 
mtDNA deletions in single COX-deficient muscle fibres, following the amplification of 
multiple mtDNA deletion bands from approximately 20% of all investigated COX-
deficient fibre regions in the longitudinal mtDNA deletion accumulation study 
discussed in Chapter 3 (see 3.4.2). As these fibres had been studied using only long-
range PCR, it was not possible to determine whether a single mtDNA species was 
dominant within the cell, or whether mtDNA deletions of different sizes had 
accumulated to similar levels within these single muscle fibres. This follow-up study 
was designed to establish whether multiple mtDNA deletion species can be seen to 
clonally accumulate to biologically significant levels in single human muscle fibres; this 
is of particular interest given that human skeletal muscle is the only tissue in which 
multiple mtDNA deletion species have previously been reported to exist in single cells 
(Kopsidas et al., 1998). 
As discussed in section 6.1.3 (page 232), the clonal accumulation of mtDNA deletions is 
typically considered to involve the accumulation of a single mtDNA deletions species; a 
logical starting point for this study was therefore to identify what proportion of COX-
deficient skeletal muscle fibres contained more than one mtDNA deletion species. The 
level to which each of these mtDNA deletion types had accumulated within the cell 
was then to be examined using a specialised technique known as single molecule PCR 
(smPCR), developed specifically to examine samples containing multiple DNA species 
(Kraytsberg and Khrapko, 2005; Kraytsberg et al., 2009). It would then be possible to 
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assess whether any pattern existed to determine a deletion type that would be most 
likely to accumulate to a high level within the cell; e.g. whether larger or smaller 
deletions tend to accumulate to higher heteroplasmy levels in instances where 
multiple mtDNA deletions. It would be expected that the largest mtDNA deletions 
would consistently accumulate to the highest levels of heteroplasmy if clonal 
expansion is driven by a replicative advantage due to a smaller genome size and 
shorter replication time; conversely, no relationship would be expected to exist 
between mtDNA deletion size and dominance in a single cell containing multiple 
mtDNA deletions if clonal expansion occurs due to random genetic drift.  
 
6.3 Methods 
6.3.1 Patient biopsies and mitochondrial enzyme histochemistry 
Skeletal muscle samples (vastus lateralis) were obtained by open biopsy from 3 
patients with multiple mtDNA deletions. The defect resulting in the formation of 
multiple mtDNA deletions was located in a different nuclear gene in each of these 
patients, as outlined below in Table 6.29.  
Patient Age at 
biopsy 
Gene defect COX-deficiency 
level 
Biopsy 
type 
 1 80 POLG – p.T251I/p.P587L and 
p.A467T 
15% COX-deficient 
fibres, 3% RRF 
PM 
2 31 PEO1 - p.Arg374Gln 10% COX-deficient 
fibres, 1% RRF 
Diagnostic 
3 37 RRM2B – p.Thr144Ile and 
p.Gly273Ser 
42% COX-deficient 
fibres, 6% RRF 
Diagnostic 
Table 6.29 - Histochemical and molecular genetic characterisation of patients with multiple 
mtDNA deletions in muscle.  
COX, cytochrome c oxidase; RRF, ragged-red fibres. 
Multiple 20µm thick transverse sections were taken from each of the biopsies and 
mounted onto PEN-membrane slides for subsequent histochemical analysis. Sequential 
tissue sections were alternately assessed for dual COX-SDH histochemistry or SDH 
histochemistry alone, as outlined in section 4.3.3. 
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6.3.2 Single fibre isolation and DNA extraction 
Individual COX-deficient muscle fibres were isolated by laser microdissection from 
tissue sections assessed only for SDH activity, using tissue sections assessed using the 
dual COX/SDH histochemical assay as a map of biochemical activity as discussed in 
section 2.2.2.1.  
Single cell lysis was performed following the protocols outlined in sections 2.2.3.2.2 or 
2.2.3.2.3; the appropriate protocol was selected based upon the laser microdissection 
system employed for single fibre isolation. DNA was purified from the cell lysate using 
a QIAamp DNA micro kit, following the standard spin protocol, in order to maximise 
the efficiency and success rate of single molecule PCR. 
 
6.3.3 Single molecule PCR 
Single molecule PCR (smPCR) is a molecular technique which was specifically designed 
to look at a range of DNA mutations present within a single sample (Kraytsberg and 
Khrapko, 2005). This variant of ‘limiting dilution’ long-range PCR was originally 
developed - following evidence that PCR can be performed using a single DNA 
template molecule (Jeffreys et al., 1990; Vogelstein and Kinzler, 1999; Mitra et al., 
2003) - as a more reliable alternative to conventional PCR fragment cloning and as  an 
alternative to some quantitative techniques, but has been shown to be particularly 
useful for mtDNA analysis in single cells (Kraytsberg et al., 2009). This was therefore an 
ideal technique to employ to investigate the presence of multiple mtDNA deletions 
within a single cell.   
Single molecule PCR was used to amplify whole, individual mtDNA molecules from a 
DNA sample extracted from a single muscle fibre, following the protocol outlined in 
section 2.2.4.4.1 - 2.2.4.4.4. The amplification of a single mtDNA molecule in any one 
reaction removes the product-size bias observed in traditional long-range PCR, 
allowing mtDNA molecules with different deletion sizes to be amplified with equal 
efficiency. Running multiple smPCR reactions simultaneously allows the amplification 
of different mtDNA deletion species in separate reactions. Following an initial round of 
smPCR, optimal template DNA concentration was calculated based on the Poisson 
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distribution for a further round of smPCR analysis; it is important to ensure that a 
maximum of 30% of reactions result in a PCR product in order to ensure that each 
successful reaction can be confidently said to have resulted from a single template 
mtDNA molecule, as a 0.3 success rate correspond to an estimate of 0.05 reactions 
with multiple mtDNA templates. 
By running sufficient reactions from a single cell – i.e. running a 96-well plate of smPCR 
with template DNA from the same single cell added to each reaction – the relative 
proportions of different deletion types can be calculated. At single molecule level, we 
would expect approximately 24 successful amplifications from a 96 well plate. 
Therefore, if a 4kb deletion is observed in 18 wells and a 6kb deletion has been 
amplified in 6 wells, we would say that these existed in the muscle fibre at a 
proportion of 0.75 to 0.25 respectively. 
 
6.3.4  Real-time PCR mtDNA deletion level analysis 
Following analysis by smPCR, mtDNA deletion heteroplasmy levels were assessed in 
total DNA extracted from single cells using the multiplex ND1/ND4 TaqMan PCR assay 
(He et al., 2002), as outlined in 4.3.6.3. This allowed for an accurate measure of the 
total mtDNA deletion heteroplasmy in the cell, though this assay is unable to 
distinguish between any two mtDNA deletions affecting the MTND4 region of the 
genome. However, this is a useful measure when assessed alongside results obtained 
by smPCR analysis; for example, in a single cell found to contain two mtDNA deletions 
of 4kb and 6kb at a 3:1 ratio, a total mtDNA deletion heteroplasmy level of 80% would 
dictate that the 4kb mtDNA deletion is present at a heteroplasmy of 60% within the 
cell, while the 6kb mtDNA deletion affects 20% of the cell’s total mtDNA.  
 
6.3.5 Statistical analysis 
All statistical analysis was carried out using GraphPad Prism v.4 statistical software. 
Relevant tests were chosen based upon data distribution; each data set was analysed 
using a battery of tests (Kolmogorov-Smirnov, D’Agostino and Pearson, and Shapiro-
Wilk normality tests), in order to assess whether or not the data conformed to a 
Gaussian distribution. This allowed the most appropriate tests to be utilised for each in 
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order to maximise the power of each statistical test. All data from this study was found 
to follow a non-parametric distribution, resulting in the use of Mann Whitney tests to 
compare unpaired datasets, Wilcoxon matched pairs tests to compare paired datasets 
and Spearman’s rho for correlative assessments. All relationships were modelled using 
simple linear regression. 
 
6.4 Results 
6.4.1 Analysis of single COX-deficient fibres by single molecule PCR. 
Each COX-deficient muscle fibre extracted from one of the three patient muscle 
biopsies was lysed in 15µl of lysis buffer optimised for use with smPCR. With 3µl 
required for accurate total mtDNA heteroplasmy analysis, this left 12µl of single cell 
lysate available for smPCR analysis; this was diluted in a 1:1 ratio with TE buffer, giving 
a total of 24µl of stock DNA to work from during smPCR analysis. In each case, an initial 
long-range PCR assessment was carried out following an identical protocol; this 
preliminary assessment was carried out with 1µ of template DNA - diluted to a 10-1 
concentration from stock – per well. With a total of 10µl reaction mix/template DNA 
per well, this gave a final concentration of 1 x 10-2 template DNA per well. 16 wells of a 
96-well PCR plate were allocated to each fibre for initial assessment, allowing 6 fibres 
to be screened per plate – the inclusion of a control sample on each plate reduced this 
to 5 investigative samples per plate.  Typically, only 1 or two fibres would successfully 
amplify from each plate of 5 samples per initial PCR screen (Figure 6.59).  
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Following this initial PCR screen, the number of wells which result in a successful 
amplification could be used to calculate an optimal template DNA concentration per 
reaction, based on the Poisson distribution table (Table 6.30). An example is outlined 
below: 
 Following product analysis by gel electrophoresis, 9/16 wells are found to have 
resulted in an amplimer during the initial PCR screen of ‘fibre x’; this is a 
success rate of approximately 0.55.  
 An observed success rate of 0.55, following the Poisson distribution table, 
translates to a ‘true’ success rate of 0.8. 
 Aiming for an observed positive success rate of 0.25; this translates to a ‘true’ 
success rate of 0.29. 
 This gives a ratio of observed to desired success of 0.8:0.29, which is expressed 
as a ratio of 2.75:1 
 Therefore to calculate the optimal template DNA concentration: 
(1x10-2) / 2.75 = 3.63 x 10-3µl template DNA per well 
 3.63 x 10-3µl template DNA per well in a 96 well plate results in a requirement 
for 3.49x10-2µl template DNA from ‘fibre x’ for optimal smPCR analysis. 
In cases where all 16 reactions were successful – i.e. where the observed success was 
1.0, and no further information could be obtained – a second round of preliminary 
smPCR was undertaken, with template DNA concentration reduced tenfold to result in 
1 x 10-3µl template DNA per reaction. Optimisation of template DNA concentration 
could then be carried out in any cases where observed success rates lay between 0.05 
and 0.95. 
Following optimisation of template DNA concentration smPCR was carried out using an 
entire 96-well PCR plate per fibre, to ensure sufficient amplimers could be observed at 
a success rate of approximately 0.25 to calculate mtDNA deletion proportions. In cells 
with one species of clonally expanded mtDNA deletion, the observed deletion band 
resulting from each successful reaction was an identical size (Figure 6.60). Multiple 
mtDNA deletions could therefore be detected by observing mtDNA deletion bands of 
different sizes resulting from independent amplifications from the same cell (Figure 
6.61).  
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Figure 6.60 – smPCR carried out with an optimised template DNA concentration, for a single 
fibre containing one mtDNA deletion species. 
Each gel depicted above shows 16 lanes of smPCR product – smPCR having been carried out with an 
optimised template DNA concentration – assessed by gel electrophoresis, for a single fibre containing 
one mtDNA deletion species, alongside a single lane of 1kb DNA ladder. Following the optimisation of 
template DNA concentration of fibre 1 (see Figure 6.59) for smPCR, it was confirmed that a single 
mtDNA deletion of 6kb was present in this fibre. A wildtype product would have been present at 16kb, 
while all observed PCR products from this sample ran at 10kb. Single molecule level was successfully 
achieved in the set of gels displayed above, with successful amplification of the mtDNA deletion in 19 
wells from a total of 96 (one 96-well PCR plate). This mtDNA deletion was found to exist at 84% 
heteroplasmy by ND1/ND4 real-time PCR analysis.  
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Figure 6.61 - smPCR carried out with an optimised template DNA concentration, for a single 
fibre containing two mtDNA deletion species. 
Each gel depicted above shows 16 lanes of smPCR product – smPCR having been carried out with an 
optimised template DNA concentration – assessed by gel electrophoresis, for a single fibre containing 
two mtDNA deletion species, alongside a single lane of 1kb DNA ladder. Following the optimisation of 
template DNA concentration of fibre 4 (see Figure 6.59) for smPCR, it was confirmed that two mtDNA 
deletion of 6kb and 10kb were present in this fibre. Single molecule level was successfully achieved in 
the set of gels displayed above, with an overall successful amplification rate of 24 wells from a total of 
96 (a 0.25 success rate from one 96-well PCR plate).  
The 6kb and 10kb mtDNA deletions were present in 19 and 5 of the total 24 successful wells 
respectively; this was calculated to show that these two deletion species existed at relative proportions 
of 0.79 and 0.21 respectively. An overall cellular heteroplasmy level of 61% was ascertained by 
ND1/ND4 real-time PCR analysis; the two mtDNA deletion species were therefore estimated to account 
for approximately 48% (6kb mtDNA deletion species) and 13% (10kb mtDNA deletion species). 
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Observed level of 
positive reactions  
1-p(0) 
True level of 
positive reactions 
Level of doublets 
p(2) 
Level of multiplets 
1-p(0)-p(1) 
0 - - - 
0.05 0.05 0 0 
0.1 0.11 0 0.01 
0.15 0.16 0.01 0.01 
0.2 0.22 0.02 0.02 
0.25 0.29 0.03 0.03 
0.3 0.36 0.04 0.05 
0.35 0.43 0.06 0.07 
0.4 0.51 0.08 0.09 
0.45 0.6 0.1 0.12 
0.5 0.69 0.12 0.15 
0.55 0.8 0.14 0.19 
0.6 0.92 0.17 0.23 
0.65 1.05 0.19 0.28 
0.7 1.2 0.22 0.34 
0.74 1.35 0.24 0.39 
0.75 1.39 0.24 0.4 
0.8 1.61 0.26 0.48 
0.85 1.9 0.27 0.57 
0.9 2.3 0.27 0.67 
0.925 2.59 0.25 0.73 
0.9333 2.71 0.24 0.75 
0.95 3 0.22 0.8 
Table 6.30 – Poisson distribution table. 
P(x) = probability of a well resulting in (x) successful amplifications. 
This distribution was employed to calculate the optimal template DNA concentration per smPCR 
reaction. An observed success rate of less than 0.3 was targeted for smPCR, as the probability of a single 
reaction resulting in amplification from more than one template copy of mtDNA became insignificant (P 
< 0.05) below this level. 
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6.4.2 Assessing the presence of multiple mtDNA deletions in single skeletal muscle 
fibres. 
A total of 70 single, COX-deficient fibres were successfully isolated from 3 different 
patient muscle biopsies and assessed for total mtDNA deletion heteroplasmy level – 
using the MTND1/MTND4 real-time PCR assay – and the presence of multiple mtDNA 
deletions using smPCR. In all 70 cases smPCR was carried out over 96 reactions, using 
an individually optimised level of mtDNA to ensure an appropriate success rate of 
approximately 25% (indicating that each successful amplification originates from a 
single template mtDNA copy, see 6.3.3, page 238). While only one mtDNA deletion 
species was detected in many cases, 29 fibres – 41% of the assessed sample group – 
were found to contain mtDNA deletions of different sizes. This ratio was found to be 
maintained in sample groups from each patient biopsy; 7 of 17 COX-deficient fibres 
assessed from patient biopsy 1 (41%) (Table 6.31) were found to contain multiple 
mtDNA deletions, 10 of 26 assessed fibres from patient biopsy 2 (38%) contained 
multiple observed mtDNA deletions (Table 6.32), and multiple mtDNA deletion species 
were amplified from 12 of 27 fibres isolated from patient biopsy 3 (44%) (Table 6.33).  
mtDNA deletion size was determined from amplimer size during gel electrophoresis for 
all 99 mtDNA deletions detected by smPCR (41 from fibres with single and 58 from 
fibres with multiple clonally expanded mtDNA deletions), this method having been 
validated by sequencing analysis in Chapter 3 (see section 3.4.3). No difference was 
found to exist between mtDNA deletion sizes observed in fibres containing single or 
multiple clonally expanded mtDNA deletions (mean = 5.78 ± 1.51kb and 6.32 ± 1.55kb 
respectively, P = 0.1273). The range of mtDNA deletion sizes observed in these two 
fibre groups was also found to be consistent; mtDNA deletion sizes ranged from 2kb to 
10 kb in single mtDNA deletion fibres and 4 to 10kb in multiple mtDNA deletion fibres, 
with all mtDNA deletions in the 2nd and 3rd quartiles of the data falling between 5 and 7 
kb in both datasets (Figure 6.62).  
The 58 mtDNA deletions observed in multiple mtDNA deletion fibres were also split 
into 2 separate groups – the larger and smaller mtDNA deletion observed in each 
individual fibre -  for mtDNA deletion size analysis. For example, where two fibres each 
contain two mtDNA deletions – fibre 1; 3kb and 5kb, fibre 2; 6kb and 8kb – the 3kb and 
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6kb mtDNA deletions would be classified as the ‘smallest’ mtDNA deletions present in 
each fibre, while the 5kb and 8kb mtDNA deletions would be classified as the ‘largest’ 
mtDNA deletions present in each fibre. This is despite the smallest mtDNA deletion 
present in fibre 2 being larger than the largest mtDNA deletion in fibre 1 in this 
example, as the ‘smallest’ and ‘largest’ mtDNA deletion labels refer to the mtDNA 
deletions present in each individual fibre. Though these groups were significantly 
different in terms of size (mean = 7.31 ± 1.43kb and 5.36 ± 0.99kb respectively, P < 
0.0001), it was interesting to observe a large degree of overlap between these two 
groups. All of the ‘largest mtDNA deletion’ group were 5kb or above, 89% of the 
‘smallest mtDNA deletion’ group also fit this criterion. Similarly, all of the ‘smallest 
mtDNA deletion’ group were 8kb or smaller in size, while 79% of the ‘largest mtDNA 
deletion’ group fit into this size bracket (Figure 6.62). This overlap in data is indicative 
of a number of scenarios where the smaller mtDNA deletion in one fibre harbouring 
multiple clonally expanded mtDNA deletion is larger than the largest mtDNA deletion 
in another.  
 
Figure 6.62 - mtDNA deletion sizes in all assessed fibre categories. 
COX-deficient muscle fibres from which a single mtDNA deletion was detected had an average observed 
mtDNA deletion size of 5.78 ± 1.51kb; this was not found to differ significantly from the average mtDNA 
deletion size of 6.32 ± 1.55kb observed in fibres in which multiple clonally expanded mtDNA deletions 
were detected (P = 0.1273). As would be expected, the smaller of two mtDNA deletions present in a 
single fibre tend to be lower than average (mean 5.36 ± 0.99kb) while the larger mtDNA deletion 
present in a fibre with multiple deletions tends to be larger than average (mean 7.31 ± 1.34kb).  
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Table 6.31 – COX-deficient fibres from patient biopsy 1 assessed by real-time PCR 
heteroplasmy analysis and smPCR. 
Heteroplasmy level was determined using the MTND1/MTND4 TaqMan assay; where this is recorded as 
‘low level’, it has been detected with an unreliable reading <10% heteroplasmy. Deletion numbers per 
fibre were assessed by smPCR. mtDNA deletion size was assessed by long-range PCR, as validated in 
Chapter 3 (see 3.4.3). Where multiple mtDNA deletions were observed, the largest is recorded as 
‘Deletion 1’ and the smallest is recorded as ‘Deletion 2’. Deletion proportion was calculated by smPCR – 
i.e. if 2 deletions were detected in a 3:1 ratio, they would have a relative proportion of 0.75 and 0.25 – 
while deletion heteroplasmy was calculated by combining total mtDNA deletion heteroplasmy with 
deletion proportion. 
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Table 6.32 – COX-deficient fibres from patient biopsy 2 assessed by real-time PCR 
heteroplasmy analysis and smPCR. 
Heteroplasmy level was determined using the MTND1/MTND4 TaqMan assay; where this is recorded as 
‘low level’, it has been detected with an unreliable reading <10% heteroplasmy. Deletion numbers per 
fibre were assessed by smPCR. mtDNA deletion size was assessed by long-range PCR, as validated in 
Chapter 3 (see 3.4.3). Where multiple mtDNA deletions were observed, the smallest is recorded as 
‘Deletion 1’ and the largest is recorded as ‘Deletion 2’. Deletion proportion was calculated by smPCR – 
i.e. if 2 deletions were detected in a 3:1 ratio, they would have a relative proportion of 0.75 and 0.25 – 
while deletion heteroplasmy was calculated by combining total mtDNA deletion heteroplasmy with 
deletion proportion. 
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Table 6.33 - COX-–deficient fibres from patient biopsy 2 assessed by real-time PCR 
heteroplasmy analysis and smPCR. 
Heteroplasmy level was determined using the MTND1/MTND4 TaqMan assay; where this is recorded as 
‘low level’, it has been detected with an unreliable reading <10% heteroplasmy. Deletion numbers per 
fibre were assessed by smPCR. mtDNA deletion size was assessed by long-range PCR, as validated in 
Chapter 3 (see 3.4.3). Where multiple mtDNA deletions were observed, the smallest is recorded as 
‘Deletion 1’ and the smallest is recorded as ‘Deletion 2’. Deletion proportion was calculated by smPCR – 
i.e. if 2 deletions were detected in a 3:1 ratio, they would have a relative proportion of 0.75 and 0.25 – 
while deletion heteroplasmy was calculated by combining total mtDNA deletion heteroplasmy with 
deletion proportion
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6.4.3 mtDNA deletion heteroplasmy assessments in COX-deficient muscle fibre with 
single or multiple mtDNA deletions. 
Total mtDNA deletion heteroplasmy was assessed in each single COX-deficient fibre 
using the MTND1/MTND4 TaqMan assay; this determined the total ratio of wildtype to 
deleted mtDNA within each fibre, regardless of the number of mtDNA deletions 
contributing to the total level of heteroplasmy. In fibres containing two clonally 
expanded mtDNA deletions, the heteroplasmy level of each mtDNA deletion species 
was calculated from the total heteroplasmy level and mtDNA deletion proportion. For 
example, in a single cell found to contain two mtDNA deletions of 4kb and 6kb at a 3:1 
ratio, a total mtDNA deletion heteroplasmy level of 80% would dictate that the 4kb 
mtDNA deletion is present at a heteroplasmy of 60% within the cell, while the 6kb 
mtDNA deletion affects 20% of the cell’s total mtDNA. 
Single cell mtDNA deletion heteroplasmy levels in the total dataset covered a wide 
range – from a minimum of 14% to a maximum of 99% total cellular mtDNA content. It 
is possible that, a number of fibres may have mtDNA deletion heteroplasmy levels 
lower than this; the limitations of the assay employed to measure heteroplasmy mean 
that very low heteroplasmy levels cannot be accurately recorded. In the 7 cases where 
mtDNA deletion levels were measured at 10% or below, total mtDNA deletion 
heteroplasmy level was recorded as ‘low level’ (Table 6.31, Table 6.32, Table 6.33) – 
these fibres were not included in any further analyses involving mtDNA deletion 
heteroplasmy levels. Mean mtDNA deletion level was found to be 70.51 ± 24.45%, 
though the median mtDNA deletion was higher at 80% (25th percentile 27% 
heteroplasmy, 75th percentile 92% heteroplasmy). 
Following this data overview, the total dataset was split into two categories – mtDNA 
deletion heteroplasmy levels in fibres with one and fibres with two observed clonally 
expanded mtDNA deletions. Both of these categories were found to be representative 
of the total dataset. mtDNA deletion heteroplasmy ranged from 14 to 98% with a 
mean mtDNA deletion level of 70.47 ± 26.18% in fibres containing a single clonally 
expanded mtDNA deletion, while fibres containing multiple clonally expanded mtDNA 
deletions had a mean mtDNA deletion level of 70.55 ± 22.72% with a range from 17 to 
99% total mtDNA deletion heteroplasmy (Figure 6.63). Neither of these groups was 
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found to differ significantly from the total dataset (Mann Whitney test at 95% 
confidence, P = 0.9277 and 0.9197 respectively), and no significant difference was 
found to exist in terms of total mtDNA deletion heteroplasmy between fibres 
containing one or two clonally expanded mtDNA deletions (Mann Whitney test at 95% 
confidence, P = 0.8686) (Figure 6.63). 
Next, mtDNA deletion heteroplasmy levels were separately assessed for the larger and 
smaller mtDNA deletions present in single fibres with two observed clonally expanded 
mtDNA deletions. Interestingly, these two groups of data were found to be very 
similar. The smaller of the two mtDNA deletions present in each of these cells covered 
an mtDNA deletion heteroplasmy range from 9.69 to 85.36 %, with a mean 
heteroplasmy level of 36.58 ± 21.38%, while the larger of the two mtDNA deletions 
present in each of these cells covered an mtDNA deletion heteroplasmy range from 
6.80 to 73.92%, with a mean heteroplasmy level of 34.31 ± 20.83%. No significant 
difference was found between these two groups of data (Wilcoxon matched pairs test 
at 95% confidence, P = 0.8246) (Figure 6.63). 
The similarities in mtDNA deletion heteroplasmy levels between the smallest and 
largest mtDNA deletions from each deletion pair observed in single cells suggested 
that it was unlikely that any correlation would exist between mtDNA deletion size and 
heteroplasmy level. This was first tested in the total dataset of 92 mtDNA deletions 
with complete deletion size and heteroplasmy data available. While no trend appeared 
to exist between mtDNA deletion size and heteroplasmy level following analysis by 
linear regression, correlation analysis using Spearman’s rho was carried out to confirm 
this. No relationship was identified to exist between these two variables (P = 0.9442), 
confirming that larger deletion sizes are not linked to higher mtDNA deletion 
heteroplasmy levels in single cells (Figure 6.64A).  
This correlation analysis was carried out in the same manner for the individual datasets 
from each of the 3 patients (Figure 6.64 B-D). Though each of the three cases appeared 
to display a different data trend by linear regression (neutral in patient 1, negative in 
patient 2 and positive in patient 3), no trend between mtDNA deletion size and 
heteroplasmy level was shown to be significant following Spearman’s rank correlation 
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(for patients 1, 2 and 3, P = 0.8391, 0.2472 and 0.1149 respectively). The dataset 
available for each patient was therefore in keeping with the total dataset. 
Similarly, no correlation was found to exist between mtDNA deletion size and 
heteroplasmy level where data is independently assessed for mtDNA deletions where 
a single or multiple mtDNA deletions have clonally expanded within a single fibre 
(Figure 6.65A). This is true for single fibres containing only a single clonally expanded 
mtDNA deletion (P = 0.1330), but is particularly noteworthy where two mtDNA 
deletions have clonally expanded within a single fibre (P = 0.4184) (Figure 6.65B), 
suggesting that the competition between two mtDNA deletions may not be affected by 
different mtDNA deletion sizes.  
 
Figure 6.63 – mtDNA deletion heteroplasmy levels in all assessed fibres. 
Muscle fibres with only 1 observed mtDNA deletion had an average mtDNA deletion heteroplasmy level 
of 70.47% (±26.18%); this was not found to vary significantly from the 70.55% (±22.72) average mtDNA 
deletion heteroplasmy level observed in fibres containing 2 mtDNA deletion species (Mann-Whitney u-
test, P =0.8686). mtDNA deletion heteroplasmy levels were also differentially assessed in each fibre 
where multiple clonally expanded mtDNA deletions were observed; no significant difference was found 
to exist between the average deletion level for the smaller (36.58 ± 21.38%) and larger (34.31 ± 20.83%) 
mtDNA deletions present in these cells (Mann-Whitney u-test, P =0.6576). mtDNA deletion 
heteroplasmy levels were lower for both the larger and smaller mtDNA deletion size compared to the 
total mtDNA deletion heteroplasmy levels detected in single fibres harbouring either one or two mtDNA 
deletions (P < 0.0001 in all cases).  
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Figure 6.64 – Correlation of mtDNA deletion level and heteroplasmy level, with linear 
regression. 
Linear regression carried out on the whole dataset of mtDNA deletion size, as determined by long-range 
smPCR, and heteroplasmy level, as determined by MTND1/MTND4 quantitative PCR analysis, revealed 
no relationship no exist between these two variables (P = 0.8400). This neutral relationship was further 
confirmed by Spearman’s rank correlation analysis (0.9442). 
Correlation analysis was carried out in the same manner for the individual datasets from each of the 3 
patients (B – D representing patients 1 – 3 respectively). While linear regression indicated a neutral 
relationship between mtDNA deletion size and heteroplasmy level in patient 1, a potentially negative 
relationship was highlighted in patient 2 (C) and a potentially positive relationship in patient 3 (D). 
Further assessment by Spearman’s rank correlation analysis showed none of these relationships to be 
significant (P = 0.8391, 0.2472 and 0.1149 respectively), in keeping with the neutral relationship in the 
total dataset. 
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Figure 6.65 – Correlating mtDNA deletion heteroplasmy and deletion size in fibres containing 
single and multiple clonally expanded mtDNA deletions. 
Correlation analysis between mtDNA deletion size, as determined by long-range smPCR, and 
heteroplasmy level, as determined by MTND1/MTND4 quantitative PCR analysis, revealed a no 
significant relationship to exist between these two factors in either fibres containing single (A) or 
multiple (B) clonally expanded mtDNA deletions. Though a positive trend was found to exist by linear 
regression between these two factors in single mtDNA deletion fibres, this was found not to be 
significant following Spearman’s rank correlation analysis (P = 0.1330). Similarly, the slight negative 
trend found to exist between these two measures in multiple mtDNA deletion fibres by linear regression 
was found not to be significant by Spearman’s rank correlation analysis (P = 0.4184). Single and multiple 
mtDNA deletion fibres were therefore independently representative of the total dataset (Figure 6.64). 
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6.4.4 Do larger mtDNA deletions accumulate to a higher proportion of heteroplasmy 
in multiple mtDNA deletion fibres? 
An initial examination of the relative proportions of mtDNA deletion species in fibres 
containing more than one clonally expanded mtDNA deletion (Table 6.34) did not 
reveal any clear trend for either the larger or smaller of two mtDNA deletions present 
to reach a higher level of heteroplasmy. From a total of 29 single fibres found to 
contain two clonally expanded mtDNA deletion species, the larger of two mtDNA 
deletions was found to accumulate to the highest heteroplasmy level in 13 cases 
(45%), while the smaller of the two mtDNA deletions was found to have reached the 
higher level of heteroplasmy in 16 cases (55%) (Table 6.34). The mtDNA deletion 
heteroplasmy level of the most prevalent mtDNA deletion was assessed in these two 
groups of fibres (Figure 6.66). Where the smaller mtDNA deletion of two was found at 
a higher proportion of total deletion load, heteroplasmy for this mtDNA deletion was 
found to range from 10.2 to 85.4% with a mean heteroplasmy level of 49.1 ± 20.9%  (N 
= 13). Similar statistics were found to describe the larger mtDNA deletion species in 
multiple mtDNA deletion fibres where the larger mtDNA deletion makes up the highest 
proportion of the total mtDNA deletion load; heteroplasmy ranged from 21.7 to 73.9% 
with a mean heteroplasmy level of 50.7 ± 17.3%. No significant difference was found 
to exist between these two groups by unpaired t-test (95% confidence, P = 0.8290).  
Following this assessment of the mtDNA deletion heteroplasmy levels for the most 
prevalent mtDNA deletion in each multiple deletion fibre, the relative proportion of 
each of these mtDNA deletions was also examined. This was to ensure that the effects 
of total mtDNA deletion heteroplasmy for each assessed fibre had not skewed the 
data. The possibility that this could occur can be demonstrated by comparing two 
separate fibres, both containing two mtDNA deletions of 4kb and 6kb but at different 
levels of total mtDNA deletion heteroplasmy. Fibre 1 has a total mtDNA deletion 
heteroplasmy level of 98%, with two mtDNA deletions present at relative proportions 
of 0.45 (4kb) and 0.55 (6kb); these two mtDNA deletions would be present at 
heteroplasmy levels of 44% and 54% respectively. In comparison, fibre 2 has a total 
mtDNA deletion heteroplasmy level of 30%, with two mtDNA deletions present at 
relative proportions of 0.8 (4kb) and 0.2 (6kb); these two mtDNA deletions would be 
present at heteroplasmy levels of 24% and 6% respectively. The effect of total cellular 
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heteroplasmy therefore means that the 4kb mtDNA deletion present at a proportion of 
0.8 in fibre 2 appears to be present at a lower level than the 6kb mtDNA deletion at a 
proportion of 0.55 in fibre 1. As for the mtDNA deletion heteroplasmy analysis, data 
was assessed for the most prevalent mtDNA deletion in each multiple mtDNA deletion 
fibre – this was the larger of two mtDNA deletions in 13 cases and the smaller of two 
mtDNA deletions in 16 cases. In instances where the smaller of two mtDNA deletions 
was found to be most prevalent, a range of relative mtDNA deletion proportion from 
0.51 to 0.88 was observed, with a mean proportion of 0.69 ± 0.12 (N = 13). A similar 
range of relative mtDNA deletion proportion was observed in instances where the 
larger of two mtDNA deletions was found to be the most prevalent – from 0.53 to 
0.83, with a mean mtDNA deletion proportion of 0.70 ±0.09 (N = 16) (Figure 6.66). No 
significant difference was found to exist between these two groups by unpaired t-test 
(95% confidence, P = 0.9410). It therefore seems clear that relative mtDNA deletion 
size does not affect the level to which an mtDNA deletion is able to accumulate within 
a single fibre.  
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Table 6.34 – Compiled data from all COX-deficient fibres containing multiple clonally 
expanded mtDNA deletions from all 3 patients. 
Fibre number is expressed as ‘N-X’, where N refers to the appropriate patient number (1 – 3) and X 
refers to the fibre number cited in Tables 3 – 5. Heteroplasmy level was determined using the 
MTND1/MTND4 TaqMan assay. Deletion numbers per fibre were assessed by smPCR. mtDNA deletion 
size was assessed by long-range PCR, as validated in Chapter 3 (see 3.4.3). Where multiple mtDNA 
deletions were observed, the smallest is recorded as ‘Deletion 1’ and the smallest is recorded as 
‘Deletion 2’. Deletion proportion was calculated by smPCR – i.e. if 2 deletions were detected in a 3:1 
ratio, they would have a relative proportion of 0.75 and 0.25 – while deletion heteroplasmy was 
calculated by combining total mtDNA 
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Figure 6.66 - Representation of the mtDNA deletion heteroplasmy level and relative mtDNA 
deletion proportion reached by the most common mtDNA deletion species in each fibre 
containing multiple clonally expanded mtDNA deletions. 
A – The mtDNA deletion heteroplasmy level of the most prevalent deletion is depicted for each fibre 
containing multiple clonally expanded mtDNA deletions (N =29). This data has been split into two 
categories, dependent on whether the most prevalent deletion is the largest or smallest of the two 
mtDNA deletions present in each of these fibres. Where the smaller mtDNA deletion is most prevalent 
(N = 16), the average heteroplasmy level is 49.13 ± 20.93%; where the larger deletion is most prevalent 
(N = 13), the average heteroplasmy level is 50.71 ± 17.34%. No significant difference was observed 
between these two groups (P = 0.8290). 
B – The same two fibre categories were assessed in terms of the ‘relative deletion proportion’ of the 
most prevalent deletion, to remove the influence of total mtDNA deletion heteroplasmy level – a 
potentially confounding factor. Where the smaller mtDNA deletion is most prevalent (N = 16), the 
smaller deletion makes up an average proportion of 0.69 ± 0.13 of the fibre’s total mtDNA deletion load; 
where the larger deletion is most prevalent (N = 13), the larger deletion makes up an average 
proportion of 0.70 ± 0.09 of the fibre’s total mtDNA deletion load. No significant difference was 
observed between these two groups (P = 0.9410). 
 
 
 
  Chapter Six  
260 
6.4.5 Is a greater variance in mtDNA deletion heteroplasmy observed where a greater 
discrepancy in size exists between two mtDNA deletions in a single fibre? 
As no significant difference was found to exist between the mtDNA deletions present 
at the highest level in multiple mtDNA deletion fibres where either the largest or 
smallest mtDNA deletion was most prevalent - in the assessed parameters of mtDNA 
deletion size (Figure 6.63), heteroplasmy level (Figure 6.66 A) and relative mtDNA 
deletion proportion (Figure 6.66 B) discussed above – the effect of different mtDNA 
deletion sizes within single fibres was investigated. The effect of increased variance of 
mtDNA deletion size on difference in mtDNA deletion heteroplasmy or relative mtDNA 
deletion proportion was investigated, to determine whether this was a more 
important factor than absolute mtDNA deletion size. The difference in size between 
the two mtDNA deletions present in each of the multiple mtDNA deletion fibres was 
calculated, and was first assessed in the total dataset (N =29) in correlation with the 
difference in mtDNA deletion heteroplasmy between the two mtDNA deletions (Figure 
6.67A). Though a slight trend towards larger differences in mtDNA deletion size 
coinciding with larger differences in mtDNA deletion heteroplasmy was indicated by 
linear regression (y = 3.794x + 21.26, where y represents the difference in mtDNA 
deletion heteroplasmy levels and x represents the difference in mtDNA deletion size, r2 
= 0.04351), this relationship was found not to be significant using Spearman’s rho (95% 
confidence, P = 0.3208). 
As for absolute mtDNA deletion size, the difference in size between the two mtDNA 
deletions present in each of the multiple mtDNA deletion fibres was next assessed in 
the total dataset (N = 29) in correlation with relative mtDNA deletion proportion 
(Figure 6.67B). Again, a weak trend was observed between the difference in absolute 
mtDNA deletion size and relative mtDNA deletion proportion following linear 
regression (y = 0.04952x + 0.2922, where y represents the difference in relative mtDNA 
deletion proportion and x represents the difference in mtDNA deletion size, r2 = 
0.06192), but this relationship was found not to be significant by Spearman’s rho (95% 
confidence, P = 0.3304). Overall, a larger variation in mtDNA deletion size between two 
species present in a single fibre does not appear to lead to a larger variance in mtDNA 
deletion accumulation. 
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Figure 6.67 – Correlating the difference between mtDNA deletion size with the difference in 
(A) mtDNA deletion heteroplasmy, and (B) relative mtDNA deletion proportion in all multiple 
mtDNA deletion fibres. 
A - Correlating variance in mtDNA deletion size and mtDNA deletion heteroplasmy levels in all multiple 
mtDNA deletion fibres. Visible trend for a larger discrepancy in deletion size to lead to a larger 
difference in heteroplasmy levels; however this trend was not found to be significant (Spearman’s rho, 
95% confidence, P = 0.3208). B - Correlating variance in mtDNA deletion size and relative mtDNA 
deletion proportion in all multiple mtDNA deletion fibres. Visible trend for a larger discrepancy in 
deletion size to lead to a larger difference in relative mtDNA deletion proportions; however this trend 
was not significant (Spearman’s rho, 95% confidence, P = 0.3304). 
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The relationship between variance in mtDNA deletion size (between mtDNA deletions 
present in the same single fibre) and the variance in mtDNA deletion heteroplasmy 
levels/relative mtDNA deletion proportions was next examined separately in multiple 
mtDNA deletion fibres where either the smallest or largest mtDNA deletion was most 
prevalent ( 
Figure 6.68).  
In instances where the smaller of two mtDNA deletions was found to be most 
prevalent, a positive trend was observed to exist - following linear regression - 
between the level of variance in mtDNA deletion size and the level of variance in both 
mtDNA deletion heteroplasmy levels and relative mtDNA deletion proportion ( 
Figure 6.68A and B). This suggests that where the smaller of two mtDNA deletions in a 
single fibre is smaller by a greater margin, it is more likely to a) accumulate to a higher 
level of heteroplasmy, and b) accumulate to a greater proportion of the overall mtDNA 
deletion load of the fibre. Correlation analysis by Spearman’s rho unfortunately 
showed both of these trends to lie just outside of significance (P = 0.0802 and 0.0578 
respectively); further work is required to assess whether this trend is real, or has been 
skewed by a low number of data-points (N = 13).  
A similar analysis carried out where the larger of two mtDNA deletions was found to be 
most prevalent in a multiple mtDNA deletion fibre uncovered no trend between the 
level of variance in mtDNA deletion size and the level of variance in either mtDNA 
deletion heteroplasmy levels or relative mtDNA deletion proportion ( 
Figure 6.68 C and D). Analysis by Spearman’s rho found no significant relationship to 
exist between variance in mtDNA deletion size and variance in either mtDNA deletion 
heteroplasmy levels or relative proportions (P = 0.5380 and 0.6307 respectively, N = 
16). This suggests that, where the larger of two mtDNA deletions in a single cell is 
found to be more prevalent, the size of the smaller mtDNA deletion is irrelevant to the 
level of heteroplasmy either mtDNA deletion reaches.  
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Figure 6.68 – Correlating the difference in mtDNA deletion size with the difference in mtDNA 
deletion heteroplasmy, and in relative mtDNA deletion proportion in multiple mtDNA 
deletion fibres where the smallest (A and B) or largest (C and D) mtDNA deletion species is 
most prevalent. 
A – Correlating variance in mtDNA deletion size and mtDNA deletion heteroplasmy levels in multiple 
mtDNA deletion fibres where the smaller mtDNA deletion is most prevalent. Trend for a larger 
discrepancy in deletion size to lead to a larger difference in heteroplasmy levels; however this trend was 
not significant (Spearman’s rho, 95% confidence, P = 0.0802). B - Correlating variance in mtDNA deletion 
size and mtDNA deletion proportions in multiple mtDNA deletion fibres where the smaller mtDNA 
deletion is most prevalent. Apparently strong trend for a larger discrepancy in deletion size to lead to a 
larger difference in relative mtDNA deletion proportions; however this trend was not significant 
(Spearman’s rho, 95% confidence, P = 0.0578). C - Correlating variance in mtDNA deletion size and 
mtDNA deletion heteroplasmy levels in multiple mtDNA deletion fibres where the larger mtDNA 
deletion is most prevalent. No significant trend linking variance in deletion size to variance in 
heteroplasmy levels was found to exist (Spearman’s rho, 95% confidence, P = 0.5380). D - Correlating 
variance in mtDNA deletion size and mtDNA deletion heteroplasmy levels in multiple mtDNA deletion 
fibres where the larger mtDNA deletion is most prevalent. No significant trend linking variance in 
deletion size to variance in relative mtDNA deletion proportions was found to exist (Spearman’s rho, 
95% confidence, P = 0.6307). 
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A final outcome of these assessments is the identification of the high level of variability 
in mtDNA deletion heteroplasmy levels in multiple mtDNA deletion fibres. While two 
mtDNA species exist at almost identical proportions in some fibres, a difference in 
relative mtDNA deletion proportions of up to 0.8 has been observed; similarly, two 
mtDNA deletions in a single fibre may exist at almost identical heteroplasmy levels, or 
differ by up to 80%. This high level of variability suggests that there is no evidence for a 
‘cut-off point’ for the clonal expansion of these mtDNA deletions, where one mtDNA 
deletion has reached an end point of accumulation before clonal expansion of a 
second mtDNA deletion begins. 
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6.5 Discussion 
The primary focus of this study was to investigate the presence of multiple clonally 
expanded mtDNA deletions in single COX-deficient muscle fibres, following the 
amplification of multiple mtDNA deletion bands from approximately 20% of all 
investigated COX-deficient fibre regions in the longitudinal mtDNA deletion 
accumulation study discussed in Chapter 3 (see 3.4.2). Single COX-deficient muscle 
fibres were isolated from three multiple mtDNA deletion patients, each with a 
different nuclear gene defect – in POLG, PEO1 and RRM2B – and investigated by 
smPCR for the presence of mtDNA deletions and real time PCR for mtDNA deletions 
heteroplasmy levels.  
Initial analysis focussed on identifying single fibres containing multiple clonally 
expanded mtDNA deletions. Of a total of 70 successfully assessed fibres, 29 (41%) were 
found to contain multiple clonally expanded mtDNA deletion species; of these, all 
contained mtDNA deletion sizes of two distinct sizes, differing by a minimum of 1kb. 
This proportion of fibres containing two clonally expanded mtDNA deletions was 
consistent across all 3 patients - 41% in patient 1 (POLG defect), 38% in patient 2 (PEO1 
defect), and 44% in patient 3 (RRM2B defect) – suggesting that this is typical for 
multiple mtDNA deletion patients regardless of the specific nuclear defect. This could 
in fact be an underestimate of the level of fibres containing multiple mtDNA deletions, 
as there are likely to be instances where two mtDNA deletions in the same fibre would 
be of a similar size; further analysis by breakpoint sequencing of the smPCR products 
from single fibres is required to distinguish mtDNA deletions of the same size from the 
same fibre.  
As this has shown the possibility of multiple mtDNA deletions clonally expanding 
within a single muscle fibre, it is perhaps surprising that only 2 mtDNA deletions 
species were detected in these fibres, and not more. However, this is likely to be due 
to current low sample numbers – if mtDNA deletions are clonally expanded to a 
significant level in perhaps 40% of fibres from these patients, and ~40% of these 
contain 2 mtDNA deletions, that is approximately a 16% chance of 2 mtDNA deletion 
species clonally expanding within a single fibre. Assuming the risk of a 3rd mtDNA 
deletion becoming clonally expanded is also 40%, this would mean that only 6% of 
fibres would be likely to contain 3 mtDNA deletion species, within further decreasing 
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chances of 4 or 5 mutations clonally expanding in the same fibre – making it unlikely 
that a sample of only 70 fibres would detect this phenomenon, particularly as mtDNA 
deletions of a similar size are currently indistinguishable by this technique. Analysis of 
more samples, and subsequent breakpoint analysis of mtDNA deletion species, would 
be likely to identify a small number of fibres with more than 2 clonally expanded 
mtDNA deletion species in single fibres. 
Prior to this study, only one research group has identified multiple mtDNA deletions to 
be present in single cells – interestingly, this study was also carried out in human 
muscle fibres (Kopsidas et al., 1998), while much other research into the clonal 
expansion of mtDNA deletions has focussed on other tissue types (Khrapko et al., 
1999; Trifunovic et al., 2004; Bender et al., 2006; Kraytsberg et al., 2006; Markaryan et 
al., 2010) or model organisms (Cao et al., 2001; Gokey et al., 2004) (as discussed more 
fully in 6.1.3). It is possible that this phenomenon is only observed in human muscle, 
though it seems unlikely that multiple mtDNA deletions would accumulate in such a 
high proportion of single cells in muscle but in no other tissue. The only likely 
explanation for this would be a different mechanism for the clonal expansion of 
mtDNA deletions in skeletal muscle compared to other tissue, which would be unlikely 
to lead to the similar spectrum of mtDNA deletions or the same common deletion 
types that have been observed across different tissue types.  
It is important to note that, while these findings support those of Kopsidas et al in that 
multiple mtDNA deletions have been detected in single mtDNA deletion fibres, 
Kopsidas et al found up to 15 mtDNA deletions to be present in any one fibre, and in 
many cases there was no detection of wildtype mtDNA. In comparison, only 2 mtDNA 
deletion species were detected in single fibres by smPCR, with a maximum total 
heteroplasmy level of 98% identified in this study (i.e. the remaining wildtype mtDNA 
accounted for 2% of the total cellular mtDNA). These discrepancies highlight the need 
for a consistent molecular approach to investigate the presence of single cells 
containing mtDNA deletions in other tissue types in the future, as this will be necessary 
to determine whether the presence of multiple mtDNA deletion in single cells is tissue 
specific to skeletal muscle. 
Following the identification of multiple mtDNA deletion in single muscle fibres, more in 
depth analyses of mtDNA deletion size and heteroplasmy levels were undertaken. No 
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significant difference was found to exist in terms of mtDNA deletion size between 
mtDNA deletion species present in single or multiple mtDNA deletion fibres (Mann 
Whitney test, P = 0.1273 at 95% confidence). This indicates that, in instances where 
multiple mtDNA deletions have accumulated within a single fibre, this is not due to an 
effect of unusually large or small mtDNA deletion size on the clonal expansion of these 
mtDNA species. Interestingly, total cellular mtDNA deletion heteroplasmy levels were 
also found to be consistent between fibres containing single or multiple mtDNA 
deletion fibres (Mann Whitney test, P =0.8686 at 95% confidence) – i.e. where two 
mtDNA deletion were found to exist in a single cell, the combined mtDNA deletion 
heteroplasmy for both deletions was, on average, a similar level to that of an mtDNA 
deletion present in a single mtDNA deletion fibre. This result was initially surprising, as 
it had been expected that higher total mtDNA deletion heteroplasmy levels would be 
observed where multiple mtDNA deletions had undergone clonal expansion in a single 
fibre. However, it is possible that the consistency of mtDNA deletion levels found 
between single and multiple mtDNA deletion fibres is indicative of a common method 
of wildtype mtDNA regulation - i.e. that each cell attempts to regulate the level of 
wildtype mtDNA rather than each mtDNA deletion species – making the number of 
mtDNA deletion species present irrelevant to the overall level of mtDNA deletion 
heteroplasmy. This would be in keeping with the importance of absolute wildtype 
mtDNA copy number in maintaining normal cellular biochemical function, as described 
by Durham et al. (2006) and Greaves et al. (2010), and as highlighted in the work 
discussed in Chapter 4. 
In single fibres containing two distinct mtDNA deletion species, no significant 
difference was found to exist between the mtDNA heteroplasmy levels of the smaller 
or larger mtDNA deletions from each cell (Mann Whitney test, P =0.6676 at 95% 
confidence), despite a significant difference in mtDNA deletion size (Mann Whitney 
test, P < 0.0001 at 95% confidence), indicating that there may be no correlation 
between mtDNA deletion size and heteroplasmy level. This was confirmed by 
Spearman’s rho correlation analyses carried out in the total dataset, which found the 
negative trend observed between mtDNA deletion size and heteroplasmy level not to 
be significant (P = 0.0838). This mirrors the weak negative trend between mtDNA 
deletion size and heteroplasmy levels observed at the whole tissue level in single 
mtDNA deletion patients in the study discussed in Chapter 5, confirming the 
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conclusion that no replicative advantage exists for larger mtDNA deletions. No 
correlation between mtDNA deletion size and level was found to exist in the separate 
datasets for single (P = 0.1033) or multiple mtDNA deletion fibres (P = 0.2870), in 
keeping with the total dataset. The difference in size between the two mtDNA 
deletions present in a multiple mtDNA deletion fibre had no impact on the difference 
in mtDNA heteroplasmy levels of relative mtDNA deletion proportion (Spearman’s rho, 
P = 0.3208 and 0.3304 respectively at 95% confidence), further confirming that specific 
mtDNA deletion size does not impact upon the level to which an mtDNA deletion may 
clonally expand.  
Overall, no evidence was found in this study to support the ‘survival of the smallest’ 
mechanism of clonal expansion (Wallace, 1992). As stated in the original project aims, 
it would be expected that the largest mtDNA deletions would consistently accumulate 
to the highest levels of heteroplasmy if clonal expansion is driven by a replicative 
advantage due to a smaller genome size and shorter replication time. In fact, no 
correlation was found to exist between mtDNA deletion size and heteroplasmy, 
indicating the presence of no selective advantage based on mtDNA deletion size. Of 
the current hypothetical mechanisms for the clonal expansion of mtDNA deletions, this 
best supports mtDNA deletion accumulation by random genetic drift (Elson et al., 
2001). When examining multiple mtDNA deletion fibres alone, if the ‘survival of the 
smallest’ mechanism were to hold true it would be expected that the largest DNA 
deletion in each fibre would clonally expand to the highest level of mtDNA deletion 
heteroplasmy; in fact, no pattern was determined to predict which mtDNA deletion 
would accumulate to the highest proportion in any given multiple mtDNA deletion 
fibre. Again, this seems to suggest that random genetic drift is the most likely driving 
force behind the clonal expansion of mtDNA deletions in these cells. Of particular 
interest is the lack of an apparent ‘cut-off point’ in terms of heteroplasmy level for one 
mtDNA deletion before another begins to clonally expand, as exemplified by the high 
level of variance in mtDNA deletion heteroplasmy levels in multiple mtDNA deletion 
fibres. While two mtDNA species exist at almost identical proportions in some fibres, a 
difference in relative mtDNA deletion proportions of up to 0.8 has been observed; 
similarly, two mtDNA deletions in a single fibre may exist at almost identical 
heteroplasmy levels, or differ by up to 80%. This is potentially the strongest evidence 
yet presented in favour of random genetic drift as a mechanism for the clonal 
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expansion of mtDNA deletions; this mechanism would likely result in a random flux of 
cellular mtDNA content, leading to variable heteroplasmy levels of different mtDNA 
deletions.  
The similarity in the conclusions reached by this study at the single cell level and 
Chapters 4 and 5 at the whole tissue level in muscle – specifically the importance of 
wildtype mtDNA in determining the pathogenicity of an mtDNA deletion in a cell, and 
the lack of correlation between mtDNA deletion size and heteroplasmy level – 
strengthens the indication that random genetic drift is the most likely cause of mtDNA 
deletion accumulation in muscle. However, the discrepancies noted above between 
this study and previous work carried out in other tissues and in model organisms 
highlight the need for further work to be carried out to characterise mtDNA deletion 
accumulation in other tissue types to assess whether a common mechanism for the 
clonal expansion of mtDNA deletions exists or whether mtDNA deletion accumulation 
is tissue specific. 
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Chapter 7 
Final Discussion 
7.1 Introduction 
Since the initial discovery of mtDNA deletion pathogenicity in 1988 (Holt et al., 1988), 
large-scale mtDNA deletions have become widely recognised as a primary cause of 
genetic disease. mtDNA deletions are cited as a cause of approximately 18% of all 
mitochondrial disease cases (Schaefer et al., 2008) and are implicated in the focal 
cellular dysfunction observed in both ageing and age-related neurodegenerative 
disease (Bender et al., 2006; Kraytsberg et al., 2006; Reeve et al., 2008b; Larsson, 
2010). Due to the multi-copy nature of mtDNA within the cell, an mtDNA deletion as a 
single entity is not thought to be harmful to the cell; all remaining wildtype mtDNA 
copies in a cell containing this deletion would be able to compensate for the presence 
of this mutation (Rossignol et al., 2004).  However, an accumulation of an mtDNA 
deletion species to a high level of heteroplasmy within a cell is known to cause 
mitochondrial dysfunction and result in cellular biochemical dysfunction. The process 
by which mtDNA deletion accumulate to a pathogenic level, known as clonal 
expansion, is key to causing mtDNA deletion related pathologies – in mtDNA deletion 
diseases, ageing and age-related diseases – due to the high mtDNA deletion 
heteroplasmy levels required for pathology to occur, but the mechanism by which 
clonal expansion  occurs remains unknown. Though three main hypotheses have come 
to the fore in this field of research – propagation by replicative advantage (Wallace, 
1992), accumulation over time due to selective advantage inherent to the dysfunction 
of mutated mtDNA deletions (De Grey, 1997), and accumulation by random genetic 
drift (Elson et al., 2001) – no consensus has been reached as to how clonal expansion 
of mtDNA deletions may occur. The main focus of this work was to determine the 
mechanism by which clonal expansion of mtDNA deletions occurs, with a specific focus 
on human muscle as this is one of the main tissues affected by mtDNA deletions in 
disease and in ageing. Secondary aims were specific to each individual project within 
this body of work, including investigating how changes to a molecular defect over time 
influence a patient’s clinical progression, whether any molecular markers could be 
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identified to determine clinical progression, and whether multiple clonally expanded 
mtDNA deletion species could be detected within single muscle fibres. 
 
7.2 Major Findings and Further Work 
7.2.1 Investigating the longitudinal spread of mtDNA deletions through muscle fibres. 
The longitudinal spread of mtDNA deletions though muscle fibres, as visualised by the 
size of the COX-deficient region caused by the presence of an mtDNA deletion, was 
investigated to determine whether a relationship exists between mtDNA deletion size 
and the subsequent rate or range of accumulation of clonal expansion. Based on 
recent evidence supporting the ‘survival of the smallest’ hypothesis of clonal 
expansion (Diaz et al., 2002; Fukui and Moraes, 2009), it was expected that the largest 
mtDNA deletions would have the greatest intra-cellular replicative advantage and so 
would accumulate at the greatest rate within a cell. It was therefore hypothesised 
that, if the ‘survival of the smallest’ mechanism was driving the clonal expansion of 
mtDNA deletions in muscle, a positive correlation would be found between mtDNA 
deletion size and COX-deficient fibre area.  
Muscle samples from six patients with multiple mtDNA deletions caused by an 
underlying nuclear defect – a different mutation in each case – were investigated as 
part of this study. mtDNA deletion size was measured, using long-range PCR analysis as 
validated by breakpoint sequencing (section 3.4.3), in isolated ‘long’ and ‘short’ fibre 
regions of COX-deficiency. While there was no overlap in terms of COX-deficient fibre 
length or area, the observed mtDNA deletion sizes were remarkably similar across 
these two groups; no evidence of a correlation between mtDNA deletion size and the 
size of the resulting area of skm fibre COX-deficiency was observed in either the 
dataset as a whole, or in data collected from each individual patient. Following the 
hypothesis that the largest mtDNA deletions accumulate at the greatest rate in muscle, 
we would expect to see a strong correlation between COX-deficient segment length 
and mtDNA deletion size. The results from this study therefore do not support the 
hypothesis that a smaller genome size creates a replicative advantage that drives the 
clonal expansion of mtDNA deletions.  
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A possible explanation for the discrepancies between our results and the findings from 
previous studies is that there are times when replication rate does become rate 
limiting. The data of Diaz and colleagues (Diaz et al., 2002) would support this given 
that a replicative advantage for mtDNA deletions was only found under relaxed copy 
number control in the mtDNA deletion cytoplasts. No accumulation of, or selective 
advantage for, mtDNA deletions was reported under normal cellular conditions (Diaz 
et al., 2002), in agreement with our own findings in patient tissue. The rate of mtDNA 
replication might be very important during the process of mtDNA deletion formation 
and in establishing which deletions clonally expand, but not the rate of clonal 
expansion once the deletions have become established.  
This could also explain the difference between our findings and those of Moraes et al 
in the mitoPst1 mouse, where smaller mitochondrial genomes were found to 
accumulate preferentially in vivo in the mitoPst1 mouse model, developed to express a 
neuronal-specific inducible mitochondrial-targeted restriction endonuclease (Pst1) 
(Fukui and Moraes, 2009). The authors concluded that this was due to a replicative 
advantage for smaller mitochondrial genomes, but could indicate, or could in fact be a 
demonstration of a preferential formation of larger mtDNA deletions. In this case, our 
findings would be in keeping with those of Fukui and Moraes, as we did observe a high 
prevalence of larger mtDNA deletions in the clonally expanded segments (75% were 
>5kb and 50% were >6.75kb). This in turn is in keeping with the observation of an 
mtDNA deletion size distribution in COX-deficient fibre regions where 70% were >5kb 
and 45% were >6.75kb in aged muscle fibres in human skeletal muscle (Bua et al., 
2006). 
Of the hypothetical mechanisms which have been proposed to drive the clonal 
expansion of mtDNA deletions, these results best fit the random genetic drift model 
(Elson et al., 2001) due to a lack of correlation between the specific genetic defect and 
the resultant biochemical defect. The evidence that larger mtDNA deletions may either 
form more commonly or be more prone to clonal expansion initiation – as gathered 
from this study and that of Bua et al (2006) in human skeletal muscle, and from the 
work of Fukui and Moraes (2009) in the MitoPst1 mouse – should be considered for 
further investigation. If larger mtDNA deletions are found to be most prevalent in 
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other tissue types, this could highlight a common mechanism for mtDNA deletion 
formation or for clonal expansion initiation. 
 
7.2.2 Investigating the change in mtDNA deletion load over time in single mtDNA 
deletion patients. 
The progression of single large-scale mtDNA disease has long been attributed to 
increasing heteroplasmy levels of the mtDNA defect, an assumption based upon the 
increased numbers of COX-deficient fibres (Chinnery et al., 2003) and decreased 
wildtype mtDNA copy numbers (Durham et al., 2006) observed over time in this 
patient group. While evidence has been found to support this in a mouse model of 
single large-scale mtDNA disease (Sato et al., 2007), conflicting reports have arisen 
from the study of human mtDNA deletion disease. Early work did suggest that the 
mtDNA defect continuously accumulated throughout a patient’s lifespan (Larsson et 
al., 1990), but  it has more recently been suggested that mtDNA deletions undergo a 
rapid accumulation early in development, after which the heteroplasmy level of the 
defect becomes more stable (Pitceathly et al., 2012).  
A null hypothesis was put forward that mtDNA deletion levels would increase over 
time in patient tissue, leading to increased levels of COX-deficiency and therefore 
driving clinical disease progression. It was also proposed that the observation of 
mtDNA deletion accumulation throughout the patient’s life would support the 
presence of a replicative advantage for mtDNA deletions over wildtype mtDNA, as 
selective pressure would dictate that mtDNA deletion levels continue to tend towards 
homoplasmy. This would be a particularly apt finding given that early evidence of 
increasing mtDNA deletion levels throughout the patient lifespan (Larsson et al., 1990) 
led to the initial proposal of a replicative advantage for mtDNA deletions over wildtype 
mtDNA (Wallace, 1992). 
To determine if an increase in mtDNA deletion heteroplasmy is seen in human tissue – 
specifically in muscle, this being a primary affected tissue in single mtDNA deletion 
disease - a case study of a single large-scale mtDNA deletion patient was undertaken. 
Two muscle biopsies – both taken from the vastus lateralis, thirteen years apart– were 
available from this patient, allowing analysis of molecular changes in this patient’s 
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tissue over time. Assessments of mtDNA deletion level and copy number were carried 
out on homogenate DNA samples (extracted from tissue sections) and on DNA lysates 
from single isolated COX-positive, intermediate and negative muscle fibres to 
accurately assess any molecular changes over time. Overall, no molecular progression 
was found to have occurred over the thirteen years between these two muscle 
biopsies; mtDNA deletion heteroplasmy levels remained stable, as did mtDNA total 
and wildtype copy numbers. This was in-keeping with the stable numbers of COX-
deficient muscle fibres across the two biopsies, which goes some way to explaining the 
slow rate of clinical progression for this patient. This suggests that the mtDNA deletion 
accumulation responsible for disease symptoms may occur early in life before a 
plateau is reached, as hypothesised by Pitceathly et al. (2012). However, a wide 
patient cohort would have to be investigated to determine whether there are cases 
where mtDNA deletion level may continue to increase through a patient’s lifespan; this 
is perhaps the case where disease progression is more severe. The lack of apparent 
mtDNA deletion accumulation over time in this patient opposes the hypothesis that 
mtDNA deletion levels would increase over time in patient tissue; the outcome of this 
investigation therefore opposes the presence of a replicative advantage for mtDNA 
deletions over wildtype mtDNA. 
Due to the stable nature of the molecular and biochemical defects over time in this 
case study, no comment can be made as to the role played by mtDNA deletion 
heteroplasmy levels in cases of increasing COX-deficiency in tissue. However, the 
importance of absolute wildtype mtDNA copy number was highlighted in the analysis 
of isolated muscle fibres – particularly outlying mtDNA deletion heteroplasmy data 
points in the analysis of COX-deficient and COX-normal fibres. 3 COX-deficient fibres 
were found to have deletion levels much lower than the norm for biochemically 
deficient fibres in the patient, while 8 COX-positive fibres contained relatively high 
deletion levels of more than 60%. All 3 COX-deficient fibres with low deletion levels 
were found to have low levels of wildtype mtDNA, while COX-positive fibres with 
unusually high mtDNA deletion levels were found to have similarly high levels of 
wildtype mtDNA. This highlights the importance of mtDNA maintenance in the muscle, 
and lends support to the hypothesis that absolute wildtype copy number may be vital 
for maintaining normal biochemical function, superseding mtDNA deletion 
heteroplasmy level in determining cellular health (Durham et al., 2005). The results of 
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the individual fibre studies, if extrapolated to whole tissue level, therefore indicate 
that decreasing levels of wildtype mtDNA below a threshold level may be the primary 
cause of patient progression in single mtDNA deletion disease, as hypothesised by 
Schroder et al. (2000). However, it is yet to be determined how significant a role 
mtDNA deletion heteroplasmy level has in regulating the effect of wildtype mtDNA 
copy number on cell fate. 
 
7.2.3 Investigating the impact of molecular mtDNA deletion characteristics on disease 
presentation and progression in single mtDNA deletion patients. 
The potential spectrum of disorders caused by single large-scale mtDNA deletions, in 
terms of both clinical presentation and progression, presents a serious problem for 
clinicians in that no genetic markers have been found to conclusively identify how 
severe a patient’s symptoms may become, or how quickly they will progress. In order 
to provide the best possible patient care and support, it is vital that we gain a better 
understanding of the causes of disease severity and progression. While previous 
studies have been carried out in this area, these have met with mixed success and 
many of the research findings have been contradictory. In an attempt to rectify this 
situation, this study was carried out to identify the relationship between the mtDNA 
defect and the resultant clinical symptoms in a large cohort of mtDNA deletion 
patients. While the primary aim of this study was to characterise the mtDNA defects 
present in this cohort and to determine whether a selective advantage could be 
observed for larger mtDNA deletions (supporting the presence of a replicative 
advantage for mtDNA deletion (Wallace, 1992), the availability of high quality data also 
allowed modelling studies to be carried out by Dr John Grady to assess the impact of 
molecular mtDNA deletion characteristics on disease presentation and progression. 
A large cohort of 113 patients with large-scale mtDNA deletions was investigated as 
part of this study – details of the specific molecular defect (mtDNA deletion size, 
heteroplasmy levels and breakpoint location and sequence) were collected specifically 
for this study, while robust clinical data was available for all patients to allow for 
evaluations of the impact of molecular factors on clinical presentation and 
progression. An initial assessment of mtDNA deletion size and level of heteroplasmy 
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revealed a negative relationship to exist between these two variables – refuting the 
presence of a replicative advantage for larger mtDNA deletions, and therefore 
providing evidence against the model of clonal expansion by replicative advantage 
(Wallace, 1992). Though this negative trend was found to be significant (P = 0.0034), 
this is likely to be a result of the clinically observed phenotypes of patients from whom 
samples are available to access; individuals with small deletions at low heteroplasmy 
levels would not be likely to present clinically with symptoms, and large deletions at 
high heteroplasmy levels may be so deleterious as to be lethal early in development. 
An important implication of this is that the heteroplasmy threshold for pathogenicity 
of a deletion is likely to be dependent on deletion size and location.   
Further molecular investigations found unimodal distributions of both 5’ and 3’ mtDNA 
deletion breakpoints - similar to the findings of (Samuels et al., 2004) but less centred 
on the 4977bp common mtDNA deletion breakpoints, suggesting these may not be as 
important in mtDNA deletion formation as previously proposed – and strong 
correlations between high mtDNA deletion breakpoint homology, high mtDNA deletion 
levels, and early symptom onset. However, the results of the breakpoint homology 
study conflict with the original findings of Sadikovic et al. (2010), highlighting a need 
for further study in this area. The analysis of the impact of molecular mtDNA deletion 
characteristics upon clinical disease presentation was hampered in this study by a low 
number of patients presenting with KSS or Pearson syndrome. Expanding the patient 
cohort to continue this work would increase the statistical strength of any analyses 
already carried out and could provisionally allow for the investigation of the 
correlation linking mtDNA deletion breakpoint homology and clinical symptoms.  
Following these analyses, the collected molecular data was combined with clinical 
information and biochemical defect measures to be used in modelling studies by Dr 
John Grady. Both deletion size and heteroplasmy were found to be predictive of 
symptom onset age and rate of NMDAS progression, though in both cases the 
predictive power of these markers was strengthened by co-regression – the 
implication of this is that each predictor modulates the effect of the other. In addition, 
deletion size is in all cases the stronger predictor. This positive result led to the 
initiation of a longitudinal modelling study, using change in NMDAS score over time as 
a measure of clinical progression. This is being developed as a prognostic tool for 
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clinicians, with mtDNA deletion size and heteroplasmy having been found to be highly 
predictive of a patient’s rate of clinical progression and deletion location found to play 
a modulatory role in determining disease course – inclusion of ND6 in an mtDNA 
deletion is predictive of faster clinical progression, while mtDNA deletions spanning 
NN4L - COX3 tend to result in a less severe disease course.  
 
7.2.4 Investigating the presence of multiple clonally expanded mtDNA deletions in 
single muscle fibres. 
The presence of multiple clonally expanded mtDNA deletions in single cells has been a 
point of dispute in this field of research since the initial discovery that mtDNA 
deletions do not accumulate heterogeneously throughout a given tissue, but rather 
accumulate to varying degrees of heteroplasmy in individual cells (Brierley et al., 
1998). Though a separate study carried out in the same year found a heterogeneous 
population of mtDNA deletion species to be present in all investigated COX-deficient or 
COX-intermediate muscle fibres (Kopsidas et al., 1998),  the clonal expansion of 
mtDNA deletions has widely been accepted to refer to the accumulation of a single 
mtDNA deletion species in a single cell as presented by Brierley et al. (1998). 
Subsequent single cell studies have largely supported the identification of a single 
clonally expanded mtDNA deletion per cell, though these have been carried out in 
other tissue types (Bender et al., 2006; Kraytsberg et al., 2006; Markaryan et al., 2010) 
or animal models (Cao et al., 2001; Gokey et al., 2004).  
Evidence that a single mtDNA deletion species is clonally expanded in an individual 
fibre fits well with a hypothetical selective advantage driving mtDNA deletion 
accumulation over time; we would expect that, in an mtDNA pool within a single cell 
where selective pressures are active, the mtDNA species with the greatest selective 
advantage would tend towards homoplasmy over time. However, the possibility of the 
clonal expansion of multiple mtDNA deletions was brought to the fore by the 
investigation of longitudinal spread of mtDNA deletions discussed earlier in this 
chapter (section 7.2.1). A number of single fibres isolated from multiple mtDNA 
deletion patient biopsy sections had to be excluded from this study due to the 
apparent presence of multiple mtDNA deletions (Section 3.4.2), warranting further 
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investigation into the clonal expansion of multiple mtDNA deletions. It was suggested 
that single molecule PCR – a specialist technique developed by Kraytsberg and Khrapko 
(2005) to assess a range of mtDNA species within a single sample – could be employed 
to investigate the presence of multiple mtDNA deletions in single cells, following 
evidence that this technique is particularly useful for mtDNA analysis in single cells 
(Kraytsberg et al., 2009).  
Single COX-deficient muscle fibres were isolated from tissue sections taken from 
available biopsy tissue from three patients with multiple mtDNA deletion disease, 
caused in each case by a different nuclear defect. Two separate species of clonally 
expanded mtDNA deletion were detected in 40% of all cells assessed; these ‘multiple 
mtDNA deletion fibres’ were evenly distributed through the three patient datasets, 
meaning approximately 40% of COX deficient fibres harboured mtDNA deletion in each 
of the three patient muscle biopsies. Following this finding, a more in-depth analysis of 
mtDNA deletion size and heteroplasmy level was undertaken. No significant difference 
was found to exist in terms of mtDNA deletion size between mtDNA deletion species 
present in single or multiple mtDNA deletion fibres. This indicates that instances of 
multiple mtDNA deletion accumulation are not due to an influencing effect of 
unusually large or small mtDNA deletion sizes. Interestingly, total cellular mtDNA 
deletion heteroplasmy levels were also found to be consistent between fibres 
containing single or multiple mtDNA deletions – i.e. where two mtDNA deletion were 
found to exist in a single cell, the combined mtDNA deletion heteroplasmy for both 
deletions was, on average, a similar level to that of an mtDNA deletion present in a 
single mtDNA deletion fibre. It is possible that the consistency of mtDNA deletion 
levels found between single and multiple mtDNA deletion fibres is indicative of a 
common method of wildtype mtDNA regulation - i.e. that each cell attempts to 
regulate the level of wildtype mtDNA rather than each mtDNA deletion species – 
making the number of mtDNA deletion species present irrelevant to the overall level of 
mtDNA deletion heteroplasmy. This would be in keeping with the importance of 
absolute wildtype mtDNA copy number in maintaining normal cellular biochemical 
function, as described by Durham et al. (2006) and Greaves et al. (2010), and as 
highlighted in the work discussed in Section 7.2.2.  
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In single fibres containing multiple clonally expanded mtDNA deletions, no apparent 
relationship was detected between mtDNA deletion size and heteroplasmy levels; 
mtDNA heteroplasmy levels of smaller or larger mtDNA deletions from each cell were 
found to be similar, with no significant difference detected in these datasets and no 
trend for either larger or smaller mtDNA deletions to tend to accumulate to the higher 
level within a single fibre. Further analyses were carried out to assess whether the 
difference in size between two mtDNA deletions in a single fibre impacted upon the 
difference in mtDNA deletion heteroplasmy levels. There was found to be no 
significant relationship between these two variables – the implication of this finding 
being that specific mtDNA deletion size does not impact upon the level to which an 
mtDNA deletion may clonally expand. This is potentially the strongest evidence yet 
presented in favour of random genetic drift as a mechanism for the clonal expansion of 
mtDNA deletions; this mechanism would likely result in a random flux of cellular 
mtDNA content, leading to variable heteroplasmy levels of different mtDNA deletions 
(Elson et al., 2001). However, future studies must be carried out in other tissue types 
in order to assess whether a common mechanism for clonal expansion of mtDNA 
deletions is likely to exist.  
The apparent lack of correlation between mtDNA deletion size and heteroplasmy 
levels prompted a more thorough evaluation of the relationship between these two 
variables. No correlation between mtDNA deletion size and level was found to exist in 
the separate datasets for single or multiple mtDNA deletion fibres, while the weak 
negative trend observed between mtDNA deletion size and heteroplasmy level in the 
total dataset was found not to be significant. This mirrors the weak negative trend 
between mtDNA deletion size and heteroplasmy levels observed in single mtDNA 
deletion patients in the study discussed in Section 7.2.3, confirming that no replicative 
advantage exists for larger mtDNA deletions over other mtDNA deletion species.  
 
7.3 Final Conclusions 
Over the course of the four studies discussed here, all evidence has suggested that the 
clonal expansion of mtDNA deletions occurs due to random genetic drift, as first 
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proposed by Elson (Elson et al., 2001). No evidence has been found to suggest that 
mtDNA deletions have any selective advantage over wildtype mtDNA, or that a 
replicative advantage exists to cause larger mtDNA deletions to preferentially 
accumulate over smaller mtDNA deletions. It is, however, important to note that this 
body of work was all conducted in human muscle tissue from mtDNA deletion patients, 
and further studies must therefore be carried out in other tissue types to assess 
whether a common mechanism is responsible for the clonal expansion of mtDNA 
deletions here. Similarly, future work must be undertaken in aged tissues to assess 
whether the same mechanisms are responsible for the accumulation of mtDNA 
deletions with age and in age-related disease as for the clonal expansion of mtDNA 
deletions in mitochondrial disease.  
While it remains crucial that we fully investigate the mechanism by which clonal 
expansion occurs, in the hope that understanding how mtDNA deletion accumulation 
occurs is the first step towards preventing this, the importance of absolute wildtype 
mtDNA copy number in determining cellular biochemical has also been highlighted 
over the course of this work (discussed in sections 4.4.6.5 and 6.5), and warrants 
further study. Further work is required to determine where the ‘functional threshold 
level’ for wildtype mtDNA copy number lies, and how significant a role mtDNA deletion 
heteroplasmy level has in regulating the effect of wildtype mtDNA copy number on cell 
fate. 
Finally, it is imperative that the longitudinal modelling of clinical disease progression is 
continued. The current model has identified larger mtDNA deletion size and higher 
mtDNA deletion heteroplasmy levels to be predictive of more rapid disease 
progression, with a number of gene loci found to modulate disease progression 
(specifically, ND6 involvement predicts faster progression while the deletion of genes 
in the region ND4L to COX3 predict slower progression). This is the first study of its 
kind and, though further verification of these results is required, is the first step 
towards providing clinicians with a better set of prognostic tools for patient analysis. 
Inclusion of a larger patient cohort will increase the accuracy of this disease model, 
while the inclusion of more data sets (such as breakpoint sequence homology) could 
potentially also improve this prognostic tool.  
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Chapter 8 
Appendices 
Appendix A  
All available data for the single large-scale mtDNA deletion patient cohort involved in 
all analyses carried out in Chapter Five. Numerical patient ID’s were assigned in order 
to de-identify clinical data. Clinical phenotypes are listed as described in clinical 
records; age at clinical symptom onset, age at biopsy and NMDAS assessment details 
were also obtained from clinical records. COX-deficiency was assessed in all cases in 
muscle sections, following the application of COX/SDH histochemical activity assays, by 
Mr Gavin Falkous from the NCG Mitochondrial Diagnostics service. All mtDNA deletion 
breakpoints were determined by breakpoint sequencing, while mtDNA deletion levels 
were measured by the quantitative ND1/ND4 real-time PCR assay. 
Appendix B 
Full breakpoint sequence details for all patients with identified breakpoint locations. 
Nucleotide sequences of 49bp (24 bases either side of the breakpoint base, which is 
enclosed by square parentheses) are provided – these were assessed for the presence 
of direct repeat sequences of more than one base by clustal alignment, as outlined by 
Sadikovic et al. (2010) 
Appendix C 
Identification of available data sets for analysis in Chapter Five, as summarised in Table 
5.4. Appropriate patient data sets marked ‘Y’ where data indicated by column heading 
was all available for data analysis; NMDAS where at least one NMDAS test result was 
available; W/O NMDAS  where no NMDAS scores were available. 
. 
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Appropriate patient data sets marked ‘Y’ where data indicated by column heading was all available for 
data analysis; NMAS where at least one NMDAS test result was available; W/O NMDAS  where no 
NMDAS scores were available. 
Patient ID - assigned patient identification number; SKM het % and mtDNA del size – where mtDNA 
deletion heteroplasmy level (%) and deletion size (bp) are both available; plus fully sequenced 
breakpoints – where mtDNA deletion heteroplasmy level (%) and deletion breakpoint location are 
available; plus onset age – mtDNA deletion heteroplasmy level and breakpoint locations plus symptom 
onset age available; plus COX-deficient fibre % - mtDNA deletion heteroplasmy level and breakpoint 
locations plus COX-deficient fibre level (%) available. 
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